Use of compounds for the elevation of pyruvate dehydrogenase activity

ABSTRACT

The use of compounds of formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs; in formula (I), Ring C is phenyl or a carbon linked heteroaryl ring substituted as defined within; R 1  is an ortho substituent as defined within; n is 1 or 2; A-B is a linking group as defined within; R 2  and R 3  are as defined within; R 4  is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described

This application is a DIV of Ser. No. 09/700,370, filed Nov. 1, 2000, U.S. Pat. No. 6,498,275.

The present invention relates to compounds which elevate pyruvate dehydrogenase (PDH) activity, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with reduced PDH activity, to their use as medicaments and to their use in the manufacture of medicaments for use in the elevation of PDH activity in warm-blooded animals such as humans.

Within tissues adenosine triphosphate (ATP) provides the energy for synthesis of complex molecules and, in muscle, for contraction. ATP is generated from the breakdown of energy-rich substrates such as glucose or long chain free fatty acids. In oxidative tissues such as muscle the majority of the ATP is generated from acetyl CoA which enters the citric acid cycle, thus the supply of acetyl CoA is a critical determinant of ATP production in oxidative tissues. Acetyl CoA is produced either by β-oxidation of fatty acids or as a result of glucose metabolism by the glycolytic pathway. The key regulatory enzyme in controlling the rate of acetyl CoA formation from glucose is PDH which catalyses the oxidation of pyruvate to acetyl CoA and carbon dioxide with concomitant reduction of nicotinamide adenine dinucleotide (NAD) to NADH.

In disease states such as both non-insulin dependent (NIDDM) and insulin-dependent diabetes mellitus (IDDM), oxidation of lipids is increased with a concomitant reduction in utilisation of glucose, which contributes to the hyperglycaemia. Reduced glucose utilisation in both IDDM and NIDDM is associated with a reduction in PDH activity. In addition, a further consequence of reduced PDH activity may be that an increase in pyruvate concentration results in increased availability of lactate as a substrate for hepatic gluconeogenesis. It is reasonable to expect that increasing the activity of PDH could increase the rate of glucose oxidation and hence overall glucose utilisation, in addition to reducing hepatic glucose output. Another factor contributing to diabetes mellitus is impaired insulin secretion, which has been shown to be associated with reduced PDH activity in pancreatic β-cells (in a rodent genetic model of diabetes mellitus Zhou et al. (1996) Diabetes 45: 580-586).

Oxidation of glucose is capable of yielding more molecules of ATP per mole of oxygen than is oxidation of fatty acids. In conditions where energy demand may exceed energy supply, such as myocardial ischaemia, intermittent claudication, cerebral ischaemia and reperfusion, (Zaidan et al., 1998; J. Neurochem. 70: 233-241), shifting the balance of substrate utilisation in favour of glucose metabolism by elevating PDH activity may be expected to improve the ability to maintain ATP levels and hence function.

An agent which is capable of elevating PDH activity may also be expected to be of benefit in treating conditions where an excess of circulating lactic acid is manifest such as in certain cases of sepsis.

The agent dichloroacetic acid (DCA) which increases the activity of PDH after acute administration in animals, (Vary et al., 1988; Circ. Shock. 24: 3-18), has been shown to have the predicted effects in reducing glycaemia, (Stacpoole et al. 1978; N. Engl. J. Med. 298: 526-530), and as a therapy for myocardial ischaemia (Bersin and Stacpoole 1997; American Heart Journal, 134: 841-855) and lactic acidaemia, (Stacpoole et al., 1983; N. Engl. J. Med. 309: 390-396).

PDH is an intramitochondrial multienzyme complex consisting of multiple copies of several subunits including three enzyme activities E1, E2 and E3, required for the completion of the conversion of pyruvate to acetyl CoA (Patel and Roche 1990; FASEB J., 4: 3224-3233). E1 catalyses the non-reversible removal of CO₂ from pyruvate; E2 forms acetyl CoA and E3 reduces NAD to NADH. Two additional enzyme activities are associated with the complex: a specific kinase which is capable of phosphorylating E1 at three serine residues and a loosely-associated specific phosphatase which reverses the phosphorylation. Phosphorylation of a single one of the three serine residues renders the E1 inactive. The proportion of the PDH in its active (dephosphorylated) state is determined by a balance between the activity of the kinase and phosphatase. The activity of the kinase may be regulated in vivo by the relative concentrations of metabolic substrates such as NAD/NADH, CoA/acetylCoA and adenine diphosphate (ADP)/ATP as well as by the availability of pyruvate itself.

European Patent Publication Nos. 617010 and 524781 describes compounds which are capable of relaxing bladder smooth muscle and which may be used in the treatment of urge incontinence. We have found that the compounds of the present invention are very good at elevating PDH activity, a property nowhere disclosed in EP 0617010 and EP 524781.

The present invention is based on the surprising discovery that certain compounds elevate PDH activity, a property of value in the treatment of disease states associated with disorders of glucose utilisation such as diabetes mellitus, obesity, (Curto et al., 1997; Int. J. Obes. 21: 1137-1142), and lactic acidaemia. Additionally the compounds may be expected to have utility in diseases where supply of energy-rich substrates to tissues is limiting such as peripheral vascular disease, (including intermittent claudication), cardiac failure and certain cardiac myopathies, muscle weakness, hyperlipidaemias and atherosclerosis (Stacpoole et al., 1978; N. Engl. J. Med. 298: 526-530). A compound that activates PDH may also be useful in treating Alzheimer's disease (AD) (J Neural Transm (1998) 105, 855-870).

According to one aspect of the present invention there is provided the use of compounds of the formula (I):

wherein:

-   ring C is as defined in (a) or (b); -   R¹ is as defined in (c) or (d); -   n is 1 or 2; -   R² and R³ are as defined in (e) or (f); -   A-B is as defined in (g) or (h) and -   R⁴ is as defined in (i) or (j)     wherein

(a) ring C is phenyl or carbon-linked heteroaryl selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; wherein said phenyl or heteroaryl is substituted on carbon at one or both positions meta to the position of A-B attachment or on carbon at the position para to the position of A-B attachment by P¹ or P² (wherein P¹ and P² are as defined hereinafter), and further, wherein said phenyl or heteroaryl is optionally substituted on carbon at any remaining meta position(s) or para position by P¹ or P³, (wherein P¹ and P³ are as defined hereinafter);

(b) ring C is selected from the following five groups:

-   (i) phenyl or carbon-linked heteroaryl selected from pyridyl,     pyrazinyl, pyrimidinyl and pyridazinyl, wherein said phenyl or     heteroaryl is unsubstituted except by (R¹)_(n) wherein R¹ and n are     as defined hereinafter; -   (ii) a carbon-linked triazine optionally substituted on a ring     carbon at a position meta or para to A-B attachment by 1 substituent     selected from P¹, P², P³ and P⁴, wherein P¹, P², P³ and P⁴ are as     defined hereinafter; -   (iii) a 6-membered carbon-linked heteroaryl group containing 1-3     nitrogen atoms wherein one or more ring nitrogen atoms are oxidised     to form the N-oxide, which heteroaryl group is optionally     substituted at any of the positions meta or para to A-B attachment     by 1-3 substituents selected from P¹, P², P³ and P⁴, wherein P¹, P²,     P³ and P⁴ are as defined hereinafter; -   (iv) phenyl or carbon-linked heteroaryl selected from pyridyl,     pyrazinyl, pyrimidinyl and pyridazinyl, wherein said phenyl or     heteroaryl is substituted at a position meta or para to A-B     attachment by 1 substituent selected from P³ and P⁴, wherein P³ and     P⁴ are as defined hereinafter; and -   (v) phenyl or carbon-linked heteroaryl selected from pyridyl,     pyrazinyl, pyrimidinyl and pyridazinyl, wherein said phenyl or     heteroaryl is substituted at any of the positions meta or para to     A-B attachment by 2-3 substituents selected from P¹, P², P³ and P⁴,     provided that if one or more of the substituents is P¹ or P² then at     least one of the other substituents is P⁴, wherein P¹, P², P³ and P⁴     are as defined hereinafter; -   P¹ is cyano, trifluoromethyl, nitro, trifluoromethoxy or     trifluoromethylsulphanyl; -   P² is —Y¹Ar¹, wherein Ar¹ is selected from the group consisting of     phenyl, a carbon-linked 6-membered heteroaryl ring containing 1-2     nitrogen atoms and a carbon-linked 5-membered heteroaryl ring     containing 1-2 heteroatoms selected independently from O, N and S,     wherein said phenyl or heteroaryl ring is optionally substituted at     carbon, with 1-4 substituents selected from Q¹, wherein Q¹ is as     defined hereinafter; and Y¹ is selected from —CO—, —SO— and —SO₂—; -   P³ is C₁₋₄alkyl, haloC₂₋₄alkyl, C₁₋₄alkoxy, haloC₂₋₄alkoxy,     C₂₋₄alkenyloxy, halo or hydroxy; -   P⁴ is selected from the following eight groups: -   1) halosulphonyl, cyanosulphanyl; -   2) —X¹—R⁵ wherein X¹ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —OSO₂—, —SO₂O—, —NR⁶—, —N⁺O⁻R⁶—, —CO—, —COO—, —OCO—, —CONR⁷—,     —NR⁸CO—, —OCONR⁹—, —CONR¹⁰SO₂—, —NR¹¹SO₂—, —CH₂—, —NR¹²COO—,     —CSNR¹³—, —NR¹⁴CS—, —NR¹⁵CSNR¹⁶—, NR¹⁷CONR¹⁸— or —NR¹⁹CONR²⁰SO₂—     (wherein R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷,     R¹⁸, R¹⁹ and R²⁰ each independently represents hydrogen or C₁₋₄alkyl     which C₁₋₄alkyl may be optionally substituted by one or more groups     selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl, carboxy,     C₁₋₆alkoxy or C₁₋₃alkylsulphanyl) and R⁵ is selected from hydrogen,     C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl and C₂₋₆alkynyl which     C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl or C₂₋₆alkynyl is optionally     substituted with one or more groups selected from hydroxy, amino,     halo, C₁₋₄alkoxycarbonyl, carboxy, C₁₋₆alkoxy and hydroxyC₁₋₆alkyl     with the proviso that P⁴ is not trifluoromethylsulphanyl, hydroxy,     C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy or     C₂₋₄alkenyloxy; -   3) —X¹—C₁₋₆alkyl-X²—R²¹ wherein X¹ is as defined hereinbefore, X² is     a direct bond, —O—, —S—, —SO—, —SO₂—, —OSO₂—, —SO₂O—, —NR²²—,     —N⁺O⁻R²²—, —CO—, —COO—, —OCO—, —CONR²³—, —NR²⁴CO—, —NR²⁵COO—,     —SO₂NR²⁶—, —NR²⁷SO₂—, —CH₂—, —SO₂NR²⁸CO—, —OCONR²⁹—, —CSNR³⁰—,     —NR³¹CS—, —NR³²CSNR³³—, —NR³⁴CONR³⁵—, —CONR³⁶SO₂—, —NR³⁷CONR³⁸SO₂,     —SO₂NR³⁹CONR⁴⁰— or —SO₂NR³⁹CNNR⁴⁰— (wherein R²², R²³, R²⁴, R²⁵, R²⁶,     R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³², R³³, R³⁴, R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and     R⁴⁰, each independently represents hydrogen or C₁₋₄alkyl which     C₁₋₄alkyl may be optionally substituted by one or more groups     selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl, carboxy,     C₁₋₆alkoxy or C₁₋₃alkylsulphanyl) and R²¹ is hydrogen or C₁₋₄alkyl     which C₁₋₄alkyl is optionally substituted with one or more groups     selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl, carboxy,     C₁₋₆alkoxy and hydroxyC₁₋₆alkyl or R²¹ is R⁴¹ wherein R⁴¹ is phenyl     or a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms     selected independently from O, N and S which heterocyclic moiety may     be aromatic or non-aromatic and which phenyl or heterocyclic moiety     is optionally substituted by 1-6 substituents selected from Q³     wherein Q³ is as defined hereinafter with the proviso that P⁴ is not     C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy or haloC₁₋₄alkoxy; -   4) —X¹—C₂₋₆alkenyl-X²—R²¹ wherein X¹, X² and R²¹ are as defined     hereinbefore with the proviso that P⁴ is not C₂₋₄alkenyloxy; -   5) —X¹—C₂₋₆alkynyl-X²—R²¹ wherein X¹, X² and R²¹ are as defined     hereinbefore; -   6) —X¹—C₃₋₇cycloalkyl-X²—R²¹ wherein X¹, X² and R²¹ are as defined     hereinbefore; -   7) —X¹—C₁₋₆alkylC₃₋₇cycloalkyl-X²—R²¹ wherein X¹, X² and R²¹ are as     defined hereinbefore; and -   8) —Y²Ar² wherein Y² is X¹ wherein X¹ is as defined hereinbefore and     Ar² is selected from the following six groups: -   (i) phenyl, a carbon-linked 6-membered heteroaryl ring containing     1-2 nitrogen atoms and a carbon-linked 5-membered heteroaryl ring     containing 1-2 heteroatoms selected independently from O, N and S,     wherein said phenyl or heteroaryl ring is substituted at carbon,     with 1-4 substituents selected from Q¹ and Q² including at least one     substituent selected from Q² wherein Q¹ and Q² are as defined     hereinafter; -   (ii) a carbon-linked triazine or a carbon-linked 5-membered     heteroaryl ring containing 3-4 heteroatoms selected independently     from O, N and S; wherein said heteroaryl ring is optionally     substituted with 1-4 substituents selected from Q¹ and Q² wherein Q¹     and Q² are as defined hereinafter; -   (iii) a 4-12 membered non-aromatic heterocyclic moiety containing     1-4 heteroatoms selected independently from O, N and S wherein said     heterocyclic moiety is optionally substituted with 1-6 substituents     selected from Q³ wherein Q³ is as defined hereinafter, with the     proviso that if Ar² is a nitrogen linked heterocyclic ring Y² is not     —SO₂—; -   (iv) a 5-membered heteroaryl ring containing 1-4 heteroatoms     selected independently from O, N and S, which heteroaryl ring     contains at least one nitrogen atom substituted by a group selected     from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl,     C₁₋₆alkoxycarbonyl, carbamoyl, N-(C₁₋₆alkyl)carbamoyl,     N,N-(C₁₋₆alkyl)₂carbamoyl, benzoyl or phenylsulphonyl and which     heteroaryl ring is optionally substituted by 1-3 substituents     selected from Q³ wherein Q³ is as defined hereinafter; -   (v) a carbon linked 7-12 membered aromatic heterocyclic moiety     containing 1-4 heteroatoms selected independently from O, N and S     wherein said heterocyclic moiety is optionally substituted with 1-6     substituents selected from Q³ wherein Q³ is as defined hereinafter;     and -   (vi) Ar¹ with the proviso that if Ar² has a value Ar¹ then Y² is not     —CO—, —SO— or —SO₂—; -   Q¹ is C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy,     C₂₋₄alkenyloxy, cyano, nitro, halo or trifluoromethylsulphanyl; -   Q² is selected from the following ten groups: -   1) oxygen (forming an oxo group when linked to a ring carbon and     forming an N-oxide when a ring nitrogen is oxidised); -   2) halosulphonyl, cyanosulphanyl; -   3) —X³—R⁵ wherein X³ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —OSO₂—, —SO₂O—, —NR⁴²—, —N⁺O⁻R⁴²—, —CO—, —COO—, —OCO—, —CONR⁴³—,     —NR⁴⁴CO—, —NR⁴⁵COO—, —SO₂NR⁴⁶—, —NR⁴⁷SO₂—, —CH₂—, —SO₂NR⁴⁸CO—,     —OCONR⁴⁹—, —CSNR⁵⁰—, —NR⁵¹CS—, —NR⁵²CSNR⁵³—, —NR⁵⁴CONR⁵⁵—,     —CONR⁵⁶SO₂—, —NR⁵⁷CONR⁵⁸SO₂—, —SO₂NR⁵⁷CNNR⁵⁸— or —SO₂NR⁵⁹CONR⁶⁰—     (wherein R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰, R⁵¹, R⁵², R⁵³,     R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, and R⁶⁰ each independently represents     hydrogen or C₁₋₄alkyl which C₁₋₄alkyl may be optionally substituted     by one or more groups selected from hydroxy, amino, halo,     C₁₋₄alkoxycarbonyl, carboxy, C₁₋₆alkoxy or C₁₋₃alkylsulphanyl) and     R⁵ is as defined hereinbefore but with the proviso that Q² is not     trifluoromethylsulphanyl, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy,     haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; -   4) R⁴¹ wherein R⁴¹ is as defined hereinbefore; -   5) —X³—C₁₋₆alkyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore but with the proviso that Q² is not C₁₋₄alkyl,     haloC₁₋₄alkyl, C₁₋₄alkoxy or haloC₁₋₄alkoxy; -   6) —X³—C₂₋₆alkenyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore but with the proviso that Q² is C₂₋₄alkenyloxy; -   7) —X³—C₂₋₆alkynyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore; -   8) —X³—C₃₋₇cycloalkyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore; -   9) —X³—C₁₋₆alkylC₃₋₇cycloalkyl-X²—R²¹ wherein X³, X² and R²¹ are as     defined hereinbefore; and -   10) —X³—R⁴¹ wherein R⁴¹ and X³ are as defined hereinbefore; -   Q³ is selected from the following four groups: -   1) oxygen (forming an oxo group when linked to a ring carbon and     forming an N-oxide when a ring nitrogen is oxidised); -   2) cyano, nitro or halo: -   3) halosulphonyl, cyanosulphanyl; and -   4) —X⁴—R⁶¹ wherein X⁴ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —OSO₂—, —SO₂O—, —NR⁶²—, —N⁺O⁻R⁶²—, —CO—, —COO—, —OCO—, —CONR⁶³—,     —NR⁶⁴CO—, —NR⁶⁵COO—, —SO₂NR⁶⁶—, —NR⁶⁷SO₂—, —CH₂—, —SO₂NR⁶⁸CO—,     —OCONR⁶⁹—, —CSNR⁷⁰—, —NR⁷¹CS—, —NR⁷²CSNR⁷³—, —NR⁷⁴CONR⁷⁵—,     —CONR⁷⁶SO₂—, —NR⁷⁷CONR⁷⁸SO₂—, —SO₂NR⁷⁹CNNR⁸⁰— or —SO₂NR⁷⁹CONR⁸⁰—     (wherein R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹, R⁷², R⁷³,     R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, R⁷⁸, R⁷⁹ and R⁸⁰ each independently represents     hydrogen or C₁₋₄alkyl which C₁₋₄alkyl may be optionally substituted     by one or more groups selected from hydroxy, amino, halo,     C₁₋₄alkoxycarbonyl, carboxy, C₁₋₆alkoxy or C₁₋₃alkylsulphanyl) and     R⁶¹ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl,     C₂₋₆alkenyl and C₂₋₆alkynyl which C₁₋₆alkyl, C₃₋₇cycloalkyl,     C₂₋₆alkenyl or C₂₋₆alkynyl is optionally substituted with one or     more groups selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl,     carboxy, C₁₋₆alkoxy and hydroxyC₁₋₆alkyl;

(c) R¹ is linked to ring C at a carbon ortho to the position of A-B attachment and is selected from the group consisting of C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy, C₂₋₄alkenyloxy, cyano, nitro, halo, trifluoromethylsulphanyl and hydroxy;

(d) R¹ is linked to ring C at a ring carbon atom ortho to the position of A-B attachment and is selected from the following two groups:

-   1) —X⁵—R⁸¹ wherein X⁵ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —OSO₂—, —SO₂O—, —NR⁸²—, —CO—, —COO—, —OCO—, —CONR⁸³—, —NR⁸⁴CO—,     —NR⁸⁵COO—, —SO₂NR⁸⁶—, —NR⁸⁷SO₂—, —CH₂—, —SO₂NR⁸⁸CO—, —OCONR⁸⁹—,     —CSNR⁹⁰—, —NR⁹¹CS—, —NR⁹²CSNR⁹³—, —NR⁹⁴CONR⁹⁵—, —CONR⁹⁶SO₂—,     —NR⁹⁷CONR⁹⁸SO₂—, —SO₂NR⁹⁹CNNR¹⁰⁰— or —SO₂NR⁹⁹CONR¹⁰⁰— (wherein R⁸²,     R⁸³, R⁸⁴, R⁸⁵, R⁸⁶, R⁸⁷, R⁸⁸, R⁸⁹, R⁹⁰, R⁹¹, R⁹², R⁹³, R⁹⁴, R⁹⁵,     R⁹⁶, R⁹⁷, R⁹⁸, R⁹⁹ and R¹⁰⁰ each independently represents hydrogen     or C₁₋₄alkyl which C₁₋₄alkyl may be optionally substituted by one or     more groups selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl,     carboxy, C₁₋₆alkoxy or C₁₋₃alkylsulphanyl) and R⁸¹ is selected from     hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl and C₂₋₆alkynyl     which C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl or C₂₋₆alkynyl is     optionally substituted with one or more groups selected from     hydroxy, amino, halo, C₁₋₄alkoxycarbonyl, carboxy, C₁₋₆alkoxy and     hydroxyC₁₋₆alkyl with the proviso that R¹ is not     trifluoromethylsulphanyl, hydroxy, C₁₋₄alkyl, haloC₁₋₄alkyl,     C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; and -   2) —X⁶—R¹⁰¹ wherein X⁶ is selected from a direct bond, —CO—, —O—,     —OCH₂—, —S—, —SO—, —SO₂— and —NR¹⁰²— (wherein R¹⁰² is hydrogen or     C₁₋₄alkyl which C₁₋₄alkyl may be optionally substituted by one or     more groups selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl,     carboxy, C₁₋₆alkoxy or C₁₋₃alkylsulphanyl) and R¹⁰¹ is phenyl which     is optionally substituted by 1-4 substituents selected from cyano,     nitro, trifluoromethylsulphanyl, C₁₋₆alkyl, haloC₁₋₆alkyl,     C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₂₋₆alkenyloxy, halo, hydroxy and amino;

n is 1 or 2;

(e) either R² and R³ are independently C₁₋₃alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is the number of carbon atoms in the said C₁₋₃alkyl, provided that R² and R³ are not both methyl;

or R² and R³, together with the carbon atom to which they are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 1 to 2m−2 fluorine atoms wherein m is the number of carbon atoms in said ring;

(f) R² and R³ are both methyl or one of R² and R³ is hydrogen or halo and the other is halo or C₁₋₃alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is the number of carbon atoms in the said C₁₋₃alkyl, with the proviso that when either R² or R³ is halo R⁴ is not hydroxy and with the proviso that when either R² or R³ is hydrogen, R⁴ is not hydrogen;

(g) A-B is selected from —NHCO—, —OCH₂—, —SCH₂—, —NHCH₂—, trans-vinylene, and ethynylene;

(h) A-B is —NHCS— or —COCH₂—;

(i) R⁴ is hydroxy;

(j) R⁴ is hydrogen, halo, amino or methyl;

-   but excluding compounds wherein ring C is selected from (a) and R¹     is selected only from (c) and R² and R³ are selected from (e) and     A-B is selected from (g) and R⁴ is selected from (i); -   and salts thereof; -   and pharmaceutically acceptable in vivo cleavable prodrugs of said     compound of formula (I); -   and pharmaceutically acceptable salts of said compound or said     prodrugs; -   in the manufacture of a medicament for use in the elevation of PDH     activity in warm-blooded animals such as humans.

Advantageously Q¹ is C₁₋₂alkyl, haloC₁₋₂alkyl, C₁₋₂alkoxy, cyano or halo.

In one embodiment of the present invention Ar¹ is phenyl or 4-pyridyl and is optionally substituted as defined hereinbefore.

In another embodiment of the present invention Ar¹ is phenyl and is optionally substituted as defined hereinbefore.

Preferably Y¹ is —SO₂— or —SO—, more preferably —SO₂—.

Advantageous values for X¹ are a direct bond, —O—, —S—, —SO—, —SO₂—, —NR⁶—, —CO—, —COO—, —OCO—, —CONR⁷—, —NR⁸CO—, —OCONR⁹—, —CONR¹⁰SO₂—, —NR¹¹SO₂—, —CH₂—, —NR¹²COO—, —CSNR¹³—, —NR¹⁴CS—, —NR¹⁵CSNR¹⁶—, NR¹⁷CONR¹⁸— and —NR¹⁹CONR²⁰SO₂— (wherein R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

Preferred values for X¹ are —O—, —SO—, —SO₂—, —NR⁶—, —COO—, —CONR⁷—, —NR⁸CO—, —NR¹¹SO₂—, —CH₂— and —NR¹²COO— (wherein R⁶, R⁷, R⁸, R¹¹ and R¹² each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

More preferred values of X¹ are —SO— and —SO₂—.

Advantageously R⁵ is selected from hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₂₋₄alkenyl and C₂₋₄alkynyl which C₁₋₄alkyl, C₃₋₇cycloalkyl, C₂₋₄alkenyl or C₂₋₄alkynyl is optionally substituted as defined hereinbefore.

Preferably R⁵ is selected from hydrogen, C₁₋₄alkyl and C₃₋₇cycloalkyl, which C₁₋₄alkyl or C₃₋₇cycloalkyl, is optionally substituted as defined hereinbefore.

Advantageous values for X² are —O—, —NR²²—, —S—, —SO— and —SO₂—, (wherein R²² is hydrogen or C₁₋₄alkyl).

Preferred values for X² are —O—, —NR²²—, —S—, —SO— and —SO₂— (wherein R²² is hydrogen or C₁₋₂alkyl).

More preferred values for X² are —O— and —NR²²— (wherein R²² is hydrogen or C₁₋₂alkyl).

Advantageous values for X⁴ are a direct bond, —O—, —S—, —SO—, —SO₂—, —NR⁶²—, —CO—, —COO—, —OCO—, —CONR⁶³—, —NR⁶⁴CO—, —NR⁶⁵COO—, —SO₂NR⁶⁶—, —NR⁶⁷SO₂—, —CH₂—, —SO₂NR⁶⁸CO—, —OCONR⁶⁹—, —CSNR⁷⁰—, —NR⁷¹CS—, —NR⁷²CSNR⁷³—, —NR⁷⁴CONR⁷⁵—, —CONR⁷⁶SO₂—, —NR⁷⁷CONR⁷⁸SO₂— and —SO₂NR⁷⁹CONR⁸⁰— (wherein R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, R⁷⁸, R⁷⁹ and R⁸⁰ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

Preferred values for X⁴ are —O—, —S—, —SO—, —SO₂—, —NR⁶²—, —COO—, —CONR⁶³—, —NR⁶⁴CO— and —NR⁶⁷SO₂— (wherein R⁶², R⁶³, R⁶⁴ and R⁶⁷ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

More preferred values for X⁴ are —O—, —S—, —SO— and —SO₂—.

In another aspect of the invention more preferred values for X⁴ are —O—, —S—, —SO—, —CONR⁶³— and —SO₂—.

Advantageously R⁶¹ is selected from hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₂₋₄alkenyl and C₂₋₄alkynyl which C₁₋₄alkyl, C₃₋₇cycloalkyl, C₂₋₄alkenyl or C₂₋₄alkynyl is optionally substituted as hereinbefore defined.

Preferably R⁶¹ is selected from hydrogen, C₁₋₄alkyl and C₃₋₇cycloalkyl, which C₁₋₄alkyl or C₃₋₇cycloalkyl is optionally substituted as hereinbefore defined.

Advantageously Q³ is selected from the following three groups:

-   (i) oxygen (forming an oxo group when linked to a ring carbon and     forming an N-oxide when a ring nitrogen is oxidised); -   (ii) cyano, nitro or halo; and -   (iii) —X⁴—R⁶¹ wherein X⁴ and R⁶¹ are as defined hereinbefore.

Advantageously R⁴¹ is phenyl, a 5-6 membered heterocyclic aromatic ring containing 1-4 heteroatoms selected independently from O, N and S or a 5-7 membered heterocyclic non-aromatic moiety containing 1-2 heteroatoms selected independently from O, N and S which phenyl, heterocyclic aromatic ring or heterocyclic non-aromatic moiety is optionally substituted as defined hereinbefore.

Advantageously R²¹ is hydrogen or C₁₋₄alkyl.

Advantageously X³ is a direct bond, —O—, —S—, —SO—, —SO₂—, —NR⁴²—, —CO—, —COO—, —OCO—, —CONR⁴³—, —NR⁴⁴CO—, —NR⁴⁵COO—, —SO₂NR⁴⁶—, —NR⁴⁷SO₂—, —CH₂—, —SO₂NR⁴⁸CO—, —OCONR⁴⁹—, —CSNR⁵⁰—, —NR⁵¹CS—, —NR⁵²CSNR⁵³—, —NR⁵⁴CONR⁵⁵—, —CONR⁵⁶SO₂—, —NR⁵⁷CONR⁵⁸SO₂— or —SO₂NR⁵⁹CONR⁶⁰— (wherein R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰, R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹ and R⁶⁰ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

Preferably X³ is —O—, —S—, —SO—, —SO₂—, —NR⁴²—, —COO—, —CONR⁴³—, —NR⁴⁴CO—, —SO₂NR⁴⁶—, —NR⁴⁷SO₂—, —SO₂NR⁴⁸CO— or —CONR⁵⁶SO₂— (wherein R⁴², R⁴³, R⁴⁴, R⁴⁶, R⁴⁷, R⁴⁸ and R⁵⁶ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

Advantageously Q² is selected from the following seven groups:

-   1) oxygen (forming an oxo group when linked to a ring carbon and     forming an N-oxide when a ring nitrogen is oxidised); -   2) halosulphonyl, cyanosulphanyl; -   3) —X³—R⁵ wherein X³ and R⁵ are as defined hereinbefore but with the     proviso that Q² is not trifluoromethylsulphanyl, C₁₋₄alkyl,     haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; -   4) R⁴¹ wherein R⁴¹ is as defined hereinbefore; -   5) —X³—C₁₋₄alkyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore; -   6) —X³—C₃₋₇cycloalkyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore; and -   7) —X³—R⁴¹ wherein R⁴¹ and X³ are as defined hereinbefore.

Preferably Q² is —X³—R⁵ wherein X³ and R⁵ are as defined hereinbefore but with the proviso that Q² is not trifluoromethylsulphanyl, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy.

Advantageously Ar² is selected from the following two groups:

-   1) phenyl, a carbon-linked 6-membered heteroaryl ring containing 1-2     nitrogen atoms and a carbon-linked 5-membered heteroaryl ring     containing 1-2 heteroatoms selected independently from O, N and S,     wherein said phenyl or heteroaryl ring is substituted at carbon,     with 1-4 substituents selected from Q¹ and Q² including at least one     substituent selected from Q² wherein Q¹ and Q² are as defined     hereinafter; and -   2) Ar¹ with the proviso that if Ar² has a value Ar¹ then Y² is not     —CO—, —SO— or —SO₂—.

Preferably Ar² is phenyl substituted with one substituent selected from Q².

Advantageously P⁴ is selected from the following five groups:

-   1) halosulphonyl, cyanosulphanyl; -   2) —X¹—R⁵ wherein X¹ and R⁵ are as defined hereinbefore with the     proviso that P⁴ is not trifluoromethyl, trifluoromethoxy,     trifluoromethylsulphanyl, hydroxy, C₁₋₄alkyl, haloC₁₋₄alkyl,     C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; -   3) —X¹—C₁₋₄alkyl-X²—R²¹ wherein X¹, X² and R²¹ are as defined     hereinbefore; -   4) —X¹—C₃₋₇cycloalkyl-X²—R²¹ wherein X¹, X² and R²¹ are as defined     hereinbefore; and -   5) —Y²Ar² wherein Y² and Ar² are as defined hereinbefore.

Preferably P⁴ is selected from the following three groups:

-   1) halosulphonyl, cyanosulphanyl; -   2) —X¹—R⁵ wherein X¹ and R⁵ are as defined hereinbefore with the     proviso that P⁴ is not trifluoromethyl, trifluoromethoxy,     trifluoromethylsulphanyl, hydroxy, C₁₋₄alkyl, haloC₁₋₄alkyl,     C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; and -   3) —Y²A² wherein Y² and Ar² are as defined hereinbefore.

Advantageously R¹⁰¹ is phenyl which is optionally substituted by 1-4 substituents selected from cyano, nitro, trifluoromethylsulphanyl, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy, C₂₋₄alkenyloxy, halo, hydroxy and amino.

Advantageously X⁶ is selected from a direct bond, —CO—, —O—, —OCH₂—, —S—, —SO—, —SO₂— and —NR¹⁰²— (wherein R¹⁰² is hydrogen or C₁₋₂alkyl).

Advantageously R⁸¹ is selected from hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₂₋₄alkenyl and C₂₋₄alkynyl which C₁₋₄alkyl, C₃₋₇cycloalkyl, C₂₋₄alkenyl or C₂₋₄alkynyl is optionally substituted as defined hereinbefore.

Preferably R⁸¹ is selected from hydrogen, C₁₋₄alkyl and C₃₋₇cycloalkyl, which C₁₋₄alkyl and C₃₋₇cycloalkyl is optionally substituted as defined hereinbefore.

Advantageously X⁵ is a direct bond, —O—, —S—, —SO—, —SO₂—, —NR⁸²—, —CO—, —COO—, —OCO—, —CONR⁸³—, —NR⁸⁴CO—, —NR⁸⁵COO—, —SO₂NR⁸⁶—, —NR⁸⁷SO₂—, —CH₂—, —SO₂NR⁸⁸CO—, —OCONR⁸⁹—, —CSNR⁹⁰—, —NR⁹¹CS—, —NR⁹²CSNR⁹³—, —NR⁹⁴CONR⁹⁵—, —CONR⁹⁶SO₂— —NR⁹⁷CONR⁹⁸SO₂— or —SO₂NR⁹⁹CONR¹⁰⁰ (wherein R⁸², R⁸³, R⁸⁴, R⁸⁵, R⁸⁶, R⁸⁷, R⁸⁸, R⁸⁹, R⁹⁰, R⁹¹, R⁹², R⁹³, R⁹⁴, R⁹⁵, R⁹⁶, R⁹⁷, R⁹⁸, R⁹⁹ and R¹⁰⁰ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

Preferably X⁵ is a direct bond, —O—, —NR⁸²—, —CO—, —COO—, —CONR⁸³—, NR⁸⁴CO—, —NR⁸⁷SO₂— (wherein R⁸², R⁸³, R⁸⁴, and R⁸⁷ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyethyl).

Advantageous values for R¹ in group (c) are C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, cyano, nitro, halo and hydroxy.

Preferred values for R¹ in group (c) are C₁₋₂alkyl, C₁₋₂alkoxy, cyano, nitro, halo and hydroxy.

More preferred values for R¹ in group (c) are methyl, methoxy, nitro, fluoro, chloro, bromo and hydroxy.

Particular values for R¹ in group (c) are methoxy, nitro, fluoro, chloro, bromo and hydroxy.

In one aspect of the invention preferably R¹ is selected from halo, nitro, C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkenyl, C₂₋₄alkynyl and hydrogen.

In another aspect of the invention preferably R¹ is selected from C₁₋₄alkoxy, halo, nitro or R¹ is X⁵—R⁸¹ wherein X⁵ is a direct bond, —NH—, —NHCO—, —SO—, —SO₂—, —NHSO₂— and R⁸¹ is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl or R¹ is —X⁶—R¹⁰¹ wherein —X⁶ is —CO— and R¹⁰¹ is phenyl substituted by halo.

In a further aspect of the invention preferably R¹ is selected from fluoro and chloro.

In an additional aspect of the invention, preferably R¹ is not hydrogen.

Preferably n is 1.

A preferred value for A-B in group (g) is NHCO.

Advantageous values for ring C in group (a) are:

phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl is substituted as defined hereinbefore.

More advantageous values for ring C in group (a) are:

phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl is substituted on carbon at the position para to the position of A-B attachment by a group selected from cyano, trifluoromethyl, nitro, trifluoromethoxy, trifluoromethylsulphanyl and a group P² (wherein A-B and P² are as defined hereinbefore).

Preferred values for ring C in group (a) are:

phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl is substituted on carbon at the position para to the position of A-B attachment by a group selected from cyano, trifluoromethyl, nitro and a group P² (wherein A-B and P² are as defined hereinbefore).

More preferred values for ring C in group (a) are:

phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl is substituted on carbon at the position para to the position of A-B attachment by a group P² (wherein A-B and P² are as defined hereinbefore).

A particular value for ring C in group (a) is phenyl which is substituted as defined hereinbefore.

A more particular value for ring C in group (a) is phenyl which is substituted on carbon at the position para to the position of A-B attachment by a group P² (wherein A-B and P² are as defined hereinbefore).

Advantageous values for ring C in group (b) are:

-   (i) phenyl or pyridyl wherein said phenyl or pyridyl is     unsubstituted except by (R¹)_(n) wherein R¹ and n are as defined     hereinbefore; -   (ii) a carbon-linked triazine optionally substituted on a ring     carbon at a position para to A-B attachment by 1 substituent     selected from P¹, P², P³ and P⁴, wherein A-B, P¹, P², P³ and P⁴ are     as defined hereinbefore; -   (iii) a 6-membered carbon-linked heteroaryl group containing 1-3     nitrogen atoms wherein one or more ring nitrogen atoms are oxidised     to form the N-oxide, which heteroaryl group is optionally     substituted at a position para to A-B attachment by 1 substituent     selected from P¹, P², P³ and P⁴, wherein A-B, P¹, P², P³ and P⁴ are     as defined hereinbefore; -   (iv) phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl     is substituted at a position para to A-B attachment by 1 substituent     selected from P³ and P⁴, wherein A-B, P³ and P⁴ are as defined     hereinbefore; and -   (v) phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl     is substituted at any of the positions meta or para to A-B     attachment by 2-3 substituents selected from P¹, P², P³ and P⁴,     provided that if one or more of the substituents is P¹ or P² then at     least one of the other substituents is P⁴, wherein A-B, P¹, P², P³     and P⁴ are as defined hereinbefore.

More advantageous values for ring C in group (b) are:

-   (i) phenyl or pyridyl wherein said phenyl or pyridyl is     unsubstituted except by (R¹)_(n) wherein R¹ and n are as defined     hereinbefore; -   (ii) a 6-membered carbon-linked heteroaryl group containing 1-3     nitrogen atoms wherein one or more ring nitrogen atoms are oxidised     to form the N-oxide, which heteroaryl group is optionally     substituted at a position para to A-B attachment by 1 substituent     selected from P¹, P², P³ and P⁴, wherein A-B, P¹, P², P³ and P⁴ are     as defined hereinbefore; and -   (iii) phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl     is substituted at a position para to A-B attachment by 1 substituent     selected from P³ and P⁴, wherein A-B, P³ and P⁴ are as defined     hereinbefore.

Preferred values for ring C in group (b) are:

-   (i) phenyl or pyridyl wherein said phenyl or pyridyl is     unsubstituted except by (R¹)_(n) wherein R¹ and n are as defined     hereinbefore; and -   (ii) phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl     is substituted at a position para to A-B attachment by 1 substituent     selected from P³ and P⁴, wherein A-B, P³ and P⁴ are as defined     hereinbefore.

More preferred values for ring C in group (b) are:

-   (i) phenyl or pyridyl wherein said phenyl or pyridyl is     unsubstituted except by (R¹)_(n) wherein R¹ and n are as defined     hereinbefore; -   (ii) phenyl or carbon-linked pyridyl wherein said phenyl or pyridyl     is substituted at a position para to A-B attachment by —Y²Ar²     wherein A-B, Y² and Ar² are as defined hereinbefore.

A particular value for ring C in group (b) is phenyl wherein said phenyl is substituted at a position para to A-B attachment by —Y²Ar² wherein A-B, Y² and Ar² are as defined hereinbefore.

In an further feature of the invention preferably ring C is phenyl substituted by one group selected from P⁴ wherein P⁴ is as defined above.

More preferably ring C is phenyl substituted at a position para to A-B by a group selected from:

-   1) —X¹—R⁵ wherein X¹ is a direct bond, —O—, —S—, —SO—, —SO₂—, —NR⁶—     or —CONR⁷— (wherein R⁶ and R⁷ each independently represents hydrogen     or C₁₋₄alkyl which C₁₋₄alkyl may be optionally substituted by one or     more groups selected from hydroxy or C₁₋₆alkoxy) and R⁵ is selected     from hydrogen and C₁₋₆alkyl, which C₁₋₆alkyl, is optionally     substituted with one or more groups selected from hydroxy and     C₁₋₆alkoxy and hydroxyC₁₋₆alkyl with the proviso that —X¹—R⁵ is not     hydroxy, C₁₋₄alkyl or C₁₋₄alkoxy; -   2) —X¹—C₁₋₆alkyl-X²—R²¹ wherein X¹ is a direct bond, —O—, —S—, —SO—,     —SO₂—, —NR⁶— or —CONR⁷— (wherein R⁶ and R⁷ each independently     represents hydrogen or C₁₋₄alkyl which C₁₋₄alkyl may be optionally     substituted by one or more groups selected from hydroxy or     C₁₋₆alkoxy), X² is a direct bond, —O—, —S—, —SO—, —SO₂—, —NR²²— or     —CONR²³— (wherein R²² and R²³ each independently represents hydrogen     or C₁₋₄alkyl which C₁₋₄alkyl may be optionally substituted by one or     more groups selected from hydroxy or C₁₋₆alkoxy) and R²¹ is hydrogen     or C₁₋₄alkyl, which C₁₋₄alkyl is optionally substituted with one or     more groups selected from hydroxy or C₁₋₆alkoxy or R²¹ is R⁴¹     wherein R⁴¹ is as defined hereinbefore with the proviso that     —X¹—C₁₋₆alkyl-X²—R²¹ is not C₁₋₄alkyl or C₁₋₄alkoxy; -   3) —Y²Ar² wherein Y² is X¹ wherein X¹ is a direct bond, —O—, —S—,     —SO—, —SO₂—, —NR⁶— or —CONR⁷— (wherein R⁶ and R⁷ each independently     represents hydrogen or C₁₋₄alkyl which C₁₋₄alkyl may be optionally     substituted by one or more groups selected from hydroxy or     C₁₋₆alkoxy) and Ar² is as defined hereinbefore.

Advantageously when selected from group (e) R² and R³ are independently C₁₋₃alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro, wherein k is the number of carbon atoms in the said C₁₋₃alkyl, provided that R² and R³ are not both methyl; or

R² and R³, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted by from 1 to 4 fluorine atoms.

Preferably when selected from group (e) R² and R³ are independently C₁₋₃alkyl optionally substituted by from 1 to 2k+1 fluorine atoms, wherein k is the number of carbon atoms in the said C₁₋₃alkyl, provided that R² and R³ are not both methyl; or

R² and R³, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted by from 1 to 4 fluorine atoms.

More preferably when selected from group (e) R² and R³ are independently methyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl and perfluoroethyl provided that R² and R³ are not both methyl; or

R² and R³, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted by from 1 to 4 fluorine atoms.

Particularly when selected from group (e) R² and R³ are independently methyl, fluoromethyl, difluoromethyl and trifluoromethyl, provided that R² and R³ are not both methyl; or

R² and R³, together with the carbon atom to which they are attached, form a cyclopropane ring optionally substituted by from 1 to 4 fluorine atoms.

Advantageously when selected from group (f) R² and R³ are both methyl or one of R² and R³ is hydrogen or halo and the other is halo or C₁₋₃alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is the number of carbon atoms in the said C₁₋₃alkyl, with the proviso that when either R² or R³ is halo R⁴ is not hydroxy and with the proviso that when either R² or R³ is hydrogen, R⁴ is not hydrogen.

More advantageously when selected from group (f) R² and R³ are both methyl or one of R² and R³ is hydrogen or chloro and the other is chloro or methyl with the proviso that when either R² or R³ is chloro R⁴ is not hydroxy and with the proviso that when either R² or R³ is hydrogen, R⁴ is not hydrogen.

Preferably when selected from group (f) R² and R³ are both methyl or both chloro with the proviso that when R² and R³ are both chloro R⁴ is not hydroxy.

More preferably when selected from group (f) R² and R³ are both methyl.

Preferably when selected from group (j) R⁴ is hydrogen.

Where applicable, the R-configuration generally represents a preferred stereochemistry for compounds of formula (I).

Preferably R¹ is selected from group (c) as defined hereinbefore.

Preferably A-B is selected from group (g) as defined hereinbefore.

Preferably R⁴ is selected from group (i) as defined hereinbefore.

In another aspect of the invention, preferably R⁴ is hydroxy, hydrogen or methyl.

Advantageously ring C is selected from the following values from group (a):

phenyl substituted at the position para to the position of A-B attachment by —Y¹Ar¹ wherein Y¹ is —SO— or —SO₂— and Ar¹ is phenyl or 3-pyridyl which phenyl or 3-pyridyl is optionally substituted as defined hereinbefore;

or from the following values from group (b):

-   (i) phenyl unsubstituted except by (R¹)_(n) wherein R¹ and n are as     defined hereinbefore; and -   (ii) phenyl substituted at the position para to A-B attachment by 1     substituent selected from P³ and P⁴ wherein P³ and P⁴ are as defined     hereinbefore.

More advantageously ring C is selected from the following values from group (a):

phenyl substituted at the position para to the position of A-B attachment by —Y¹Ar¹ wherein Y¹ is —SO— or —SO₂— and Ar¹ is phenyl or 3-pyridyl which phenyl or 3-pyridyl is optionally substituted as defined hereinbefore;

or from the following values from group (b):

-   (i) phenyl unsubstituted except by (R¹)_(n) wherein R¹ and n are as     defined hereinbefore; and -   (ii) phenyl substituted at the position para to A-B attachment by 1     substituent selected from halo and P⁴ wherein P⁴ is selected from     the three following groups: -   1) halosulphonyl, cyanosulphanyl; -   2) —X¹—R⁵ wherein X¹ and R⁵ are as defined hereinbefore with the     proviso that P⁴ is not trifluoromethyl, trifluoromethoxy,     trifluoromethylsulphanyl, hydroxy, C₁₋₄alkyl, haloC₁₋₄alkyl,     C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; and -   3) —Y²Ar² wherein Y² and Ar² are as defined hereinbefore.

Preferably ring C is selected from the following values from group (a):

phenyl substituted at the position para to the position of A-B attachment by —Y¹Ar¹ wherein Y¹ is —SO— or —SO₂— and Ar¹ is phenyl or 3-pyridyl which phenyl or 3-pyridyl is optionally substituted as defined hereinbefore;

or from the following values from group (b):

-   (i) phenyl unsubstituted except by (R¹)_(n) wherein R¹ and n are as     defined hereinbefore; and -   (ii) phenyl substituted at the position para to A-B attachment by 1     substituent selected from halo and P⁴ wherein P⁴ is selected from     the three following groups: -   1) halosulphonyl; -   2) —X¹—R⁵ wherein X¹ and R⁵ are as defined hereinbefore with the     proviso that P⁴ is not trifluoromethyl, trifluoromethoxy,     trifluoromethylsulphanyl, hydroxy, C₁₋₄alkyl, haloC₁₋₄alkyl,     C₁₋₄alkoxy, haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; and -   3) —Y²Ar² wherein either -   (i) Ar² is phenyl or 3-pyridyl wherein said phenyl or pyridyl is     substituted at carbon with 1-4 substituents selected from Q¹ and Q²     including at least one substituent selected from Q² wherein Q¹ and     Q² are as defined hereinbefore, and Y² is —S—, —SO—, —SO₂— or     —CONR⁷— wherein R⁷ is hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl; or -   (ii) Ar² is phenyl or 3-pyridyl wherein said phenyl or pyridyl is     substituted at carbon with 1-4 substituents selected from Q¹ wherein     Q¹ is as defined hereinbefore and Y² is —S— or —CONR⁷— wherein R⁷ is     hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl.

Preferably R² and R³ are selected from the following values from group (e):

-   R² and R³ are independently methyl, fluoromethyl, difluoromethyl and     trifluoromethyl, provided that R² and R³ are not both methyl; or -   R² and R³ are selected from the following values from group (f): -   R² and R³ are both methyl.

More preferably one of R² and R³ is trifluoromethyl and the other is methyl or both R² and R³ are methyl.

In one aspect of the invention preferably R² and R³ are independently C_(k)alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is 1-3,

or R² and R³ together with the carbon atom to which they are attached, form a 3-membered cycloalkyl ring.

In another aspect of the invention preferably R² and R³ are independently C_(k)alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is 1-3.

According to a further aspect of the present invention there are provided compounds of the formula (I), as defined hereinbefore,

-   and salts thereof; and pharmaceutically acceptable in vivo cleavable     prodrugs of said compound of formula (I); and pharmaceutically     acceptable salts of said compound or said prodrugs; but excluding     the following compounds:     2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide;     2-hydroxy-N-(2-methylphenyl)-2-methylpropanamide;     2-hydroxy-N-(2-methylphenyl)propanamide;     N-(2,4-dimethylphenyl)-2-hydroxypropanamide;     N-(2,5-dimethylphenyl)-2-hydroxypropanamide;     N-(2,6-dimethylphenyl)-2-hydroxypropanamide;     N-(2-chlorophenyl)-2-hydroxypropanamide;     2-hydroxy-N-(2-methoxyphenyl)propanamide;     N-(2,5-dimethoxyphenyl)-2-hydroxypropanamide;     N-(2-ethoxyphenyl)-2-hydroxypropanamide;     N-(2,5-dimethoxyphenyl)-2-hydroxy-2-methylpropanamide;     N-(2-ethoxyphenyl)-2-hydroxy-2-methylpropanamide;     3-chloro-N-(2,5-dichlorophenyl)-2-hydroxy-2-methylpropanamide;     3-chloro-N-(2,4-dichlorophenyl)-2-hydroxy-2-methylpropanamide;     N-(2,3-dichloro-5-nitrophenyl)-2-hydroxy-2-methylpropanamide;     2-hydroxy-2-methyl-N-(2,3,4-trichlorophenyl)propanamide;     1-(2,5-dihydroxyphenyl)-3-hydroxy-3-methylbut-1-ene;     1-(2,4-dichlorophenyl)-3-hydroxy-4,4,4-trifluoro-3-trifluoromethylbut-1-ene;     2-hydroxy-N-(5-methoxycarbonyl-2-methylphenyl)-2-methylpropylamine;     1-(2,6-dimethoxyphenoxy)-2-isopropylpropan-2-ol;     1-(2,6-dimethoxyphenoxy)-2-methylpentan-2-ol;     1-(2,6-dimethoxyphenoxy)-2-methylbutan-2-ol;     1-(2,5-dimethoxyphenoxy)-2-methylpentan-2-ol;     1-(2,4-dimethoxyphenoxy)-2-methylpentan-2-ol;     1-(2,3-dimethoxyphenoxy)-2-methylpentan-2-ol;     1-(2,6-dimethoxyphenoxy)-2-ethylbutan-2-ol;     2-ethyl-1-(2-methylphenoxy)butan-2-ol;     1-(2-[2-ethyl-2-hydroxybutoxy]phenoxy)-2-ethylbutan-2-ol;     2-ethyl-1-(2-methoxyphenoxy)butan-2-ol;     1-(2-methoxyphenoxy)-2-methylbutan-2-ol and     2-ethyl-1-(2-methoxyphenoxy)pentan-2-ol; for use as medicaments.

According to a further aspect of the present invention there are provided compounds of the formula (I), as defined hereinbefore, with the provisos that:

-   (i) ring C bears a group other than hydrogen at the position para to     A-B attachment; -   (ii) when A-B is —COCH₂—, —SCH₂—, —OCH₂—, trans-vinylene or     ethynylene, ring C does not have an oxygen atom linked at a position     ortho to A-B attachment; -   (iii) when A-B is ethynylene, ring C does not have fluorine atoms     linked at both of the positions ortho to A-B attachment; -   (iv) when A-B is trans-vinylene, ring C does not bear methyl groups     at both of the positions ortho to A-B attachment, and does not bear     a formyl group at a position ortho to A-B attachment; -   (v) when A-B is —COCH₂—, ring C does not bear methyl groups at both     of the positions ortho to A-B attachment; -   (vi) when A-B is —OCH₂—, ring C does not have chlorine atoms linked     at both of the positions ortho to A-B attachment and does not bear     nitro groups at both of the positions ortho to A-B attachment; -   (vii) when A-B is —NHCH₂—, ring C does not bear two nitro groups at     positions ortho and para to A-B attachment and does not bear two     methyl groups at positions meta and para to A-B attachment; and -   (viii) when A-B is —SCH₂—, ring C does not simultaneously bear an     amino group at a position ortho to A-B attachment and a nitro group     at the position para to A-B attachment; and excluding the following     compounds: N-(4-chloro-2-nitrophenyl)-2-hydroxy-2-methylpropanamide;     N-(4,5-dichloro-2-(2-hydroxy-2-methylpropanamido)phenyl)-2-hydroxy-2-methylpropanamide;     N-(4-chloro-2-benzoylphenyl)-2-hydroxy-2-methylpropanamide;     N-(2,4-dimethylphenyl)-2-hydroxypropanamide;     3-chloro-N-(2,4-dichlorophenyl)-2-hydroxy-2-methylpropanamide;     2-hydroxy-2-methyl-N-(2,3,4-trichlorophenyl)propanamide;     1-(2,4-dichlorophenyl)-3-hydroxy-4,4,4-trifluoro-3-trifluoromethylbut-1-ene;     1-(4-bromo-2-fluorophenyl)-3-hydroxy-3-methylbut-1-yne;     1-(2-fluoro-4-pent-1-enylphenyl)-3-hydroxy-3-methylbut-1-yne;     1-(4-[3-hydroxy-3-methylbut-1-yn-1-yl]-2-phenylphenyl)-3-hydroxy-3-methylbut-1-yne;     1-(2-fluoro-4-pentoxyphenyl)-3-hydroxy-3-methylbut-1-yne;     1-(2-fluoro-4-trifluoromethylphenyl)-3-hydroxy-3-methylbut-1-yne;     1-(2,5-dimethyl-4-[3-hydroxy-3-methylbut-1-yn-1-yl]phenyl)-3-hydroxy-3-methylbut-1-yne;     1-(2,4-di[3-hydroxy-3-methylbut-1-yn-1-yl]phenyl)-3-hydroxy-3-methylbut-1-yne;     3-hydroxy-3-methyl-1-(2,4,5-tri[3-hydroxy-3-methylbut-1-yn-1-yl]phenyl)but-1-yne;     3-hydroxy-3-methyl-1-(2,3,4,5-tetra[3-hydroxy-3-methylbut-1-yn-1-yl]phenyl)but-1-yne     and     3-hydroxy-3-methyl-1-(2,3,4,5,6-penta[3-hydroxy-3-methylbut-1-yn-1-yl]phenyl)but-1-yne;     and salts thereof; -   and pharmaceutically acceptable in vivo cleavable prodrugs of said     compound of formula (I); -   and pharmaceutically acceptable salts of said compound or said     prodrugs.

According to a further aspect of the present invention there are provided compounds of the formula (I), as defined hereinbefore, wherein A-B is —NHCO— and with the proviso that ring C bears a group other than hydrogen at the position para to A-B attachment and excluding the following compounds: N-(4-chloro-2-nitrophenyl)-2-hydroxy-2-methylpropanamide; N-(4,5-dichloro-2-(2-hydroxy-2-methylpropanamido)phenyl)-2-hydroxy-2-methylpropanamide; N-(4-chloro-2-benzoylphenyl)-2-hydroxy-2-methylpropanamide; N-(2,4-dimethylphenyl)-2-hydroxypropanamide; 3-chloro-N-(2,4-dichlorophenyl)-2-hydroxy-2-methylpropanamide and 2-hydroxy-2-methyl-N-(2,3,4-trichlorophenyl)propanamide; and salts thereof;

-   and pharmaceutically acceptable in vivo cleavable prodrugs of said     compound of formula (I); -   and pharmaceutically acceptable salts of said compound or said     prodrugs.

According to a further aspect of the present invention there is provided the use of compounds of the formula (I):

wherein:

-   ring C is as defined in (a) or (b); -   R¹ is as defined in (c) or (d); -   n is 1 or 2; -   R² and R³ are as defined in (e) or (f); -   A-B is as defined in (g) or (h) and -   R⁴ is as defined in (i) or (j)     wherein

(a) ring C is phenyl or carbon-linked heteroaryl selected from pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl; wherein said phenyl or heteroaryl is substituted on carbon at one or both positions meta to the position of A-B attachment or on carbon at the position para to the position of A-B attachment by P¹ or P² (wherein P¹ and P² are as defined hereinafter), and further, wherein said phenyl or heteroaryl is optionally substituted on carbon at any remaining meta position(s) or para position by P¹ or P³, (wherein P¹ and P³ are as defined hereinafter);

(b) ring C is selected from the following five groups:

-   (i) phenyl or carbon-linked heteroaryl selected from pyridyl,     pyrazinyl, pyrimidinyl and pyridazinyl wherein said phenyl or     heteroaryl is unsubstituted except by (R¹)_(n) wherein R¹ and n are     as defined hereinafter; -   (ii) a carbon-linked triazine optionally substituted on a ring     carbon at a position meta or para to A-B attachment by 1 substituent     selected from P¹, P², P³ and P⁴, wherein P¹, P², P³ and P⁴ are as     defined hereinafter; -   (iii) a 6-membered carbon-linked heteroaryl group containing 1-3     nitrogen atoms wherein one or more ring nitrogen atoms are oxidised     to form the N-oxide, which heteroaryl group is optionally     substituted at any of the positions meta or para to A-B attachment     by 1-3 substituents selected from P¹, P², P³ and P⁴, wherein P¹, P²,     P³ and P⁴ are as defined hereinafter; -   (iv) phenyl or carbon-linked heteroaryl selected from pyridyl,     pyrazinyl, pyrimidinyl and pyridazinyl, wherein said phenyl or     heteroaryl is substituted at a position meta or para to A-B     attachment by 1 substituent selected from P³ and P⁴, wherein P³ and     P⁴ are as defined hereinafter; and -   (v) phenyl or carbon-linked heteroaryl selected from pyridyl,     pyrazinyl, pyrimidinyl and pyridazinyl, wherein said phenyl or     heteroaryl is substituted at any of the positions meta or para to     A-B attachment by 2-3 substituents selected from P¹, P², P³ and P⁴,     provided that if one or more of the substituents is P¹ or P² then at     least one of the other substituents is P⁴, wherein P¹, P², P³ and P⁴     are as defined hereinafter; -   P¹ is cyano, trifluoromethyl, nitro, trifluoromethoxy or     trifluoromethylsulphanyl;     -   P² is —Y¹Ar¹, wherein Ar¹ is selected from the group consisting         of phenyl, a carbon-linked 6-membered heteroaryl ring containing         1-2 nitrogen atoms and a carbon-linked 5-membered heteroaryl         ring containing 1-2 heteroatoms selected independently from O, N         and S, wherein said phenyl or heteroaryl ring is optionally         substituted at carbon, with 1-4 substituents selected from Q¹,         wherein Q¹ is as defined hereinafter; and Y¹ is selected from         —CO—, —SO— and —SO₂—;     -   P³ is C₁₋₄alkyl, haloC₂₋₄alkyl, C₁₋₄alkoxy, haloC₂₋₄alkoxy,         C₂₋₄alkenyloxy, halo or hydroxy;     -   P⁴ is selected from the following five groups: -   1) halosulphonyl, cyanosulphanyl; -   2) —X¹—R⁵ wherein X¹ is a direct bond, —O—, —S—, —SO—, —SO₂—, —NR⁶—,     —CO—, —COO—, —OCO—, —CONR⁷—, —NR⁸CO—, —OCONR⁹—, —CONR¹⁰SO₂—,     —NR¹¹SO₂—, —CH₂—, —NR¹²COO—, —CSNR¹³—, —NR¹⁴CS—, —NR¹⁵CSNR¹⁶—,     NR¹⁷CONR¹⁸— or —NR¹⁹CONR²⁰SO₂— (wherein R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹,     R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰ each independently     represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁵ is     selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl and     C₂₋₆alkynyl which C₁₋₆alkyl, C₃₋₇cycloalkyl, C₂₋₆alkenyl or     C₂₋₆alkynyl is optionally substituted with one or more groups     selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl, carboxy,     C₁₋₆alkoxy and hydroxyC₁₋₆alkyl with the proviso that P⁴ is not     trifluoromethyl, trifluoromethoxy, trifluoromethylsulphanyl,     hydroxy, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy or     C₂₋₄alkenyloxy; -   3) —X¹—C₁₋₆alkyl-X²—R²¹ wherein X¹ is as defined hereinbefore, X² is     a direct bond, —O—, —S—, —SO—, —SO₂—, —NR²²—, —CO—, —COO—, —OCO—,     —CONR²³—, —NR²⁴CO—, —NR²⁵COO—, —SO₂NR²⁶—, —NR²⁷SO₂—, —CH₂—,     —SO₂NR²⁸CO—, —OCONR²⁹—, —CSNR³⁰—, —NR³¹CS—, —NR³²CSNR³³—,     —NR³⁴CONR³⁵—, —CONR³⁶SO₂—, —NR³⁷CONR³⁸SO₂— or —SO₂NR³⁹CONR⁴⁰—     (wherein R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³², R³³,     R³⁴, R³⁵, R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰, each independently represents     hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²¹ is hydrogen,     C₁₋₄alkyl or R⁴¹ wherein R⁴¹ is phenyl or a 4-12 membered     heterocyclic moiety containing 1-4 heteroatoms selected     independently from O, N and S which heterocyclic moiety may be     aromatic or non-aromatic and which phenyl or heterocyclic moiety is     optionally substituted by 1-6 substituents selected from Q³ wherein     Q³ is as defined hereinafter; -   4) —X¹—C₃₋₇cycloalkyl-X²—R²¹ wherein X¹, X² and R²¹ are as defined     hereinbefore; and -   5) —Y²Ar² wherein Y² is X¹ wherein X¹ is as defined hereinbefore and     Ar² is selected from the following four groups: -   (i) phenyl, a carbon-linked 6-membered heteroaryl ring containing     1-2 nitrogen atoms and a carbon-linked 5-membered heteroaryl ring     containing 1-2 heteroatoms selected independently from O, N and S,     wherein said phenyl or heteroaryl ring is substituted at carbon,     with 1-4 substituents selected from Q¹ and Q² including at least one     substituent selected from Q² wherein Q¹ and Q² are as defined     hereinafter; -   (ii) a carbon-linked triazine or a carbon-linked 5-membered     heteroaryl ring containing 3-4 heteroatoms selected independently     from O, N and S; wherein said heteroaryl ring is optionally     substituted with 1-4 substituents selected from Q¹ and Q² wherein Q¹     and Q² are as defined hereinafter; -   (iii) a 4-12 membered non-aromatic heterocyclic moiety containing     1-4 heteroatoms selected independently from O, N and S wherein said     heterocyclic moiety is optionally substituted with 1-6 substituents     selected from Q³ wherein Q³ is as defined hereinafter, with the     proviso that if Ar² is a nitrogen linked heterocyclic ring Y² is not     —SO₂—; and -   (iv) Ar¹ with the proviso that if Ar² has a value Ar¹ then Y² is not     —CO—, —SO— or —SO₂—; -   Q¹ is C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy,     C₂₋₄alkenyloxy, cyano, nitro, halo or trifluoromethylsulphanyl; -   Q² is selected from the following seven groups: -   1) oxygen (forming an oxo group when linked to a ring carbon and     forming an N-oxide when a ring nitrogen is oxidised); -   2) halosulphonyl, cyanosulphanyl; -   3) —X³—R⁵ wherein X³ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —NR⁴²—, —CO—, —COO—, —OCO—, —CONR⁴³—, —NR⁴⁴CO—, —NR⁴⁵COO—,     —SO₂NR⁴⁶—, —NR⁴⁷SO₂—, —CH₂—, —SO₂NR⁴⁸CO—, —OCONR⁴⁹—, —CSNR⁵⁰—,     —NR⁵¹CS—, —NR⁵²CSNR⁵³—, —NR⁵⁴CONR⁵⁵—, —CONR⁵⁶SO₂—, —NR⁵⁷CONR⁵⁸SO₂—     or —SO₂NR⁵⁹CONR⁶⁰— (wherein R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹,     R⁵⁰, R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹ and R⁶⁰ each     independently represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl)     and R⁵ is as defined hereinbefore but with the proviso that Q² is     not trifluoromethylsulphanyl, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy,     haloC₁₋₄alkoxy or C₂₋₄alkenyloxy; -   4) R⁴¹ wherein R⁴¹ is as defined hereinbefore; -   5) —X³—C₁₋₆alkyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore; -   6) —X³—C₃₋₇cycloalkyl-X²—R²¹ wherein X³, X² and R²¹ are as defined     hereinbefore; and -   7) —X³—R⁴¹ wherein R⁴¹ and X³ are as defined hereinbefore; -   Q³ is selected from the following four groups: -   1) oxygen (forming an oxo group when linked to a ring carbon and     forming an N-oxide when a ring nitrogen is oxidised); -   2) cyano, nitro or halo; -   3) halosulphonyl, cyanosulphanyl; and -   4) —X⁴—R⁶¹ wherein X⁴ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —NR⁶²—, —CO—, —COO—, —OCO—, —CONR⁶³—, —NR⁶⁴CO—, —NR⁶⁵COO—,     —SO₂NR⁶⁶—, —NR⁶⁷SO₂—, —CH₂—, —SO₂NR⁶⁸CO—, —OCONR⁶⁹—, —CSNR⁷⁰—,     —NR⁷¹CS—, —NR⁷²CSNR⁷³—, —NR⁷⁴CONR⁷⁵—, —CONR⁷⁶SO₂—, —NR⁷⁷CONR⁷⁸SO₂—     or —SO₂NR⁷⁹CONR⁸⁰— (wherein R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶, R⁶⁷, R⁶⁸, R⁶⁹,     R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, R⁷⁸, R⁷⁹ and R⁸⁰ each     independently represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl)     and R⁶¹ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl,     C₂₋₆alkenyl and C₂₋₆alkynyl which C₁₋₆alkyl, C₃₋₇cycloalkyl,     C₂₋₆alkenyl or C₂₋₆alkynyl is optionally substituted with one or     more groups selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl,     carboxy, C₁₋₆alkoxy and hydroxyC₁₋₆alkyl;

(c) R¹ is linked to ring C at a carbon ortho to the position of A-B attachment and is selected from the group consisting of C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy, C₂₋₄alkenyloxy, cyano, nitro, halo, trifluoromethylsulphanyl and hydroxy;

(d) R¹ is linked to ring C at a ring carbon atom ortho to the position of A-B attachment and is selected from the following two groups:

-   1) —X⁵—R⁸¹ wherein X⁵ is a direct bond, —O—, —S—, —SO—, —SO₂—,     —NR⁸²—, —CO—, —COO—, —OCO—, —CONR⁸³—, —NR⁸⁴CO—, —NR⁸⁵COO—,     —SO₂NR⁸⁶—, —NR⁸⁷SO₂—, —CH₂—, —SO₂NR⁸⁸CO—, —OCONR⁸⁹—, —CSNR⁹⁰—,     —NR⁹¹CS—, —NR⁹²CSNR⁹³—, —NR⁹⁴CONR⁹⁵—, —CONR⁹⁶SO₂—, —NR⁹⁷CONR⁹⁸SO₂—     or —SO₂NR⁹⁹CONR¹⁰⁰— (wherein R⁸², R⁸³, R⁸⁴, R⁸⁵, R⁸⁶, R⁸⁷, R⁸⁸, R⁸⁹,     R⁹⁰, R⁹¹, R⁹², R⁹³, R⁹⁴, R⁹⁵, R⁹⁶, R⁹⁷, R⁹⁸, R⁹⁹ and R¹⁰⁰ each     independently represents hydrogen, C₁₋₄ alkyl or     C₁₋₃alkoxyC₂₋₃alkyl) and R⁸¹ is selected from hydrogen, C₁₋₆alkyl,     C₃₋₇cycloalkyl, C₂₋₆alkenyl and C₂₋₆alkynyl which C₁₋₆alkyl,     C₃₋₇cycloalkyl, C₂₋₆alkenyl or C₂₋₆alkynyl is optionally substituted     with one or more groups selected from hydroxy, amino, halo,     C₁₋₄alkoxycarbonyl, carboxy, C₁₋₆alkoxy and hydroxyC₁₋₆alkyl with     the proviso that R¹ is not trifluoromethylsulphanyl, hydroxy,     C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy or     C₂₋₄alkenyloxy; and -   2) —X⁶—R¹⁰¹ wherein X⁶ is selected from a direct bond, —CO—, —O—,     —OCH₂—, —S—, —SO—, —SO₂— and —NR¹⁰²— (wherein R¹⁰² is hydrogen or     C₁₋₄alkyl) and R¹⁰¹ is phenyl which is optionally substituted by 1-4     substituents selected from cyano, nitro, trifluoromethylsulphanyl,     C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy,     C₂₋₆alkenyloxy, halo, hydroxy and amino;

n is, 1 or 2;

(e) either R² and R³ are independently C₁₋₃alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is the number of carbon atoms in the said C₁₋₃alkyl, provided that R² and R³ are not both methyl;

or R² and R³, together with the carbon atom to which they are attached, form a 3-5 membered cycloalkyl ring optionally substituted by from 1 to 2m−2 fluorine atoms wherein m is the number of carbon atoms in said ring;

(f) R² and R³ are both methyl or one of R² and R³ is hydrogen or halo and the other is halo or C₁₋₃alkyl optionally substituted by from 1 to 2k+1 atoms selected from fluoro and chloro wherein k is the number of carbon atoms in the said C₁₋₃alkyl, with the proviso that when either R² or R³ is halo R⁴ is not hydroxy and with the proviso that when either R² or R³ is hydrogen, R⁴ is not hydrogen;

(g) A-B is selected from —NHCO—, —OCH₂—, —SCH₂—, —NHCH₂—, trans-vinylene, and ethynylene;

(h) A-B is —NHCS— or —COCH₂—;

(i) R⁴ is hydroxy;

(j) R⁴ is hydrogen, halo or methyl;

-   but excluding compounds wherein ring C is selected from (a) and R¹     is selected only from (c) and R² and R³ are selected from (e) and     A-B is selected from (g) and R⁴ is selected from (i); -   and salts thereof; -   and pharmaceutically acceptable in vivo cleavable prodrugs of said     compound of formula (I); -   and pharmaceutically acceptable salts of said compound or said     prodrugs; -   in the manufacture of a medicament for use in the elevation of PDH     activity in warm-blooded animals such as humans.

In a further aspect of the invention there is provided a compound of formula (I′):

wherein:

-   n is 1 or 2; -   R^(a) is chloro, fluoro, bromo, nitro or methoxy; -   R^(b) is C₁₋₆alkyl optionally substituted by one or more groups     selected from hydroxy, amino, halo, C₁₋₄alkoxycarbonyl, carboxy or     C₁₋₆alkoxy or R^(b) is phenyl, a carbon-linked 6-membered heteroaryl     ring containing 1-2 nitrogen atoms or a carbon-linked 5-membered     heteroaryl ring containing 1-3 heteroatoms selected independently     from O, N and S, wherein said phenyl or heteroaryl ring is     substituted by one or more groups selected from i)-iii) and is     optionally further substituted with a group selected from iv): -   i) —X^(a)—R^(c) wherein X^(a) is a direct bond, —O—, —S—, —SO—,     —SO₂—, —NR^(d)— or —CONR^(e)— (wherein R^(d) and R^(e) each     independently represents hydrogen or C₁₋₄alkyl which C₁₋₄alkyl is     optionally substituted with one or more groups selected from hydroxy     or C₁₋₄alkoxy) and R^(c) is selected from hydrogen or C₁₋₆alkyl     which C₁₋₆alkyl is optionally substituted with one or more hydroxy     or C₁₋₄alkoxy with the proviso that —X^(a)—R^(c) is not C₁₋₄alkyl or     C₁₋₄alkoxy; -   ii) a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms     selected independently from O, N and S which heterocyclic moiety may     be aromatic or non-aromatic and is optionally substituted with one     or more groups selected from hydroxy, halo, C₁₋₄alkoxy, C₁₋₄alkyl or     cyano; -   iii) —X^(a)—C₁₋₆alkyl-X^(b)—R^(c) wherein X^(a) and R^(c) are as     defined hereinbefore and X^(b) is —S—, —SO— or —SO₂—; -   iv) cyano, hydroxy, halo, C₁₋₄alkoxy, C₁₋₄alkyl; and -   and salts thereof; -   and pharmaceutically acceptable in vivo cleavable prodrugs of said     compound of formula (I); -   and pharmaceutically acceptable salts of said compound or said     prodrugs.

Preferable values for a compound of formula (I′) are as follows:

Preferably R^(a) is chloro or fluoro.

More preferably R^(a) is chloro.

Preferably R^(b) is C₁₋₄alkyl optionally substituted by one or more hydroxy or R^(b) is phenyl, a carbon-linked 6-membered heteroaryl ring containing 1-2 nitrogen atoms or a carbon-linked 5-membered heteroaryl ring containing 1-2 heteroatoms wherein said phenyl or heteroaryl ring is substituted by one or more groups selected from i)-iii):

-   i) —X^(a)—R^(c) wherein X^(a) is —SO—, —SO₂—, —NR^(d)— or —CONR^(e)—     (wherein R^(d) and R^(e) each independently represents hydrogen or     C₁₋₄alkyl) and R^(c) is selected from hydrogen or C₁₋₆alkyl which     C₁₋₆alkyl is optionally substituted with one or more hydroxy; -   ii) a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms     selected independently from O, N and S which heterocyclic moiety may     be aromatic or non-aromatic; -   iii) —X^(a)—C₁₋₆alkyl-X^(b)—R^(c) wherein X^(a) and R^(c) are as     defined hereinbefore and X^(b) is —S—.

More preferably R^(b) is C₁₋₄alkyl optionally substituted by hydroxy or R^(b) is phenyl wherein said phenyl is substituted by one group selected from i)-iii):

-   i) —X^(a)—R^(c) wherein X^(a) is —SO—, —SO²—, —NR^(d)— or —CONR^(e)—     (wherein R_(d) and R^(e) each independently represents hydrogen or     C₁₋₄alkyl) and R^(c) is selected from hydrogen or C₁₋₄alkyl which     C₁₋₆alkyl is optionally substituted with one or more hydroxy; -   ii) a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms     selected independently from O, N and S which heterocyclic moiety may     be aromatic or non-aromatic; -   iii) —X^(a)—C₁₋₆alkyl-X¹—R¹ wherein X^(a) and R^(c) are as defined     hereinbefore and X^(b) is —S—.

Particularly R^(b) is ethyl, 2-hydroxyethyl, 4-N,N-dimethylcarbamoylphenyl, 4-(2-hydroxyethlyamino)phenyl, 4-methylsulphinylphenyl, 4-mesylphenyl, 4-aminophenyl, 4-(2-oxopyrrolidi-1-yl)phenyl and 4-(2-methylthioethylamino)phenyl.

In one aspect of the invention preferably n is 1.

In another aspect of the invention preferably n is 2.

In one aspect of the invention preferably the group R^(b)—S(O)_(n)— is para to the —NH—C(O)— group.

In another aspect of the invention preferably the group R^(b)—S(O)_(n)— is meta to the —NH—C(O)— group.

Preferably the tertiary centre of formula (I′) —C(OH)(CF₃)(Me) has the R stereochemistry.

Preferred compounds of formula (I) or (I′) are those of Examples 14, 43, 63, 71, 74, 87, 128, 144, 215 and 355 and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs.

Compounds of the present invention include:

-   N-(2,6-dimethylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide. -   N-(2-cyanophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-2-chloro-4-[(2-hydroxy-2-methyl-3,3,3-trifluoropropanamide]phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-2-nitro-4-[(2-hydroxy-2-methyl-3,3,3-trifluoropropanamide]phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-(4-chlorobenzoyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-carboxy-4-(phenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-bromo-2-chlorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2,4-dichlorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-chlorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-fluorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(biphen-2-yl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-acetylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-bromophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   2-hydroxy-2-methyl-N-[2-(phenylsulphonyl)phenyl]-3,3,3-trifluoropropanamide; -   N-(2-methoxyphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-hydroxyphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   (R)-N-(4-bromo-2,6-dichlorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   (R)-N-[2-chloro-4-(phenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   (S)-N-[2-chloro-4-(phenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   (R)-N-[2-fluoro-4-(phenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   (R)-N-(4-bromo-2-methylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-chloro-4-(phenylsulphonyl)phenyl]-2-hydroxypropanamide; -   N-(2-fluoro-4-iodophenyl)-2-hydroxypropanamide; -   N-{4-[(benzyloxycarbonyl)amino]-2-fluorophenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-(hydroxymethyl)-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-benzyl-2-methylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-carbamoyl-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-iodo-2-methoxycarbonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-iodo-2-nitrophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-bromo-4-methoxycarbonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-bromo-2-methylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-chloro-4-(benzoylamino)phenyl]-2-hydroxy-2-methylpropanamide; -   N-2-chloro-4-[(phenylsulphonyl)amino]phenyl-2-hydroxy-2-methylpropanamide; -   N-(4-chloro-2-methoxyphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   2-hydroxy-N-(4-methoxy-2-methylphenyl)-2-methyl-3,3,3-trifluoropropanamide; -   N-(2,3-dimethylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(3-chloro-2-methylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-bromo-2-trifluoromethylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-chloro-2-benzoylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-chloro-2-trifluoromethylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-chloro-2-methylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-chloro-4-mesylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-chloro-4-fluorosulphonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2,4-diiodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-bromo-4-methylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-bromo-4-butylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(2-chloro-4-thiocyanatophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-fluoro-4-(allyloxycarbonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-[2-fluoro-4-{N-[(1,3-diethoxycarbonyl)propyl]carbamoyl}phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide; -   N-(4-amino-2-chlorophenyl)-2-hydroxy-2-methylpropanamide: -   N-[2-chloro-4-(4-aminophenylsulphanyl)phenyl]-2-hydroxy-2-methylpropanamide; -   and Examples 106, 108, 110-113, 149, 151, 171, 173, 197 and 205; -   and salts thereof and pharmaceutically acceptable in vivo cleavable     esters or sulphides of said compounds; and pharmaceutically     acceptable salts of said compounds or esters or sulphides.

Advantageous compounds of the present invention include Examples 184-186 and salts thereof and pharmaceutically acceptable in vivo cleavable esters or sulphides of said compounds; and pharmaceutically acceptable salts of said compounds or esters or sulphides.

Preferred compounds of the present invention include Examples 15, 114, 171, 172 and 182 and salts thereof and pharmaceutically acceptable in vivo cleavable esters or sulphides of said compounds; and pharmaceutically acceptable salts of said compounds or esters or sulphides.

More preferred compounds of the present invention include Examples 14 and 87 and salts thereof and pharmaceutically acceptable in vivo cleavable esters or sulphides of said compounds; and pharmaceutically acceptable salts of said compounds or esters or sulphides.

Particular compounds of the present invention include Examples 1, 2, 13, 16, 54, 86, 104, 212, 213 and 214 and salts thereof and pharmaceutically acceptable in vivo cleavable esters or sulphides of said compounds; and pharmaceutically acceptable salts of said compounds or esters or sulphides.

In another aspect of the invention, preferred compounds of the invention are any one of Examples 1-428 and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs.

Preferred aspects of the invention are those which relate to the compound or a pharmaceutically acceptable salt thereof.

In this specification the term “alkyl” includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only. An analogous convention applies to other generic terms. Unless otherwise stated the term “alkyl” advantageously refers to chains with 1-6 carbon atoms, preferably 1-4 carbon atoms.

In this specification the term “alkoxy” refers to an alkyl group as defined hereinbefore linked to an oxygen atom.

In this specification the term “cycloalkyl” refers to cyclic non-aromatic rings of carbon atoms.

In this specification the term “cycloalkoxy” refers to a cycloalkyl group as defined hereinbefore linked to an oxygen atom.

In this specification the term “halo” includes fluoro, chloro, bromo and iodo unless stated otherwise.

In this specification the term “haloalkyl” includes an alkyl group as defined hereinbefore substituted with one or more halo groups, including for example trifluoromethyl.

In this specification the term “hydroxyalkyl” includes an alkyl group as defined hereinbefore substituted with one or more hydroxy groups.

In this specification the term “aryl” includes C₅₋₁₂aromatic groups which may, if desired and unless otherwise defined, carry one or more substituents selected from halo, alkyl, alkoxy, cyano, nitro or trifluoromethyl (wherein alkyl and alkoxy are as hereinbefore defined). Suitable values for aryl include phenyl and naphthyl.

The term “aryloxy” means an aryl group as defined hereinbefore linked to an oxygen atom. Suitable values for aryloxy include phenoxy and naphth-1-yloxy.

The term “heteroaryl” includes aryl groups, as defined hereinbefore, containing one or more heteroatoms selected from O, N and S.

Suitable values for “a 6-membered carbon-linked heteroaryl group containing 1-3 nitrogen atoms wherein one or more ring nitrogen atoms are oxidised to form the N-oxide” include pyridyl-N-oxide, pyrimidyl-N-oxide and pyrazinyl-N-oxide.

Suitable values for “a carbon-linked 6-membered heteroaryl ring containing 1-2 nitrogen atoms” include pyridyl, pyrimidyl, pyrazinyl and pyridadzinyl.

Suitable values for “a carbon-linked 5-membered heteroaryl ring containing 1-2 heteroatoms selected independently from O, N and S” include furyl, thienyl, pyrrolyl, thiazolyl, isoxazolyl, oxazolyl, imidazolyl and pyrazolyl.

Suitable values for “a carbon-linked 5-membered heteroaryl ring containing 3-4 heteroatoms selected independently from O, N and S” include oxadiazolyl, furazanyl, triazolyl and thiadiazolyl.

Suitable values for a “5-6 membered heterocyclic aromatic ring containing 1-4 heteroatoms selected independently from O, N and S” include furyl, thienyl, pyrrolyl, thiazolyl, isoxazolyl, oxazolyl and pyrazolyl, tetrazolyl, imidazolyl, oxadiazolyl, furazanyl, triazolyl, thiadiazolyl pyridyl, pyrimidyl, pyrazinyl and pyridazinyl.

Suitable values for a “5-7 membered heterocyclic non-aromatic moiety containing 1-2 heteroatoms selected independently from O, N and S” include morpholino, piperazinyl, piperidinyl, homopiperazinyl, oxazolidinyl, thiazolinyl, oxaxolinyl, dihydropyranyl and tetrapyranyl.

Suitable values for “a 5-membered heteroaryl ring containing 1-4 heteroatoms selected independently from O, N and S” include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, triazolyl and tetrazolyl.

Suitable values for “a carbon-linked 5-membered heteroaryl ring containing 1-3 heteroatoms” include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl and triazolyl.

Suitable values for “a 7-12 membered aromatic heterocyclic moiety containing 1-4 heteroatoms selected independently from O, N and S” include indolyl, benzofuryl, benzothienyl, benzimidazolyl, purinyl, quinolinyl and isoquinolinyl.

A “4-12 membered heterocyclic moiety containing 1-4 heteroatoms selected independently from O, N and S which heterocyclic moiety may be aromatic or non-aromatic” is a saturated, partially saturated or unsaturated (including aromatic) mono or bicyclic ring, which may, unless otherwise specified, be carbon or nitrogen linked, and, unless otherwise specified, any (optional) substituents may be substituents on a ring carbon or nitrogen (where said ring is a ring containing an —NH— moiety the substitution thus replacing the hydrogen), wherein a —CH₂— group can optionally be replaced by a —C(O)—, a ring nitrogen atom may optionally bear a C₁₋₆alkyl group and form a quaternary compound or a ring nitrogen and/or sulphur atom may be optionally oxidised to form the N-oxide and or the S-oxides. Examples and suitable values of the term “heterocyclic group” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, oxazolinyl, oxazolidinyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-N-oxide.

A “4-12 membered non-aromatic heterocyclic moiety containing 1-4 heteroatoms selected independently from O, N and S” is as defined in the above paragraph, but excludes those compounds which are fully aromatic.

In this specification “non-aromatic” includes fully saturated rings as well as partially saturated rings but does not include aromatic unsaturated rings.

The term “heterocyclic” includes aromatic and non-aromatic cyclic moieties containing one or more heteroatoms selected from O, N and S.

In this specification unless stated otherwise the term “alkenyl” includes both straight and branched chain alkenyl groups but references to individual alkenyl groups such as 2-butenyl are specific for the straight chain version only. In this specification unless stated otherwise the term “alkynyl” includes both straight and branched chain alkynyl groups but references to individual alkynyl groups such as 2-butynyl are specific for the straight chain version only.

For the avoidance of any doubt, it is to be understood that when X¹ is, for example, a group of formula —NR⁸CO—, it is the nitrogen atom bearing the R⁸ group which is attached to ring C and the carbonyl group is attached to R⁵, whereas when X¹ is, for example, a group of formula —CONR⁷—, it is the carbonyl group which is attached to ring C and the nitrogen atom bearing the R⁷ group is attached to R⁵. When X¹ is —NR¹¹SO₂— it is the nitrogen atom bearing the R¹¹ group which is attached to ring C and the sulphonyl group which is attached to R⁵. Analogous conventions apply to similar groups. When X¹ is —NR⁶— it is the nitrogen atom bearing the R⁶ group which is linked to ring C and to R⁵. When X¹ is —OCO— it is the first oxygen atom which is attached to ring C and the carbonyl group is attached to R⁵. When X¹ is —COO— it is the carbonyl group which is linked to ring C and the other oxygen atom is attached to R⁵. Analogous conventions apply to similar groups. It is further to be understood that when X¹ represents —NR⁶— and R⁶ is C₁₋₃alkoxyC₂₋₃alkyl it is the C₂₋₃alkyl moiety which is linked to the nitrogen atom of X¹ and an analogous convention applies to other groups.

When X³ is —OCONR⁴⁹— it is the first oxygen which is linked to ring Ar² and the carbonyl group while the nitrogen atom is linked to the carbonyl group, R⁴⁹ and R⁵.

When X³ is —NR⁴⁷SO₂— it is the nitrogen atom which is linked to Ar², R⁴⁷ and the sulphonyl group, and it is the sulphonyl group which is linked to R⁵ and analogous conventions apply to similar groups.

For the avoidance of any doubt, it is to be understood that when a group C₅₋₆alkyl carries a C₁₋₄alkoxycarbonyl substituent it is the carbonyl moiety which is attached to C₅₋₆alkyl and an analogous convention applies to other groups.

Within the present invention it is to be understood that a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which elevates PDH activity and is not to be limited merely to any one tautomeric form utilized within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.

It will be appreciated by those skilled in the art that certain compounds of formula (I) contain an asymmetrically substituted carbon and/or sulphur atom, and accordingly may exist in, and be isolated in, optically-active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the elevation of PDH activity, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, (for example WO 9738124), by biotransformation, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the elevation of PDH activity by the standard tests described hereinafter.

In vivo cleavable prodrugs of compounds of formula (I) include for example in vivo hydrolysable esters of compounds of the formula (I) containing a carboxy group, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid, for example, a pharmaceutically acceptable ester formed with a C₁₋₆alcohol such as methanol, ethanol, ethylene glycol, propanol or butanol, or with a phenol or benzyl alcohol such as phenol or benzyl alcohol or a substituted phenol or benzyl alcohol wherein the substituent is, for example, a halo (such as fluoro or chloro), C₁₋₄alkyl (such as methyl) or C₁₋₄alkoxy (such as methoxy) group.

In vivo cleavable prodrugs of compounds of formula (I) also include for example in vivo hydrolysable amides of compounds of the formula (I) containing a carboxy group, for example, a N—C₁₋₆alkyl or N,N-di-C₁₋₆alkyl amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.

It is also to be understood that certain compounds of the formula (I) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which elevate PDH activity.

A compound of the formula (I), or salt thereof, and other compounds of the invention (as hereinafter defined) may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes include, for example, those illustrated in European Patent Applications, Publication Nos. 0524781, 0617010, 0625516, and in GB 2278054, WO 9323358 and WO 9738124.

Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, which process (in which variable groups are as defined for formula (I) unless otherwise stated) comprises of:

-   (a) for compounds of formula (I) where R⁴ is hydroxy: deprotecting a     protected compound of formula (II):     where Pg is an alcohol protecting group; -   (b) for compounds of formula (I) where Y¹, Y² or X¹ is —C(O)—:     oxidising a corresponding alcohol of formula (III):     wherein ring D¹ has any of the values defined hereinbefore for ring     C but in which the place of one of the possible substituents on ring     C is taken by ArCH(OH) and R^(a1) is a group attached to Y¹, Y² or     X¹ (possible valued as defined above); -   (c) for compounds of formula (I) where Y¹, Y² or X¹ is —C(O)—:     deprotecting a corresponding compound of formula (IV):     wherein ring D² has any of the values defined hereinbefore for ring     C but in which the place of one of the possible substituents on ring     C is taken by Ar—C(—O—(CH₂)₃—O—)— and R^(a1) is as defined above; -   (d) for compounds of formula (I) where Ring C has an R^(a2)—CH₂—     substituent attached to it wherein R^(a2) is a group that is     attached via —CH₂— moiety to ring C (possible values as defined     above): reduction of a compound of formula (III) or (V):     wherein ring D¹ has any of the values defined hereinbefore for ring     C but in which the place of one of the possible substituents on ring     C is taken by ArC(O)—; -   (e) for compounds of formula (I) where ring C has a R^(a3)—C(O)—     substituent wherein R^(a3) is and aromatic moiety or alkenyl moiety     (possible values as defined above): treating a compound of formula     (VI):     wherein ring D³ has any of the values defined hereinbefore for ring     C but in which the place of one of the possible substituents on ring     C is taken by G¹ and G¹ is a leaving group; with carbon monoxide and     a tin compound having the formula (R⁶)_(p1)Sn(R^(a3))_(p2) (wherein     R⁶ is C₁₋₄alkyl and p1+p2=4) or an aluminium compound having the     formula (R⁶)_(p3)Al(R^(a3))_(p4) (wherein R⁶ is C₁₋₄alkyl and     p3+p4=3); -   (f) for compounds of formula (I) where Ring C has an R^(a4)S(O)— or     R^(a4)S(O)₂— substituent, R^(a4) is a group attached through a     sulphoxide or sulphone moiety (possible values as defined above) and     A-B is not SCH₂ or NHCH₂: oxidising a compound of formula (VI)     wherein G¹ is R^(a4)S; -   (g) for a compound of formula (I) in which A-B is —NHC(O)—: coupling     compounds of formula (VII):     wherein J is NH₂, with an acid of formula (VIII):     wherein X is OH; -   (h) for a compound of formula (I) in which A-B is —NHC(O)—: coupling     an aniline of formula (VII) wherein J is —NH₂ with an activated acid     derivative of formula (VIII); -   (i) for a compound of formula (I) in which A-B is —NHC(O)— or     —NHC(S)— and R⁴ is hydroxy:     reacting a compound of formula (IX):     wherein X is O or S: with a base to yield the dianion, followed by     treatment of the dianion with oxygen in the presence of a reducing     agent; or by treatment with a peroxyacid; -   (j) for a compound of formula (I) in which A-B is —NHC(O)—: reacting     a compound of formula (VII) wherein J is chloro or fluoro, with an     alkali metal amide anion having formula (X):     wherein M is an alkali metal; -   (k) for a compound of formula (I) that contains no carbonyl     moieties, R⁴ is hydroxy and R²═R³: reacting a compound of formula     (XI):     wherein R⁴ is C₁₋₄ alkyl, with a Grignard reagent of formula R²MgBr     or R²MgCl or an organolithium reagent of formula LiR²; -   (l) for a compound of formula (I) that contains no carbonyl moieties     and R⁴ is hydroxy: reacting a compound of formula (XII):     with a compound of formula R²M wherein M is an alkali metal or a     Grignard compound of formula R²MgBr or R²MgCl; -   (m) for a compound of formula (I) which has an N-linked     sulphonamide, an N-linked N-alkyl sulphonamide or a sulphinate ester     substituent attached to ring C: treating a corresponding compound of     formula (XIII):     wherein ring D³ has any of the values defined hereinbefore for ring     C but in which the place of one of the possible substituents on ring     C is taken by G² wherein G² is amino or hydroxy with a sulphonyl     chloride; -   (n) for a compound of formula (I) in which A-B is ethynylene and R⁴     is not chloro and when R⁴ is hydroxy it is protected: coupling a     corresponding compound of formula (VII) wherein J is a leaving     group, with a corresponding acetylene of formula (XIV): -   (o) for a compound of formula (I) in which A-B is ethynylene and R⁴     is hydroxy: reacting a corresponding alkyne of formula (XV):     wherein Z is hydrogen, with a base, followed by treatment with a     ketone of formula (XVI): -   (p) for a compound of formula (I) in which A-B is trans-vinylene:     reducing a corresponding compound of formula (I) in which A-B is     ethynylene with a suitable reducing agent; -   (q) for a compound of formula (I) in which A-B is trans-vinylene:     dehydration of a compound of formula (XVII): -   (r) for a compound of formula (I) in which A-B is trans-vinylene and     R⁴ is hydroxy: base catalysed opening of an epoxide of formula     (XVIII): -   (s) for a compound of formula (I) in which A-B is —NHCH₂—: reducing     a corresponding compound of formula (I) in which A-B is —NHC(O)—; -   (t) for a compound of formula (I) in which A-B is —OCH₂—, —SCH₂— or     —NHCH₂: reacting an ethylene oxide of formula (XIX):     with a corresponding compound of formula (VII) where J is —OH, —SH     or —NH₂; -   (u) for a compound of formula (I) in which A-B is —NHC(S)—: reacting     a compound of formula (I) in which A-B is —NHC(O)— with a     sulphonating reagent; -   (v) a compound of formula (I) in which ring C is substituted by     ArC(O)— wherein Ar is an aromatic group (possible values as defined     for formula (I) above) and A-B is —NHCO—: by acylation of a compound     of formula (I); -   w) for a compound of formula (I) in which A-B is —C(O)CH₂— and R⁴ is     hydroxy: reacting a ketone of formula (XX)     with a strong base followed by reaction with a ketone of formula     (XVI); -   x) for a compound of formula (I) in which A-B is —C(O)CH₂— and R⁴ is     hydroxy: reaction of a compound of formula (XXI):     wherein R″ is a C₁₋₆alkyl group, with a ketone of formula (XVI); -   y) for a compound of formula (I) in which A-B is —C(O)CH₂—: reaction     of a compound of formula (VII) wherein J is Li with a compound of     formula (XXII): -   z) for a compound of formula (I) in which A-B is —C(O)CH₂—: reaction     of a compound of formula (XXIII):     with a compound of formula (XXIV): -   a1) for compounds of formula (I) where Ring C has an PhS—     substituent: treatment of a compound of formula (VI), wherein G¹ is     a leaving group, with a thiophenol in the presence of a catalyst; -   b1) for compounds of formula (I) where Ring C has an ArS—     substituent wherein Ar as defined above: treating a compound of     formula (VI), wherein G¹ is SH with an aromatic compound containing     a displaceable group, in the presence of a catalyst; -   c1) for compounds of formula (I) where Ring C has an ArS—     substituent wherein Ar is as defined above and A-B is not NHCO:     treating a compound of formula (VI), wherein G¹ is a leaving group     with a compound of formula ArSH in the presence of a base; -   d1) for compounds of formula (I) where ring C has a R^(a2)—NC(O)—     substituent wherein R^(a2) is a group that is attached through an     amide linker (possible values as defined above): treating a compound     of formula (VI) wherein ring D³ has any of the values defined     hereinbefore for ring C but in which the place of one of the     possible substituents on ring C is taken by G¹ and G¹ is a leaving     group; with carbon monoxide and an amine having the formula     —NR^(a2); and -   e1) for compounds of formula (I) where ring C has a R^(a2)—OSO₂—     substituent wherein R^(a2) is a group that is attached through a     sulphinate ester linker (possible values as defined above): treating     a compound of formula (VI) wherein ring D³ has any of the values     defined hereinbefore for ring C but in which the place of one of the     possible substituents on ring C is taken by G¹ and G¹ is a sulphonyl     chloride ClO₂S—; with an alcohol having the formula —OR^(a2); and     thereafter if necessary: -   i) converting a compound of the formula (I) into another compound of     the formula (I); -   ii) removing any protecting groups; or -   iii) forming a pharmaceutically acceptable salt or in vivo     hydrolysable ester.

Examples of reactions to convert a compound of the formula (I) into another compound of the formula (I) are known in the art. By way of illustration these include:

-   (i) formation of a hydroxy as a substituent on an aryl or heteroaryl     group by cleaving the corresponding alkyl ether or acyloxy ester.     Convenient methods include, for example, the cleavage of a methoxy     group using boron tribromide and the cleavage of a tert-butoxy group     using trifluoroacetic acid; and the cleavage of an acetate group     using for example lithium hydroxide in a lower alcohol (such as for     example methanol or ethanol); -   (ii) formation of R⁴ as hydroxy. For example, a compound of     formula (I) where R⁴ is chloro can be prepared by reaction of a     compound of formula (I) in which R⁴ is hydroxy with a reagent such     as thionyl chloride in a suitable solvent such as dichloromethane or     tetrahydrofuran and at a temperature in the range of 0 to 70° C. The     reaction can optionally be carried out in the presence of a catalyst     such as N,N-dimethylformamide.

Pg is an alcohol protecting group suitable values for Pg are groups such as a benzyl groups, silyl groups or a acetyl protecting groups.

When G¹ is a leaving group suitable values are bromo, iodo or triflate.

Where formula (VIII) is an activated acid derivative, suitable values for X include halo (for example chloro or bromo), anhydrides and aryloxys (for example phenoxy or pentafluorophenoxy).

In formula (X) M is an alkali metal, suitable values for M include sodium or lithium. Suitable values for M in formula (XII) include lithium.

In formula (VII) wherein J is a leaving group suitable values are bromo, iodo or triflate.

Specific conditions of the above reactions are as follows:

-   (a) Examples of suitable reagents for deprotecting an alcohol of     formula (II) are: -   1) when Pg is benzyl: -   (i) hydrogen in the presence of palladium/carbon catalyst, i.e.     hydrogenolysis: or -   (ii) hydrogen bromide or hydrogen iodide; -   2) when Pg is a silyl protecting group: -   (i) tetrabutylammonium fluoride; or -   (ii) aqueous hydrofluoric acid; -   3) when Pg is acetyl: -   i) mild aqueous base for example lithium hydroxide.

The reaction can be conducted in a suitable solvent such as ethanol, methanol, acetonitrile, or dimethylsulphoxide and may conveniently be performed at a temperature in the range of −40 to 100° C.

-   (b) These conditions are well known in the art for example suitable     oxidising agents such as pyridinium dichromate and solvents such as     methanol or dichloromethane, may be employed. -   (c) A saturated aqueous acid such as oxalic or a mineral acid such     as hydrochloric acid or sulphuric acid may conveniently be employed     for this deprotection. The reaction may conveniently be performed at     a temperature in the range of 0 to 100° C. in a solvent such as a     lower alcohol (e.g. methanol or ethanol), or mixtures of solvent     pairs such as water/dichloromethane, water/tetrahydrofuran or     water/acetone. -   (d) Reducing agents such as sodium borohydride (for compounds of     formula (V) yielding compounds of formula (III)) and triethylsilane     (for compounds of formula (III)) may be used. A reduction involving     sodium borohydride is conveniently carried out in solvents such as     for example a lower alcohol (e.g. methanol or ethanol) and a     reduction using triethylsilane is conveniently carried out in a     solvent such as trifluoromethylsulphonic acid. -   (e) This reaction with the tin compound is conveniently performed in     the presence of a suitable catalyst such as for example     bis(triphenylphosphine)palladium dichloride, and at a temperature in     the range of 0 to 100° C. and in a solvent such as for example     tetrahydrofuran, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone,     or dimethyl sulphoxide. The reaction with the aluminium compound is     conveniently performed in the presence of a similar catalyst and     temperature and in a solvent such as for example diethyl ether,     benzene, toluene, or tetrahydrofuran. -   (f) Suitable oxidising agents include potassium permanganate, OXONE,     sodium periodate, tert-butyl hydroperoxide (as solution in toluene),     peracids (such as for example 3-chloroperoxybenzoic acid), hydrogen     peroxide, TPAP (tetrapropylammonium perruthenate) or oxygen. The     reaction may be conducted in a suitable solvent such as diethyl     ether, dichloromethane, methanol, ethanol, water, acetic acid, or     mixtures of two or more of these solvents. The reaction may     conveniently be performed at a temperature in the range of −40 to     100° C. -   (g) The reaction can be conducted in the presence of a suitable     coupling reagent. Standard peptide coupling reagents known in the     art can be employed as suitable coupling reagents, for example     dicyclohexyl-carbodiimide, optionally in the presence of a catalyst     such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally     in the presence of a base for example triethylamine, pyridine, or     2,6-di-alkyl-pyridines (such as 2,6-lutidine or     2,6-di-tert-butylpyridine) or 2,6-diphenylpyridine. Suitable     solvents include dimethylacetamide, dichloromethane, benzene,     tetrahydrofuran, and dimethylformamide. The coupling reaction may     conveniently be performed at a temperature in the range of −40 to     40° C. -   (h) This coupling may be achieved optionally in the presence of a     base for example triethylamine, pyridine, 2,6-di-alkyl-pyridines     (such as 2,6-lutidine or 2,6-di-tert-butylpyridine) or     2,6-diphenylpyridine. Suitable solvents include dimethylacetamide,     dichloromethane, benzene, tetrahydrofuran, and dimethylformamide.     The coupling reaction may conveniently be performed at a temperature     in the range of −40 to 40° C. -   (i) Suitable bases to yield a dianion are strong bases such as a     lithium dialkylamides (for example lithium diisopropyl amide).     Suitable reducing agents include triphenylphosphine. Suitable     peroxyacids include 3-chloroperoxybenzoic acid. The reactions may     conveniently be performed at a temperature in the range of −100° C.     to room temperature, in a suitable solvent such as tetrahydrofuran     or diethyl ether. -   (j) The reaction may conveniently be performed at a temperature in     the range of −40 to 100° C. and in a suitable solvent such as     dimethylformamide, DMSO, or tetrahydrofuran. Where R⁴ is hydroxy the     corresponding dianion is formed. -   (k) The reaction may conveniently be performed at a temperature in     the range of −100 to 20° C., preferably at a temperature in the     range of −20 to 20° C., in a suitable solvent such as     tetrahydrofuran or diethyl ether. -   (l) The reaction may conveniently be performed at a temperature in     the range of −100 to 25° C. and in a solvent such as     tetrahydrofuran, diethyl ether, or 1,2-dimethoxyethane. -   (m) The reaction may be conveniently carried out in the presence of     a base such as for example pyridine, triethylamine or potassium     carbonate, at a temperature in the range of 0 to 120° C. in a     suitable solvent such as for example N,N-dimethylformamide, or     acetonitrile. For N-linked N-alkylsulphonamides this is followed by     alkylation with, for example, an alkyl iodide or bromide. The     alkylation reaction may conveniently be performed at a temperature     in the range of 0 to 120° C. in a suitable solvent such as for     example N,N-dimethylformamide, or acetone in the presence of a base     such as for example potassium carbonate. -   (n) The reaction may be conveniently carried out in the presence of     a catalyst such as a combination of cuprous iodide and     bis(triphenyl-phosphine)palladium dichloride or palladium (II)     acetate. The reaction can be conducted in an inert solvent such as     tetrahydrofuran, benzene, or toluene, or in a basic solvent such as     diethylamine (DEA) or triethylamine (TEA), and at a temperature in     the range of −20 to 110° C. -   (o) Suitable bases include lithium diisopropylamide (LDA),     n-butyllithium or tert-butyllithium. The reaction may be performed     at a temperature in the range of −100 to −40° C. preferably at a     temperature in the range of −70 to −40° C. and in a solvent such as     tetrahydrofuran, diethyl ether, or 1,2-dimethoxyethane. -   (p) Suitable reducing agents are, for example, lithium aluminium     hydride or sodium bis(methoxyethoxy)aluminium hydride. The reaction     can be conducted in a suitable solvent such as tetrahydrofuran or     diethyl ether, and at a temperature in the range of 0 to 50° C. -   (q) This reaction may be conveniently performed in the presence of     an acid catalyst (for example p-toluenesulphonic acid), in a solvent     such as toluene or dichloromethane at a temperature in the range of     0 to 200° C. preferably a temperature in the range of 20 to 100° C. -   (r) The opening may be carried out in a suitable organic solvent for     example, ethers or toluene. Ethers such as tetrahydrofuran are     preferred. Suitable bases include potassium tert-butoxide or sodium     hydride. The opening may be carried out at a temperature in the     range of −50 to 100° C., preferably at a temperature in the range of     0 to 50° C. -   (s) Suitable reducing agent include lithium aluminium hydride or     borane. The reaction can conveniently be carried out at a     temperature in the range of 0° C. to reflux, in solvents such as for     example diethyl ether, tetrahydrofuran, or 1,2-dimethoxyethane. -   (t) Where J is —OH or —SH; the reaction may be conveniently carried     out in the presence of a base for example sodium hydride or     triethylamine. The reaction can be conducted at a temperature of     0° C. to reflux in a solvent such as dichloromethane,     tetrahydrofuran, or diethyl ether. Where J is —NH₂; the reaction may     be conveniently carried out by the procedure as described in JOC     (1999), 64, p. 287-289 using copper (I) triflate as a catalyst. -   (u) Suitable sulphonating reagents are for example phosphorus     pentasulphide or Lawesson's reagent     (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide).     The reaction may optionally be carried out in the presence of a     suitable base such as for example pyridine or triethylamine.     Suitable solvents for the reaction include for example toluene,     tetrahydrofuran, 1,3-dioxane or acetonitrile. The reaction is     conveniently performed at a temperature in the range of from 0° C.     to reflux. -   (v) Acylating reagents such as carboxylic acids, or derivatives     thereof, may be employed in the presence of the appropriate     activating reagent such as for example polyphosphoric acid. The     reaction may conveniently be performed at a temperature in the range     of 0 to 200° C. employing a solvent such as N,N-dimethylformamide,     1,3-dimethyl-3,4,5,6-tetra-hydro-2(1H)-pyrimidinone, DMSO, or     ethylene glycol if required, followed by (2) the formation of an     amide as described in (g) or (h) hereinbefore (Staskum, B., J. Org.     Chem. (1964), 29, 2856-2860; Ohnmacht C., J. Med. Chem. (1996), 39,     4592-4601). -   (w) suitable strong bases are for example: -   i) sodium hydride in a suitable solvent such as tetrahydrofuran or     N,N-dimethylformamide. The reaction is conveniently performed at a     temperature in the range of from −78° C. to 25° C. -   ii) lithium diisopropylamide in a suitable solvent such as     tetrahydrofuran. The reaction is conveniently performed at a     temperature in the range of from −78 to 25° C. -   (x) R″ is preferably methyl. This reaction may be carried out in the     presence of a Lewis acid such as titanium tetrachloride in a     suitable solvent such as dichloromethane. This reaction is     conveniently performed at a temperature in the range of −78 to 50°     C. -   (y) This reaction is preferably carried out in a suitable solvent,     for example tetrahydrofuran at a temperature of −78 to 100° C. -   z) This reaction is conveniently performed under standard Friedel     Crafts conditions, for example in the presence of aluminium     trichloride in a solvent such as dichloromethane or nitrobenzene at     a temperature of 0 to 150° C. -   a1) Suitable catalysts include     tetrakis(triphenylphosphine)palladium(0), cuprous chloride or a     stoichiometric amount of cupurous oxide. The reaction may     conveniently be conducted in a suitable inert solvent such as a     lower alcohol, a mixture of pyridine and quinoline,     dimethylformamide, N-methylpyrrolidinone or toluene and optionally     in the presence of a base such as for example sodium methoxide or     potassium carbonate. -   b1) Suitable displaceable groups include halo or triflate. Suitable     catalysts include tetrakis(triphenylphosphine)palladium(0), cuprous     chloride or a stoichiometric amount of cupurous oxide. The reaction     may conveniently be conducted in a suitable inert solvent such as a     lower alcohol or a mixture of pyridine and quinoline or     N-methylpyrrolidinone or dimethylformamide and in the presence of a     base such as for example sodium methoxide if required at a     temperature of 25-180° C. -   c1) A suitable leaving group is fluoro. A suitable base is potassium     carbonate. The reaction may conveniently be performed at a     temperature in the range of 30 to 200° C. and in a solvent such as     N,N-dimethylformamide,     1,3-dimethyl-3,4,5,6-tetra-hydro-2(1H)-pyrimidinone, DMSO, or     ethylene glycol. -   d1) This reaction with an amine is conveniently performed in the     presence of a suitable catalyst such as for example     bis(triphenylphosphine)palladium dichloride or     dichiorobis-(triphenylphosphine) palladium(II), and at a temperature     in the range of 0° C. to reflux and in a solvent such as for example     tetrahydrofuran, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone,     dimethyl sulphoxide or using an amine as the required solvent such     as for example tributylamine. -   e2) The reaction may be conveniently carried out in the presence of     a base such as for example pyridine, triethylamine or potassium     carbonate, at a temperature in the range of 0 to 120° C. in a     suitable solvent such as for example dichloromethane, diethyl ether,     N,N-dimethylformamide, or acetonitrile.

If not commercially available, the necessary starting materials for the procedures such as that described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples.

For example, it will be appreciated that certain of the optional aromatic substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acylhalide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by, for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl using, for example, hydrogen peroxide in acetic acid with heating or 3-chloroperoxybenzoic acid.

Specific examples of the techniques used to make the starting materials described above are illustrated, but not limited by, the following examples in which variable groups are as defined for formula (I) unless otherwise stated.

1) Preparation of Compounds of Formula (II)

-   a) compounds of formula (II) in which A-B is —OCH₂—, —SCH₂— or     —NHCH₂—may be made by treating the corresponding compound of     formula (VII) wherein J is —OH, —SH or —NH₂ with a compound of     formula (XXV):     where Z is a leaving group for example mesylate; in the presence of     a base such as an alkali metal hydride (e.g. sodium hydride), in a     solvent such as tetrahydrofuran, dimethyl sulphoxide,     N,N-dimethylformamide or     1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, and at a     temperature of room temperature to reflux.

A compound of formula (XXV), wherein Z is mesylate may be prepared by reacting a compound of formula (XXV) wherein Z is OH with methanesulphonyl chloride in the presence of a base such as triethylamine, in a solvent such as dichloromethane, and at a temperature of about −78 to 25° C.

Compounds of formula (XXV) wherein Z is OH are prepared by reducing a compound of formula (VIII) wherein X is OH and R⁴ is a protected hydroxy group or a compound of formula (XXVI):

where E is a carboxy protecting group (e.g. Me) and R⁴ is a protected hydroxy group with a suitable reducing agent such as lithium aluminium hydride in a solvent such as diethyl ether or tetrahydrofuran and at a temperature of about 0 to about 25° C.

-   b) A compound of formula (II), wherein A-B is —NHC(O)—, may be made     by coupling a compound of formula (VII) wherein J is —NH₂ with a     compound of formula (VIII) wherein X is OH and R⁴ is a protected     hydroxy group in a manner analogous to that described for     procedure (g) or (h) of preparations of a compound of formula (I)     hereinabove. Compounds of formula (VIII) wherein X is OH and R⁴ is a     protected hydroxy group may be made by conventional procedures. For     example, cleavage of the ester group of a compound of formula (XXVI)     where E is a carboxy protecting group (e.g. Me), under standard     conditions such as mild alkaline conditions, for example, aqueous     lithium hydroxide.

Compounds of formula (XXVI) where R⁴ is protected hydroxy may be prepared by protecting a compound of formula (XXVI) where R⁴ is hydroxy by reaction with a compound such as benzyl chloride or benzyl bromide (in the presence of a suitable base such as sodium hydride and optionally with a catalyst such as sodium or ammonium iodide, to provide a benzyl protecting group) or any of the conventional silylating agents known and used for such purpose (for example 2-trimethylsilylethoxymethyl chloride, in the presence of a suitable base such as triethylamine optionally in the presence of a catalyst such as N,N-dimethylaminopyridine).

Compounds of formula (XXVI) where R⁴ is hydroxy are prepared by esterifying an acid of formula (VIII) wherein X is OH by a conventional esterification procedure such as reaction with a C₁₋₆alcohol (e.g. methanol) in the presence of an acid catalyst (for example sulphuric acid).

-   c) A compound of formula (II), wherein A-B is ethynylene, may be     made by reacting a compound of formula (VII) wherein J is a leaving     group such as bromo, iodo, or triflate, with an acetylene of formula     (XXVII)     wherein if R⁴ is protected hydroxy in the presence of a catalyst     such as a combination of copper (I) iodide and     bis(triphenylphosphine)palladium dichloride or palladium (II)     acetate. The reaction can be conducted in an inert solvent such as     tetrahydrofuran, benzene, or toluene, or in a basic solvent such as     diethylamine or triethylamine, and at a temperature in the range of     −20 to 110° C.

A compound of formula (XXVII) wherein R⁴ is a protected hydroxy group may be made by reacting a compound of formula (XXVII) where R⁴ is OH with a conventional hydroxy protecting group reagent such as those described herein before and herein after.

-   d) A compound of formula (II), wherein A-B is trans-vinylene, may be     made by reacting a compound of formula (XXVIII):     where M is an alkylmetal group such as a trialkyltin (for example     tributyl- or trimethyl-tin) or a bisalkyloxyborane (for example     catecholborane) and R⁴ is protected hydroxy with a compound of     formula (VII), wherein J is a leaving group for example iodide,     bromide or triflate in the presence of a catalyst such as     bis(triphenylphosphine)palladium dichloride or     tetrakis(triphenylphosphine)palladium (0). The reaction may     conveniently be conducted in a suitable inert solvent such as a     tetrahydrofuran or dimethylformamide at a temperature of 0-150° C.     under an inert atmosphere.

A compound of formula (XXVIII) may be made by a reaction of a compound of formula (XXVII)

-   i) with an agent such as catecholborane, to form the vinylborane     compound of formula (XXVIII) where M is catecholborane; or -   ii) a trialkyltinhydride in the presence of a catalytic amount of a     radical chain initiator such as, for example,     aza-bis-isobutyronitrile or by using trialkyltinhydride pre-treated     with a strong base (such as an alkyllithium) and copper (I) cyanide,     or by using a transition metal catalyst such as, for example,     tetrakis(triphenylphosphine)palladium(0) to form a compound of     formula (XXVIII) where M is trialkyltin.

These reactions may conveniently be conducted in a suitable inert solvent such as tetrahydrofuran, toluene or xylene at a temperature of from 0-150° C. under an inert atmosphere.

Compounds of formula (XXVII) may be made by reacting a compound of formula (XVI) with an alkali metal acetylide (for example lithium acetylide) or alkaline earth metal acetylide (for example magnesium acetylide). The reaction may be conducted in a solvent such as tetrahydrofuran, diethyl ether, or 1,2-dimethoxyethane and at a temperature of −100 to 25° C.

2) Preparation of a Compound of Formula (IV):

-   a) A compound of formula (IV), wherein A-B is ethynylene and R⁴ is     OH, may be made by reacting a corresponding compound of formula     (XXIX):     wherein ring D⁵ has any of the values defined hereinbefore for ring     C but in which the place of one of the possible substituents on ring     C is taken by Ar(—C—O—(CH₂)₃—O—)— with a base such as an     alkyllithium (for example, butyllithium) followed by addition of a     ketone having the formula (XVI). The reaction may be conducted at a     temperature of from about −100 to about −40° C. and in a solvent     such as tetrahydrofaran, dimethyl ether, or 1,2-dimethoxyethane.

b) A compound of formula (IV), wherein A-B is trans-vinylene, may be made by reducing a corresponding compound of formula (IV), wherein A-B is ethynylene, with a suitable reducing agent such as lithium aluminium hydride or sodium bis(2-methoxyethoxy)aluminium, in a solvent such as tetrahydrofuran. The reaction may be conducted at a temperature of from about −40 to about 40° C.

c) a compound of formula (XXIX) may be made by treating the corresponding ketone with 1,3-propanediol in the presence of an acid catalyst such as p-toluenesulphonic acid (TsOH) and in a refluxing solvent such as toluene using a Dean Stark apparatus or dried Molecular Sives.

3) Preparation of a Compound of Formula (VI):

a) A compound of formula (VI) wherein G¹ is halo, such as for example bromo or iodo may be made by (1) treating a corresponding compound of formula (VI), wherein G¹ is nitro, with a reducing agent such as tin(II)chloride, in the presence of an aqueous acid such as acetic acid to obtain the corresponding amine, followed by (2) treating the amine with a combination of nitric acid and sulphuric acid or tert-butyl nitrite to effect diazotization, and thereafter (3) treating the diazotized compound with a corresponding copper(I)halide such as for example cuprous bromide or potassium iodide.

b) A compound of formula (VI), wherein G¹ is SH can be made by:

-   (1) coupling of a compound of formula (VI) wherein G¹ is a leaving     group such as halo or triflate with triisopropylsilanethiolate under     palladium catalysis as described by Arnould et. al. in Tet. Let.     (1996), 37 (26), p. 4523, followed by deprotection with     tetrabutylammonium fluoride in a solvent such as tetrahydrofuran at     a temperature of −78 to about 25° C.; or -   (2) by Pummerer rearrangement as described in Tet. Let. (1984), 25     (17), p. 1753 of a compound of formula (VI) wherein G¹ is CH₃S(O)—,     which can be made from a compound of formula (VI) wherein G¹ is a     leaving group such as halo of triflate, using a palladium catalysed     coupling with methanethiol as described for example in Zheng et. al.     in J. Org. Chem. (1998), 63, p. 9606 followed by an oxidation of the     resulting sulphide to the corresponding sulphoxide using, for     example, tert-butyl hydroperoxide as oxidant; or -   (3) reduction of a compound of formula (VI), wherein G¹ is SO₂Cl, by     reducing the sulphonyl chloride using a small excess of for example     triphenylphosphine in a solvent such as, for example,     dichloromethane in the presence of a catalyst such as, for example,     dimethylformamide, followed by an acidic workup.

c) a compound of formula (VI), wherein G¹ is SO₂Cl can be made by treatment with chlorosulphonic acid of a compound of formula (VI), wherein G¹ is H, under standard conditions.

4) Preparation of Compounds of Formula (XII).

A compound of formula (XII), wherein A-B is ethynylene, may be made by treating a corresponding compound of formula (XV) wherein Z is a protecting group such as, for example, trimethylsilyl with a fluoride base (for example, tetrabutylammonium fluoride (TBAF)) and an acid chloride of formula R³—CO—Cl, thereby making the desired compound.

5) Preparation of Compounds of Formula (VII).

A compound of formula (VII), wherein J is halo, may be made by treating a corresponding compound of formula (VII), wherein J is nitro, with (1) as tin (II) chloride or (2) iron dust and concentrated hydrochloric acid in 95% ethanol to reduce the nitro group and thereby form the corresponding amine; (2) the amine may then be treated for example with a nitrite (such as tert-butyl nitrite or sodium nitrite in the presence of a mineral acid) to form the corresponding diazonium salt which may in turn be treated with a copper(I) salt (such as copper(I)bromide or copper(I)chloride) or potassium iodide. The diazotization and displacement reactions may be conducted in a solvent such as acetonitrile and at a temperature of from 0 to 25° C.

6) Preparation of Compounds of Formula (XIV).

A compound of formula (XIV) wherein R⁴ is OH may be made by reacting a corresponding ketone having the formula (XVI) with an alkali metal acetylide (for example lithium acetylide) or alkaline earth metal acetylide (for example magnesium acetylide). The reaction may be conducted in a solvent such as tetrahydrofuran, diethyl ether, or 1,2-dimethoxyethane and at a temperature of about −100 to about 25° C.

7) Preparation of Compounds of Formula (XIII).

A compound of formula (XIII), wherein G² is amino and A-B is NHCO may be made by treating a compound of formula (XIII), wherein G² is nitro, under standard conditions for example by a reducing agent such as tin (II) chloride or iron dust in conjunction with concentrated acid, or using palladium metal supported on charcoal and hydrogen gas in a solvent such as a lower alcohol (methanol or ethanol) or ethyl acetate.

8) Preparation of Compounds of Formula (VII).

-   i) a compound of formula (VII) wherein R¹ is ortho-halo or     ortho-hydroxy and J is —NH₂, may be made by treatment of a compound     of formula (XXX):     wherein the amino group is in a position ortho to the nitro group,     with (1) a combination of nitric acid and sulphuric acid or     tert-butyl nitrite to effect diazotization, and thereafter (2)     treating the diazotized compound with a corresponding copper (I)     halide such as for example cuprous bromide or chloride, or heating     in dilute sulphuric acid to form the corresponding phenol, followed     by (3) reduction of the nitro group (see 8) ii) or 7)). The     diazotization and displacement reactions may be conducted in a     solvent such as acetonitrile and at a temperature of from 0-25° C. A     compound of formula (XXX) may be made for example according to     procedures similar to those described in J. Med. Chem., (1975), 18,     1164. -   ii) a compound of formula (VII) wherein J is NH₂ may be prepared by     reducing a compound of formula (XXXI):     under standard conditions for example by a reducing agent such as     tin (II) chloride or iron dust in conjunction with concentrated     acid, or using palladium metal supported on charcoal and hydrogen     gas in a solvent such as a lower alcohol (methanol or ethanol) or     ethyl acetate.     -   iii) a compound of formula (VII) wherein J is NH₂, R¹ is —NO₂         and ring C is substituted by ArSO₂: reacting a compound of         formula (XXXII):         wherein ring D⁴ has any of the values defined hereinbefore for         ring C but in which the place of one of the possible         substituents on ring C is taken by ArSO₂, with nitric acid,         followed by treating the nitrated compound under mild alkaline         conditions (i.e. employing a base such as lithium hydroxide) to         cleave the acetate group to yield the amine. -   iv) a compound of formula (VII) wherein J is —OH, may be prepared by     diazotizing a compound of formula (VII) wherein J is —NH₂ under     standard conditions followed by heating the resulting compound in     dilute sulphuric acid. -   v) a compound of formula (VII), wherein J is —SH, may be prepared by     reacting a compound of formula (VII) where J is a leaving group (for     example fluoro or chloro) with an excess of methanethiol in the     presence of sodium hydride. -   vi) a compounds of formula (VII) wherein J is Li may be prepared by -   a) halogen metal exchange. For example by treatment of a compound of     formula (VII) wherein J is Br or I; with an organolithium reagent     such as n-butyl lithium or t-butyllithium in a solvent such as     tetrahydrofuran at low temperature such as −100-−50° C. -   b) for compounds where R¹ is an ortho directing metallating     substituent by treatment of a compound of formula (XXIII) with an     alkyl lithium base. Reactions of this type are reviewed in V.     Snieckus, Chem Rev, 1990, 90, 879-933.     9) Resolution of Compounds of Formula (VIII) wherein X is OH.

If the resolved acid is required it may be prepared by any of the known methods for preparation of optically-active forms (for example, by recrystallization of the chiral salt {for example WO 9738124}, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase). For example if an (R)-(+) resolved acid is required it may be prepared by the method of Scheme 2 in World Patent Application Publication No. WO 9738124 for preparation of the (S)-(−) acid, i.e. using the classical resolution method described in European Patent Application Publication No. EP 0524781, also for preparation of the (S)-(−) acid, except that (1S,2R)-norephedrine may be used in place of (S)-(−)-1-phenylethylamine.

10) Preparation of Compounds of Formula (XV).

A compound of formula (XV) wherein Z is H, may be prepared by reacting a compound of formula (VII), wherein J is a leaving group such as bromo, iodo or triflate with trimethylsilylacetylene in the presence of a catalyst such as a combination of bis(triphenylphosphine)palladium dichloride and copper(I) iodide in diethylamine or triethylamine, followed by treatment with a base (for example potassium carbonate) in a C₁₋₆alcohol (such as methanol) as the solvent to remove the trimethylsilyl group.

11) Preparation of Compounds of Formula (XVII).

A compound of formula (XVII) may be prepared from a compound of formula (XXXIII):

by reduction under standard conditions for example by using a hydride, such as sodium borohydride.

A compound of formula (XXXIII) may be prepared by deprotonation of a compound of formula (VII) where J is Me, with a strong base, for example lithium diisopropyl amide in an organic solvent, for example tetrahydrofuran at a temperature of −78 to 100° C. followed by addition of an amide of formula (XXXIV):

in which R¹⁹ and R²⁰ are each independently C₁₋₆alkyl, preferably methyl, or together with the atoms to which they are attached form a 5-7 membered ring.

An amide of formula (XXXIV) may be prepared from an acid of formula (VIII), or a reactive derivative thereof, by reaction with a hydroxyamine of formula R¹⁹(R²⁰O)NH under standard conditions such as those described in process (g) or (h) for preparation of a compound of formula (I) hereinabove.

12) Preparation of Compounds of Formula (XVIII).

A compound of formula (XVIII) may be prepared from a diol of formula (XXXV):

using a suitable dehydrating agent, for example bis[α,α-bis(trifluoromethyl)benzene methanolato]diphenyl sulphur. 13) Preparation of Compounds of Formula (XIX).

A compound of formula (XIX) may be made by treating a compound of formula (XVI) with a trimethylsulphonium salt (such as trimethylsulphonium iodide) and a base (such as an alkali metal hydroxide) in a solvent such as dichloromethane.

14) Preparation of Compounds of Formula (XX).

Compounds of formula (XX) can be made by synthetic reactions well known in the art for example:

-   i) a Friedel Crafts acylation of a compound of formula (XXIII) with     acetyl chloride under conditions such as those described in (z)     above. -   ii) reaction of a compound of formula (VII) wherein J is Li with an     amide of formula (XXXVI):     under conditions such as those described in 8)vi)b) hereinabove. -   iii) oxidation of a compound of formula (XXXVII):     15) Preparation of Compounds of Formula (XXI).

Compounds of formula (XXI) can be prepared from compounds of formula (XX) by treatment with a base such as lithium diisopropylamide or triethylamine and a silylating agent such as trimethylsilyl chloride in a solvent such as tetrahydrofuran or trimethylsilyl triflate in a solvent such as dichloromethane. The reaction can conveniently be performed at a temperature in the range of −78 to 70° C.

16) Preparation of Compounds of Formula (XXII).

Compounds of formula (XXII) can be prepared from an acid of formula (XXXVIII):

or a reactive derivative thereof, by reaction with a hydroxyamine of formula R¹⁹(R²⁰O)NH under standard conditions such as those described in process (g) or (h) for preparation of a compound of formula (I) hereinabove.

According to a further feature of the invention, there is provided a process for preparing a compound of formula (I′) using any one of processes a), f), g), h), i) or l); and thereafter if necessary:

-   i) converting a compound of the formula (I′) into another compound     of the formula (I′); -   ii) removing any protecting groups; or -   iii) forming a pharmaceutically acceptable salt or in vivo cleavable     ester.

It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a phenol is, for example, an alkylether, for example, methyl, a silyl ether, for example, trimethylsilyl ether or t-butyldimethylsilyl ether, an oxyalkylether, for example, methoxymethyl ether or methoxyethoxymethyl ether or an ester, for example acetate or benzoate. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an alkylether may be removed by treatment with a suitable reagent such as iodotrimethylsilane or a suitable Lewis acid such as borontribromide. Alternatively a silyl ether may be removed by acid- or fluoride ion-catalysed hydrolysis. Alternatively oxyalkylethers may be removed by treatment with a suitable acid such as acetic acid or hydrochloric acid. Alternatively esters may be removed by hydrolysis by a suitable acid or a suitable base.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

In cases where compounds of formula (I) are sufficiently basic or acidic to form stable acid or basic salts, administration of the compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following. Examples of suitable pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiologically acceptable anion, for example, tosylate, methanesulphonate, acetate, tartrate, citrate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed such as sulphate, nitrate, and hydrochloride.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound of formula (I) (or its ester) with a suitable acid affording a physiologically acceptable anion. It is also possible with most compounds of the invention to make a corresponding alkali metal (e.g., sodium, potassium, or lithium) or alkaline earth metal (e.g., calcium) salt by treating a compound of formula (I) (and in some cases the ester) with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (e.g. the ethoxide or methoxide in aqueous medium followed by conventional purification techniques.

In vivo cleavable esters of compounds of the invention may be made by coupling with a pharmaceutically acceptable carboxylic acid or an activated derivative thereof. For example, the coupling may be carried out by treating a compound of formula (I) with an appropriate acid chloride (for example, acetyl chloride, propionyl chloride, or benzoyl chloride) or acid anhydride (for example, acetic anhydride, propionic anhydride, or benzoic anhydride) in the presence of a suitable base such as triethylamine. Those skilled in the art will appreciate that other suitable carboxylic acids (including their activated derivatives) for the formation of in vivo cleavable esters are known to the art and these are also intended to be included within the scope of the invention. Catalysts such as 4-dimethylaminopyridine may also be usefully employed.

Many of the intermediates defined herein are novel and these are provided as a further feature of the invention.

The identification of compounds which elevate PDH activity is the subject of the present invention. These properties may be assessed, for example, using one or more of the procedures set out below:

(a) In Vitro Elevation of PDH Activity

This assay determines the ability of a test compound to elevate PDH activity. cDNA encoding PDH kinase may be obtained by Polymerase Chain Reaction (PCR) and subsequent cloning. This may be expressed in a suitable expression system to obtain polypeptide with PDH kinase activity. For example rat PDHkinaseII (rPDHKII) obtained by expression of recombinant protein in Escherichia coli (E. Coli), was found to display PDH kinase activity.

In the case of the rPDHKII (Genbank accession number U10357) a 1.3 kb fragment encoding the protein was isolated by PCR from rat liver cDNA and cloned into a vector (for example pQE32—Quiagen Ltd.). The recombinant construct was transformed into E. coli (for example M15pRep4—Quiagen Ltd.). Recombinant clones were identified, plasmid DNA was isolated and subjected to DNA sequence analysis. One clone which had the expected nucleic acid sequence was selected for the expression work. Details of the methods for the assembly of recombinant DNA molecules and the expression of recombinant proteins in bacterial systems can be found in standard texts for example Sambrook et al, 1989, Molecular Cloning—A Laboratory Manual, 2^(nd) edition, Cold Spring Harbour Laboratory Press. Other known PDH kinases for use in assays, may be cloned and expressed in a similar manner.

For expression of rPDHKII activity, E. coli strain M15pRep4 cells were transformed with the pQE32 vector containing rPDHKII cDNA. This vector incorporates a 6-His tag onto the protein at its N-terminus. E. coli were grown to an optical density of 0.6 (600 nM) and protein expression was induced by the addition of 10 μM isopropylthio-β-galactosidase. Cells were grown for 18 hours at 18° C. and harvested by centrifugation. The resuspended cell paste was lysed by homogenisation and insoluble material removed by centrifugation at 24000×g for 1 hour. The 6-His tagged protein was removed from the supernatant using a nickel chelating nitrilotriacetic acid resin (Ni—NTA: Quiagen Ltd.) matrix (Quiagen) which was washed with 20 mM tris(hydroxymethyl)aminomethane-hydrogen chloride, 20 mM imidazole, 0.5 M sodium chloride pH 8.0, prior to elution of bound protein using a buffer containing 20 mM tris(hydroxymethyl)aminomethane-hydrogen chloride, 200 mM imidazole, 0.15 M sodium chloride pH 8.0. Eluted fractions containing 6-His protein were pooled and stored in aliquots at −80° C. in 10% glycerol.

Each new batch of stock enzyme was titrated in the assay to determine a concentration giving approximately 90% inhibition of PDH in the conditions of the assay. For a typical batch, stock enzyme was diluted to 7.5 μg/ml.

For assay of the activity of novel compounds, compounds were diluted with 10% dimethylsulphoxide (DMSO) and 10 μl transferred to individual wells of 96-well assay plates. Control wells contained 20 μl 10% DMSO instead of compound. 40 μl Buffer containing 50 mM potassium phosphate buffer pH 7.0, 10 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N,N-tetracetic acid (EGTA), 1 mM benzamidine, 1 mM phenylmethylsulphonyl fluoride (PMSF), 0.3 mM tosyl-L-lysine chloromethyl ketone (TLCK), 2 mM dithiothreitol (DTT), recombinant rPDHKII and compounds were incubated in the presence of PDH kinase at room temperature for 45 minutes. In order to determine the maximum rate of the PDH reaction a second series of control wells were included containing 10% DMSO instead of compound and omitting rPDHKII. PDH kinase activity was then initiated by the addition of 5 μM ATP, 2 mM magnesium chloride and 0.04 U/ml PDH (porcine heart PDH Sigma P7032) in a total volume of 50 μl and plates incubated at ambient temperature for a further 45 minutes. The residual activity of the PDH was then determined by the addition of substrates (2.5 mM coenzyme A. 2.5 mM thiamine pyrophosphate (cocarboxylase), 2.5 mM sodium pyruvate, 6 mM NAD in a total volume of 80 μl and the plates incubated for 90 minutes at ambient temperature. The production of reduced NAD (NADH) was established by measured optical density at 340 nm using a plate reading spectrophotometer. The ED₅₀ for a test compound was determined in the usual way using results from 12 concentrations of the compound.

(b) In Vitro Elevation of PDH Activity in Isolated Primary Cells

This assay determines the ability of compounds to stimulate pyruvate oxidation in primary rat hepatocytes.

Hepatocytes were isolated by the two-step collagenase digestion procedure described by Seglen (Methods Cell Biol. (1976) 13, 29-33) and plated out in 6-well culture plates (Falcon Primaria) at 600000 viable cells per well in Dulbecco's Modified Eagles Medium (DMEM, Gibco BRL) containing 10% foetal calf serum (FCS), 10% penicillin/streptomycin (Gibco BRL) and 10% non-essential amino acids (NEAA, Gibco BRL). After 4 hours incubation at 37° C. in 5% CO₂, the medium was replaced with Minimum Essential Medium (MEM, Gibco BRL) containing NEAA and penicillin/streptomycin as above in addition to 10 nM dexamethasone and 10 nM insulin.

The following day cells were washed with phosphate buffered saline (PBS) and medium replaced with 1 ml HEPES-buffered Krebs solution (25 mM HEPES, 0.15M sodium chloride, 25 mM sodium hydrogen carbonate, 5 mM potassium chloride, 2 mM calcium chloride, 1 mM magnesium sulphate, 1 mM potassium dihydrogen phosphate) containing the compound to be tested at the required concentration in 0.1% DMSO. Control wells contained 0.1% DMSO only and a maximum response was determined using a 10 μM treatment of a known active compound. After a preincubation period of 40 minutes at 37° C. in 5% CO₂, cells were pulsed with sodium pyruvate to a final concentration of 0.5 mM (containing 1-¹⁴C sodium pyruvate (Amersham product CFA85) 0.18 Ci/mmole) for 12 minutes. The medium was then removed and transferred to a tube which was immediately sealed with a bung containing a suspended centre well. Absorbent within the centre well was saturated with 50% phenylethylamine, and CO₂ in the medium released by the addition of 0.2 μl 60% (w/v) perchloric acid (PCA). Released ¹⁴CO₂ trapped in the absorbent was determined by liquid scintillation counting. The ED₅₀ for a test compound was determined in the usual way using results from 7 concentrations of the compound.

(c) In vivo Elevation of PDH Activity

The capacity of compounds to increase the activity of PDH in relevant tissues of rats may be measured using the test described hereinafter. Typically an increase in the proportion of PDH in its active, nonphosphorylated form may be detected in muscle, heart, liver and adipose tissue after a single administration of an active compound. This may be expected to lead to a decrease in blood glucose after repeated administration of the compound. For example a single administration of DCA, a compound known to activate PDH by inhibition of PDH kinase (Whitehouse, Cooper and Randle (1974) Biochem. J. 141, 761-774) 150 mg/kg, intraperitoneally, increased the proportion of PDH in its active form (Vary et al. (1988) Circ. Shock 24, 3-18) and after repeated administration resulted in a significant decrease in plasma glucose (Evans and Stacpoole (1982) Biochem. Pharmacol. 31, 1295-1300).

Groups of rats (weight range 140-180 g) are treated with a single dose or multiple doses of the compound of interest by oral gavage in an appropriate vehicle. A control group of rats is treated with vehicle only. At a fixed time after the final administration of compound, animals are terminally anaesthetised, tissues are removed and frozen in liquid nitrogen. For determination of PDH activity, muscle samples are disrupted under liquid nitrogen prior to homogenisation by one thirty-second burst in a Polytron homogenizer in 4 volumes of a buffer containing 40 mM potassium phosphate pH 7.0, 5 mM EDTA, 2 mM DTT, 1% Triton X-100, 10 mM sodium pyruvate, 10 μM phenylmethylsulphonyl chloride (PMSF) and 2 μg/ml each of leupeptin, pepstain A and aprotinin. Extracts are centrifuged before assay. A portion of the extract is treated with PDH phosphatase prepared from pig hearts by the method of Siess and Wieland (Eur. J. Biochem (1972) 26, 96): 20 μl extract, 40 μl phosphatase (1:20 dilution), in a final volume of 125 μl containing 25 mM magnesium chloride, 1 mM calcium chloride. The activity of the untreated sample is compared with the activity of the dephosphorylated extract thus prepared. PDH activity is assayed by the method of Stansbie et al., (Biochem. J. (1976)154, 225). 50 μl Extract is incubated with 0.75 mM NAD, 0.2 mM CoA, 1.5 mM thiamine pyrophosphate (TPP) and 1.5 mM sodium pyruvate in the presence of 20 μg/ml p-(p-amino-phenylazo) benzene sulphonic acid (AABS) and 50 mU/ml arylamine transferase (AAT) in a buffer containing 100 mM tris(hydroxymethyl)aminomethane, 0.5 mM EDTA, 50 mM sodium fluoride, 5 mM 2-mercaptoethanol and 1 mM magnesium chloride pH 7.8. AAT is prepared from pigeon livers by the method of Tabor et al. (J. Biol. Chem. (1953) 204, 127). The rate of acetyl CoA formation is determined by the rate of reduction of AABS which is indicated by a decrease in optical density at 460 nm.

Liver samples are prepared by an essentially similar method, except that sodium pyruvate is excluded from the extraction buffer and added to the phosphatase incubation to a final concentration of 5 mM.

Treatment of an animal with an active compound results in an increase in the activity of PDH complex in tissues. This is indicated by an increase in the amount of active PDH (determined by the activity of untreated extract as a percentage of the total PDH activity in the same extract after treatment with phosphatase).

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

According to an additional aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I′) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square metre body area of the animal, i.e. approximately 0.1-100 mg/kg. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.

According to a further aspect of the present invention there is provided a compound of the formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

According to an additional aspect of the present invention there is provided a compound of the formula (I′) or a pharmaceutically acceptable salt thereof as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that compounds of the present invention elevate PDH activity and are therefore of interest for their blood glucose-lowering effects.

A further feature of the present invention is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament, conveniently a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament for producing an elevation of PDH activity in a warm-blooded animal such as a human being.

A further feature of the present invention is a compound of formula (I′), or a pharmaceutically acceptable salt thereof, for use as a medicament, conveniently a compound of formula (I′), or a pharmaceutically acceptable salt thereof, for use as a medicament for producing an elevation of PDH activity in a warm-blooded animal such as a human being.

Thus according to a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an elevation of PDH activity in a warm-blooded animal such as a human being.

Thus according to an additional aspect of the invention there is provided the use of a compound of the formula (I′), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an elevation of PDH activity in a warm-blooded animal such as a human being.

According to a further feature of the invention there is provided a method for producing an elevation of PDH activity in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

The elevation of PDH activity described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. For example in the treatment of diabetes mellitus chemotherapy may include the following main categories of treatment:

-   i) insulin; -   ii) insulin secretagogue agents designed to stimulate insulin     secretion (for example glibenclamide, tolbutamide, other     sulphonylureas); -   iii) oral hypoglycaemic agents such as metformin,     thiazolidinediones; -   iv) agents designed to reduce the absorption of glucose from the     intestine (for example acarbose); -   v) agents designed to treat complications of prolonged     hyperglycaemia; -   vi) other agents used to treat lactic acidaemia; -   vii) inhibitors of fatty acid oxidation; -   viii) lipid lowering agents; -   ix) agents used to treat coronary heart disease and peripheral     vascular disease such as aspirin, pentoxifylline, cilostazol; and/or -   x) thiamine.

As stated above the compounds defined in the present invention are of interest for their ability to elevate the activity of PDH. Such compounds of the invention may therefore be useful in a range of disease states including diabetes mellitus, peripheral vascular disease, (including intermittent claudication), cardiac failure and certain cardiac myopathies, myocardial ischaemia, cerebral ischaemia and reperfusion, muscle weakness, hyperlipidaemias, Alzheimer's disease and atherosclerosis.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of elevators of PDH activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

It is to be understood that where the term “ether” is used anywhere in this specification it refers to diethyl ether.

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

-   (i) temperatures are given in degrees Celsius (° C.); operations     were carried out at room or ambient temperature, that is, at a     temperature in the range of 18-25° C. and under an atmosphere of an     inert gas such as argon; -   (ii) organic solutions were dried over anhydrous magnesium sulphate;     evaporation of solvent was carried out using a rotary evaporator     under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath     temperature of up to 60° C.; -   (iii) chromatography means flash chromatography on silica gel; thin     layer chromatography (TLC) was carried out on silica gel plates;     where a silica Mega Bond Elut column is referred to, this means a     column containing 10 g or 20 g of silica of 40 micron particle size,     the silica being contained in a 60 ml disposable syringe and     supported by a porous disc, obtained from Varian. Harbor City,     Calif., USA under the name “Mega Bond Elut SI”; “Mega Bond Elut” is     a trademark; -   (iv) where a Chem Elut column is referred to, this means a     “Hydromatrix” extraction cartridge for adsorption of aqueous     material, i.e. a polypropylene tube containing a special grade of     flux-calcined, high purity, inert diatomaceous earth, pre-buffered     to pH 4.5 or 9.0, incorporating a phase-separation filtering     material, used according to the manufacturers instructions, obtained     from Varian, Harbor City, Calif., USA under the name of “Extube,     Chem Elut”; “Extube” is a registered trademark of International     Sorbent Technology Limited; -   (v) where an ISOLUTE column is referred to, this means an “ion     exchange” extraction cartridge for adsorption of basic or acid     material, i.e. a polypropylene tube containing a special grade of     ion exchange sorbent, high purity, surface to pH˜7, incorporating a     phase-separation filtering material, used according to the     manufacturers instructions, obtained from Varian, Harbor City,     Calif., USA under the name of “Extube, Chem Elut, ISOLUTE”; “Extube”     is a registered trademark of International Sorbent Technology     Limited; -   (vi) in general, the course of reactions was followed by TLC and     reaction times are given for illustration only; -   (vii) melting points are uncorrected and (dec) indicates     decomposition; the melting points given are those obtained for the     materials prepared as described; polymorphism may result in     isolation of materials with different melting points in some     preparations; -   (viii) final products had satisfactory proton nuclear magnetic     resonance (NMR) spectra and/or mass spectral data; -   (ix) yields are given for illustration only and are not necessarily     those which can be obtained by diligent process development;     preparations were repeated if more material was required; -   (x) where given, NMR data is in the form of delta values for major     diagnostic protons, given in parts per million (ppm) relative to     tetramethylsilane (TMS) as an internal standard, determined at 300     MHz using perdeuterio dimethyl sulphoxide (DMSO-δ₆) as solvent     unless otherwise indicated, other solvents (where indicated in the     text) include deuterated chloroform —CDCl₃ and deuterated acetic     acid AcOH-δ₄; coupling constants (J) are given in Hz; Ar designates     an aromatic proton when such an assignment is made; -   (xi) chemical symbols have their usual meanings; SI units and     symbols are used; -   (xii) reduced pressures are given as absolute pressures in Pascals     (Pa); elevated pressures are given as gauge pressures in bars; -   (xiii) solvent ratios are given in volume : volume (v/v) terms; -   (xiv) mass spectra (MS) were run with an electron energy of 70     electron volts in the chemical ionisation (CI) mode using a direct     exposure probe; where indicated ionisation was effected by electron     impact (EI), fast atom bombardment (FAB) or electrospray (ESP);     values for m/z are given; generally, only ions which indicate the     parent mass are reported and unless otherwise stated the value     quoted is (M−H)⁻; -   (xv) Oxone is a Trademark of E.I. du Pont de Nemours & Co., Inc.,     and refers to potassium peroxymonosulphate; -   xvi) The following abbreviations are used:

EA elemental analysis; DMF N,N-dimethylformamide; DMA N,N-dimethylacetamide; TFA trifluoroacetic acid; NMP N-methylpyrrolidin-2-one SM starting material; DCM dichloromethane; and THF tetrahydrofuran;

-   (xvii) HPLC Methods referred to in the text are as follows:

Methods a and b LC/MS method: Machine Model HP1100 Column 4.6 mm × 10 cm Hichrom RPB 100A Wavelength 254 nm Injection 10 μl Flow rate 1 ml/minute Solvent A 0.1% Formic Acid/Water Solvent B 0.1% Formic Acid/Acetonitrile. Time/minutes A% B% Solvent gradient for Method a: 0.00 95 5 1.50 95 5 7.50 5 95 9.00 5 95 Solvent gradient for Method b: 0.00 95 5 1.50 95 5 11.50 5 95 13.50 5 95 Method c: Column 7.5 mm × 25 cm Dynamax −60A C18 83-201-C Flow rate 1 ml/minute Time/minutes % MeCN in water + 0.1% TFA Solvent gradient for Method c: 0 10 2 10 32 90 Method d: Column 4.5 mm × 10 cm HIRPB Flow rate   1 ml/min Solvent Gradient 50-70% MeOH in water + 0.1% TFA over 10 minutes (xviii) where (R) or (S) stereochemistry is quoted at the beginning of a name, unless further clarified, it is to be understood that the indicated stereochemistry refers to the A-B-C*(R²)(R³)(R⁴) centre as depicted in formula (I).

EXAMPLE 1

(R)-N-[2-Chloro-4-(2-methylsulphanylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Sodium methanethiolate (49.5 mg) was added to a solution of (R)-N-[2-chloro-4-(2-fluorophenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Method 63) (0.15 g) in NMP (1.5 ml) and the mixture was heated at 120° C. for 18 hours then cooled. Saturated aqueous ammonium chloride solution (15 ml) was added and the mixture was extracted with ethyl acetate (2×50 ml). The organic extracts were combined, washed with brine and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-20% ethyl acetate/hexane to give the title compound (0.10 g) as a solid. NMR: (CDCl₃): 1.75 (s, 3H), 2.4 (s, 3H), 3.6 (brs, 1H), 7.3 (t, 1H), 7.35 (t, 1H), 7.55 (m, 1H), 7.9 (dd, 1H), 8.05 (d, 1H) 8.25 (dd, 1H), 8.6 (d, 1H), 9.25 (brs, 1H); MS (ESP⁻): 452.

EXAMPLES 2-12

Following the procedure of Example 1 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR (CDCl₃) MS SM 2 (R)-N-[2-Chloro-4-(4-methyl- 1.75 (s, 3H), 2.5 (s, 3H), 3.7 (s, 452 Meth sulphanylphenylsulphonyl) 1H), 7.28 (d, 2H), 7.8 (d, 2H), 69 phenyl]-2-hydroxy-2-methyl- 7.83 (dd, 1H), 7.98 (d, 1H), 8.6 (d, 3,3,3-trifluoropropanamide 1H), 9.25 (brs, 1H) 3 (R)-N-{2-Chloro-4-[2-(ethyl- 1.25 (t, 3H), 1.75 (s, 3H), 2.90 (q, 466 Meth sulphanyl)phenylsulphonyl] 2H), 3.75 (s, 1H), 7.30-7.35 (m, 63 phenyl}-2-hydroxy-2-methyl- 2H), 7.45-7.50 (m, 1H), 7.90-7.95 3,3,3-trifluoropropanamide (m, 1H), 8.10 (d, 1H), 8.25 (d, 1H), 8.60 (d, 1H), 9.30 (s, 1H) 4 (R)-N-[2-Chloro-4-(3-methyl- 1.75 (s, 3H), 2.52 (s, 3H), 3.5 (s, 452 Meth sulphanylphenylsulphonyl) 1H), 7.37-7.41 (m, 2H), 7.6-7.65 70 phenyl]-2-hydroxy-2-methyl- (m, 1H), 7.75 (s, 1H), 7.85 (d, 3,3,3-trifluoropropanamide 1H), 8.0 (d, 1H), 8.60 (d, 1H), 9.2 (s, 1H) 5 (R)-N-[2-Chloro-4-(4-methyl- 1.72 (s, 3H), 2.5 (s, 3H), 4.45 436 Meth sulphanylphenylsulphinyl) (2xbrs, 1H), 7.3 (d, 2H), 7.49 (m, 75 phenyl]-2-hydroxy-2-methyl- 1H), 7.5 (d, 2H), 7.7 (m, 1H), 8.5 3,3,3-trifluoropropanamide (2xd, 1H), 9.2 (2xbrs, 1H) 6 (R)-N-{2-Chloro-4-[4-(iso- 1.35 (d, 6H), 1.7 (s, 3H), 3.5 (m, 480 Meth propylsulphanyl)phenyl- 1H), 5.35 (s, 1H), 7.35 (d, 2H), 69 sulphonylphenyl}-2-hydroxy- 7.75-7.85 (m, 3H), 8.0 (dd, 1H), 2-methyl-3,3,3- 8.6 (d, 1H), 9.5 (brs, 1H) trifluoropropanamide 7 (R)-N-[2-Chloro-4-(4-ethyl- 1.35 (t, 3H), 1.7 (s, 3H), 3.0 (q, 466 Meth sulphanylphenylsulphonyl) 2H), 5.2 (s, 1H), 7.3 (m, 1H), 7.7- 69 phenyl]-2-hydroxy-2-methyl- 8.0 (m, 5H), 8.6 (d, 1H), 9.45 (brs, 3,3,3-trifluoropropanamide 1H) 8 (R)-N-[2-Chloro-4-(3-chloro-4- 1.75 (s, 3H), 2.5 (s, 3H), 3.80 (s, 488 Meth methylsulphanylphenyl 1H), 7.2 (d, 1H), 7.75 (dd, 1H). (M + H)⁺ 72 sulphonyl)phenyl]-2-hydroxy- 7.8-7.85 (m, 2H), 7.95 (d, 1H), 2-methyl-3,3,3- 8.6 (d, 1H), 9.30 (brs, 1H) trifluoropropanamide 9 (R)-N-[2-Chloro-4-(3-fluoro-4- 1.75 (s, 3H), 2.5 (s, 3H), 3.6 (s, 470 Meth methylsulphanylphenyl 1H), 7.25 (m, 1H), 7.5 (dd, 1H), 66 sulphonyl)phenyl]-2-hydroxy- 7.65 (d, 1H), 7.85 (dd, 1H), 7.95 2-methyl-3,3,3- (d, 1H), 8.6 (d, 1H), 9.25 (brs, 1H) trifluoropropanamide 10  (R)-N-[2-Fluoro-4-(4-ethyl- 450 Meth sulphanylphenylsulphonyl) 71 phenyl]-2-hydroxy-2-methyl- 3,3,3-trifluoropropanamide  11¹  (R)-N-[2-Methylsulphanyl-4- R.f. = 0.37; 1:1 iso-hexane:Ethyl Meth (2-methylsulphanylphenyl acetate 64 sulphonyl)phenyl]-2-hydroxy- 2-methyl-3,3,3- trifluoropropanamide 12  (R)-N-[2-Fluoro-4-(2-methyl- 436 Meth sulphanylphenylsulphonyl) 64 phenyl]-2-hydroxy-2-methyl- 3,3,3-trifluoropropanamide ¹Three equivalents of sodium methanethiolate were added.

EXAMPLE 13

(R)-N-{2-Chloro-4-[2-(methylsulphinyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

m-Chloroperoxybenzoic acid (50%, 0.293 g) was added to a solution of (R)-N-[2-chloro-4-(2-methylsulphanylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 1) (0.384 g) in DCM (40 ml). The mixture was stirred at ambient temperature for 6 hours then washed with saturated aqueous sodium hydrogen carbonate solution (3×100 ml), water (100 ml) and brine and then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 50-70% ethyl acetate/hexane to give the title compound (0.26 g) as a solid. Mp 118-120° C.; NMR (CDCl₃): 1.70 (s, 3H), 3.0 (m, 3H), 4.85 (brs, 1H), 7.75 (t, 1H), 7.85 (m, 2H), 8.0 (m, 1H), 8.15 (d, 1H), 8.3 (d, 1H), 8.65 (dd, 1H), 9.40 (brs, 1H); MS (ESP⁻): 468; EA: found: C, 44.3; H, 3.7; N, 2.6%; C₁₇H₁₅ClF₃NO₅S₂.0.125 C₄H₈O₂.0.3 C₄H₁₀O requires: C, 44.64; H, 3.81; N, 2.78%.

EXAMPLES 14-15

Following the procedure of Example 13 and using the appropriate starting materials the following compound was prepared.

Ex Compound NMR (CDCl₃) MS SM 14¹ (R)-N-[2-Chloro-4-(4- 1.72 (s, 3H), 3.02 (s, 3H), 3.9 (brs, 468 Ex 87 mesylphenylsulphinyl)- 1H), 7.58 (m, 1H), 7.72 (m, 1H), phenyl]-2-hydroxy-2-methyl- 7.82 (d, 2H), 8.05 (d, 2H), 8.58 3,3,3-trifluoropropanamide (m, 1H), 9.2 (brs, 1H) 15² N-(2-Fluoro-4-phenyl- 1.35 (s, 6H), 6.0 (brs, 1H), 7.5- 320  Ex 205 sulphinylphenyl)-2-hydroxy- 7.56 (m, 4H), 7.64 (d, 1H), 7.7 2-methylpropanamide (m, 2H), 8.18 (t, 1H), 9.4 (brs, 1H) ¹A second molar equivalent of m-chloroperoxybenzoic acid was added after 4 hours and the reaction was allowed to proceed for a further 18 hours at ambient temperature. ²Chromatography was using 30-50% ethyl acetate/hexane and the resultant material was triturated with ether.

EXAMPLE 16

(R)-N-[2-Chloro-4-(2-mesylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

m-Chloroperoxybenzoic acid (50%, 2.39 g) was added to a solution of (R)-N-[2-chloro-4-(2-methylsulphanylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 1) (1.3 g) in DCM (100 ml) and the mixture was stirred at ambient temperature for 3 hours. A further portion of m-chloroperoxybenzoic acid (0.82 g) was added and the mixture was stirred for 24 hours and then washed with saturated aqueous sodium hydrogen carbonate solution (3×70 ml), water (50 ml) and brine and then dried. Volatile material was removed by evaporation and the residue was purified by flash chromatography eluting with 50% ethyl acetate/hexane to give the title compound (0.606 g) as a solid. Mp 114-116° C.; NMR (CDCl₃): 1.75 (s, 3H), 3.45 (s, 3H), 3.65 (brs, 1H), 7.8-7.95 (m, 3H), 8.10 (d, 1H), 8.35 (dd, 1H), 8.55 (dd, 1H), 8.60 (d, 1H) 9.30 (brs, 1H); MS (ESP⁻): 484; EA: found: C, 42.3; H, 3.3; N, 2.6%; C₁₇H₁₅ClF₃NO₆S₂ requires: C, 42.02; H, 3.11; N, 2.88%.

EXAMPLES 17-53

Following the procedure of Example 16 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 17 (R)-N-{2-Chloro-4-[2-(ethyl- (CDCl₃) 1.25 (t, 3H), 1.75 (s, 498 Ex 3 sulphonyl)phenylsulphonyl] 3H), 3.70 (q, 2H), 3.75 (brs, phenyl}-2-hydroxy-2-methyl-3,3,3- 1H). 7.80-7.95 (m, 3H), 8.10 trifluoropropanamide (s, 1H), 8.30 (d, 1H), 8.60 (d, 2H), 9.25 (s, 1H) 18 (R)-N-{2-Chloro-4-[4-(2- (CDCl₃ + trace of DMSO-δ₆) 514 Ex hydroxyethylsulphonyl)phenyl- 1.59 (s, 3H), 3.29 (t, 2H), 3.85 284 sulphonyl]phenyl}-2-hydroxy-2- (m, 2H), 4.0 (m, 1H), 7.3 (s, methyl-3,3,3-trifluoropropanamide 1H), 7.78 (dd, 1H), 7.9 (d, 1H), 8.0 (s, 4H), 8.6 (d, 1H), 9.72 (brs, 1H) 19 (R)-N-{2-Chloro-4-[2-(2- (CDCl₃ + AcOH-δ₄) 1.71 (s, 514 Ex hydroxyethylsulphonyl)phenyl- 3H), 4.0 (t, 2H), 4.08 (t, 2H), 290 sulphonyl]phenyl}-2-hydroxy-2- 7.8-7.95 (m, 3H), 8.08 (d, 1H), methyl-3,3,3-trifluoropropanamide 8.31 (d, 1H), 8.52 (d, 1H), 8.62 (d, 1H) 20 (R)-N-[2-Chloro-4-(3-mesyl- (CDCl₃) 1.75 (s, 3H), 3.08 (s, 484 Ex 4 phenylsulphonyl)phenyl]-2- 3H), 3.5 (s, 1H), 7.75 (t, 1H), hydroxy-2-methyl-3,3,3- 7.88 (dd, 1H), 8.01 (d, 1H), trifluoropropanamide 8.17 (dd, 1H), 8.48 (s, 1H), 8.67 (d, 1H), 9.3 (brs, 1H) 21 (R)-N-[2-Chloro-4-(4-benzoyl- 1.6 (s, 3H), 7.6 (m, 3H), 8.0 525 Ex aminophenylsulphonyl)phenyl]-2- (m, 8H), 8.1 (s, 1H), 8.3 (d, 337 hydroxy-2-methyl-3,3,3- 1H), 9.9 (s, 1H), 10.6 (s, 1H) trifluoropropanamide 22 (R)-N-{2-Chloro-4-[4-(t-butyl- 1.2 (s, 9H), 1.6 (s, 3H), 7.9 (s, 505 Ex carbonylamino)phenylsulphonyl] 5H), 8.1 (s, 1H), 8.3 (d, 1H), 338 phenyl}-2-hydroxy-2-methyl-3,3,3- 9.6 (s, 1H) trifluoropropanamide 23 (R)-N-{2-Chloro-4-[4-(4-chloro- 1.6 (s, 3H), 7.6 (d, 2H), 8.0 (m, 559 Ex benzoylamino)phenylsulphonyl] 8H), 8.1 (s, 1H), 8.3 (d, 1H), 339 phenyl}-2-hydroxy-2-methyl-3,3,3- 9.9 (s, 1H), 10.7 (s, 1H) trifluoropropanamide 24 (R)-N-{2-Chloro-4-[4-(2-methoxy- 1.6 (s, 3H), 3.3 (s, 3H), 4.0 (s. 493 Ex acetylamino)phenylsulphonyl] 2H), 7.9 (m, 6H), 8.1 (s, 1H), 340 phenyl}-2-hydroxy-2-methyl-3,3,3- 8.3 (d, 1H), 10.2 (s, 1H) trifluoropropanamide 25 (R)-N-{2-Chloro-4-[4-(1-oxy- 1.6 (s, 3H), 8.0 (m, 8H), 8.1 (s, 542 Ex pyridin-3-ylcarbonylamino)phenyl- 1H), 8.3 (d, 1H), 8.4 (d, 2H), 341 sulphonyl]phenyl}-2-hydroxy-2- 9.9 (s, 1H), 10.75 (s, 1H) methyl-3,3,3-trifluoropropanamide 26 (R)-N-[2-Chloro-4-(4-ureido- 1.6 (s, 3H), 4.0 (d, 1H), 6.1 (s, 464 Ex phenylsulphonyl)phenyl]-2- 2H), 7.6 (d, 2H), 7.8 (d, 2H), 174 hydroxy-2-methyl-3,3,3- 7.9 (d, 1H), 8.0 (s, 1H), 8.3 (d, trifluoropropanamide 1H), 9.0 (s, 1H), 9.8 (s, 1H) 27 (R)-N-[2-Chloro-4-(2-ureido- 1.6 (s, 3H), 6.7 (s, 2H), 7.2 (t, 464 Ex phenylsulphonyl)phenyl]-2- 1H), 7.6 (m, 2H), 8.0 (m, 3H), 175 hydroxy-2-methyl-3,3,3- 8.2 (d, 2H), 8.3 (s, 1H), 9.9 (s, trifluoropropanamide 1H) 28 (R)-N-[2-Chloro-4-(2-mesylamino- 1.6 (s, 3H), 3.3 (s, 3H), 7.4 (t, 499 Ex phenylsulphonyl)phenyl]-2- 1H), 7.5 (d, 1H), 7.7 (t, 1H), 342 hydroxy-2-methyl-3,3,3- 8.0 (m, 4H), 8.3 (d, 1H), 9.1 (s, trifluoropropanamide 1H), 9.9 (s, 1H) 29 (R)-N-[2-Chloro-4-(2-acetylamino- 1.6 (s, 3H), 2.0 (s, 3H), 7.4 (m, 463 Ex phenylsulphonyl)phenyl]-2- 1H), 7.7 (d, 2H), 7.9 (d, 1H), 343 hydroxy-2-methyl-3,3,3- 8.0 (d, 2H), 8.1 (d, 1H), 8.3 (d, trifluoropropanamide 1H), 9.4 (s, 1H), 9.9 (s, 1H) 30 (R)-N-[2-Chloro-4-(N-methyl-4- 1.6 (s, 3H), 3.0 (s, 3H), 3.3 (s, 513 Ex mesylaminophenylsulphonyl) 3H), 7.6 (d, 2H), 8.0 (m, 4H), 263 phenyl]-2-hydroxy-2-methyl-3,3,3- 8.1 (s, 1H), 8.3 (d, 1H), 9.9 (s, trifluoropropanamide 1H) 31 (R)-N-[2-Chloro-4-(4-mesylamino- 1.6 (s, 3H), 3.1 (s, 3H), 7.4 (d, 499 Ex phenylsulphonyl)phenyl]-2- 2H), 7.9 (m, 3H), 8.0 (s, 1H), 344 hydroxy-2-methyl-3,3,3- 8.1 (s, 1H), 8.3 (d, 1H), 9.9 (s, trifluoropropanamide 1H), 10.48 (s, 1H) 32 (R)-N-{2-Chloro-4-[4-(phenyl- 1.6 (s, 3H), 7.2 (d, 2H), 7.6 (m, 561 Ex sulphonylamino)phenylsulphonyl] 3H), 7.8 (m, 5H), 8.0 (d, 2H), 345 phenyl}-2-hydroxy-2-methyl-3,3,3- 8.2 (d, 1H), 9.9 (s, 1H), 11.0 (s, trifluoropropanamide 1H) 33 (R)-N-[2-Chloro-4-(4-ethenyl- 1.6 (s, 3H), 6.1 (d, 1H), 6.2 (d, 511 Ex sulphonylaminophenylsulphonyl) 1H), 6.9 (m, 1H), 7.3 (d, 2H), 346 phenyl]-2-hydroxy-2-methyl-3,3,3- 7.9 (d, 3H), 8.0 (s, 1H), 8.1 (s, trifluoropropanamide 1H), 8.3 (d, 1H), 9.9 (s, 1H), 10.75 (s, 1H) 34 (R)-N-[2-Chloro-4-(3-mesylamino- 1.6 (s, 3H), 3.0 (s, 3H), 7.5 (d, 499 Ex phenylsulphonyl)phenyl]-2- 1H), 7.6 (t, 1H), 7.7 (m, 2H), 347 hydroxy-2-methyl-3,3,3- 8.0 (m, 3H), 8.3 (d, 1H), 9.9 (s, trifluoropropanamide 1H), 10.2 (s, 1H) 35 (R)-N-[2-Fluoro-4-(4-mesylamino- 1.6 (s, 3H), 3.2 (s, 3H), 7.3 (d, 483 Ex phenylsulphonyl)phenyl]-2- 2H), 7.7 (m, 2H), 7.9 (m, 3H), 348 hydroxy-2-methyl-3,3,3- 8.0 (t, 1H), 9.9 (s, 1H), 10.5 (s, trifluoropropanamide 1H) 36 (R)-N-[2-Fluoro-4-(4-acetylamino- 1.6 (s, 3H), 2.1 (s, 3H), 7.7 (m, 447 Ex phenylsulphonyl)phenyl]-2- 4H), 7.8 (m, 3H), 8.0 (t, 1H), 349 hydroxy-2-methyl-3,3,3- 9.9 (s, 1H), 10.35 (s, 1H) trifluoropropanamide 37 (R)-N-{2-Chloro-4-[4-(2-chloro- 1.6 (s, 3H), 4.3 (s, 2H), 7.8 (d, 497 Ex acetylamino)phenylsulphonyl] 2H), 8.0 (m, 4H), 8.1 (s, 1H), 177 phenyl}-2-hydroxy-2-methyl-3,3,3- 8.3 (d, 1H), 9.9 (s, 1H), 10.72 trifluoropropanamide (s, 1H) 38 (R)-N-(2-Chloro-4-{4-[2-(N′-oxy- 1.6 (s, 3H), 3.2 (s, 6H), 4.0 (s, 522 Ex N′,N′-dimethylamino)acetylamino] 2H), 7.7 (d, 2H), 7.9 (m, 4H), 353 phenylsulphonyl}phenyl)-2- 8.0 (s, 1H), 8.3 (d, 1H) hydroxy-2-methyl-3,3,3- trifluoropropanamide 39 (R)-N-{2-Chloro-4-[4-(3-t- 1.2 (s, 9H), 1.6 (s, 3H), 6.2 (s, 520 Ex butylureido)phenylsulphonyl] 1H), 7.5 (d, 2H), 7.8 (d, 2H), 179 phenyl}-2-hydroxy-2-methyl-3,3,3- 7.9 (d, 1H), 8.0 (d, 2H), 8.2 (d, trifluoropropanamide 1H), 8.8 (s, 1H), 9.9 (s, 1H) 40 (R)-N-{2-Chloro-4-[4-(3-phenyl- 1.6 (s, 3H), 7.0 (t, 1H), 7.3 (t, 540 Ex ureido)phenylsulphonyl]phenyl}-2- 2H), 7.4 (d, 2H), 7.7 (d, 2H), 180 hydroxy-2-methyl-3,3,3- 7.9 (m, 4H), 8.0 (s, 1H), 8.3 (d, trifluoropropanamide 1H), 8.8 (s, 1H), 9.2 (s, 1H), 9.8 (s, 1H) 41 (R)-N-[2-Chloro-4-(2,3-H-2-oxo-3- 1.6 (s, 3H), 3.3 (s, 3H), 7.4 (d, 477 Ex methylbenzoxazol-6-ylsulphonyl) 1H), 7.9 (m, 3H), 8.1 (s, 1H), 265 phenyl]-2-hydroxy-2-methyl-3,3,3- 8.2 (d, 1H), 9.9 (s, 1H) trifluoropropanamide 42 (R)-N-[2-Chloro-4-(2-oxo-1,3- 1.5 (s, 3H), 3.3 (d, 6H), 7.3 (d, 490 Ex dimethylbenzimidazolidin-5- 1H), 7.7 (t, 2H), 8.0 (t, 2H), 8.1 266 ylsulphonyl)phenyl]-2-hydroxy-2- (s, 1H), 8.2 (d, 1H), 9.9 (s, 1H) methyl-3,3,3-trifluoropropanamide 43 (R)-N-{2-Chloro-4-[4-(2-oxo- 1.6 (s, 3H), 2.1 (m, 2H), 2.5 (t, 489 Ex pyrrolidin-1-yl)phenylsulphonyl] 2H), 3.9 (t, 2H), 7.9 (m, 6H), 267 phenyl}-2-hydroxy-2-methyl-3,3,3- 8.1 (s, 1H), 8.3 (d, 1H), 9.9 (s, trifluoropropanamide 1H) 44 (R)-N-[2-Chloro-4-(1,2,3,4-H-1,3- 1.6 (s, 3H), 3.2 (s, 3H), 3.5 (s, 518 Ex dimethyl-2,4-dioxoquinazolin-6- 3H), 7.6 (d, 1H), 8.0 (d, 2H), 268 ylsulphonyl)phenyl]-2-hydroxy-2- 8.2 (s, 1H), 8.3 (m, 2H), 8.5 (s, methyl-3,3,3-trifluoropropanamide 1H), 9.9 (s, 1H) 45 (R)-N-{2-Chloro-4-(4,5-diphenyl- (CDCl₃) 1.75 (s, 3H), 3.8 (brs, 551 Ex 2-oxazolylsulphonyl)phenyl}-2- 1H), 7.3-7.45 (m, 6H), 7.5-7.65 (M + H)⁺ 272 hydroxy-2-methyl-3,3,3- (m, 4H), 8.1 (dd, 1H), 8.2 (d, trifluoropropanamide 1H), 8.75 (d, 1H), 9.4 (brs, 1H) 46 (R)-N-{2-Chloro-4-(1-ethyltetrazol- (CDCl₃) 1.65 (t, 3H), 1.75 (s, 428 Ex 5-ylsulphonyl)phenyl}-2-hydroxy- 3H), 3.7 (brs, 1H), 4.85 (q, (M + H)⁺ 273 2-methyl-3,3,3- 2H), 8.05 (dd, 1H), 8.2 (d, 1H), trifluoropropanamide 8.8 (d, 1H), 9.5 (brs, 1H) 47 (R)-N-{2-Chloro-4-(4-iso-propyl- (CDCl₃) 1.55 (d, 6H), 1.75 (s, 457 Ex 4,5-dihydro-1H-1,2,4-triazol-5-one- 3H), 3.8 (brs, 1H), 4.8 (m, 1H), (M + H)⁺ 274 3-ylsulphonyl)phenyl}-2-hydroxy- 7.9 (dd, 1H), 8.05 (d, 1H), 8.8 2-methyl-3,3,3- (d, 1H), 9.45 (brs, 1H), 10.2 trifluoropropanamide (brs, 1H) 48 (R)-N-{2-Chloro-4-[3-fluoro-4-(2- 1.6 (s, 3H), 3.55-3.65 (m, 2H), 532 Ex hydroxyethylsulphonyl)- 3.65-3.8 (m, 2H), 4.80 (m 1H), 311 phenylsulphonyl]phenyl}-2- 8.00-8.15 (m, 4H), 8.15-8.3 (m, hydroxy-2-methyl-3,3,3- 2H), 8.35 (d, 1H), 9.95 (brs, trifluoropropanamide 1H) 49 (R)-N-[2-Chloro-4-(3-chloro-4- (CDCl₃) 1.75 (s, 3H), 3.25 (s, 518 Ex 8 methylsulphonylphenylsulphonyl) 3H), 3.45 (brs, 1H), 7.9 (dd, phenyl]-2-hydroxy-2-methyl-3,3,3- 1H), 7.95-8.1 (m, 2H), 8.1 (d, trifluoropropanamide 1H), 8.3 (d, 1H), 8.56 (d, 1H), 9.3 (brs, 1H) 50 (R)-N-[2-Chloro-4-(3-fluoro-4- (CDCl₃) 1.75 (s, 3H), 3.2 (s, 502 Ex 9 methylsulphonylphenylsulphonyl) 3H), 3.4 (s, 1H), 7.8 (dd, 1H), phenyl]-2-hydroxy-2-methyl-3,3,3- 7.9 (dd, 2H), 8.0 (d, 1H), 8.1- trifluoropropanamide 8.15 (m, 1H), 8.7 (d, 1H), 9.3 (brs, 1H) 51 (R)-N-{2-Chloro-4-(3-t-butoxy- (CDCl₃): 1.55 (s, 9H), 1.78 (s, 487 Ex carbonylaminopropylsulphonyl) 3H), 1.86-1.97 (m, 2H), 3.13 (t, 405 phenyl}-2-hydroxy-2-methyl-3,3,3- 2H), 3.21-3.26 (m, 2H), 3.86 trifluoropropanamide (s, 1H), 4.65 (t, 1H), 7.80-7.82 (m, 1H), 8.04 (s, 1H), 8.68 (d, 1H), 9.34 (s, 1H) 52 (R)-N-{2-Chloro-4-(2H- 1.6 (s, 3H), 7.1 (d, 1H), 7.4 (s, 462 Ex benzimidazole-2-one-5-yl- 1H), 7.6 (d, 1H), 7.9 (d, 1H), 269 sulphonyl)phenyl}-2-hydroxy-2- 8.0 (s, 1H), 8.2 (d, 1H), 11.0 (s, methyl-3,3,3-trifluoropropanamide 1H), 11.2 (s, 1H) 53 (R)-N-{2-Chloro-4-(4-acetyl- 1.6 (s, 3H), 2.6 (s, 3H), 8.0 (s, 448 Ex phenylsulphonyl)phenyl}-2- 2H), 8.1 (s, 3H), 8.2 (s, 1H), 270 hydroxy-2-methyl-3,3,3- 8.3 (d, 1H), 9.9 (s, 1H) trifluoropropanamide

EXAMPLE 54

(R)-N-{2-Chloro-4-[2-(2-hydroxyethylamino)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Ethanolamine (0.014 ml) was added to a solution of (R)-N-[2-chloro-4-(2-fluoro-phenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Method 63) (0.10 g) in NMP (1.5 ml) and the solution was heated at 120° C. for 18 hours then cooled. Saturated aqueous ammonium chloride solution (10 ml) was added and the mixture was extracted with ethyl acetate (2×20 ml). The organic extracts were combined, washed with brine and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-50% ethyl acetate/hexane to give the title compound (0.074 g) as a solid. Mp 68-70° C.; NMR (CDCl₃): 1.75 (s, 3H), 3.3 (q, 2H), 3.90 (m, 2H), 3.95 (brs, 1H), 6.50 (brt, 1H), 6.70 (d, 1H) 6.80 (m, 1H), 7.4 (m, 1H), 7.85 (m, 2H), 8.00 (d, 1H), 8.55 (d, 1H), 9.25 (brs, 1H); MS (ESP⁻): 465; EA: found: C, 46.6; H, 4.0; N, 5.8%; C₁₈H₁₈ClF₃N₂O₅S requires: C, 46.31; H, 3.89; N, 6.00%.

EXAMPLES 55-85

Following the procedure of Example 54 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS 55 (R)-N-{2-Chloro-4-[4-(3- 1.6 (s, 3H), 1.66 (m, 2H), 3.1 (m, 479 hydroxypropylamino)phenyl- 2H), 3.46 (m, 2H), 4.45 (t, 1H), sulphonyl]phenyl}-2-hydroxy-2- 6.64 (d, 2H), 6.74 (t, 1H), 7.6 (d, methyl-3,3,3-trifluoropropanamide 2H), 7.82 (dd, 1H), 7.98 (d, 1H), 8.2 (d, 1H), 9.8 (brs, 1H) 56 (R)-N-{2-Chloro-4-[4-(2- 1.09 (d, 3H), 1.6 (s, 3H), 3.0 (m, 479 hydroxypropylamino)phenyl- 2H), 3.77 (m, 1H), 4.72 (d, 1H), sulphonyl]phenyl}-2-hydroxy-2- 6.7 (d, 2H), 6.74 (t, 1H), 7.59 (d, methyl-3,3,3-trifluoropropanamide 2H), 7.85 (dd, 1H), 7.96 (d, 1H), 8.22 (d, 1H), 9.8 (brs, 1H) 57 (R)-N-{2-Chloro-4-[4-(2-acetamido- 1.6 (s, 3H), 1.79 (s, 3H), 3.15 (m, 506 ethylamino)phenylsulphonyl]phenyl}- 4H), 6.69 (d, 2H), 6.82 (m, 1H), 2-hydroxy-2-methyl-3,3,3- 7.63 (d, 2H), 7.85 (dd, 1H), 7.93 trifluoropropanamide (m, 1H), 8.0 (d, 1H), 8.2 (d, 1H), 9.8 (brs, 1H) 58 (R)-N-(2-Chloro-4-{4-[2-(2- 1.6 (s, 3H), 3.25 (m, 2H), 3.4-3.6 511 hydroxyethoxy)ethylamino]phenyl- (m, 6H), 4.59 (m, 1H), 6.7 (d, 2H), (M + H)⁺ sulphonyl}phenyl)-2-hydroxy-2- 6.79 (t, 1H), 7.68 (d, 2H), 7.88 (dd, methyl-3,3,3-trifluoropropanamide 1H), 7.99 (d, 1H), 8.22 (d, 1H), 9.8 (brs, 1H) 59 (R)-N-{2-Chloro-4-[4-(4-hydroxy- 1.4-1.63 (m, 7H), 3.04 (m, 2H), 3.4 495 butylamino)phenylsulphonyl]phenyl}- (m, 2H), 4.38 (t, 1H), 6.62 (d, 2H), (M + H)⁺ 2-hydroxy-2-methyl-3,3,3- 6.76 (t, 1H), 7.6 (d, 2H), 7.82 (dd, trifluoropropanamide 1H), 7.46 (d, 1H), 8.22 (d, 1H), 9.78 (brs, 1H) 60 (R)-N-{2-Chloro-4-[4-(2,2-dimethyl- 0.84 (s, 6H), 1.59 (s, 3H), 2.97 (d, 509 3-hydroxypropylamino)phenyl- 2H), 3.19 (d, 2H), 4.59 (m, 1H), (M + H)⁺ sulphonyl]phenyl}-2-hydroxy-2- 6.52 (m, 1H), 6.72 (d, 2H), 7.59 (d, methyl-3,3,3-trifluoropropanamide 2H), 7.83 (dd, 1H), 7.94 (d, 1H), 8.21 (d, 1H), 9.8 (brs, 1H) 61 (R)-N-[2-Chloro-4-[4-(2,3- 1.59 (s, 3H), 2.99 (m, 1H), 3.2 (m, 495 dihydroxypropylamino)phenyl- 1H), 3.3 (m, partially obscured by sulphonyl]phenyl}-2-hydroxy-2- water peak), 3.59 (m, 1H), 4.63 (t, methyl-3,3,3-trifluoropropanamide 1H), 4.83 (d, 1H), 6.7 (d, 2H), 6.78 (t, 1H), 7.6 (d, 2H), 7.84 (dd, 1H), 7.99 (d, 1H), 8.2 (d, 1H), 9.85 (brs, 1H) 62 (R)-N-{2-Chloro-4-[4-(1,3- 1.45 (s, 3H), 3.3 (brs, 5H), 4.5 (brs, 495 dihydroxyprop-2-ylamino)phenyl- 2H), 6.3 (d, 1H), 6.59 (d, 2H), 7.47 sulphonyl]phenyl}-2-hydroxy-2- (d, 2H), 7.7 (dd, 1H), 7.83 (d, 1H), methyl-3,3,3-trifluoropropanamide 8.08 (d, 1H), 9.7 (brs, 1H) 63 (R)-N-{2-Fluoro-4-[4-(2-hydroxy- (CDCl₃) 1.69 (s, 3H), 2.84 (t, 1H), 449 ethylamino)phenylsulphonyl]phenyl}- 3.27-3.33 (m, 2H), 3.8-3.86 (m, 2-hydroxy-2-methyl-3,3,3- 2H), 5.9 (t, 1H), 6.59 (d, 1H), 6.75 trifluoropropanamide (s, 1H), 7.60-7.68 (m, 4H), 8.53 (t, 1H), 9.27 (s, 1H) 64 (R)-N-{2-Chloro-4-[2-(3-hydroxy- (CDCl₃) 1.75 (s, 3H), 1.85-1.95 491 pyrrolidin-1-yl)phenylsulphonyl] (m, 1H), 2.1-2.25 (m, 1H), 2.9 (q, phenyl}-2-hydroxy-2-methyl-3,3,3- 1H), 3.05-3.2 (m, 3H), 3.75 (d, trifluoropropanamide 1H), 4.48 (brs, 1H), 7.27-7.32 (m, 2H), 7.55 (t, 1H), 7.8 (t, 1H), 8.07 (dd, 1H), 8.14 (d, 1H), 8.5 (d, 1H), 9.2 (brs, 1H) 65 (R)-N-{2-Chloro-4-[2-(N,N- (CDCl₃) 1.75 (s, 3H), 2.3 (s, 6H), 492 dimethylaminoethylamino)phenyl- 2.6 (t, 2H), 3.14 (q, 2H), 6.5 (brt, sulphonyl]phenyl}-2-hydroxy-2- 1H), 6.6 (d, 1H), 6.72 (t, 1H), 7.35 methyl-3,3,3-trifluoropropanamide (t, 1H), 7.86 (t, 2H), 8.0 (d, 1H), 8.55 (d, 1H), 9.3 (brs, 1H) 66 (R)-N-{2-Chloro-4-[2-morpholino (CDCl₃) 1.76 (s, 3H), 2.8 (brs, 4H), 491 phenylsulphonyl]phenyl}-2-hydroxy- 3.6 (brs, 1H), 3.74 (brs, 4H), 7.3 2-methyl-3,3,3-trifluoropropanamide (d, 1H), 7.4 (t, 1H), 7.62 (t, 1H), 7.75 (d, 1H), 8.1 (s, 1H), 8.27 (d, 1H), 8.52 (d, 1H), 9.2 (brs, 1H) 67 (R)-N-{2-Chloro-4-[2-(4-methyl- (CDCl₃) 1.75 (s, 3H), 2.32 (s, 3H), 504 piperazin-1-yl)phenylsulphonyl] 2.5 (brs, 4H), 2.83 (t, 4H), 7.3 (d, phenyl}-2-hydroxy-2-methyl-3,3,3- 1H), 7.37 (t, 1H), 7.6 (t, 1H), 7.72 trifluoropropanamide (dd, 1H), 8.1 (s, 1H), 8.25 (d, 1H), 8.53 (d, 1H), 9.4 (brs, 1H) 68 (R)-N-[2-Chloro-4-(4-benzyl- 1.74 (s, 3H), 4.35 (s, 2H), 6.58- 511 aminophenylsulphonyl)phenyl]-2- 6.63 (m, 2H), 7.26-7.39 (m, 5H), hydroxy-2-methyl-3,3,3- 7.62-7.70 (m, 2H), 7.72-7.80 (m, trifluoropropanamide 1H), 7.94 (s, 1H), 8.50-8.57 (m, 1H), 9.18 (brs, 1H) 69 (R)-N-[2-Chloro-4-(3-chloro-4-(2- (CDCl₃) 1.75 (s, 3H), 3.4 (q, 2H), 501 hydroxyethylamino)phenylsulphonyl) 3.5 (s, 1H), 3.85 (q, 2H), 5.25 (m, (M + H)⁺ phenyl]-2-hydroxy-2-methyl-3,3,3- 1H), 6.65 (d, 1H), 7.65 (dd, 1H), trifluoropropanamide 7.75-7.85 (m, 2H), 7.95 (d, 1H), 8.55 (d, 1H), 9.15 (brs, 1H) 70 (R)-N-[2-Chloro-4-(3-fluoro-4-(2- (CDCl₃) 1.75 (s, 3H), 3.35 (q, 2H), 485 hydroxyethylamino)phenylsulphonyl) 3.65 (s, 1H), 3.9 (t, 2H), 4.8 (m, (M + H)⁺ phenyl]-2-hydroxy-2-methyl-3,3,3- 1H), 6.7 (t, 1H), 7.5 (dd, 1H), 7.60 trifluoropropanamide (dd, 1H), 7.8 (dd, 1H), 7.9 (d, 1H), 8.55 (d, 1H), 9.2 (brs, 1H) 71 (R)-N-{2-Chloro-4-[4-(2- (CDCl₃ + DMSO-δ₆) 1.6 (s, 3H), 465 hydroxyethylamino)phenylsulphonyl] 3.2 (q, 2H), 3.7 (m, 3H), 5.15 (t, phenyl}-2-hydroxy-2-methyl-3,3,3- 1H), 6.51 (d, 2H), 7.14 (s, 1H), trifluoropropanamide 7.58 (d, 2H), 7.68 (d, 1H), 7.83 (d, 1H), 8.49 (d, 1H), 9.64 (brs, 1H) 72 (R)-N-{2-Chloro-4-[4-(2- (CDCl₃) 1.76 (s, 3H), 3.29-3.28 481 methoxyethylamino)phenylsulphonyl] (m, 2H), 3.39 (s, 3H), 3.6 (t, 2H), (M + H)⁺ phenyl}-2-hydroxy-2-methyl-3,3,3- 3.75 (s, 1H), 4.64 (t, 1H), 6.59 (d, trifluoropropanamide 2H), 7.69 (d, 2H), 7.8 (dd, 1H), 7.94 (d, 1H), 8.54 (d, 1H), 9.2 (brs, 1H) 73 (R)-N-(2-Chloro-4-[4-morpholino (CDCl₃) 1.73 (s, 3H), 3.25-3.34 493 phenylsulphonyl]phenyl}-2-hydroxy- (m, 4H), 3.8-3.9 (m, 5H), 6.99 (d, (M + H)⁺ 2-methyl-3,3,3-trifluoropropanamide 2H), 7.72-7.86 (m, 3H), 7.96 (d, 1H), 8.57 (d, 1H), 9.29 (brs, 1H) 74 (R)-N-{2-Chloro-4-[4-(2-methyl- (CDCl₃) 1.74 (s, 3H), 2.1 (s, 3H), 497 sulphanylethylamino)phenyl- 2.76 (t, 2H), 3.36 (q, 2H), 3.7 (s, (M + H)⁺ sulphonyl]phenyl}-2-hydroxy-2- 1H), 4.72 (t, 1H), 6.6 (d, 2H), 7.7 methyl-3,3,3-trifluoropropanamide (d, 2H), 7.79 (dd, 1H), 7.94 (d, 1H), 8.54 (d, 1H), 9.21 (brs, 1H) 75 (R)-N-{2-Chloro-4-[4-(2- (CDCl₃) 1.78 (s, 3H), 3.66 (brs, 501 furylmethylamino)phenylsulphonyl] 1H), 4.34 (d, 2H), 4.63 (t, 1H), phenyl}-2-hydroxy-2-methyl-3,3,3- 6.22 (m, 1H), 6.35 (m, 1H), 6.66 trifluoropropanamide (d, 2H), 7.36 (d, 1H), 7.69 (d, 2H), 7.8 (dd, 1H), 7.93 (d, 1H), 8.55 (d, 1H), 9.2 (brs, 1H) 76 (R)-N-{2-Chloro-4-[4-({1- (CDCl₃) 1.1 (t, 3H), 1.73 (s, 3H), 532 ethylpyrrolidin-2-yl}methylamino) 3.4 (t, 1H), 5.4 (brs, 1H), 6.59 (d, phenylsulphonyl]phenyl}-2-hydroxy- 2H), 7.68 (d, 2H), 7.7-7.8 (m, 1H), 2-methyl-3,3,3-trifluoropropanamide 7.93 (d, 1H), 8.54 (d, 1H), 9.36 (brs, 1H)  77¹ (R)-N-{2-Chloro-4-[4-(iso-propyl- 1.12 (s, 3H), 1.14 (s, 3H), 1.6 (s, 463 amino)phenylsulphonyl]phenyl}-2- 3H), 3.61 (m, 1H), 6.62 (m, 3H), hydroxy-2-methyl-3,3,3- 7.6 (d, 2H), 7.83 (dd, 1H), 7.97 (d, trifluoropropanamide 1H), 8.20 (d, 1H), 9.86 (brs, 1H)  78¹ (R)-N-{2-Chloro-4-[4-(cyclopropyl- 0.18 (m, 2H), 0.46 (m, 2H), 0.99 475 methylamino)phenylsulphonyl] (m, 1H), 1.58 (s, 3H), 2.9 (m, 2H), phenyl}-2-hydroxy-2-methyl-3,3,3- 6.65 (d, 2H), 6.90 (t, 1H), 7.60 (d, trifluoropropanamide 2H), 7.83 (dd, 1H), 7.95 (m, 2H), 8.19 (d, 1H), 9.87 (brs, 1H)  79¹ (R)-N-{2-Chloro-4-[4-(pyrrolidin-1- 1.6 (s, 3H), 1.94 (m, 4H), 3.28 (m, 475 yl)phenylsulphonyl]phenyl}-2- 4H), 6.62 (d, 2H), 7.7 (d, 2H), 7.85 hydroxy-2-methyl-3,3,3- (dd, 1H), 7.9-8.02 (brs, 1H), 7.99 trifluoropropanamide (d, 1H), 8.2 (d, 1H), 9.86 (brs, 1H) 80 (R)-N-{2-Chloro-4-[4-(3-hydroxy- 1.68 (s, 3H), 1.99 (m, 1H), 2.08 491 pyrrolidin-1-yl)phenylsulphonyl] (m, 1H), 3.2 (d, 1H), 3.37-3.42 (m, phenyl}-2-hydroxy-2-methyl-3,3,3- 2H), 4.47 (brs, 1H), 5.04 (d, 1H), trifluoropropanamide 6.66 (d, 2H), 7.75 (d, 2H), 7.9 (dd, 1H), 8.04 (d, 1H), 8.26 (d, 1H), 9.9 (brs, 1H) 81 (R)-N-{2-Chloro-4-[4-(4-hydroxy- 1.42 (m, 2H), 1.68 (s, 3H), 1.82 505 piperidin-1-yl)phenylsulphonyl] (m, 2H), 3.12 (m, 2H), 3.75 (m, phenyl}-2-hydroxy-2-methyl-3,3,3- 3H), 4.77 (d, 1H), 7.08 (d, 2H), trifluoropropanamide 7.79 (d, 2H), 7.9-8.1 (brs), 7.94 (dd, 1H), 8.09 (d, 1H), 8.3 (d, 1H), 9.9 (brs, 1H) 82 (R)-N-{2-Chloro-4-[4-thiomorpholino 1.59 (s, 3H), 2.6 (m, 4H), 3.78 (m, 509 phenylsulphonyl]phenyl}-2-hydroxy- 4H), 7.0 (d, 2H), 7.71 (d, 2H), 7.88 (M + H)⁺ 2-methyl-3,3,3-trifluoropropanamide (dd, 1H), 8.0 (brs, 1H), 8.02 (d, 1H), 8.25 (d, 1H), 9.87 (brs, 1H) 83 (R)-N-{2-Chloro-4-[4-(4-hydroxy- 1.15 (m, 2H), 1.6 (s, 3H), 1.69 (m, 519 methylpiperidin-1-yl)phenyl- 2H), 2.82 (m, 2H), 3.27 (m, 2H), sulphonyl]phenyl}-2-hydroxy-2- 3.9 (m, 2H), 4.45 (t, 1H), 7.0 (d, methyl-3,3,3-trifluoropropanamide 2H), 7.69 (d, 2H), 7.89 (dd, 1H), 8.0 (d, 1H), 8.22 (d, 1H), 9.85 (brs, 1H) 84 (R)-N-{2-Chloro-4-[4-(3- 1.27 (m, 1H), 1.5 (m, 1H), 1.69 (s, 519 hydroxymethylpiperidin-1- 3H), 1.7 (m, 3H), 2.76 (m, 2H), yl)phenylsulphonyl]phenyl}-2- 2.94 (m, 1H), 3.89 (m, 2H), 4.6 (t, hydroxy-2-methyl-3,3,3- 1H), 7.03 (d, 2H), 7.77 (d, 2H), trifluoropropanamide 7.94 (dd, 1H), 8.09 (d, 1H), 8.3 (d, 1H), 9.92 (brs, 1H) 85 (R)-N-{2-Chloro-4-[4-(4-{2- 1.15 (m, 2H), 1.6 (s, 3H), 1.69 (m, 534 hydroxyethyl}piperazin-1- 2H), 2.82 (m, 2H), 3.27 (m, 2H), yl)phenylsulphonyl]phenyl}-2- 3.9 (m, 2H), 4.45 (t, 1H), 7.0 (d, hydroxy-2-methyl-3,3,3- 2H), 7.69 (d, 2H), 7.89 (dd, 1H), trifluoropropanamide 8.0 (d, 1H), 8.22 (d, 1H), 9.85 (brs, 1H) ¹Reaction was carried out in a sealed tube

EXAMPLE 86

(R)-N-{2-Chloro-4-[4-(methylsulphinyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

t-Butylhydroperoxide (0.36 ml of a 3M solution in toluene) was added to a solution of (R)-N-{2-chloro-4-[4-(methylsulphanyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 2) (0.247 g) and d-10-camphorsulphonic acid (0.012 g) in chloroform (5 ml) and the mixture was stirred at ambient temperature for 64 hours. The reaction mixture was transferred directly to a silica gel Mega Bond Elut column and eluted with 0-80% ethyl acetate/hexane to give the title compound (0.237 g) as a foam. NMR (CDCl₃): 1.74 (s, 3H), 2.74 (s, 3H), 4.2 (brs, 1H), 7.79 (d, 2H), 7.89 (dd, 1H), 8.0 (m, 1H), 8.1 (d, 2H) 8.65 (d, 1H), 9.38 (brs, 1H); MS (ESP⁻): 468; EA: found: C, 43.3; H, 3.1; N, 2.98%; C₁₇H₁₅ClF₃NO₅S₂ requires: C, 43.3; H, 3.1; N, 2.8%.

EXAMPLES 87-103

Following the procedure of Example 86 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR (CDCl₃) MS SM  87¹ (R)-N-{2-Chloro-4-[4-(methyl- 1.72 (s, 3H), 2.76 (s, 3H), 5.0 452 Ex sulphinyl)phenylsulphinyl] (brm, 1H), 7.53 (m, 1H), 7.7-7.82 189 phenyl}-2-hydroxy-2-methyl- (m, 5H), 8.56 (m, 1H), 9.35 (brs, 3,3,3-trifluoropropanamide 1H) 88 (R)-N-{2-Chloro-4-[3-(methyl- 1.70 (s, 3H), 2.80 (s, 3H), 5.60 468  Ex 4 sulphinyl)phenylsulphonyl] (brs, 1H), 7.70-7.75 (m, 1H), 7.85 phenyl}-2-hydroxy-2-methyl- (d, 2H), 8.00 (s, 1H), 8.05 (d, 1H), 3,3,3-trifluoropropanamide 8.20 (s, 1H), 8.65 (d, 1H), 9.55 (s, 1H) 89 (R)-N-[2-Chloro-4-(4- (DMSO-δ₆) 1.6 (s, 3H), 6.9-7.0 406 Ex hydroxyphenylsulphinyl) (m, 3H), 7.5 (d, 2H), 7.6 (dd, 1H), 252 phenyl]-2-hydroxy-2-methyl- 7.8 (s, 1H), 7.9 (s, 1H), 8.1 (d, 3,3,3-trifluoropropanamide 1H), 9.8 (s, 1H) 90 (R)-N-{2-Chloro-4-[4-(methyl- 1.72 (s, 3H), 2.73 (m, 3H), 4.72 436 Ex sulphinyl)phenylsulphanyl] (m, 1H), 7.34 (d, 2H), 7.41 (d, 189 phenyl}-2-hydroxy-2-methyl- 1H), 7.5-7.6 (m, 3H), 8.45 (d, 3,3,3-trifluoropropanamide 2H), 9.2 (brd, 1H) 91 (R)-N-{2-Chloro-4-[4-(2- (CDCl₃ + DMSO-δ₆) 1.58 (s, 3H), 498 Ex hydroxyethylsulphinyl)phenyl- 2.84 (m, 1H), 2.98 (m, 1H), 3.75 284 sulphonyl]phenyl}-2-hydroxy- (m, 1H), 3.94 (m, 1H), 4.66 (t, 2-methyl-3,3,3- 1H), 7.45 (s, 1H), 7.73 (d, 2H), trifluoropropanamide 7.76 (dd, 1H), 7.91 (d, 1H), 7.99 (d, 2H), 8.6 (d, 1H), 9.72 (brs, 1H) 92 (R)-N-(2-Chloro-4-methyl- 1.77 (s, 3H), 2.74 (s, 3H), 4.7 and 328 Ex sulphinylphenyl)-2-hydroxy-2- 4.75 (2xbrs, 1H), 7.49 (t, 1H), 191 methyl-3,3,3- 7.74 (d, 1H), 8.59 (m, 1H), 9.3 trifluoropropanamide (brd, 1H) 93 (R)-N-(2-Fluoro-4-ethyl- (DMSO-δ₆) 1.09-1.18 (m, 3H), 326 Ex sulphinylphenyl)-2-hydroxy-2- 1.68 (s, 3H), 2.65-2.76 (m, 1H), 424 methyl-3,3,3- 2.78-2.86 (m, 1H), 4.54 (s, 1H), trifluoropropanamide 7.21-7.28 (m, 1H), 7.34-7.43 (m, 1H), 8.42-8.50 (m, 1H), 8.85 (brs, 1H) 94 (R)-N-(2-Fluoro-4-methyl- (DMSO-δ₆) 1.68 (s, 3H), 2.65 (s, 312 Ex sulphinylphenyl)-2-hydroxy-2- 3H), 4.50 (s, 1H), 7.26-7.32 (m, 196 methyl-3,3,3- 1H), 7.42-7.50 (m, 1H), 8.47 (t, trifluoropropanamide 1H), 8.85 (s, 1H) 95 (R)-N-[2-Chloro-4-(3- (DMSO-δ₆) 1.44-1.56 (m, 1H), 372 Ex hydroxypropylsulphinyl) 1.6 (s, 3H), 1.69-1.78 (m, 1H), 328 phenyl]-2-hydroxy-2-methyl- 2.77-2.87 (m, 1H), 2.98-3.08 (m, 3,3,3-trifluoropropanamide 1H), 3.43 (t, 2H), 7.65 (d, 1H), 7.81 (s, 1H), 7.92 (s, 1H), 8.18 (d, 1H), 9.85 (s, 1H) 96 (R)-N-[2-Chloro-4-(cyclo- 1.20-1.26 (m, 6H), 1.76 (s, 3H), 396 Ex hexylsulphinyl)phenyl]-2- 1.80-1.86 (m, 4H), 2.52-2.60 (m, 417 hydroxy-2-methyl-3,3,3- 1H), 4.60 and 4.89 (2xs, 1H), trifluoropropanamide 7.36-7.44 (m, 1H), 7.57 and 7.68 (2xs, 1H), 8.50-8.55 (m, 1H), 9.21 and 9.23 (2xs, 1H) 97 (R)-N-[2-Fluoro-4-(4-ethyl- (DMSO-δ₆) 0.98 (t, 3H), 1.56 (s, 466  Ex 10 sulphinylphenylsulphonyl) 3H), 2.73-2.81 (m, 1H), 3.02-3.13 phenyl]-2-hydroxy-2-methyl- (m, 1H), 7.84-7.86 (m, 2H), 7.94- 3,3,3-trifluoropropanamide 8.05 (m, 2H), 8.14 (d, 2H) 98 (R)-N-{2-Chloro-4-[3-chloro- 1.75 (s, 3H), 2.55 (t, 1H), 2.85- 532 Ex 4-(2-hydroxyethylsulphinyl)- 2.95 (m, 1H), 3.40-3.55 (m, 2H), 310 phenylsulphonyl]phenyl}-2- 4.05-4.15 (m, 1H), 7.95 (dd, 1H), hydroxy-2-methyl-3,3,3- 7.95 (d, 1H), 8.00-8.15 (m, 3H), trifluoropropanamide 8.65 (d, 1H), 9.3 (brs, 1H) 99 (R)-N-{2-Chloro-4-[3-fluoro-4- (DMSO-δ₆) 1.6 (s, 3H), 2.9-3.0 518 Ex (2-hydroxyethylsulphinyl)- (m, 1H), 3.1-3.23 (m, 1H), 3.65- (M + H)⁺ 311 phenylsulphonyl]phenyl}-2- 3.85 (m, 2H), 5.1 (t, 1H), 7.95 (t, hydroxy-2-methyl-3,3,3- 1H), 8.0-8.15 (m, 3H), 8.2 (m, trifluoropropanamide 1H), 8.3 (d, 1H), 9.9 (brs, 1H) 100  (R)-N-[2-Chloro-4-(3-chloro-4- 1.75 (s, 3H), 2.85 (s, 3H), 3.65 504  Ex 8 methylsulphinylphenyl- (brs, 1H), 7.9 (m, 1H), 7.95 (s, (M + H)⁺ sulphonyl)phenyl]-2-hydroxy- 1H), 8.0-8.1 (m, 2H), 8.15 (d, 2-methyl-3,3,3- 1H), 8.65 (d, 1H), 9.3 (brs, 1H) trifluoropropanamide 101  (R)-N-[2-Chloro-4-(3-fluoro-4- 1.74 (s, 3H), 2.85 (s, 3H), 3.95 (d, 488  Ex 9 methylsulphinylphenyl- 1H), 7.70 (d, 1H), 7.8-8.1 (m, (M + H)⁺ sulphonyl)phenyl]-2-hydroxy- 4H), 8.65 (d, 1H), 9.35 (brs, 1H) 2-methyl-3,3,3- trifluoropropanamide 102  (R)-N-[2-Chloro-4-(4-N,N- (DMSO-δ₆) 1.0-1.1 (m, 3H), 1.1- 491 Ex diethylcarbamoylphenyl- 1.20 (m, 3H), 1.6 (s, 3H), 3.1-3.2 (M + H)⁺ 234 sulphinyl)phenyl]-2-hydroxy- (m, 2H), 3.3-3.4 (m, 2H), 7.5 (d, 2-methyl-3,3,3- 2H), 7.7-7.80 (m, 3H), 7.85-7.95 trifluoropropanamide (m, 2H), 8.2 (d, 1H), 9.85 (s, 1H) 103  (R)-N-[2-Chloro-4-(4-{3- (DMSO-δ₆) 1.1-1.15 (m, 4H), 1.6 519 Ex hydroxypiperidin-1-yl- (s, 3H), 2.9 (s, 1H), 3.5 (s, 1H), (M + H)⁺ 238 carbonyl}phenylsulphinyl) 3.7-3.9 (m, 4H), 7.5 (d, 2H), 7.85 phenyl]-2-hydroxy-2-methyl- (s, 1H), 7.7-7.9 (m, 3H), 7.95 (s, 3,3,3-trifluoropropanamide 1H), 8.2 (d, 1H), 9.8 (s, 1H) ¹A further molar equivalent of t-butylhydroperoxide solution was added after 18 hours, and the eluent used in the purification was 0-100% ethyl acetate/hexane

EXAMPLE 104

(R)-N-[4-(4-Acetamidophenylsulphonyl)-2-chlorophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Oxalyl chloride (0.047 ml) was added to a stirred suspension of (R)-(+)-2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid (Method 9) (0.077 g) in DCM (2.5 ml) containing DMF (1 drop). The mixture was stirred at ambient temperature for 2 hours and was then added to a solution of 4-(4-acetamidophenylsulphonyl)-2-chloroaniline (Method 10) (0.160 g) in DCM (2.5 ml) and stirred a further 2 hours. Ether (50 ml) was added and the mixture was washed with water (2×50 ml) and brine then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-70% ethyl acetate/toluene to give the title compound (0.025 g) as a solid. NMR: 1.6 (s, 3H), 2.05 (s, 3H), 7.1-7.3 (brm, 1H), 7.8 (d, 2H), 7.9 (m, 3H), 7.97-8.05 (brs, 2H), 8.25 (d, 1H), 10.36 (brs, 1H); MS (ESP⁻): 463; EA: found: C, 47.8; H, 3.6; N, 5.4%; C₁₈H₁₆ClF₃N₂O₅S.0.2 C₇H₈ requires: C, 48.2; H, 3.7; N, 5.8%.

EXAMPLES 105-112

Following the procedure of Example 104 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS  105 (R)-N-{2-Chloro-4-[2-(methoxy- 432 carbonyl)phenylsulphanyl]phenyl}- 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide  106 (R)-N-{2-Chloro-4-[2-(ethoxy- 1.3 (t, 3H), 1.6 (s, 3H), 4.3 (q, 2H), 446 carbonyl)phenylsulphanyl]phenyl}- 6.85 (d, 1H), 7.25 (t, 1H), 7.35-7.55 2-hydroxy-2-methyl-3,3,3- (m, 2H), 7.7 (d, 1H), 7.9 (dd, 2H), trifluoropropanamide 8.15 (d, 1H), 9.8 (brs, 1H)  107 (R)-N-(2-Fluoro-4-phenylsulphanyl- 1.55 (s, 3H), 7.1 (d, 1H), 7.2 (m, 1H), 358 phenyl)-2-hydroxy-2-methyl-3,3,3- 7.3-7.5 (m, 5H), 7.6 (s, 1H), 7.7 (t, trifluoropropanamide 1H), 9.65 (s, 1H)   108¹ N-(2,4-Dimethoxyphenyl)-2- 1.6 (s, 3H), 3.8 (s, 3H), 3.9 (s, 3H), 292 hydroxy-2-methyl-3,3,3- 6.55 (dd, 1H), 6.7 (d, 1H), 7.7 (s, 1H), trifluoropropanamide 8.05 (d, 1H), 9.3 (brs, 1H)   109¹ N-[4-Chloro-2-(2-chlorobenzoyl) 1.6 (s, 3H), 7.26 (s, 1H), 7.5-7.57 (m, 404 phenyl]-2-hydroxy-2-methyl-3,3,3- 1H), 7.6-7.7 (m, 4H), 7.8 (d, 1H), 7.9 trifluoropropanamide (brs, 1H), 8.7 (d, 1H), 12.2 (brs, 1H)   110¹ N-(2-Methoxy-4-methoxycarbonyl- 1.6 (s, 3H), 3.85 (s, 3H), 4.0 (s, 3H), 320 phenyl)-2-hydroxy-2-methyl-3,3,3- 7.6 (s, 1H), 7.65 (d, 1H), 7.93 (s, 1H), trifluoropropanamide 8.37 (d, 1H), 9.7 (brs, 1H)   111¹ N-[2-Bromo-4-(iso-propyl)phenyl]- 1.2 (d, 6H), 1.6 (s, 3H), 2.9 (m, 1H), 352 2-hydroxy-2-methyl-3,3,3- 7.28 (dd, 1H), 7.5 (d, 1H), 7.75 (brs, and trifluoropropanamide 1H), 7.9 (d, 1H), 9.6 (brs, 1H) 354   112¹ N-[2-Chloro-4-(t-butyl)phenyl]-2- 1.25 (s, 9H), 1.6 (s, 3H), 7.4 (dd, 1H), 322 hydroxy-2-methyl-3,3,3- 7.5 (d, 1H), 7.7 (brs, 1H), 7.9 (d, 1H), trifluoropropanamide 9.6 (brs, 1H)   113¹ N-(2-Bromo-4-ethylphenyl)-2- 1.2 (t, 3H), 1.6 (s, 3H), 2.6 (q, 2H), 7.2 338 hydroxy-2-methyl-3,3,3- (dd, 1H), 7.5 (d, 1H), 7.7 (brs, 1H), 7.9 and trifluoropropanamide (d, 1H), 9.6 (brs, 1H) 340 ¹Racemic 2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid was used

EXAMPLE 114

N-(2-Fluoro-4-phenylsulphonylphenyl)-2-hydroxy-2-methylpropanamide

Hydrogen peroxide (0.45 ml of a 30 wt. % solution in water) was added to a solution of N-(2-fluoro-4-phenylsulphanylphenyl)-2-hydroxy-2-methylpropanamide (Example 205) (0.34 g) in glacial acetic acid (1.1 ml) and the mixture was stirred and heated at 100° C. for 2 hours then cooled Water (2 ml) was added to the resultant precipitate and the solid was collected, washed further with water (2×5 ml) and dried in vacuo at 60° C. to give the title compound (0.347 g) as a solid. Mp 155.5-156.5° C.; NMR: 1.34 (s, 6H), 6.08 (brs, 1H), 7.56-7.7 (m, 3H), 7.8 (d, 1H), 7.9 (d, 1H), 7.96 (d, 2H), 8.31 (t, 1H), 9.5 (s, 1H); MS (ESP⁻): 336; EA: found: C, 57.1; H, 4.7; N, 4.1; S, 9.7%; C₁₆H₁₆FNO₄S requires: C, 57.0; H, 4.8; N, 4.2; S, 9.5%

EXAMPLES 115-170

Following the procedure of Example 114, using the appropriate starting materials, and using extraction followed by chromatography to isolate and purify the product when necessary, the following compounds were prepared.

Ex Compound NMR MS SM 115 (R)-N-{2-Chloro-4-[4-(dimethyl- 1.6 (s, 3H), 2.65 (s, 6H), 7.9- 513 Ex aminosulphonyl)phenylsulphonyl] 7.95 (d, 3H), 8.0 (dd, 1H), 251 phenyl}-2-hydroxy-2-methyl- 8.2-8.25 (m, 3H), 8.35 (d, 3,3,3-trifluoropropanamide 1H), 9.3 (s, 1H) 116 (R)-N-[2-Chloro-4-(4- 1.70 (s, 3H), 6.40 (brs, 2H), 485 Ex sulphamoylphenylsulphonyl) 7.20 (s, 1H), 7.80 (d, 1H), 254 phenyl]-2-hydroxy-2-methyl- 7.95 (s, 1H), 8.00-8.10 (m, 3,3,3-trifluoropropanamide 4H), 8.7 (d, 1H), 9.80 (s, 1H) 117 (R)-N-{2-Chloro-4-[4- 1.60 (s, 3H), 6.7 (s, 4H), 7.15 527 Ex (guanidinosulphonyl)phenyl- (d, 2H), 7.25 (d, 1H), 7.65- 255 sulphonyl]phenyl}-2-hydroxy-2- 7.70 (m, 3H), 7.90 (s, 1H), methyl-3,3,3- 8.1 (d, 1H), 9.75 (s, 1H) trifluoropropanamide 118 (R)-N-{2-Chloro-4-[4-(pyrrolidin- (CDCl₃) 1.75 (s, 3H), 1.8- 539 Ex 1-ylsulphonyl) phenylsulphonyl] 1.85 (m, 4H), 3.2-3.3 (m, 250 phenyl}-2-hydroxy-2-methyl- 4H), 3.55 (s, 1H), 7.85 (dd, 3,3,3-trifluoropropanamide 1H), 7.95 (d, 2H), 8.05 (d, 1H), 8.1 (d, 2H), 8.65 (d, 1H), 9.3 (s, 1H) 119 (R)-N-[2-Chloro-4-(4-hydroxy- 1.6 (s, 3H), 6.95 (d, 2H), 7.8 422 Ex phenylsulphonyl)phenyl]-2- (d, 2H), 7.9 (dd, 1H), 8.05 252 hydroxy-2-methyl-3,3,3- (dd, 2H), 9.9 (s, 1H), 10.7 (s, trifluoropropanamide 1H) 120 (R)-N-{2-Chloro-4-[4-(ethoxy- 1.4 (t, 3H), 1.76 (s, 3H), 3.6 478 Ex carbonyl)phenylsulphonyl] (s, 1H), 4.4 (q, 2H), 7.88 (dd, 190 phenyl}-2-hydroxy-2-methyl- 1H), 7.99 (m, 3H), 8.18 (d, 3,3,3-trifluoropropanamide 2H), 8.64 (d, 1H), 9.3 (brs, 1H) 121 (R)-N-[2-Chloro-4-(4-carboxy- 1.79 (s, 3H), 8.19 (dd, 2H), 450 Ex phenylsulphonyl)phenyl]-2- 8.32 (s, 4H), 8.36 (d, 1H), 291 hydroxy-2-methyl-3,3,3- 8.52 (d, 1H), 10.1 (brs, 1H), trifluoropropanamide 13.7 (brs, 1H) 122 (R)-N-{2-Chloro-4-[4-(1,1- 1.61 (s, 3H), 3.1-3.4 (brs, 567 Ex dioxothiomorpholinocarbonyl) 4H), 3.6 (brs, 2H), 4.0 (brs, 300 phenylsulphonyl]phenyl}-2- 2H), 7.73 (d, 2H), 8.02 (dd, hydroxy-2-methyl-3,3,3- 1H), 8.09 (d, 2H), 8.2 (d, 1H), trifluoropropanamide 8.32 (d, 1H), 9.9 (brs, 1H) 123 (R)-N-[2-Chloro-4-(1-methyl- 1.7 (s, 3H), 4.01 (s, 3H), 7.18 410 Ex imidazol-2-ylsulphonyl)phenyl]- (d, 1H), 7.56 (d, 1H), 8.05 257 2-hydroxy-2-methyl-3,3,3- (dd, 1H), 8.13 (d, 1H), 8.42 trifluoropropanamide (d, 1H), 10.0 (brs, 1H) 124 (R)-N-{2-Chloro-4-[4-(1,1-dioxo- 1.6 (s, 3H), 3.45 (m, 2H), 553 Ex thiazolidin-3-ylcarbonyl)phenyl- 4.02 (brs, 2H), 4.64 (s, 2H), 301 sulphonyl]phenyl}-2-hydroxy-2- 7.74 (d, 2H), 8.02 (dd, 1H), methyl-3,3,3- 8.1 (d, 2H), 8.19 (d, 1H), 8.33 trifluoropropanamide (d, 1H), 9.9 (brs, 1H) 125 (R)-N-[2-Chloro-4-(2-carboxy- 1.60 (s, 3H), 7.47-7.57 (m, 450 Ex phenylsulphonyl)phenyl]-2- 2H), 7.63-7.68 (m, 1H), 7.98 292 hydroxy-2-methyl-3,3,3- (d, 1H), 8.06 (d, 1H), 8.22 (d, trifluoropropanamide 1H), 8.27 (s, 1H), 9.92 (s, 1H) 126 (R)-N-(2-Fluoro-4-ethyl- (DMSO-δ₆ + AcOH-δ₄) 1.07 342  Ex 93 sulphonylphenyl)-2-hydroxy-2- (t, 3H), 1.81 (s, 3H), 3.17- methyl-3,3,3- 3.23 (q, 2H), 7.67-7.75 (m, trifluoropropanamide 2H), 8.15-8.21 (t, 2H) 127 (R)-N-(2-Fluoro-4-mesyl-phenyl)- 1.57 (s, 3H), 3.23 (s, 3H), 328 Ex 2-hydroxy-2-methyl-3,3,3- 7.73-7.76 (m, 2H), 7.85 (d, 196 trifluoropropanamide 1H), 8.03 (d, 1H), 9.92 (s, 1H) 128 (R)-N-[2-Chloro-4-(2-hydroxy- 1.60 (s, 3H), 3.5 (t, 2H), 3.65- 374 Ex ethylsulphonyl)phenyl]-2- 3.71 (m, 2H), 4.84 (t, 1H), 415 hydroxy-2-methyl-3,3,3- 7.86-7.89 (m, 1H), 8.05 (s, trifluoropropanamide 1H), 8.31 (d, 1H), 9.89 (brs, 1H) 129 (R)-N-[2-Chloro-4-(cyclopropyl- 0.11-0.14 (m, 1H), 0.43-0.45 384 Ex methylsulphonyl)phenyl]-2- (m, 1H), 0.81-0.87 (m, 1H), 416 hydroxy-2-methyl-3,3,3- 1.61 (s, 3H), 3.32 (d, 2H), trifluoropropanamide 7.85-7.90 (m, 1H), 8.01 (m, 1H), 8.34 (d, 1H) 130 (R)-N-[2-Chloro-4-(3- 1.61 (s, 3H), 1.64-1.71 (m, 388 Ex hydroxypropylsulphonyl)phenyl]- 2H), 3.32-3.43 (m, 4H), 7.87- 328 2-hydroxy-2-methyl-3,3,3- 7.90 (m, 1H), 8.03 (s, 1H), trifluoropropanamide 8.34 (d, 1H) 131 (R)-N-[2-Chloro-4-(N-methyl- 1.63 (s, 3H), 2.52 (d, 3H), 401 Ex carbamoylmethylsulphonyl) 4.28 (s, 2H), 7.83 (d, 1H), 420 phenyl]-2-hydroxy-2-methyl- 8.10-8.13 (m, 1H), 8.29 (d, 3,3,3-trifluoropropanamide 1H) 132 (R)-N-[2-Chloro-4-(iso-propyl- 1.10-1.13 (d, 6H), 1.60 (s, 372 Ex sulphonyl)phenyl]-2-hydroxy-2- 3H), 3.34-3.42 (m, 1H), 7.8- 421 methyl-3,3,3- 7.82 (d, 1H), 8.92 (s, 1H), trifluoropropanamide 8.41 (d, 1H). 133 (R)-N-[2-Chloro-4-(cyclopentyl- 1.55-1.60 (m, 7H), 1.76-1.86 398 Ex sulphonyl)phenyl]-2-hydroxy-2- (m, 4H), 3.81-3.89 (m, 1H), 422 methyl-3,3,3- 7.86-7.89 (m, 1H), 8.02 (s, trifluoropropanamide 1H), 8.34 (d, 1H). 134 (R)-N-[2-Chloro-4-(iso-butyl- 0.97 (s, 6H), 1.61 (s, 3H), 386 Ex sulphonyl)phenyl]-2-hydroxy-2- 1.97-2.05 (m, 1H), 3.26-3.34 423 methyl-3,3,3- (m, 2H), 7.68-7.92 (m, 1H), trifluoropropanamide 8.05 (s, 1H), 8.31 (d, 1H), 9.92 (s, 1H) 135 (R)-N-[2-Chloro-4-(cyclohexyl- 1.13-1.26 (m, 6H), 1.61 (s, 412  Ex 96 sulphonyl)phenyl]-2-hydroxy-2- 3H), 1.71-1.76 (m, 2H), 1.84- methyl-3,3,3- 1.88 (m, 2H), 3.31-3.35 (m, trifluoropropanamide 1H), 7.80-7.84 (m, 1H), 7.92 (s, 1H), 8.34 (d, 1H) 136 N-[2-Fluoro-4-(4-mesylphenyl- 3.26 (s, 3H), 6.42 (t, 2H), 486 Ex sulphonyl)phenyl]-2-hydroxy-2- 7.85-7.94 (m, 2H), 8.01 (d, 200 difluoromethyl-3,3- 1H), 8.14 (d, 1H), 8.25 (d, difiuoropropanamide 1H) 137 (R)-N-{2-Fluoro-4-[4-(2- 1.57 (s, 3H), 3.54 (t, 2H), 498 Ex hydroxyethylsulphonyl)phenyl- 3.65-3.71 (m, 2H), 4.66 (t, 309 sulphonyl]phenyl}-2-hydroxy-2- 1H), 7.86 (d, 1H), 7.97-8.05 methyl-3,3,3- (m, 2H), 8.07 (d, 1H), 8.21 trifluoropropanamide (d, 1H) 138 (R)-N-[2-Fluoro-4-(4-ethyl- 1.05-1.10 (t, 3H), 1.55 (s, 482  Ex 97 sulphonylphenylsulphonyl) 3H), 3.31-3.39 (q, 2H), 7.87 phenyl]-2-hydroxy-2-methyl- (d, 1H), 7.98-8.05 (m, 1H), 3,3,3-trifluoropropanamide 8.11 (d, 2H), 8.24 (d, 2H) 139 (R)-N-{2-Fluoro-4-[4-(N- 1.57 (s, 3H), 2.5 (d, 3H), 4.34 525 Ex methylcarbamoylmethyl (s, 2H), 7.86 (d, 1H), 8.0-8.02 308 sulphonyl)phenylsulphonyl] (m, 1H), 8.07-8.13 (m, 3H), phenyl}-2-hydroxy-2-methyl- 8.23 (d, 2H) 3,3,3-trifluoropropanamide 140 (R)-N-[2-Bromo-4-(4-mesyl- 1.6 (s, 3H), 3.27 (s, 3H), 528 Ex phenylsulphonyl)phenyl]-2-hydroxy-2- 8.02-8.08 (m, 2H), 8.15 (d, 201 methyl-3,3,3- 2H), 8.26 (d, 2H), 8.33 (s, trifluoropropanamide 1H), 8.36 (s, 1H), 9.91 (s, 1H) 141 (R)-N-[2-Chloro-4-(N,N- 1.68 (s, 3H), 2.85 (s, 3H), 415 Ex dimethylcarbamoylmethyl- 3.05 (s, 3H), 4.72 (s, 2H), 402 sulphonyl)phenyl]-2-hydroxy-2- 7.93 (d, 2H), 8.08 (s, 1H), methyl-3,3,3- 8.44 (d, 1H) trifluoropropanamide 142 (R)-N-[2-Chloro-4-(methoxy- 1.62 (s, 3H), 3.6 (s, 3H), 4.74 402 Ex carbonylmethylsulphonyl) (s, 2H), 7.9 (d, 2H), 8.07 (s, 403 phenyl]-2-hydroxy-2-methyl- 1H), 8.33 (d, 1H) 3,3,3-trifluoropropanamide 143 (R)-N-[2-Mesyl-4-(2-mesyl- 1.6 (s, 3H), 3.28 (s, 3H), 3.5 528  Ex 11 phenylsulphonyl)phenyl]-2- (s, 3H), 8.02-8.05 (m, 2H), hydroxy-2-methyl-3,3,3- 8.18-8.21 (m, 2H), 8.39 (s, trifluoropropanamide 1H), 8.5-8.53 (d, 1H), 8.62 (d, 1H), 11.1 (brs, 1H) 144 (R)-N-(2-Chloro-4-ethyl- 1.07 (t, 3H), 1.6 (s, 3H), 3.32 358 Ex sulphonylphenyl)-2-hydroxy-2- (q, 2H), 7.85 (d, 1H), 8.01 (s, 327 methyl-3,3,3- 1H), 8.32 (d, 1H) trifluoropropanamide 145 (R)-N-{2-Chloro-4-[4-(N- 1.60 (s, 3H), 3.3 (3H, s), 4.35 541 Ex methylcarbamoylmethyl- (s, 2H), 8.0-8.40 (m, 7H), 288 sulphonyl)phenylsulphonyl] 9.95 (bs, 1H) phenyl}-2-hydroxy-2-methyl- 3,3,3-trifluoropropanamide 146 (R)-N-[2-Chloro-4-(4- 0.15 (q, 2H), 0.55 (q, 2H), 524 Ex cyclopropylmethylsulphonyl- 0.9-1.00 (m, 1H), 1.75 (s, 287 phenylsulphonyl)-phenyl]-2- 3H), 3.05 (d, 2H), 3.65 (s, hydroxy-2-methyl-3,3,3- 1H), 7.9 (dd, 1H), 8. (dd, 1H), trifluoropropanamide 8.05-8.15 (m, 4H), 8.65 (d, 1H), 9.35 (brs, 1H) 147 (R)-N-[2-Chloro-4-(4- 1.25 (t, 3H), 1.75 (s, 3H), 3.1 498  Ex 7 ethylsulphonylphenylsulphonyl) (q, 2H), 3.5 (s, 1H), 7.9 (dd, phenyl]-2-hydroxy-2-methyl- 1H), 8.0-8.15 (m, 5H), 8.65 3,3,3-trifluoropropanamide (d, 1H), 9.3 (brs, 1H) 148 (R)-N-{2-Chloro-4-[4-(iso- 1.3 (d, 6H), 1.75 (s, 3H), 3.2 512  Ex 6 propylsulphonyl)phenyl- (m, 1H), 3.95 (s, 1H), 7.9 (dd, sulphonyl]phenyl}-2-hydroxy-2- 1H), 8.05 (m, 3H), 8.1 (dd, methyl-3,3,3- 2H), 8.7 (dd, 1H), 9.4 (brs trifluoropropanamide 1H).  149¹ N-(2-Chloro-4-phenylsulphonyl- 6.86 (s, 1H), 7.5-7.75 (m, 376 and See¹     phenyl)dichloroacetamide 3H), 7.9-8.03 (m, 4H), 10.47 378 (brs, 1H)  150¹ N-(2-Chloro-4-phenylsulphonyl- 1.2 (s, 9H), 7.6 (t, 2H), 7.7 (t, 350 See¹     phenyl)-2,2-dimethyl- 1H), 7.84-7.92 (m, 2H), 8.0 propanamide (d, 2H), 8.05 (d, 1H), 9.1 (brs, 1H)  151¹ N-(2-Chloro-4-phenylsulphonyl- 0.8 (m, 4H), 2.1 (m, 1H), 7.6- 334 See¹     phenyl)cyclopropylcarboxamide 7.72 (m, 3H), 7.85 (dd, 1H), 7.95 (d, 2H), 8.03 (s, 1H), 8.1 (d, 1H), 9.9 (brs, 1H)  152¹ N-(2-Chloro-4-phenylsulphonyl- 1.6 (d, 3H), 4.95 (q, 1H), 7.6 356 and See¹     phenyl)-2-chloropropanamide (t, 2H), 7.7 (t, 1H), 7.9 (dd, 358 1H), 8.0 (d, 2H), 8.05-8.1 (m, 2H), 10.09 (brs, 1H)  153¹ N-(2-Chloro-4-phenylsulphonyl- 1.1 (d, 6H), 2.8 (m, 1H), 7.6 336 See¹     phenyl)-2-methylpropanamide (t, 2H), 7.7 (t, 1H), 7.85 (dd, 1H), 7.95 (d, 2H), 8.0-8.1 (m, 2H), 9.6 (s, 1H) 154 (R)-N-[2-Fluoro-4-(2-mesyl- 1.55 (s, 3H), 3.5 (s, 3H), 468  Ex 12 phenylsulphonyl)phenyl]-2- 7.73-7.78 (m, 2H), 7.85 (dd, hydroxy-2-methyl-3,3,3- 1H), 7.98 (d, 1H), 8.0-8.06 trifluoropropanamide (m, 2H), 8.2 (m, 1H), 8.5 (m, 1H), 9.9 (brs, 1H) 155 (R)-N-[2-Fluoro-4-(4-mesyl- 1.6 (s, 3H), 3.3 (s, 3H), 7.78 468 Ex phenylsulphonyl)phenyl]-2- (s, 1H), 7.9 (d, 1H), 7.95-8.1 194 hydroxy-2-methyl-3,3,3- (m, 2H), 8.15 (d, 2H), 8.25 trifluoropropanamide (d, 2H), 9.85 (s, 1H) 156 (R)-N-{2-Chloro-4-[2-(N,N- 1.06 (m, 3H), 1.25 (m, 3H), 505 Ex diethylcarbamoyl)phenyl 1.59 (s, 3H), 3.08 (m, 2H), 232 sulphonyl]phenyl}-2-hydroxy-2- 3.39 (m, 1H), 3.67 (m, 1H), methyl-3,3,3- 7.41 (d, 1H), 7.66 (t, 1H), trifluoropropanamide 7.78 (t, 1H), 7.98 (d, 1H), 8.16 (m, 2H), 8.27 (d, 1H), 9.90 (brs, 1H) 157 (R)-N-[2-Chloro-4-(2,3- 1.60 (s, 3H), 3.15-3.23 (m, 404 Ex dihydroxypropyl)sulphonyl- 2H), 3.36-3.44 (m, 2H), 3.36- 425 phenyl]-2-hydroxy-2-methyl- 3.44 (m, 2H), 3.81-3.89 (m, 3,3,3-trifluoropropanamide 1H), 4.86 (t, 1H), 4.94 (d, 1H), 7.86-7.89 (m, 1H), 8.02 (s, 1H), 8.31 (d, 1H), 9.89 (s, 1H) 158 (R)-N-[2-Chloro-4-(2-hydroxy- 1.11 (d, 3H), 1.60 (s, 3H), 388 Ex propyl)sulphonylphenyl]-2- 3.39-3.44 (m, 2H), 4.00-4.05 426 hydroxy-2-methyl-3,3,3- (m, 1H), 4.84 (d, 1H), 7.86- trifluoropropanamide 7.89 (m, 1H), 8.02 (s, 1H). 8.31 (d, 1H), 9.89 (s, 1H) 159 (R)-N-[2-Chloro-4-t-butyl- 1.26 (s, 9H), 1.63 (s, 3H), 386 Ex sulphonylphenyl]-2-hydroxy-2- 7.81-7.84 (m, 1H), 7.89 (s, 427 methyl-3,3,3- 1H), 8.39 (d, 1H) trifluoropropanamide 160 (R)-N-[2-Chloro-4-(4-{3- (CDCl₃) 1.75 (s, 3H), 2.1-2.2 480 Ex hydroxy- (m, 2H), 3.8-3.9 (m, 1H), 397 propoxy}phenylsulphonyl)phenyl]- 4.05-4.2 (m, 2H), 4.2-4.25 2-hydroxy-2-methyl-3,3,3- (m, 1H), 4.65 (s, 1H), 7.0 (d, trifluoropropanamide 2H), 7.7-7.85 (m, 3H), 7.9 (s, 1H), 8.6 (d, 2H), 9.4 (s, 1H) 161 (R)-N-[2-Chloro-4-(4- 1.6 (s, 3H), 4.55 (s, 2H), 7.1- 481 Ex {carbamoylmethoxy}phenyl- 7.2 (m, 2H), 7.35 (s, 1H), 7.5 (M + H)⁺ 399 sulphonyl)phenyl]-2-hydroxy-2- (s, 1H), 7.85-7.95 (m, 3H), methyl-3,3,3- 8.0 (s, 1H), 8.1 (s, 1H), 8.2- trifluoropropanamide 8.3 (m, 1H), 9.85 (s, 1H) 162 (R)-N-[2-Chloro-4-(4-{N,N- (CDCl₃) 1.75 (s, 3H), 3.0 (s, 507 Ex dimethylcarbamoylmethoxy} 3H), 3.1 (s, 3H), 4.75 (s, 2H), 400 phenylsulphonyl)phenyl]-2- 6.9 (d, 1H), 7.0 (d, 1H), 7.8- hydroxy-2-methyl-3,3,3- 7.9 (m, 3H), 8.0 (s, 1H), 8.6 trifluoropropanamide (d, 2H), 9.3 (s, 1H) 163 (R)-N-(2-Chloro-4-{4-[2-(N-oxy- 1.6 (s, 3H), 3.1 (d, 2H), 3.2- 580 Ex morpholino)ethylaminocarbonyl] 3.3 (m, 2H), 3.3-3.4 (m, 2H), (M + H)⁺ 237 phenylsulphonyl}phenyl)-2- 3.7 (d, 2H), 3.8 (d, 2H), 4.1- hydroxy-2-methyl-3,3,3- 4.2 (m, 2H), 7.9-8.0 (m, 5H), trifluoropropanamide 8.1-8.2 (m, 3H), 8.3 (d, 1H), 10.6 (s, 1H) 164 (R)-N-[2-Chloro-4-(4-{3- 1.3-1.5 (2H, m), 1.6 (s, 3H), 535 Ex hydroxypiperidin-1-ylcarbonyl} 1.7-1.9 (m, 2H), 2.8-3.0 (m, (M + H)⁺ 238 phenyl-sulphonyl)phenyl]-2- 2H), 3.4-3.6 (m, 2H), 3.6-3.7 hydroxy-2-methyl-3,3,3- (m, 1H), 4.1 (d, 1H), 7.6 (d, trifluoropropanamide 2H), 8.0-8.1 (m, 4H), 8.2 (s, 1H), 8.3 (d, 1H), 9.9 (s, 1H) 165 (R)-N-[2-Fluoro-4-(4- 3.33 (s, 3H), 7.72-7.77 (m, 522 Ex mesylphenylsulphonyl)phenyl]-2- 1H), 7.86-7.91 (m, 1H), 8.02 413 hydroxy-2-trifluoromethyl-3,3,3- (d, 1H), 8.16 (d, 2H), 8.27 (d, trifluoropropanamide 2H), 9.91 (s, 1H), 10.6 (s, 1H) 166 (R)-N-[2-Chloro-4-(2- 0.80 (t, 3H), 1.28-1.33 (m, 402 Ex hydroxybutylsulphonyl)phenyl}- 1H), 1.41-1.50 (m, 1H), 1.61 408 2-hydroxy-2-methyl-3,3,3- (s, 3H), 3.40 (d, 2H), 3.78- trifluoropropanamide 3.80 (m, 1H), 4.80 (d, 1H), 7.86-7.89 (m, 1H), 8.02 (s, 1H), 8.29 (d, 1H) 167 (R)-N-{2-Chloro-4-(2-hydroxy-2- 1.25 (s, 6H), 1.61 (s, 3H), 402 Ex methylpropylsulphonyl) phenyl}- 3.47 (s, 2H), 7.86-7.89 (m, 409 2-hydroxy-2-methyl-3,3,3- 1H), 8.01 (s, 1H), 8.29 (d, trifluoropropanamide 1H) 168 (R)-N-{2-Chloro-4-propyl- 0.90 (t, 3H), 1.26-1.35 (m, 372 Ex sulphonylphenyl}-2-hydroxy-2- 2H), 1.61 (s, 3H), 3.32-3.38 410 methyl-3,3,3- (m, 2H), 7.86-7.89 (m, 1H), trifluoropropanamide 8.02 (s, 1H), 8.32 (d, 1H), 9.88 (s, 1H) 169 (R)-N-{2-Chloro-4-(butyl- 0.82 (t, 3H), 1.26-1.35 (m, 386 Ex sulphonyl)phenyl}-2-hydroxy-2- 2H), 1.45-1.55 (m, 2H), 1.61 411 methyl-3,3,3- (s, 3H), 3.31-3.41 (m, 2H), trifluoropropanamide 7.86-7.90 (m, 1H), 8.02 (s, 1H), 8.32 (d, 1H) 170 (R)-N-{2-Chloro-4-(3-carboxy- 1.58 (s, 3H), 7.76 (t, 1H), 450 Ex phenylsulphonyl)phenyl}-2- 8.03 (d, 2H), 8.22 (m, 3H), 293 hydroxy-2-methyl-3,3,3- 8.3 (d, 1H), 8.4 (s, 1H), 9.88 trifluoropropanamide (s, 1H) ¹The starting material was prepared by acylation of 2-chloro-4-phenylsulphanylaniline (Method 5) with the appropriate acid chloride using procedure of Method 23. Solvent was removed under a stream of argon and the intermediate was used without purification.

EXAMPLE 171

N-[2-Chloro-4-(4-acetamidophenylsulthonyl)phenyl]-2-hydroxy-2-methylpropanamide

A solution of lithium hydroxide monohydrate (0.106 g) in water (1 ml) was added to a stirred solution of N-[2-chloro-4-(4-acetamidophenylsulphonyl)phenyl]-2-acetoxy-2-methylpropanamide (Method 16) (0.230 g) in methanol (2 ml) and the mixture was stirred at ambient temperature for 2 hours. Water (5 ml) was added and the solution was acidified to pH 2-3 with 1M hydrochloric acid. Ethyl acetate (20 ml) was added and the organic layer was washed with water (20 ml) and brine, then dried. Volatile material was removed by evaporation and the off-white solid was washed with ether to give the title compound (0.150 g) as a solid. NMR (CDCl₃):1.3 (s, 6H), 2.2 (s, 3H), 7.4 (s, 1H), 7.7 (d, 2H), 7.8 (m, 3H), 7.9 (s, 1H), 8.7 (d, 1H), 9.6 (s, 1H); MS (ESP⁻): 409.

EXAMPLES 172-181

Following the procedure of Example 171 and using the appropriate starting material the following compounds were prepared.

Ex Compound NMR MS SM 172 N-{2-Chloro-4-[4-N-(2,2- (CDCl₃) 1.3 (s, 9H), 1.6 (s, 6H), 451 Meth dimethylpropanamido)phenyl- 7.5-7.9 (m, 7H), 8.6 (d, 1H), 9.6 25 sulphonyl]phenyl}-2-hydroxy-2- (s, 1H) methylpropanamide 173 N-(2-Chloro-4-phenyl- 1.37 (s, 6H), 6.26 (s, 1H), 7.6-7.7 352 Meth sulphonylphenyl)-2-hydroxy-2- (m, 3H), 7.9-8.0 (m, 3H), 8.1 (d, 33 methylpropanamide 1H), 8.51 (d, 1H), 9.8 (brs, 1H) 174 (R)-N-[2-Chloro-4-(4-ureido- 1.6 (s, 3H), 5.9 (s, 2H), 7.1 (d, 432 Meth phenylsulphanyl)phenyl]-2- 1H), 7.2 (s, 1H), 7.3 (d, 2H), 7.5 34 hydroxy-2-methyl-3,3,3- (d, 2H), 7.7 (s, 1H), 7.8 (d, 1H), trifluoropropanamide 8.7 (s, 1H), 9.6 (s, 1H) 175 (R)-N-[2-Chloro-4-(2-ureido- 432 Meth phenylsulphanyl)phenyl]-2- 35 hydroxy-2-methyl-3,3,3- trifluoropropanamide 176 (R)-N-[2-Fluoro-4-(4-nitro- 1.6 (s, 3H), 7.3 (d, 2H), 7.4 (d, 403 Meth phenylsulphanyl)phenyl]-2- 1H), 7.6 (d, 1H), 7.9 (t, 1H), 8.2 39 hydroxy-2-methyl-3,3,3- (d, 2H) trifluoropropanamide 177 (R)-N-{2-Chloro-4-[4-(2-chloro- 465 Meth acetylamino)phenylsulphanyl] 19 phenyl}-2-hydroxy-2-methyl- 3,3,3-trifluoropropanamide 178 (R)-N-{2-Chloro-4-[4-(2- 1.6 (s, 3H), 3.2 (s, 6H), 3.8 (s, 516 Meth morpholinoacetylamino)phenyl- 4H), 7.2 (d, 1H), 7.3 (s, 1H), 7.4 41 sulphanyl]phenyl}-2-hydroxy-2- (d, 2H), 7.7 (d, 2H), 7.8 (s, 1H), methyl-3,3,3- 7.9 (d, 1H), 9.7 (s, 1H) trifluoropropanamide 179 (R)-N-{2-Chloro-4-[4-(3-t- 1.2 (s, 9H), 1.6 (s, 3H), 6.1 (s, 488 Meth butylureido)phenylsulphanyl] 1H), 7.1 (d, 1H), 7.2 (s, 1H), 7.3 43 phenyl}-2-hydroxy-2-methyl- (d, 2H), 7.4 (d, 2H), 7.7 (s, 1H), 3,3,3-trifluoropropanamide 7.8 (d, 1H), 8.6 (s, 1H), 9.6 (s, 1H) 180 (R)-N-{2-Chloro-4-[4-(3- 1.6 (s, 3H), 7.0 (t, 1H), 7.1 (d, 508 Meth phenylureido)phenylsulphanyl] 1H), 7.3 (m, 3H), 7.4 (t, 4H), 7.6 44 phenyl}-2-hydroxy-2-methyl- (d, 2H), 7.8 (s, 1H), 7.9 (d, 1H) 3,3,3-trifluoropropanamide 8.8 (s, 1H), 9.0 (s, 1H) 9.6 (s, 1H) 181 (R)-N-(2-Chloro-4-{3-t-butoxy-2- (CDCl₃) 1.23 (s, 9H), 1.73 (s, 411 Meth hydroxypropylamino}phenyl)-2- 3H), 2.55 (d, 1H), 3.12 (m, 1H), 50 hydroxy-2-methyl-3,3,3- 3.27 (m, 1H), 3.4 (m, 1H), 3.5 (m, trifluoropropanamide 1H), 3.95 (s, 2H), 4.24 (s, 1H), 6.53 (dd, 1H), 6.67 (s, 1H), 7.95 (d, 1H), 8.34 (s, 1H)

EXAMPLE 182

N-[2-Chloro-4-(4-mesylaminophenylsulphonyl)phenyl]-2-hydroxy-2-methylpropanamide

m-Chloroperoxybenzoic acid (50%, 0.55 g) was added to a solution of N-[2-chloro-4-(4-mesylaminophenylsulphanyl)phenyl]-2-hydroxy-2-methylpropanamide (Example 207) (0.22 g) in DCM (5 ml) and the mixture was stirred at ambient temperature for 15 hours. DCM (10 ml) was added, followed by saturated aqueous sodium carbonate solution (20 ml) and the mixture was poured onto a Varian Chem Elut column. After 3 minutes the column was washed through with DCM (20 ml) and the organic fractions concentrated. The residue was purified by flash chromatography eluting with 40-70% ethyl acetate/hexane to give the title compound (0.15 g) as a foam. NMR (CDCl₃): 1.8 (s, 6H), 3.1 (s, 3H), 7.3 (m, 3H), 7.9 (m, 4H), 9.6 (m, 2H); MS (ESP⁻): 445; EA: found: C, 45.1; H, 4.4; N, 6.2%, C₁₇H₁₉ClN₂O₆S₂.0.3H₂O requires C, 45.1; H, 4.4; N, 6.2%.

EXAMPLE 183

Following the procedure of Example 182 and using the appropriate starting materials the following compound was prepared.

Ex Compound NMR MS SM 183 (R)-N-(1-Oxy-6-methyl-5- 1.6 (s, 3H), 2.5 (s, 3H), 7.7 (m, 403 Ex phenylsulphonylpyridin-2-yl)-2- 3H), 7.9 (s, 2H), 8.1 (m, 2H), 211 hydroxy-2-methyl-3,3,3- 8.4 (d, 1H) trifluoropropanamide

EXAMPLE 184

N-[2-Amino-4-(phenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A suspension of N-[2-nitro-4-(phenylsulphonyl)phenyl]2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (J. Med. Chem., 1996, 39, 4592) (0.293 g) in methanol (5 ml) was added to a stirred suspension of 10% palladium on carbon (0.03 g) in methanol (2 ml) under an atmosphere of argon. A solution of ammonium formate (0.176 g) in water (2 ml) was added and the mixture was heated under reflux for 2 hours then cooled. Ethyl acetate (20 ml) was added and the mixture was filtered through diatomaceous earth. The filter was washed with ethyl acetate (2×10 ml) and the filtrates were combined, washed with water and brine then dried. Volatile material was removed by evaporation to give the title compound (0.261 g) as a solid. NMR: 1.55 (s, 3H), 5.3 (s, 2H), 7.1 (dd, 1H), 7.3 (d, 1H), 7.4 (m, 2H), 7.5-7.7 (m, 3H), 7.85 (d, 2H), 9.6 (s, 1H); MS (ESP⁻): 387.

EXAMPLE 185

N-[2-Acetamido-4-(phenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Acetyl chloride (0.018 ml) was added to an ice-cooled solution of N-[2-amino-4-(phenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 184) (0.097 g) in pyridine (1 ml) and the solution was allowed to warm up to ambient temperature over 2 hours. Water was added and the mixture was extracted with ethyl acetate. The organic extracts were combined, washed with brine and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 10-40% ethyl acetate/hexane to give the title compound (0.89 g) as a solid. Mp 205-207° C., NMR: 1.5 (s, 3H), 2.1 (s, 3H), 7.57-7.75 (m, 4H), 7.8-7.9 (m, 2H) 7.9-8.05 (m, 3H), 9.8 (brs, 1H), 10.1 (brs, 1H); MS (ESP⁻): 429.

EXAMPLE 186

Following the procedure of Example 185 and using methanesulphonyl chloride to replace acetyl chloride the following compound was prepared.

Ex Compound NMR MS 186 2-Hydroxy-2-methyl-N-[2-mesyl- 1.55 (s, 3H), 3.0 (s, 3H), 7.5-7.75 465 amino-4-(phenylsulphonyl)phenyl]- (m, 3H), 7.8-8.0 (m, 5H), 8.3 (d, 3,3,3-trifluoropropanamide 1H), 9.6 (brs, 1H), 10.1 (brs, 1H)

EXAMPLE 187

(R)-N-[2-Chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Tetrakis(triphenylphosphine)palladium(0) (0.147 g) was added to a deoxygenated mixture of (R)-N-(2-chloro-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (1.0 g), 2-fluorothiophenol (0.263 ml) and sodium methoxide (0.288 g) in ethanol (50 ml). The mixture was then further deoxygenated by evacuation and refilling with argon (3 cycles), and then heated under reflux with stirring under argon for 18 hours. The mixture was treated with a further portion of tetrakis(triphenylphosphine)palladium(0) (0.147 g), heated for a further 24 hours then cooled and filtered. Volatile material was removed by evaporation and the residue was purified by flash chromatography eluting with 20% ethyl acetate/hexane to give the title compound (0.906 g) as an oil. NMR (CDCl₃): 1.75 (s, 3H), 3.58 (s, 1H), 7.1 (t, 2H), 7.2-7.35 (m, 3H), 7.37 (d, 1H), 8.3 (d, 1H), 8.82 (brs, 1H); MS (ESP⁻): 392.

EXAMPLES 188-196

Following the procedure of Example 187 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR and MS 188 (R)-N-[2-Chloro-4-(4-fluorophenylsulphanyl) (CDCl₃): 1.74 (s, 3H), 3.79 (s, 1H), phenyl]-2-hydroxy-2-methyl-3,3,3- 7.04 (t, 2H), 7.2 (dd, 1H), 7.27 (d, trifluoropropanamide 1H), 7.38 (dd, 2H), 8.27 (d, 1H), 8.87 (brs, 1H); MS (ESP⁺): 394 (M + H)⁺. 189 (R)-N-[2-Chloro-4-{4-(methylsulphanyl) 1.57 (s, 3H), 3.29 (s, 3H), 7.2-7.4 (m, phenylsulphanyl}phenyl]-2-hydroxy-2-methyl- 6H), 7.8 (brs, 1H), 7.9 (d, 1H), 9.7 3,3,3-trifluoropropanamide (brs, 1H)  190¹ (R)-N-[2-Chloro-4-{4-(ethoxycarbonyl) (CDCl₃): 1.4 (t, 3H), 1.79 (s, 3H), phenylsulphanyl}phenyl]-2-hydroxy-2-methyl- 3.68 (s, 1H), 4.35 (q, 2H), 7.24 (d, 3,3,3-trifluoropropanamide 2H), 7.41 (dd, 1H), 7.51 (d, 1H), 7.92 (d, 2H), 8.42 (d, 1H), 9.0 (brs, 1H)  191² (R)-N-[2-Chloro-4-methylsulphanylphenyl]-2- (CDCl₃): 1.76 (s, 3H), 2.5 (s, 3H), hydroxy-2-methyl-3,3,3-trifluoropropanamide 3.82 (brs, 1H), 7.19 (dd, 1H). 7.3 (d, 1H), 8.28 (d, 1H), 8.8 (brs, 1H) 192 (R)-N-[2-Chloro-4-(pyrid-4-ylsulphanyl) (CDCl₃): 1.68 (s, 3H), 6.98 (m, 2H), phenyl]-2-hydroxy-2-methyl-3,3,3- 7.26 (s, 1H), 7.5 (dd, 1H), 7.6 (d, trifluoropropanamide 1H), 8.32 (m, 2H), 8.56 (d, 1H), 9.38 (brs, 1H) 193 (R)-N-[2-Fluoro-4-(4-fluorophenylsulphanyl) (CDCl₃): 1.73 (s, 3H), 3.63 (s, 1H), phenyl]-2-hydroxy-2-methyl-3,3,3- 7.02-7.07 (m, 4H), 7.36-7.42 (m, trifluoropropanamide 2H), 8.19-8.23 (m, 1H), 8.50 (s, 1H); MS (ESP⁻): 376. 194 (R)-N-[2-Fluoro-4-(4-methylsulphanylphenyl- 1.6 (s, 3H), 7.05 (d, 1H), 7.1 (d, 1H), sulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3- 7.3 (d, 2H), 7.35 (d, 2H), 7.5-7.7 (m, trifluoropropanamide 2H), 9.6 (s, 1H); MS (ESP⁻): 404. 195 (R)-N-[2-Fluoro-4-(2-fluorophenylsulphanyl) 1.6 (s, 3H), 7.1 (d, 1H), 7.15-7.5 phenyl]-2-hydroxy-2-methyl-3,3,3- (brm, 5H), 7.6 (brs, 1H), 7.7 (t, 1H), trifluoropropanamide 9.6 (brs, 1H); MS (ESP⁻): 376.  196² (R)-N-[2-Fluoro-4-(methylsulphanyl)phenyl]- (CDCl₃) 1.73 (s, 3H), 2.47 (s, 3H), 2-hydroxy-2-methyl-3,3,3- 3.63 (s, 1H), 7.0-7.05 (m, 2H), 8.17 trifluoropropanamide (t, 1H), 8.83 (s, 1H) ¹The thiol used as starting material was methyl 4-mercaptobenzoate ²Sodium methanethiolate was used instead of a thiol as starting material

EXAMPLE 197

(R)-N-(2-Chloro-4-iodonhenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Oxalyl chloride (1.07 ml) was added dropwise to a stirred suspension of (R)-(+)-2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid (Method 9) (1.95 g) in DCM (42 ml) and DMF (0.8 ml). The mixture was stirred at ambient temperature for 2 hours and was then added over 35 minutes to a solution of 2-chloro-4-iodoaniline (2.5 g) and 2,6-di-t-butylpyridine (2.94 ml) in DCM (40 ml) and stirred a further 18 hours. Volatile material was removed by evaporation and the residue was purified by flash chromatography on silica gel eluting with DCM to give the title compound (2.85 g) as a solid. NMR: 1.6 (s, 3H), 7.7 (m, 2H), 7.8 (d, 1H), 7.9 (brs, 1H); MS (ESP⁻): 392.

EXAMPLES 198-201

Following the procedure of Example 197 and using the appropriate starting material the following compounds were prepared.

Ex Compound NMR MS SM 198 (R)-N-(2-Chloro-4-benzyl- 1.7 (s, 3H), 3.75 (brs, 1H), 358 Meth 30 phenyl)-2-hydroxy-2-methyl- 3.95 (s, 2H), 7.1-7.25 (m, 3,3,3-trifluoropropanamide 7H), 8.15 (d, 1H), 8.75 (brs, 1H) 199 (R)-N-[2-Fluoro-4-iodophenyl]- (CDCl₃) 1.56 (s, 3H), 3.57 376 2-Fluoro-4- 2-hydroxy-2-methyl-3,3,3- (s, 1H), 7.44-7.50 (m, 2H), iodoaniline trifluoropropanamide 8.08 (t, 2H), 8.56 (brs, 1H)  200¹ N-[2-Fluoro-4-(4-methyl- (CDCl₃) 2.47 (s, 3H), 3.94 422 Meth 6  sulphanylphenylsulphanyl) (brs, 2H), 6.15 (t, 1H), phenyl]-2-hydroxy-2- 6.94-7.00 (d, 1H), 7.02- difluoromethyl-3,3- 7.05 (d, 1H), 7.18-7.21 (d, difluoropropanamide 2H), 7.28-7.31 (d, 2H), 8.15 (t, 1H), 8.52 (s, 1H)  201² (R)-N-[2-Bromo-4-{4-methyl- (CDCl₃) 1.76 (s, 3H), 2.5 466 Meth 11 sulphanylphenylsulphanyl} (s, 3H), 3.66 (s, 1H), 7.2 (d, phenyl]-2-hydroxy-2-methyl- 2H), 7.3-7.33 (m, 3H), 7.47 3,3,3-trifluoromethyl- (d, 1H), 8.25 (d, 1H), 9.8 propanamide (s, 1H) ¹2-Difluoromethyl-2-hydroxy-3,3-difluoropropanoic acid (prepared as described by W.J. Middleton and R.V. Lindsey Jnr. J. Am. Chem. Soc., 1964, 86, 4948) was used instead of (R)-(+)-2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid. ²2,6-diphenylpyridine was used in place of 2,6-di-t-butylpyridine

EXAMPLE 202

(R)-N-{2-Chloro-4-([5-ethoxycarbonyl-3-pyridyl]sulphanyl)phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Caesium fluoride (0.26 g) was added to a solution of (R)-N-(2-chloro-4-(triisopropylsilylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (0.74 g) (Method 28) in anhydrous DMA (5 ml) under argon and the mixture was stirred for 17 hours. Copper(I) chloride (0.17 g) followed by 3-bromo-5-carboethoxypyridine (0.37 g) were added and the mixture was heated to 155° C. for 4 hours and allowed to cool to ambient temperature. Ethyl acetate (20 ml) and brine (20 ml) were added and the mixture was filtered through a pad of diatomaceous earth which was washed with ethyl acetate (3×50 ml). The filtrates were combined, washed with brine (3×50 ml) and then dried. Volatile material was removed by evaporation and the residue was purified on a silica gel Mega Bond Elut column eluting with 10-40% ethyl acetate/iso-hexane to give the title compound (in 53% yield) as a foam. NMR (CDCl₃): 1.39 (t, 3H), 1.57 (s, 3H), 4.00 (s, 1H), 4.40 (q, 2H), 7.34-7.37 (m, 1H), 7.46 (d, 1H), 8.18 (s, 1H), 8.42 (d, 1H), 8.62 (s, 1H), 9.03 (s, 1H), 9.04 (s, 1H); MS (ESP⁻): 447.

EXAMPLE 203

By the method of Example 202 and using the appropriate starting materials the following compound was prepared.

Ex Compound NMR MS SM 203 (R)-N-{2-Chloro-4-(4-{pyrimidin- 1.6 (s, 3H), 7.38-7.52 (m, 4H), 452 Ex 197 2-yl}phenylsulphanyl)phenyl}-2- 7.65 (d, 1H), 7.9 (brs, 1H), 8.06 and hydroxy-2-methyl-3,3,3- (d, 1H), 8.38 (d, 2H), 8.9 (d, Meth trifluoropropanamide 2H), 9.79 (brs, 1H) 52

EXAMPLE 204

Following the procedure of Method 22 (see below) and using Example 197 as the starting material the following compound was prepared.

Ex Compound NMR 204 (R)-N-[2-Chloro-4-{4-nitrophenyl- (CDCl₃) 1.8 (s, 3H), 5.0 (s, 1H), 7.2 (d, sulphanyl}phenyl]-2-hydroxy-2-methyl- 2H), 7.5 (d, 1H), 7.6 (s, 1H), 8.1 (d, 3,3,3-trifluoropropanamide 2H), 8.6 (d, 1H), 9.3 (s, 1H).

EXAMPLE 205

N-(2-Fluoro-4-phenylsulphanylphenyl)-2-hydroxy-2-methylpropanamide

2-Acetoxy-2-methylpropanoyl chloride (0.47 ml) was added to a solution of 2-fluoro-4-phenylsulphanylaniline (Method 7) (0.64 g) and pyridine (0.28 ml) in DCM (10 ml). The solution was stirred at ambient temperature for 90 minutes then volatile material was removed by evaporation. The residue was dissolved in methanol (20 ml) and a solution of lithium hydroxide monohydrate (0.378 g) in water (2.5 ml) was added. Stirring was continued for another 1 hour then the mixture was acidified to pH 1 with 2M hydrochloric acid and concentrated by evaporation to about 5 ml. Water (10 ml) was added and the product was extracted with ethyl acetate. Organic layers were washed with brine then combined and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 10-20% ethyl acetate/hexane to yield the title compound (0.784 g) as a solid. Mp 91-92.5° C.; NMR: 1.34 (s, 6H), 5.96 (s, 1H), 7.15 (d, 1H), 7.23 (dd, 1H), 7.27-7.4 (m, 5H), 8.02 (t, 1H), 9.3 (s, 1H); MS (ESP⁻): 304; EA: found: C, 62.8; H, 5.3; N. 4.5; S. 10.5%; C₁₆H₁₆FNO₂S requires: C, 62.9; H, 5.3; N, 4.6; S, 10.5%.

EXAMPLE 206

Following the procedure of Example 205 using the appropriate starting materials the following compound was prepared.

Ex Compound HPLC MS SM 206 (R)-N-[2-Chloro-4-(2-nitro- 8.08 minutes 402 Meth anilino)phenyl]-2-hydroxy-2- (HPLC Method d) 47 methyl-3,3,3-trifluoropropanamide

EXAMPLE 207

N-[2-Chloro-4-(4-mesylaminophenylsulphanyl)phenyl]-2-hydroxy-2-methylpropanamide

A solution of lithium hydroxide monohydrate (0.177 g) in water (1.8 ml) was added to a stirred solution of N-{2-chloro-4-[4-(N,N-dimesylamino)phenylsulphanyl]phenyl}-2-acetoxy-2-methylpropanamide (Method 26) (0.45 g) in methanol (3.5 ml) and the mixture was stirred at ambient temperature for 4 hours. Water (3 ml) was added and the solution was acidified to pH 2-3 with 1M hydrochloric acid. DCM (20 ml) was added and the organic layer was washed with water (20 ml) and brine, then dried. Volatile material was removed by evaporation and the residue was purified by flash chromatography eluting with 30-70% ethyl acetate/hexane to give the title compound (0.30 g) as a solid. Mp 138-140° C.; NMR (CDCl₃): 1.5 (s, 6H), 3.0 (s, 3H), 7.1-7.4 (m, 7H), 8.4 (d, 1H), 9.3 (s, 1H); MS (ESP⁻):413; EA: found: C, 48.9; H, 4.4; N, 6.5%; C₁₇H₁₉ClN₂O₄S₂ requires C, 49.2; H, 4.6; N, 6.8%.

EXAMPLES 208-209

Following the procedure of Method 30 (see below) and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 208 (R)-N-(2-Chloro-4-amino- 1.53 (s, 3H), 5.32 (s, 2H), 6.50 281 Meth phenyl)-2-hydroxy-2-methyl- (d, 1H), 6.66 (s, 1H), 7.39 (d, 60 3,3,3-trifluoropropanamide 1H), 7.45 (s, 1H), 9.30 (s, 1H) 209 (R)-N-(2-Methyl-4-amino- (CDCl₃) 1.69 (s, 3H), 2.15 (s, 261 Meth phenyl)-2-hydroxy-2- 3H), 3.60 (brs, 2H), 4.02 (brs, 62 methyl-3,3,3-trifluoropropanamide 1H), 6.48-6.57 (m, 2H), 7.28- 7.35 (m, 1H), 7.62 (brs, 1H).

EXAMPLE 210

(R)-N-(2-Chloro-4-mercaptophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Trifluoroacetic anhydride (5 ml) was added to (R)-N-(2-chloro-4-methylsulphinyl-phenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 92) (0.188 g). The mixture was stirred and heated under reflux for 45 minutes then cooled and evaporated to dryness. A mixture of triethylamine (5 ml) and methanol (5 ml) was added to the residue. This mixture was stirred for a further 45 minutes then evaporated to dryness. The residue was dissolved in chloroform (50 ml), washed with saturated aqueous ammonium chloride solution (50 ml), dried and concentrated by evaporation to give the title compound (0.177 g) as a gum which was used without purification. MS (ESP⁻): 298.

EXAMPLE 211

The indicated starting material was coupled with an appropriate thiol or halide using the method of Example 250 and acylated using the procedure of Example 197.

Ex Compound MS SM 211 (R)-N-[6-Methyl-5- 357 2-methyl-3-bromo- phenylsulphanylpyridin-2-yl]-2- (M + H)⁺ 6-aminopyridine hydroxy-2-methyl-3,3,3- trifluoropropanamide

EXAMPLE 212

Following the procedure of Method 63 (see below) and using the appropriate starting material the following compound was prepared.

Ex Compound NMR SM 212¹ (R)-N-[2-Chloro-4-(4-mesyl (CDCl₃) 1.73 (s, 3H), 3.08 (s, Ex 189 phenylsulphonyl)phenyl]-2-hydroxy- 3H), 3.7 (brs, 1H), 7.89 (dd, 1H), 2-methyl-3,3,3-trifluoropropanamide 8.02 (d, 1H), 8.08-8.15 (m, 4H), 8.67 (d, 1H), 9.33 (brs, 1H) ¹5 equivalents of m-Chloroperoxybenzoic acid

EXAMPLES 213-214

Following the procedure of Method 13 (see below) and using the appropriate starting material the following compounds were prepared.

Ex Compound NMR MS SM 213 (R)-N-{2-Chloro-4-[2-(methoxy- 1.6 (s, 3H), 3.85 (s, 3H), 7.6 (m, 464 Ex carbonyl)phenylsulphonyl]- 1H), 7.8-7.9 (m, 2H), 7.95 (dd, 1H), 105 phenyl}-2-hydroxy-2-methyl- 7.9-8.05 (brs, 1H), 8.1 (d, 1H), 8.2- 3,3,3-trifluoropropanamide 8.35 (m, 2H), 9.9 (brs, 1H) 214 (R)-N-{2-Chloro-4-[2-(ethoxy- 1.3 (t, 3H), 1.58 (s, 3H), 4.3 (q, 478 Ex carbonyl)phenylsulphonyl]- 2H), 7.65 (dd, 1H), 7.8 (m, 2H), 106 phenyl}-2-hydroxy-2-methyl- 7.95 (dd, 1H), 9.0 (brs, 1H), 8.1 (d, 3,3,3-trifluoropropanamide 1H), 8.2 (dd, 1H), 8.3 (d, 1H), 9.95 (brs, 1H)

EXAMPLE 215

(R)-N-{2-Chloro-4-[4-(N,N-dimethylcarbamoyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Oxalyl chloride (0.45 ml) was added to a stirred suspension of (R)-N-[2-chloro-4-(4-carboxyphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 121) (1.81 g) in DCM (100 ml) containing DMF (10 drops). The mixture was stirred for 5 hours and then a solution of dimethylamine (4.2 ml, 2M solution in methanol) was added, and the solution was stirred overnight. The reaction mixture was washed with dilute hydrochloric acid solution (2×25 ml) then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-10% methanol/DCM to yield the title compound (0.68 g) as a solid. M.p. 120.5° C. (Mettler FP62 apparatus); NMR: (CDCl₃): 1.70 (s, 3H), 2.90 (s, 3H), 3.10 (s, 3H), 5.20 (s, 1H), 7.55 (d, 2H), 7.85 (d, 1H), 7.90-8.00 (m, 3H), 8.60 (d, 1H), 9.40 (s, 1H); MS (ESP⁻): 477.

EXAMPLES 216-249

Following the procedure of Example 215 using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 216 (R)-N-{2-Chloro-4-[4-(N,N- (CDCl₃) 1.05-1.15 (brm, 3H), 1.2- 505 Ex diethylcarbamoyl)phenyl- 1.3 (brm, 3H), 1.7 (s, 3H), 3.1-3.3 121 sulphonyl]phenyl}-2-hydroxy- (m, 2H), 3.5-3.65 (m, 2H), 5.1 (s, 2-methyl-3,3,3- 1H), 7.5 (d, 2H), 7.85 (d, 1H), 7.95- trifluoropropanamide 8.0 (m, 3H), 8.6 (d, 1H), 9.4 (brs, 1H) 217 (R)-N-(2-Chloro-4-{4-[N-(3- 1.65 (s, 3H), 1.7-1.75 (m, 2H), 507 Ex hydroxypropyl)carbamoyl] 3.25-3.35 (m, 2H), 3.4-3.5 (m, 2H), 121 phenylsulphonyl}phenyl)-2- 4.45 (dd, 1H), 7.95-8.05 (m, 4H), hydroxy-2-methyl-3,3,3- 8.1 (d, 2H), 8.2 (s, 1H), 8.35 (d, trifluoropropanamide 1H), 8.6-8.7 (m, 1H), 9.9 (brs, 1H) 218 (R)-N-(2-Chloro-4-{4-[N-(2,3- 1.6 (s, 3H), 3.1-3.2 (m, 1H), 3.3-3.5 523 Ex dihydroxypropyl)carbamoyl] (m, 2H), 3.6-3.7 (m, 2H), 7.85 (brs, 121 phenylsulphonyl}phenyl)-2- 1H), 7.95-8.0 (m, 1H), 8.05-8.10 hydroxy-2-methyl-3,3,3- (m, 3H), 8.10-8.15 (m, 1H), 8.2 (d, trifluoropropanamide 1H), 8.3 (d, 1H), 8.7 (dd, 1H), 9.9 (s, 1H) 219 R)-N-[2-Chloro-4-(4- (CDCl₃) 1.65 (s, 3H), 7.60 (s, 1H), 449 Ex carbamoylphenylsulphonyl) 7.95 (dd, 1H), 8.0-8.05 (m, 4H), 121 phenyl]-2-hydroxy-2-methyl- 8.05-8.1 (m, 1H), 8.1-8.2 (m, 2H), 3,3,3-trifluoropropanamide 8.3 (d, 1H), 9.9 (s, 1H) 220 (R)-N-{2-Chloro-4-[4-(4-t- (CDCl₃) 1.45 (s, 9H), 1.7 (s, 3H), 618 Ex butoxycarbonylpiperazin-1-yl- 3.25-3.55 (brm, 7H), 3.7-3.8 (m, 121 carbonyl)phenylsulphonyl] 2H), 7.5 (d, 2H), 7.85 (dd, 1H), phenyl}-2-hydroxy-2-methyl- 7.95-8.0 (m, 3H), 8.6 (d, 1H), 9.35 3,3,3-trifluoropropanamide (s, 1H) 221 (R)-N-(2-Chloro-4-{4-[N-(2- 1.25 (s, 6H), 1.6 (s, 3H), 3.5 (d, 521 Ex hydroxy-1.1-dimethylethyl) 2H), 4.8 (dd, 1H), 7.75 (s, 1H), 7.9 121 carbamoyl]phenylsulphonyl} (d, 2H), 7.95 (dd, 2H), 8.05 (d, 2H), phenyl)-2-hydroxy-2-methyl- 8.15 (d, 2H), 8.3 (d, 1H), 9.90 (s, 3,3,3-trifluoropropanamide 1H) 222 (R)-N-{2-Chloro-4-[4-(N- (CDCl₃) 1.75 (s, 3H), 5.2 (brs, 1H), 527 Ex pyrimidin-2-ylcarbamoyl) 6.6 (dd, 1H), 7.1 (dd, 1H), 7.8-7.9 121 phenylsulphonyl]phenyl}-2- (m, 1H), 8.0 (d, 1H), 8.05 (s, 1H), hydroxy-2-methyl-3,3,3- 8.25 (d, 2H), 8.60-8.7 (m, 3H), 9.05 trifluoropropanamide (s, 1H), 9.6 (s, 1H) 223 (R)-N-{2-Chloro-4-[4-(N- (CDCl₃) 1.7 (s, 3H), 3.0 (d, 3H), 4.2 463 Ex methylcarbamoyl)phenyl- (s, 1H), 6.2 (brs, 1H), 7.8-7.9 (m, 121 sulphonyl]phenyl}-2-hydroxy- 3H), 7.9-8.0 (m, 3H), 8.6 (d, 1H), 2-methyl-3,3,3- 9.35 (brs, 1H) trifluoropropanamide 224 (R)-N-{2-Chloro-4-[2-(4- (DMSO-δ₆ + AcOH-δ₄) 1.55 (s, 532 Ex methylpiperazin-1-ylcarbonyl) 3H), 2.68 (brs, 3H), 2.97-3.02 (brm, 125 phenylsulphonyl]phenyl}-2- 2H), 3.10-3.13 (brm, 2H), 3.30-3.32 hydroxy-2-methyl-3,3,3- (brm, 2H), 3.84-3.86 (brm, 2H), trifluoropropanamide 7.40 (d, 1H), 7.6 (t, 1H), 7.7 (t, 1H), 7.89-7.94 (m, 1H), 8.05-8.07 (m, 2H), 8.32 (d, 1H) 225 (R)-N-{2-Chloro-4-[2- (DMSO-δ₆ + AcOH-δ₄) 1.55 (s, 519 Ex (morpholinocarbonyl)phenyl- 3H), 3.02-3.07 (m, 2H), 3.52-3.94 125 sulphonyl]phenyl}-2-hydroxy- (m, 6H), 7.35 (d, 1H), 7.58 (t, 1H), 2-methyl-3,3,3- 7.89-7.92 (m, 1H), 8.03 (d, 1H), trifluoropropanamide 8.10 (s, 1H), 8.32 (d, 1H); 226 (R)-N-{2-Chloro-4-[2- (At 373K): 1.64 (s, 3H), 3.0-3.06 521 Ex (thiazolidin-3-ylcarbonyl) (brm, 2H), 3.40-3.45 (brm, 1H), 125 phenylsulphonyl]phenyl}-2- 3.87-3.9 (brm, 1H), 4.12-4.2 (brm, hydroxy-2-methyl-3,3,3- 1H), 4.61-4.67 (brm, 1H), 7.47 (d, trifluoropropanamide 1H), 7.68 (t, 1H), 7.78 (t, 1H), 7.95 (d, 1H), 8.09-8.12 (m, 1H), 8.31 (d, 1H), 9.71 (brs, 1H) 227 (R)-N-[2-Chloro-4-(N,N- 0.92-0.97 (t, 3H), 1.06-1.1 (t, 3H), 445 Ex diethylcarbamoylmethyl- 1.62 (s, 3H), 3.15-3.2 (q, 2H), 3.33- 314 sulphonyl)phenyl]-2-hydroxy- 3.38 (q, 2H), 4.68 (s, 2H), 7.86-7.9 2-methyl-3,3,3- (m, 1H), 8.02 (s, 1H), 8.29 (d, 1H), trifluoropropanamide 9.94 (s, 1H) 228 (R)-N-[2-Chloro-4-(carbamoyl- 1.62 (s, 3H), 4.29 (s, 2H), 7.86 (d, 387 Ex methylsulphonyl)phenyl]-2- 1H), 8.0 (s, 1H), 8.3 (d, 1H), 9.92 314 hydroxy-2-methyl-3,3,3- (s, 1H) trifluoropropanamide 229 (R)-N-{2-Chloro-4-[N-(2- 1.63 (s, 3H), 3.02-3.07 (m, 2H), 431 Ex hydroxyethyl)carbamoylmethyl 3.28-3.34 (m, 2H), 4.44 (s, 2H), 314 sulphonyl]phenyl}-2-hydroxy- 4.65 (t, 1H), 7.84-7.86 (m, 2H), 8.0 2-methyl-3,3,3- (s, 1H), 8.31 (d, 1H). trifluoropropanamide 230 (R)-N-[2-Chloro-4-(N-iso- 0.97 (d, 6H), 1.63 (s, 3H), 3.65- 429 Ex propylcarbamoylmethyl- 3.73 (m, 1H), 4.26 (s, 2H), 7.81- 314 sulphonyl)phenyl]-2-hydroxy- 7.84 (m, 1H), 7.92 (s, 1H), 8.31 (d, 2-methyl-3,3,3- 1H). trifluoropropanamide 231 (R)-N-[2-Chloro-4-(N- 1.62 (s, 3H), 4.81 (s, 2H), 6.51-6.55 467 Ex pyrimidin-2-ylcarbamoyl- (m, 2H), 7.2-7.23 (m, 1H), 7.88- (M + H)⁺ 314 methylsulphonyl)phenyl]-2- 7.91 (m, 1H), 7.97 (s, 1H), 8.33 (d, hydroxy-2-methyl-3,3,3- 1H), 9.95 (s, 1H), 10.9 (s, 1H) trifluoropropanamide 232 (R)-N-{2-Chloro-4-[2-(N,N- 1.0 (t, 3H), 1.14 (t, 3H), 1.60 (s, 473 Ex diethylcarbamoyl)phenyl- 3H), 3.05 (q, 2H), 3.44 (m, 2H), 292 sulphanyl]phenyl}-2-hydroxy- 7.30 (m, 3H), 7.41 (m, 2H), 7.49 (s, 2-methyl-3,3,3- 1H), 7.86 (brs, 1H), 7.95 (d, 1H), trifluoropropanamide 9.73 (brs, 1H) 233 (R)-N-[2-Chloro-4-(4- 1.60 (s, 3H), 7.3 (d, 2H), 7.4 (d, 435 Ex carbamoylphenylsulphinyl) 2H), 7.50 (dd, 1H), 7.65 (d, 1H), (M + H)⁺ 280 phenyl]-2-hydroxy-2-methyl- 7.8-8.0 (m, 3H), 8.1 (d, 1H), 9.80 3,3,3-trifluoropropanamide (s, 1H) 234 (R)-N-[2-Chloro-4-(4-N,N- (CDCl₃) 1.05-1.25 (m, 6H), 1.7 (s, 475 Ex diethylcarbamoylphenyl- 3H), 3.2-3.3 (m, 2H), 3.4-3.5 (m, (M + H)⁺ 291 sulphanyl)phenyl]-2-hydroxy- 2H), 5.25 (s, 1H), 7.2-7.3 (m, 3H), 2-methyl-3,3,3- 7.35 (d, 1H), 7.45-7.5 (m, 1H), 7.95 trifluoropropanamide (dd, 1H), 8.4 (d, 1H), 9.2 (s, 1H) 235 (R)-N-[2-Chloro-4-(4-N,N- 1.60 (s, 3H), 2.95 (d, 6H), 7.3 (d, 464 Ex dimethylcarbamoylphenyl- 2H), 7.35-7.4 (m, 3H), 7.6 (s, 1H), (M + H)⁺ 280 sulphinyl)phenyl]-2-hydroxy- 7.8-8.0 (m, 1H), 8.05 (d, 1H), 9.8 2-methyl-3,3,3- (s, 1H) trifluoropropanamide 236 (R)-N-[2-Chloro-4-(4-(2- 1.6 (s, 3H), 1.75 (s, 1H), 3.9-4.0 480 Ex hydroxyethoxycarbonyl)phenyl (m, 2H), 4.4-4.5 (m, 2H), 7.35 (d, (M + H)⁺ 280 sulphinyl)phenyl]-2-hydroxy- 2H), 7.5 (d, 1H), 7.7 (s, 1H), 7.8- 2-methyl-3,3,3- 8.0 (m, 3H), 8.1 (d, 1H), 9.8 (s, 1H) trifluoropropanamide 237 (R)-N-[2-Chloro-4-(4-{2- (CDCl₃) 1.75 (s, 3H), 2.4-2.6 (m, 532 Ex morpholinoethylamino 4H), 2.6-2.7 (m, 2H), 3.5-3.6 (m, (M + H)⁺ 291 carbonyl}phenylsulphanyl) 2H), 3.7-3.8 (m, 4H), 6.8-6.9 (s, phenyl]-2-hydroxy-2-methyl- 1H), 7.2-7.3 (m, 3H), 7.35 (dd, 1H), 3,3,3-trifluoropropanamide 7.5 (s, 1H), 7.65 (d, 2H), 8.4 (d, 1H), 9.25 (s, 1H) 238 (R)-N-[2-Chloro-4-(4-{3- 1.0-1.05 (m, 1H), 1.05-1.10 (m, 503 Ex hydroxypiperidin-1-yl- 4H), 1.3-1.4 (s, 2H), 1.6 (s, 3H), (M + H)⁺ 291 carbonyl}phenylsulphanyl) 4.0-4.1 (m, 3H), 7.25-7.4 (m, 4H), phenyl]-2-hydroxy-2-methyl- 7.4-7.45 (m, 1H), 7.6 (s, 1H), 7.85 3,3,3-trifluoropropanamide (s, 1H), 8.05 (d, 1H), 9.80 (s, 1H) 239 (R)-N-[2-Chloro-4-(4-{N-[5- (CDCl₃) 1.75 (s, 3H), 2.2 (s, 3H), 497 Ex methylpyrazol-3-yl] 5.35 (s, 1H), 5.6 (brs, 2H), 7.2-7.25 (M + H)⁺ 291 carbamoyl}phenylsulphanyl) (m, 3H), 7.45 (dd, 1H), 7.55 (d, phenyl]-2-hydroxy-2-methyl- 1H), 8.0 (d, 2H), 8.4 (d, 1H), 9.0 (s, 3,3,3-trifluoropropanamide 1H) 240 (R)-N-[2-Chloro-4-(4-{N- 1.6 (s, 3H), 5.5 (s, 2H), 5.85 (d, 484 Ex [isoxazol-3-yl]carbamoyl} 1H), 7.35 (d, 2H), 7.5 (d, 1H), 7.95 291 phenylsulphanyl)phenyl]-2- (d, 1H), 8.1 (d, 1H), 8.3 (d, 2H), 8.8 hydroxy-2-methyl-3,3,3- (s, 1H), 9.8 (s, 1H) trifluoropropanamide 241 (R)-N-{2-Chloro-4-[3-(4- 1.6 (s, 3H), 2.23 (m, 5H), 2.36 (brs, 532 Ex methylpiperazin-1-ylcarbonyl) 1H), 3.2 (brs, 2H), 3.6 (brs, 2H), 170 phenylsulphonyl]phenyl}-2- 7.7 (d, 2H), 7.9-8.13 (m, 4H), 8.23 hydroxy-2-methyl-3,3,3- (s, 1H), 8.31 (d, 1H), 9.9 (brs, 1H) trifluoropropanamide 242 (R)-N-{2-Chloro-4-[3-(N- 1.58 (s, 3H), 2.8 (d, 3H), 7.71 (t, 463 Ex methylcarbamoyl)phenyl- 1H), 8.0 (d, 1H), 8.12 (m, 3H), 8.3 170 sulphonyl]phenyl}-2-hydroxy- (d, 1H), 8.38 (s, 1H), 8.7 (d, 1H) 2-methyl-3,3,3- trifluoropropanamide 243 (R)-N-{2-Chloro-4-[3- 1.59 (s, 3H), 1.84 (m, 4H), 3.32 (m, 505 Ex (pyrrolidin-1-ylcarbonyl) 2H), 3.48 (t, 2H), 7.68 (t, 1H), 7.83 (M + H)⁺ 170 phenylsulphonyl]phenyl}-2- (d, 1H), 7.98-8.1 (m, 3H), 8.19 (s, hydroxy-2-methyl-3,3,3- 1H), 8.3 (d, 1H) trifluoropropanamide 244 (R)-N-{2-Chloro-4-[3- 1.58 (s, 3H), 7.6 (s, 1H), 7.7 (t, 1H), 449 Ex carbamoylphenylsulphonyl] 8.0 (d, 1H), 8.13 (m, 3H), 8.25 (brs, 170 phenyl}-2-hydroxy-2-methyl- 1H), 8.3 (d, 1H), 8.41 (s, 1H) 3,3,3-trifluoropropanamide 245 (R)-N-{2-Chloro-4-{3-[N′-(2- 1.58 (s, 3H), 2.20 (s, 6H), 2.44 (m, 522 Ex N,N-dimethylaminoethyl) 2H), 3.37 (m, 2H), 7.71 (t, 1H), 170 carbamoyl]phenylsulphonyl} 7.99 (dd, 1H), 8.14 (m, 3H), 8.32 phenyl}-2-hydroxy-2-methyl- (d, 1H), 8.4 (s, 1H), 8.7 (t, 1H) 3,3,3-trifluoropropanamide 246 (R)-N-{2-Chloro-4-[3-N,N- (CDCl₃) 1.71 (s, 3H), 2.98 (s, 3H), 477 Ex dimethylcarbamoylphenyl- 3.12 (s, 3H), 4.35 (s, 1H), 7.6 (m, 170 sulphonyl]phenyl}-2-hydroxy- 2H), 7.84 (dd, 1H), 7.98 (m, 3H), 2-methyl-3,3,3- 8.6 (d, 1H), 9.23 (s, 1H) trifluoropropanamide 247 (R)-N-{2-Chloro-4-[3- Retention time 25.39 minutes 533 Ex (pyrrolidin-1-ylcarbonyl) (HPLC Method c) 170 phenylsulphonyl]phenyl}-2- hydroxy-2-methyl-3,3,3- trifluoropropanamide 248 (R)-N-{2-Chloro-4-[3- Retention time 27.28 minutes 519 Ex (morpholinocarbonyl)phenyl- (HPLC Method c) 170 sulphonyl]phenyl}-2-hydroxy- 2-methyl-3,3,3- trifluoropropanamide 249 (R)-N-{2-Chloro-4-[3- Retention time 29.70 minutes 535 Ex (thiomorpholinocarbonyl) (HPLC Method c) 170 phenylsulphonyl]phenyl}-2- hydroxy-2-methyl-3,3,3- trifluoropropanamide

EXAMPLE 250

(R)-N-{2-Chloro-4-[4-(pyrrolidin-1-ylsulphonyl)phenylsulphanyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Copper (1) chloride (0.038 g) was added to a mixture of (R)-N-(2-chloro-4-mercaptophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 210) (0.21 g), N-(4-iodobenzenesulphonyl)pyrrolidine (0.258 g) and sodium methoxide (0.042 g) in DMA (5 ml). The mixture was heated at 150° C. with stirring for 4 hours then cooled and the DMA removed by evaporation. Ethyl acetate (20 ml) and water (20 ml) was added and the mixture was filtered. The aqueous layer was extracted with ethyl acetate (3×20 ml) and the organic layers were combined and dried. Volatile material was removed by evaporation and the residue was purified on a silica gel Mega Bond Elut column, eluting with methanol/DCM 0-10% to give the title compound (0.16 g) as a solid. NMR (CDCl₃): 1.75 (s, 3H), 1.75-1.85 (m, 4H), 3.2-3.3 (m, 4H), 4.0 (s, 1H), 7.2-7.3 (m, 2H), 7.4-7.45 (m, 1H), 7.6 (s, 1), 7.7 (d, 2H), 8.45 (d, 1H), 9.15 (s, 1H); MS (ESP⁻): 507.

EXAMPLES 251-279

Following the procedure of Example 250 using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 251 (R)-N-{2-Chloro-4-[4-(dimethyl- (CDCl₃) 1.75 (s, 3H), 2.7 481 Ex aminosulphonyl)phenylsulphanyl] (s, 6H), 3.6 (s, 1H), 7.25 210 phenyl}-2-hydroxy-2-methyl- (d, 2H), 7.45 (dd, 1H), 7.6 3,3,3-trifluoropropanamide (d, 1H), 7.7 (d, 2H), 8.45 (d, 1H), 9.1 (s, 1H) 252 (R)-N-[2-Chloro-4-(4-hydroxy- (CDCl₃) 1.75 (s, 3H), 4.1 390 Ex phenylsulphanyl)phenyl]-2-hydroxy- (s, 1H), 6.75 (d, 2H), 6.85 197 2-methyl-3,3,3- (d, 2H), 7.3-7.4 (m, 3H), trifluoropropanamide 8.2 (d, 1H), 8.9 (s, 1H) 253 (R)-N-[2-Chloro-4-(3-fluoro- (CDCl₃) 1.75 (s, 3H), 392 Ex phenylsulphanyl)phenyl]-2-hydroxy- 3.75 (s, 1H), 6.9-7.0 (m, 197 2-methyl-3,3,3- 2H), 7.05 (d, 1H), 7.2-7.3 trifluoropropanamide (m, 1H), 7.35 (dd, 1H), 7.45 (d, 1H), 8.4 (d, 1H), 9.0 (s, 1H) 254 (R)-N-[2-Chloro-4-(4-sulphamoyl- (CDCl₃) 1.7 (s, 3H), 5.2 453 Ex phenylsulphanyl)phenyl]-2- (s, 2H), 6.7 (s, 1H), 7.2- 210 hydroxy-2-methyl-3,3,3- 7.25 (m, 2H), 7.4 (dd, trifluoropropanamide 1H), 7.5 (d, 1H), 7.8 (d, 2H), 8.5 (d, 1H), 9.55 (s, 1H) 255 (R)-N-{2-Chloro-4-[4-(guanidino- 1.6 (s, 3H), 6.75 (s, 4H), 495 Ex sulphonyl)phenylsulphanyl] 7.35 (d, 2H), 7.5 (d, 1H), 210 phenyl}-2-hydroxy-2-methyl- 7.6-7.7 (m, 3H), 7.9 (s, 3,3,3-trifluoropropanamide 1H), 8.1 (d, 1H), 9.8 (s, 1H) 256 (R)-N-[2-Chloro-4-(thiazol-2-yl- 1.62 (s, 3H), 7.64 (dd, 383 Ex sulphanyl)phenyl]-2-hydroxy-2- 1H), 7.75 (d, 1H), 7.82 (d, (M + H)⁺ 197 methyl-3,3,3- 1H), 7.87 (d, 1H), 8.12 (d, trifluoropropanamide 1H), 9.8 (brs, 1H) 257 (R)-N-[2-Chloro-4-(1-methyl- 1.6 (s, 3H), 3.64 (s, 3H), 380 Ex imidazol-2-ylsulphanyl)phenyl]-2- 7.1 (dd, 1H), 7.12 (d, 1H), (M + H)⁺ 197 hydroxy-2-methyl-3,3,3- 7.23 (d, 1H), 7.49 (d, 1H), trifluoropropanamide 7.86 (d, 1H), 9.7 (brs, 1H) 258 (R)-N-[2-Chloro-4-(5-methyl- 1.63 (s, 3H), 2.66 (s, 3H), 396 Ex 1,3,4-thiadiazol-2-ylsulphanyl) 7.7 (dd, 1H), 7.94 (d, 1H), 197 phenyl]-2-hydroxy-2-methyl- 8.15 (d, 1H), 9.7 (brs, 1H) 3,3,3-trifluoropropanamide 259 (R)-N-[2-Chloro-4-(pyrimidin-2- 1.64 (s, 3H), 7.29 (t, 1H), 378 Ex ylsulphanyl)phenyl]-2-hydroxy-2- 7.62 (dd, 1H), 7.83 (d, (M + H)⁺ 197 methyl-3,3,3- 1H), 7.9 (brs, 1H), 8.1 (d, trifluoropropanamide 1H), 8.63 (d, 2H), 9.8 (brs, 1H) 260 (R)-N-[2-Chloro-4-(imidazol-2-yl- 1.6 (s, 3H), 7.2 (d, 1H), 364 Ex sulphanyl)phenyl]-2-hydroxy-2- 7.3 (s, 2H), 7.75 (d, 1H), 197 methyl-3,3,3- 7.87 (dd, 1H), 9.7 (brs, trifluoropropanamide 1H), 12.9 (brs, 1H) 261 (R)-N-[2-Chloro-4-(benzothiazol- (CDCl₃) 1.8 (s, 3H), 3.9 433 Ex 2-ylsulphanyl)phenyl]-2-hydroxy- (s, 1H), 7.25-7.3 (m, 1H), (M + H)⁺ 197 2-methyl-3,3,3- 7.4 (t, 1H), 7.7 (dd, 2H), trifluoropropanamide 7.8 (dd, 1H), 7.9 (d, 1H), 8.5 (d, 1H), 9.2 (brs, 1H) 262 (R)-N-[2-Chloro-4-(5-chloro- (CDCl₃) 1.75 (s, 3H), 2.7 467 Ex benzothiazol-2-ylsulphanyl) (s, 6H), 3.6 (s, 1H), 7.25 (M + H)⁺ 210 phenyl]-2-hydroxy-2-methyl- (d, 2H), 7.45 (dd, 1H), 7.6 3,3,3-trifluoropropanamide (d, 1H), 7.7 (d, 2H), 8.45 (d, 1H), 9.1 (s, 1H) 263 (R)-N-[2-Chloro-4-(N-methyl-4- 1.6 (s, 3H), 2.9 (s, 3H), 481 Ex mesylaminophenylsulphanyl) 3.2 (s, 3H), 7.4 (m, 5H), 210 phenyl]-2-hydroxy-2-methyl- 7.5 (s, 1H), 7.8 (s, 1H), 3,3,3-trifluoropropanamide 8.0 (d, 1H) 264 (R)-N-[2-Chloro-4-(2-nitrophenyl- 419 Ex sulphanyl)phenyl]-2-hydroxy-2- 210 methyl-3,3,3- trifluoropropanamide   265^(1,2) (R)-N-[2-Chloro-4-(2,3-H-2-oxo- 1.6 (s, 3H), 3.4 (s, 3H), 445 Ex 3-methylbenzoxazol-6- 7.2 (d, 1H), 7.4 (m, 3H), 210 ylsulphanyl)phenyl]-2-hydroxy-2- 7.5 (s, 1H), 7.8 (s, 1H), methyl-3,3,3- 7.9 (d, 1H), 9.7 (s, 1H) trifluoropropanamide   266^(1,3) (R)-N-[2-Chloro-4-(2-oxo-1,3- 458 Ex dimethylbenzimidazolidin-5- 210 ylsulphanyl)phenyl]-2-hydroxy-2- methyl-3,3,3- trifluoropropanamide   267^(1,4) (R)-N-{2-Chloro-4-[4-(2-oxo- 1.6 (s, 3H), 2.0 (m, 2H), 457 Ex pyrrolidin-1-yl)phenylsulphanyl] 2.7 (s, 1H), 2.9 (s, 1H), 210 phenyl}-2-hydroxy-2-methyl- 3.8 (t, 2H), 7.2 (d, 1H), 3,3,3-trifluoropropanamide 7.3 (s, 1H), 7.4 (d, 2H), 7.7 (d, 2H), 7.9 (d, 1H) 268 (R)-N-[2-Chloro-4-(1,2,3,4-H-1,3- 1.6 (s, 3H), 3.2 (s, 3H), 486 Ex dimethyl-2,4-dioxoquinazolin-6- 3.5 (s, 3H), 7.3 (d, 1H), 210 ylsulphanyl)phenyl]-2-hydroxy-2- 7.5 (m, 2H), 7.8 (d, 2H), and methyl-3,3,3- 7.9 (s, 1H), 8.0 (d, 2H) Meth trifluoropropanamide 54 269 (R)-N-{2-Chloro-4-(2H- 1.6 (s, 3H), 7.0 (m, 2H), 430 Ex benzimidazol-2-one-5- 7.1 (m, 3H), 7.7 (s, 1H), 210 ylsulphanyl)phenyl}-2-hydroxy-2- 7.8 (d, 1H), 9.6 (s, 1H) and methyl-3,3,3- 10.7 (s, 1H), 10.8 (s, 1H) Meth trifluoropropanamide 58 270 (R)-N-{2-Chloro-4-(4- 1.6 (s, 3H), 2.6 (s, 3H), 416 Ex acetylphenylsulphanyl)phenyl}-2- 7.3 (d, 2H), 7.5 (d, 1H), 210 hydroxy-2-methyl-3,3,3- 7.7 (s, 1H), 7.9 (d, 2H), trifluoropropanamide 8.1 (d, 1H) 271 (R)-N-{2-Chloro-4-(4-amino-3- 1.6 (s, 3H), 6.8 (d, 1H), 433 Ex carboxyphenylsulphanyl)phenyl}- 7.0 (d, 1H), 7.1 (s, 1H), 210 2-hydroxy-2-methyl-3,3,3- 7.4 (d, 1H), 7.7 (s, 1H), trifluoropropanamide 7.8 (d, 1H), 7.9 (s, 1H), 9.6 (s, 1H) 272 (R)-N-{2-Chloro-4-(4,5-diphenyl- (CDCl₃) 1.75 (s, 3H), 4.0 519 Ex 2-oxazolylsulphanyl)phenyl}-2- (s, 1H), 7.25-7.4 (m, 6H), (M + H)⁺ 197 hydroxy-2-methyl-3,3,3- 7.45-7.55 (m, 2H), 7.65 trifluoropropanamide (dd, 3H), 7.75 (d, 1H), 8.45 (d, 1H), 9.1 (brs, 1H) 273 (R)-N-{2-Chloro-4-(1- (CDCl₃) 1.55 (t, 3H), 1.75 396 Ex ethyltetrazol-5-ylsulphanyl) (s, 3H), 4.40 (q, 2H), 4.55 (M + H)⁺ 197 phenyl}-2-hydroxy-2-methyl- (s, 1H), 7.5 (dd, 1H), 7.65 3,3,3-trifluoropropanamide (d, 1H), 8.45 (d, 1H), 9.20 (brs, 1H) 274 (R)-N-{2-Chloro-4-(4-iso-propyl- (CDCl₃) 1.55 (d, 6H), 1.8 457 Ex 4,5-dihydro-1H-1,2,4-triazol-5- (s, 3H), 3.7 (brs, 1H), 4.8 (M + H)⁺ 197 one-3-ylsulphanyl)phenyl}-2- (m, 1H), 7.9 (m, 1H), hydroxy-2-methyl-3,3,3- 8.05 (d, 1H), 8.8 (d, 1H), trifluoropropanamide 9.45 (brs, 1H), 10.15 (brs, 1H) 275 (R)-N-{2-Chloro-4-(3-chloro-4- 1.75 (s, 3H), 3.55 (s, 1H), 428 Ex fluorophenylsulphanyl)phenyl}-2- 7.1 (t, 1H), 7.2-7.3 (m, (M + H)⁺ 197 hydroxy-2-methyl-3,3,3- 2H), 7.33-7.45 (m, 2H), trifluoropropanamide 8.35 (d, 1H), 8.9 (brs, 1H) 276 (R)-N-{2-Chloro-4-(3,4- (CDCl₃) 1.75 (s, 3H), 3.7 410 Ex difluorophenylsulphanyl)phenyl}- (s, 1H), 7.0-7.1 (m, 3H), 197 2-hydroxy-2-methyl-3,3,3- 7.3 (dd, 1H), 7.4 (d, 1H), and trifluoropropanamide 8.35 (d, 1H), 8.95 (brs, Meth 1H) 51 277 (R)-N-{2-Chloro-4-(4- 1.25 (t, 3H), 1.4 (s, 3H), 438 Ex ethoxycarbonylimidazol-2- 4.2 (q, 2H), 7.25 (d, 1H), (M + H)⁺ 197 ylsulphanyl)phenyl}-2-hydroxy-2- 7.45 (s, 1H), 7.8 (s, 1H), methyl-3,3,3- 7.90 (d, 1H), 8.0 (s, 1H), trifluoropropanamide 9.7 (s, 1H), 13.35 (s, 1H)  278⁵ (R)-N-{2-Chloro-4-(4-{3-methyl- 1.62 (s, 3H), 2.41 (s, 3H), 456 Ex 1,2,4-oxadiazol-5- 7.38 (d, 2H), 7.56 (dd, 210 yl}phenylsulphanyl)phenyl}-2- 1H), 7.77 (d, 1H), 7.97 hydroxy-2-methyl-3,3,3- (brs, 1H), 8.02 (d, 2H), trifluoropropanamide 8.15 (d, 1H), 9.82 (brs, 1H)  279⁵ (R)-N-{2-Chloro-4-(4-{5-methyl- 1.6 (s, 3H), 2.68 (s, 3H), 456 Ex 1,2,4-oxadiazol-3- 7.4 (d, 2H), 7.5 (dd, 1H), 210 yl}phenylsulphanyl)phenyl}-2- 7.70 (d, 1H), 7.95 (m, hydroxy-2-methyl-3,3,3- 3H), 8.09 (d, 1H), 9.8 trifluoropropanamide (brs, 1H) ¹Potassium carbonate and DMF were used in place of sodium methoxide and DMA ²The 6-iodo-3-methyl-2(3H)-benzoxazolone used as starting material was prepared as described in European Patent Application EP 90-401759, CA 116:128665, RN 139487-06-2. ³The 1,3-dihydro-5-iodo-1,3-dimethyl-2H-benzimidazol-2-one used as starting material was prepared as described in European Patent Application EP 90-401759, CA 116:128665, RN 139487-04-0. ⁴The 1-(4-iodophenyl)-2-pyrrolidinone used as starting material was prepared as described in European Patent Application EP 89-402046, CA 115:183096, RN 7661-34-9. ⁵The oxadiazolylphenyliodide used as starting material was prepared as described in British patent application GB 92-18334.

EXAMPLE 280

(R)-N-[2-Chloro-4-(4-carboxyphenylsulphinyl)phenyl]2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Oxone (1.47 g) as a solution in 1M sodium acetate solution (12 ml) was added to a mixture of (R)-N-[2-chloro-4-(4-carboxyphenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 291) (1 g) in methanol (25 ml) and stirred for 2 hours. The reaction mixture was filtered and the solid washed with water and dried under vacuum to give the title compound as a solid (1.02 g) containing 9% of the corresponding sulphone. NMR: 1.6 (s, 3H), 7.75 (d, 1H), 7.8-7.9 (m, 3H), 7.95 (d, 1H), 8.0-8.05 (m, 3H), 8.15 (d, 1H), 9.8 (s, 1H); MS (ESP⁻); 434.

EXAMPLES 281-283

Following the procedure of Example 280 (except that products were purified by chromatography with ethyl acetate/hexane as eluent) and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 281 (R)-N-[2-Chloro-4-(5-methyl- (CDCl₃) 1.76 (s, 3H), 2.81 (s, 412 Ex 258 1,3,4-thiadiazol-2-ylsulphinyl) 3H), 3.9 and 3.91 (2xs, 1H), phenyl]-2-hydroxy-2-methyl- 7.7-7.78 (m, 1H), 7.87-7.9 3,3,3-trifluoropropanamide (m, 1H), 8.69 (d, 1H), 9.23 (brs, 1H) 282 (R)-N-[2-Chloro-4-(5-methyl- 1.62 (s, 3H), 2.84 (s, 3H), 428 Ex 281 1,3,4-thiadiazol-2-ylsulphonyl) 8.12 (dd, 1H), 8.22 (d, 1H), phenyl]-2-hydroxy-2-methyl- 8.44 (d, 1H), 9.9 (brs, 1H) 3,3,3-trifluoropropanamide 283 (R)-N-[2-Chloro-4-(4-ethenyl- (CDCl₃) 1.76 (s, 3H), 3.05 (s, 356 Ex 419 sulphonyl)phenyl]-2-hydroxy-2- 1H), 6.07 (d, 1H), 6.46 (d, methyl-3,3,3- 1H), 6.57-6.68 (dd, 1H), trifluoropropanamide 7.76-7.81 (m, 1H), 7.92 (s, 1H), 8.65 (d, 1H), 9.52 (s, 1H)

EXAMPLE 284

(R)-N-{2-Chloro-4-[4-(2-hydroxyethylsulphanyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

2-Mercaptoethanol (0.358 ml) was added dropwise to an ice/water-cooled suspension of sodium hydride (0.205 g) in NMP (6 ml). After effervescence had ceased, the cooling was removed and stirring continued a further 15 minutes. (R)-N-[2-Chloro-4-(4-fluorophenyl-sulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Method 69) (1.556 g) was added and the mixture was heated at 118° C. for 2 hours then cooled and poured onto saturated aqueous ammonium chloride solution (60 ml). The mixture was extracted with ethyl acetate (2×200 ml) and the organic extracts were washed with brine (300 ml) then dried. Volatile material was removed by evaporation and the residue was purified by chromatography eluting with 60% ethyl acetate/hexanes to give the title compound as a solid. NMR (CDCl₃): 1.74 (s, 31H), 1.91 (t, 1H), 3.19 (t, 2H), 3.62 (s, 1H), 3.82 (q, 21H), 7.4 (d, 2H), 7.8 (d, 2H), 7.83 (dd, 1H), 7.97 (d, 1H), 8.59 (d, 2H), 9.25 (brs, 1H); MS (ESP⁻); 482; EA: found: C, 44.6; H, 3.6; N, 2.7%; C₁₈H₁₇ClF₃NO₅S₂ requires: C, 44.7; H, 3.5; N, 2.9%.

EXAMPLES 285-290

Following the procedure of Example 284 using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM  285¹ (R)-N-[2-Chloro-4-(pyrid-4- (CDCl₃ + DMSO-δ₆) 1.58 (s, 515 Meth ylsulphanylphenylsulphonyl) 3H), 7.06 (d, 2H), 7.49 (brm, 69 phenyl]-2-hydroxy-2-methyl- 3H), 7.75 (dd, 1H), 7.83 (d, 2H), 3,3,3-trifluoropropanamide 7.9 (d, 1H), 8.35 (d, 2H), 8.57 (d, 1H), 9.73 (brs, 1H) 286 (R)-N-{2-Chloro-4-[4-(N,N- (CDCl₃) 1.7 (s, 3H), 2.3 (s, 6H), 511 Meth dimethylaminoethylsulphanyl) 2.6 (t, 2h), 3.1 (t, 2H), 7.35 (d, (M + H)⁺ 69 phenylsulphonyl]phenyl}-2- 2H), 7.75-7.7 (m, 3H), 7.95 (dd, hydroxy-2-methyl-3,3,3- 1H), 8.6 (d, 1H), 9.4 (brs, 1H) trifluoropropanamide 287 (R)-N-{2-Chloro-4-[4-(cyclo- 0.3 (q, 2H), 0.6 (q, 2H), 1.05 (m, 492 Meth propylmethylsulphanyl)phenyl 1H), 1.7 (s, 3H), 3.5 (d, 2H), 4.9 69 sulphonyl]phenyl}-2-hydroxy-2- (s, 1H), 7.35 (d, 2H), 7.8 (d, 2H), methyl-3,3,3- 7.9 (m, 2H), 8.6 (d, 1H), 9.4 trifluoropropanamide (brs, 1H) 288 (R)-N-{2-Chloro-4-[4-(N-methyl- 1.75 (s, 3H), 2.8 (d, 3H), 3.70 (s, 509 Meth carbamoylmethylsulphanyl) 2H), 4.7 (s, 1H), 6.65 (m, 1H), 69 phenylsulphonyl]phenyl}-2- 7.3 (d, 2H), 7.7 (m, 3H), 7.95 hydroxy-2-methyl-3,3,3- (dd, 1H), 8.6 (d, 1H), 9.45 (brs, trifluoropropanamide 1H) 289 (R)-N-{2-Chloro-4-[4-(N,N- 1.05 (t, 6H), 1.8 (s, 3H), 2.6 (q, 537 Meth diethylaminoethylsulphanyl) 4H), 2.85 (t, 2H), 3.1 (t, 2H), 7.3 69 phenylsulphonyl]phenyl}-2- (d, 2H), 7.7-7.85 (m, 3H), 7.95 hydroxy-2-methyl-3,3,3- (dd, 1H), 8.6 (d, 1H), 9.5 (brs, trifluoropropanamide 1H) 290 (R)-N-{2-Chloro-4-[2-(2- (CDCl₃) 1.75 (s, 3H), 2.67 (brt, 482 Meth hydroxyethylsulphanyl)phenyl- 1H), 3.12 (t, 2H), 3.65 (q, 2H), 63 sulphonyl]phenyl}-2-hydroxy-2- 3.75 (brs, 1H), 7.4-7.47 (m, 1H), methyl-3,3,3- 7.5-7.6 (m, 2H), 7.86 (dd, 1H), trifluoropropanamide 8.07 (d, 1H), 8.26 (d, 1H), 8.6 (d, 1H), 9.3 (brs, 1H) ¹Two equivalents of sodium hydride and 4-mercaptopyridine were used.

EXAMPLE 291

(R)-N-[2-Chloro-4-(4-carboxyphenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A mixture of 4-mercaptobenzoic acid (0.308 g), (R)-N-(2-chloro-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (0.786 g) and copper (I) oxide (0.143 g) in DMF (5 ml) was stirred and heated under reflux for 1 hour. More 4-mercaptobenzoic acid (0.308 g) was added and heating was continued for a further 2 hours. The mixture was cooled, filtered, and the filter washed with DMF (5 ml). The filtrates were concentrated by evaporation and the residual solid was extracted with boiling ethyl acetate (2×60 ml). The extracts were absorbed onto deactivated silica (silica deactivated by treatment with 10% water) and purified by chromatography eluting with 5% methanol/ethyl acetate to give the title compound (0.803 g) as a solid. NMR: 1.63 (s, 3H), 7.31 (d, 2H), 7.5 (dd, 1H), 7.68 (d, 1H), 7.89 (d, 2H), 8.22 (d, 1H), 9.8 (brs, 1H); MS (ESP⁻): 418; EA: found: C, 48.2; H, 3.1; N. 3.2%; CH₁₇H₁₃NClF₃O₄S requires C, 48.6; H, 3.1; N, 3.3%.

EXAMPLES 292-293

Following the procedure of Example 291 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS 292 (R)-N-[2-Chloro-4-{2-carboxy- 1.6 (s, 3H), 6.52 (d, 1H), 7.24 (t, 418 phenylsulphanyl}phenyl]-2- 1H), 7.40 (t, 1H), 7.50-7.55 (m, 1H), hydroxy-2-methyl-3,3,3- 7.71 (s, 1H), 7.89-7.92 (m, 1H), 8.15 trifluoropropanamide (d, 1H), 9.8 (s, 1H) 293 (R)-N-{2-Chloro-4-(3-carboxy- 1.58 (s, 3H), 7.39 (d, 1H), 7.48-7.59 418 phenylsulphanyl)phenyl}-2- (m, 3H), 7.83 (m, 3H), 8.01 (d, 1H), hydroxy-2-methyl-3,3,3- 9.72 (s, 1H) trifluoropropanamide

EXAMPLE 294

(R)-N-{2-Chloro-4-[4-(N-2-hydroxyethylcarbamoyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A solution of 1,1′-carbonyldiimidazole (0.169 g) and (R)-N-[2-chloro-4-(4-carboxyphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 121) (0.30 g) in DMF (1 ml)/ethyl acetate (9 ml) was heated at 50° C. for 30 minutes. Ethanolamine (0.055 ml) was added and the mixture was heated and stirred a further 17 hours. The mixture was cooled, diluted with ethyl acetate (50 ml), washed with dilute aqueous hydrochloric acid (25 ml), water (25 ml), saturated aqueous sodium hydrogen carbonate solution (25 ml) and brine, then dried. Volatile material was removed by evaporation and the residue was purified by chromatography, eluting with 2.5% methanol/ethyl acetate to give the title compound (0.25 g) as a solid. NMR (CDCl₃+DMSO-δ₆): 1.58 (s, 3H), 3.44 (m, 2H), 3.62 (m, 2H), 4.26 (t, 1H), 7.05 (s, 1H), 7.76 (dd, 1H), 7.83-8.01 (m, 6H), 8.56 (d, 1H); 9.73 (brs, 1H); MS (ESP⁻): 495.

EXAMPLES 295-303

Following the procedure of Example 294 using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 295 (R)-N-(2-Chloro-4-{4-[N′-(2-N,N- (CDCl₃ + DMSO-δ₆) 1.6 (s, 520 Ex dimethylaminoethyl)carbamoyl] 3H), 2.26 (s, 6H), 2.47 (m, 2H), 121 phenylsulphonyl}phenyl)-2- 3.43 (m, 2H), 7.48 (s, 1H), 7.75 hydroxy-2-methyl-3,3,3- (m, 1H), 7.82-7.98 (m, 5H), trifluoropropanamide 8.54 (d, 1H), 9.73 (brs, 1H) 296 (R)-N-{2-Chloro-4-[4-(morpholino- (DMSO-δ₆ + AcOH-δ₄) 1.62 (s, 519 Ex carbonyl)phenylsulphonyl]phenyl}- 3H), 3.4 (s, 4H), 3.58 (m, 4H), 121 2-hydroxy-2-methyl-3,3,3- 7.6 (d, 2H), 7.9-8.1 (m, 4H), trifluoropropanamide 8.35 (d, 1H) 297 (R)-N-{2-Chloro-4-[4-(4-methyl- (DMSO-δ₆ + AcOH-δ₄) 1.6 (s, 532 Ex piperazin-1-ylcarbonyl)phenyl- 3H), 2.35 (s, 1H), 2.68 (m, 4H), 121 sulphonyl]phenyl}-2-hydroxy-2- 3.5 (brs, 4H), 7.58 (d, 2H), 7.85- methyl-3,3,3-trifluoropropanamide 8.05 (m, 4H), 8.38 (d, 1H) 298 (R)-N-{2-Chloro-4-[4-(pyrrolidin- 1.58 (s, 3H), 1.7-1.89 (m, 4H), 503 Ex 1-ylcarbonyl)phenylsulphonyl] 3.23 (m, 2H), 3.41 (m, 2H), 7.7 121 phenyl}-2-hydroxy-2-methyl-3,3,3- (d, 2H), 8.0 (m, 4H), 8.18 (s, trifluoropropanamide 1H), 8.3 (d, 1H), 9.88 (brs, 1H) 299 (R)-N-(2-Chloro-4-{4-[N-(2- 1.57 (s, 3H), 3.22 (m, 2H), 3.4 507 Ex methoxyethyl)carbamoyl]phenyl- (m, 2H), 7.9-8.02 (m, 4H), 8.08 121 sulphonyl}phenyl)-2-hydroxy-2- (d, 2H), 8.14 (s, 1H), 8.3 (d, methyl-3,3,3-trifluoropropanamide 1H), 8.72 (m, 1H), 9.9 (brs, 1H) 300 (R)-N-{2-Chloro-4-[4- 1.59 (s, 3H), 2.52 (brs, 2H), 535 Ex (thiomorpholinocarbonyl)phenyl- 2.64 (brs, 2H), 3.42 (brs, 2H), 121 sulphonyl]phenyl}-2-hydroxy-2- 3.81 (brs, 2H), 7.72 d, 2H), methyl-3,3,3-trifluoropropanamide 7.96-8.1 (m, 4H), 8.17 (s, 1H), 8.31 (d, 1H), 9.89 (brs, 1H) 301 (R)-N-{2-Chloro-4-[4-(thiazolidin- 1.59 (s, 3H), 2.96 (brs, 1H), 521 Ex 3-ylcarbonyl)phenylsulphonyl] 3.03 (brs, 1H), 3.6 (brs, 1H), 3.8 121 phenyl}-2-hydroxy-2-methyl-3,3,3- (brs, 1H), 4.42 (brs, 1H), 4.62 trifluoropropanamide (brs, 1H), 7.76 (d, 2H), 8.02 (m, 2H), 8.06 (d, 2H), 8.18 (s, 1H), 8.32 (d, 1H), 9.9 (brs, 1H) 302 (R)-N-(2-Chloro-4-{2-[N-(2- 1.65 (s, 3H), 3.3-3.5 (m, 4H), 493 Ex hydroxyethyl)carbamoyl]phenyl- 4.7 (t, 1H), 7.55 (d, 1H), 7.7- 125 sulphonyl}phenyl)-2-hydroxy-2- 7.82 (m, 2H), 8.05-8.1 (m, 2H), methyl-3,3,3-trifluoropropanamide 8.1 (dd, 1H), 8.28 (d, 1H), 8.34 (d, 1H), 8.55 (brt, 1H), 9.97 (brs, 1H) 303 (R)-N-(2-Chloro-4-{4-[N-(2- 1.0-1.1 (m, 3H), 1.6 (s, 3H), 493 Ex hydroxy-1-methylethyl)carbamoyl] 3.3-3.4 (m, 1H), 4.6-4.7 (m, (M + H)⁺ 280 phenyl-sulphinyl}phenyl)-2- 2H), 6.8 (d, 1H), 7.3 (d, 1H), 7.7 hydroxy-2-methyl-3,3,3- (d, 1H), 7.7-7.8 (m, 1H), 7.9- trifluoropropanamide 7.95 (m, 3H), 8.0-8.2 (m, 3H), 9.8 (s, 1H)

EXAMPLE 304

(R)-N-[2-Chloro-4-(4-anilinocarbonylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.195 g) was added to a solution of 4-(dimethylamino)pyridine (0.25 g), (R)-N-[2-chloro-4-(4-carboxyphenyl-sulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 121) (0.317 g) and aniline (0.075 ml) in DCM (30 ml) and the mixture was stirred for 6 days. Solvent was then removed by evaporation and the residue was partitioned between ethyl acetate (50 ml) and dilute aqueous hydrochloric acid (25 ml). The aqueous layer was further extracted with ethyl acetate (50 ml). The organic extracts were combined, washed with brine and dried. Volatile material was removed by evaporation and the residue was purified by chromatography eluting with 40% ethyl acetate/hexane to give the title compound (0.179 g) as a solid. NMR (CDCl₃+DMSO-δ₆): 1.59 (s, 3H), 7.03 (t, 1H), 7.25 (t, 2H), 7.48 (brs, 1H), 7.64 (d, 2H), 7.78 (dd, 1H), 7.92 (m, 3H), 8.06 (d, 2H), 8.56 (d, 1H), 9.72 (s, 1H), 9.9 (s, 1H); MS (ESP⁻): 525.

EXAMPLES 305-306

Following the procedure of Example 304 and using Example 125 as the starting material the following compounds were prepared.

Ex Compound NMR MS 305 (R)-N-{2-Chloro-4-[2-(pyrrolidin- 1.59 (s, 3H), 1.76-1.89 (m, 4H), 3.02 (t, 503 1-ylcarbonyl)phenylsulphonyl] 2H), 3.47 (t, 2H), 7.44-7.47 (m, 1H), phenyl}-2-hydroxy-2-methyl-3,3,3- 7.63-7.68 (m, 1H), 7.97-8.0 (m, 1H), trifluoropropananiide 8.12 (d, 1H), 8.18 (s, 1H), 8.24 (d, 1H)  306¹ (R)-N-(2-Chloro-4-{2-[N′-(2-N,N- (DMSO-δ₆ + AcOH-δ₄): 1.56 (s, 3H), 520 dimethylaminoethyl) 2.85 (s, 6H), 3.30 (t, 2H), 3.62 (t, 2H), carbamoyl]phenylsulphonyl} 7.52 (d, 1H), 7.64-7.73 (m, 2H), 7.96- phenyl)-2-hydroxy-2-methyl-3,3,3- 8.00 (m, 1H), 8.07-8.1 (m, 1H), 8.15 (s, trifluoropropanamide hydrochloride 1H), 8.15 (d, 1H) ¹The initially formed product was treated with hydrogen chloride (1M solution in ethyl acetate).

EXAMPLE 307

(R)-N-[2-Chloro-4-(thien-2-ylmethylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

N-Methylmorpholine-N-oxide (0.75 g) and 4 Å molecular sieves (0.215 g) were added to a solution of (R)-N-[2-chloro-4-(thien-2-ylmethylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 418) (0.085 g) in deoxygenated acetonitrile (10 ml) and the mixture was stirred for 5 minutes. Tetrapropylammonium perruthenate (0.037 g) was then added and the mixture was heated at 45° C. for 2.5 hours then cooled. Ethyl acetate (50 ml) was added, the mixture filtered and volatile material was removed by evaporation. The residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 20-50% ethyl acetate/iso-hexane to give the title compound (0.034 g) as a yellow solid. NMR (CDCl₃): 1.61 s, 3H), 5.05 (s, 2H), 6.94 (s, 1H), 6.98-7.0 (m, 1H), 7.53 (d, 1H), 7.91 (s, 1H), 8.28 (d, 1H), 9.94 (s, 1H); MS (ESP⁻): 426.

EXAMPLE 308

(R)-N-{2-Fluoro-4-[4-(N-methylcarbamoylmethylsulphanyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

(R)-N-[2-Fluoro-4-(4-fluorophenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (0.65 g) (Method 71) was added to a deoxygenated mixture of mercaptoacetamide (0.14 ml) and sodium methoxide (0.08 g) in anhydrous NMP (2 ml). The reaction mixture was heated to 140° C. for 6 hours then cooled, diluted with ether (80 ml), washed with saturated aqueous ammonium chloride (100 ml) and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 10-60% ethyl acetate/hexane to give the title compound (0.46 g) as a gum. NMR (CDCl₃) 1.75 (s, 3H), 2.8 (d, 3H), 3.69 (s, 2H), 7.3 (d, 2H), 7.69-7.75 (m, 2H), 7.83 (d, 1H), 8.8-8.85 (m, 1H), 9.0 (s 1H); MS (ESP⁻): 493.

EXAMPLES 309-311

Following the procedure of Example 308 using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 309 (R)-N-{2-Fluoro-4-[4-(2- (CDCl₃) 1.73 (s, 3H), 3.18 (t, 2H), 466 Meth hydroxyethylsulphanyl)phenyl 3.52 (s, 1H), 3.8-3.84 (m, 2H), 7.39 71 sulphonyl]phenyl}-2-hydroxy- (d, 2H), 7.65-7.73 (m, 1H), 7.78 (d, 2-methyl-3,3,3- 1H), 8.5-8.55 (m, 1H), 8.84 (s, 1H) trifluoropropanamide 310 (R)-N-{2-Chloro-4-[3-chloro- (CDCl₃) 1.75 (s, 3H), 1.95 (t, 1H), 516 Meth 4-(2-hydroxyethylsulphanyl)- 3.2 (t, 2H), 3.75 (s, 1H), 3.9 (q, 2H), 72 phenylsulphonyl]phenyl}-2- 7.35 (d, 1H), 7.7 (dd, 1H), 7.8-7.9 hydroxy-2-methyl-3,3,3- (m, 2H), 7.95 (d, 1H), 8.60 (d, 1H), trifluoropropanamide 9.3 (s, 1H) 311 (R)-N-{2-Chloro-4-[3-fluoro- 1.6 (s, 3H), 3.15 (t, 2H), 3.6 (q, 2H), 500 Meth 4-(2-hydroxyethylsulphanyl)- 5.0 (t, 1H), 7.65 (t, 1H), 7.75 (dd, 66 phenylsulphonyl]phenyl}-2- 1H), 7.85 (dd, 1H), 7.90-8.1 (m, hydroxy-2-methyl-3,3,3- 2H), 8.2 (d, 1H), 8.3 (d, 1H), 9.9 trifluoropropanamide (brs, 1H)

EXAMPLE 312

(R)-N-[2-Chloro-4-(N,N-dimethylaminoethylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A 2M solution of dimethylamine (0.06 ml) in anhydrous methanol was added to a deoxygenated solution of (R)-N-[2-chloro-4-(ethenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 283) (0.044 g) in anhydrous THF (1 ml). The mixture was allowed to stir at ambient temperature under argon for 2 hours then volatile material was removed by evaporation to give the title compound (in 89% yield) as a solid. NMR: 1.69 (s, 3H), 2.65 (s, 6H), 2.55 (t, 2H), 3.55 (t, 2H), 7.9 (d, 1H), 8.08 (s, 1H), 8.34 (d, 1H); MS (ESP⁻): 403.

EXAMPLE 313

(R)-N-[2-Ethenyl-4-(4-mesylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Tributylvinyltin (0.28 ml) was added to a deoxygenated suspension of (R)-N-[2-bromo-4-(4-mesylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 140) (0.50 g) and tris(dibenzylideneacetone)dipalladium(O) (0.05 g) in anhydrous toluene (10 ml). The mixture was heated under reflux with stirring. After 14 hours a further portion of tris(dibenzylideneacetone)dipalladium(0) (0.05 g) and tributylvinyltin (0.28 ml) was added and heating was continued for a further 7 hours. The reaction mixture was allowed to cool and volatile materials were removed by evaporation. The residue was purified on a silica gel Mega Bond Elut column eluting with 5-50% ethyl acetate/hexane to give the title compound (0.146 g) as a solid. NMR (CDCl₃) 1.74 (s, 3H), 3.06 (s, 3H), 5.65-5.82 (dd, 2H), 6.67-6.77 (dd, 1H), 7.86-7.89 (dd, 1H), 7.95 (s, 1H), 8.06-8.16 (m, 4H), 8.35 (d, 1H), 8.79 (s, 1H); MS (ESP⁻): 477.

EXAMPLE 314

(R)-N-[2-Chloro-4-(carboxymethylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Sodium hydroxide (2.5 ml of a 2M aqueous solution) was added to a stirred solution of (R)-N-[2-chloro-4-(methoxycarbonylmethylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 142) (0.36 g) in methanol (6 ml) and the mixture was stirred for 1 hour. Hydrochloric acid (3 ml of a 2M aqueous solution) was added and volatile material was removed by evaporation. Ethyl acetate (80 ml) was added and the mixture washed with brine (50 ml), dried and volatile material removed by evaporation. The residue was dissolved in DCM (50 ml), washed with saturated sodium hydrogen, carbonate solution (100 ml). The aqueous layer was treated with hydrochloric acid (25 ml, 10% v/v) and extracted into ethyl acetate (2×100 ml) and dried. Volatile material was removed by evaporation to give the title compound (0.28 g) as a foam. NMR: 1.62 (s, 3H), 4.57 (s, 2H), 7.9 (d, 2H), 8.02 (s, 1H), 8.06 (s, 1H), 8.32 (d, 1H). 9.92 (s, 1H); MS (ESP⁻): 388.

EXAMPLE 315

(R)-N-[2-Chloro-4-(N,N-dimethylaminopropylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A solution of potassium permanganate (0.12 g) in water (8 ml) was added to a stirred solution of (R)-N-[2-chloro-4-(3-N,N-dimethylaminopropylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 404) (0.198 g) in glacial acetic acid (10 ml). The reaction mixture was stirred for 30 minutes then sodium sulphite was added until the reaction mixture became clear and colourless. Ethyl acetate (100 ml) was added and the mixture was washed with brine (2×50 ml), saturated aqueous sodium hydrogencarbonate solution (150 ml) and dried. Volatile material was removed by evaporation and the residue purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-15% methanol/ethyl acetate to give the title compound (in 33% yield) as a solid. NMR: 1.61 (s, 3H), 1.61-1.68 (m, 2H), 2.05 (s, 6H), 2.23 (t, 2H), 3.28-3.36 (m, 2H), 7.89 (d, 1H), 8.04 (s, 1H), 8.33 (d, 1H); MS (ESP⁻): 415.

EXAMPLES 316-326

Following the procedure of Example 315 and using the appropriate starting materials following compounds were prepared.

Ex Compound NMR MS SM 316 (R)-N-[2-Chloro-4-(benzo- (CDCl₃) 1.75 (s, 3H), 3.4 (brs, 1H), 465 Ex 261 thiazol-2-ylsulphonyl)phenyl]- 7.5-7.6 (m, 2H), 7.95 (dd, 1H), 8.1 (M + H)⁺ 2-hydroxy-2-methyl-3,3,3- (dd, 1H), 8.15 (dd, 1H), 8.2 (d, 1H), trifluoropropanamide 8.7 (d, 1H), 9.3 (bis, 1H) 317 (R)-N-[2-Chloro-4-(5-chloro- (CDCl₃) 1.75 (s, 3H), 3.4 (s, 1H), 498 Ex 262 benzothiazol-2-ylsulphonyl) 7.5-7.55 (m, 2H), 8.0-8.15 (m, 2H), (M + H)⁺ phenyl]-2-hydroxy-2-methyl- 8.2 (d, 1H), 8.7 (d, 1H), 9.35 (brs, 3,3,3-trifluoropropanamide 1H) 318 (R)-N-[2-Chloro-4-(4-{N-[5- 1.65 (s, 3H), 2.25 (s, 3H), 5.4 (brs, 530 Ex 239 methylpyrazol-3-yl] 2H), 5.6 (s, 1H), 7.95-8.05 (m, 2H), (M + H)⁺ carbamoyl}phenylsulphonyl) 8.1-8.2 (m, 5H), 8.3 (d, 1H), 9.90 (s, phenyl]-2-hydroxy-2-rnethyl- 1H) 3,3,3-trifluoropropanamide 319 (R)-N-[2-Chloro-4-(4-{N- 1.6 (s, 3H), 7.0 (s, 1H), 8.0 (d, 2H), 516 Ex 240 [isoxazol-3-yl]carbamoyl} 8.05 (d, 1H), 8.1-8.15 (m, 3H), 8.2 phenylsulphonyl)phenyl]-2- (d, 1H), 8.3 (d, 1H), 8.85 (d, 1H), hydroxy-2-methyl-3,3,3- 9.90 (s, 1H), 11.65 (s, 1H) trifluoropropanamide 320 (R)-N-[2-Chloro-4-(4- 1.25 (t, 3H), 1.6 (s, 3H), 4.25 (q, 470 Ex 277 ethoxycarbonylimidazol-2- 2H), 8.0 (dd, 1H), 8.1 (s, 1H), 8.15 (M + H)⁺ ylsulphonyl)phenyl]-2- (d, 2H), 8.4 (d, 1H), 9.95 (s, 1H), hydroxy-2-methyl-3,3,3- 11.95 and 14.55 (2xbrs, 1H) trifluoropropanamide 321 (R)-N-{2-Chloro-4-[4-(1′,1′- 1.6 (s, 3H), 3.12 (brs, 4H), 3.9 (brs, 539 Ex 82 dioxothiomorpholino)phenyl 4H), 7.14 (d, 2H), 7.78 (d, 2H), 7.92 sulphonyl]phenyl}-2-hydroxy- (dd, 1H), 8.06 (d, 1H), 8.22 (d, 1H), 2-methyl-3,3,3- 9.9 (brs, 1H) trifluoropropanamide 322 (R)-N-{2-Chloro-4-(4-{3- 1.6 (s, 3H), 2.43 (s, 3H), 8.04 (dd, 488 Ex 278 methyl-1,2,4-oxadiazol-5- 2H), 8.20-8.25 (m, 3H), 8.27-8.37 yl}phenylsulphonyl)phenyl}- (m, 3H), 9.94 (brs, 1H) 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 323 (R)-N-{2-Chloro-4-(4-{5- 1.61 (s, 3H), 2.69 (s, 3H), 8.02 (dd, 488 Ex 279 methyl-1,2,4-oxadiazol-3- 1H) : 8.15-8.25 (m, 5H), 8.34 (d, yl}phenylsulphonyl)phenyl}- 1H), 9.9 (brs, 1H) 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 324 (R)-N-{2-Chloro-4-(4- (CDCl₃) 1.76 (s, 3H), 3.82 (s, 1H), 484 Ex 203 pyrimidin-2-ylphenyl- 7.28 (m, 1H), 7.9 (dd, 1H), 8.0-8.08 sulphonyl)phenyl}-2-hydroxy- (m, 3H), 8.58-8.67 (m, 3H), 8.85 (d, 2-methyl-3,3,3- 2H), 9.3 (brs, 1H) trifluoropropanamide 325 (R)-N-{2-Chloro-4-(3- (DMSO-δ₆ + AcOD-d₄): 1.59 (s, 3H), 429 Ex 406 acetamidopropylsulphonyl) 1.61-1.69 (m, 2H), 1.73 (s, 3H), phenyl}-2-hydroxy-2-methyl- 3.05 (t, 2H), 3.25-3.31 (m, 2H), 3,3,3-trifluoropropanamide 7.82-7.86 (m, 1H), 7.97 (s, 1H), 8.39 (s, 1H) 326 (R)-N-{2-Chloro-4-([5- 1.34 (t, 3H), 1.59 (s, 3H), 4.37 (q, 479 Ex 202 ethoxycarbonyl-3- 2H), 8.07 (s, 1H), 8.12 (d, 1H), pyridyl]sulphonyl)phenyl}-2- 8.33-8.36 (m, 2H), 8.69 (s, 1H), hydroxy-2-methyl-3,3,3- 9.30 (s, 1H), 9.43 (s, 1H), 9.93 (s, trifluoropropanamide 1H)

EXAMPLE 327

(R)-N-[2-Chloro-4-(ethylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Copper (I) chloride (0.5 g) and sodium ethanethiolate (0.54 g) were added sequentially to a deoxygenated solution of (R)-N-(2-chloro-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (2.0 g) in quinoline (6 ml) and pyridine (1.5 ml). The mixture was heated to 200° C. under argon for 18 hours, cooled dissolved in ethyl acetate (200 ml), washed with dilute aqueous hydrochloric acid (2×100 ml) and brine (2×50 ml) and then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on silica gel eluting with 10-40% ethyl acetate/iso-hexane to give the title compound as a gum (1.4 g). NMR (CDCl₃): 1.29 (t, 3H), 1.57 (s, 3H), 2.91 (q, 2H), 3.69 (s, 1H), 7.24 (d, 1H), 7.35 (s, 1H), 8.24 (d, 1H), 8.77 (s, 1H); MS (ESP⁻): 326.

EXAMPLE 328

Following the procedure of Example 327 and using the appropriate starting materials the following compound was prepared.

Ex Compound NMR (CDCl₃) MS 328¹ (R)-N-[2-Chloro-4-(3-hydroxy- 1.74 (s, 3H), 1.86-1.92 (m, 2H), 3.00-3.05 356 propylsulphanyl)phenyl]-2- (t, 2H), 3.75-3.83 (t, 2H), 7.27 (d, 1H), hydroxy-2-methyl-3,3,3- 7.39 (s, 1H), 8.28 (d, 1H), 8.83 (brs, 1H). trifluoropropanamide ¹Sodium ethanethiolate was replaced with the appropriate thiol and sodium methoxide was added to the reaction mixture.

EXAMPLE 329

(R)-N-{2-Chloro-4-[4-(N-methylcarbamoylmethylsulphinyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropronanamide

A sample of (R)-N-{2-chloro-4-[4-(N-methylcarbamoylmethylsulphanyl)phenyl-sulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 288) was left standing open to air for approximately one week then purified by chromatography on silica gel eluting with 0-5% methanol/DCM to give (in 10% yield) the title compound as a solid. NMR (CDCl₃): 1.7 (s, 3H), 2.8 (d, 3H), 3.4 (d, 1H), 3.75 (d, 1H), 3.9 (s, 1H), 6.6 (m, 1H), 7.75 (d, 2H), 7.85 (m, 1H), 8.0 (dd, 1H), 8.1 (d, 2H), 8.65 (d, 1H), 9.35 (brs, 1H); MS (ESP⁻): 525.

EXAMPLE 330

By the method of Example 329 using the appropriate starting material the following compound was prepared.

Ex Compound NMR MS SM 330¹ (R)-N-[2-Chloro-4-(4- (CDCl₃) 0.3 (m, 2H), 0.65 (m, 2H), 0.9- 508 Ex 287 cyclopropylmethylsulphinyl- 1.0 (m, 1H), 1.7 (s, 3H), 2.65-2.8 (m, phenylsulphonyl)phenyl]- 1H), 2.8-2.95 (m, 1H), 5.64 (d, 1H), 2-hydroxy-2-methyl-3,3,3- 7.7-7.9 (m, 3H), 7.95 (m, 1H), 8.05-8.1 trifluoropropanamide (d, 2H), 8.65 (d, 1H), 9.6 (brs, 1H) ¹The eluent for chromatography was 25-100% DCM/hexane

EXAMPLE 331

(R)-N-[2-Chloro-4-(3-nitrophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A mixture of 3-nitrophenyldisulphide (0.176 g) and (R)-N-(2-chloro-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (0.15 g) in diphenyl ether (5 ml) was heated and stirred at 250° C. for 2 days. The reaction mixture was cooled, diluted with iso-hexane (5 ml) and purified by chromatography eluting with 10-100% DCM/hexane to give the title compound (0.05 g) as an oil. NMR (CDCl₃): 1.8 (s, 3H), 3.6 (s, 1H), 7.4-7.55 (m, 4H), 8.1 (brs, 2H), 8.45 (d, 1H), 9.05 (brs, 1H); MS (ESP⁺): 421 (M+H)⁺.

EXAMPLE 332

(R)-N-[2-Chloro-4-(N-phenylcarbamoyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A mixture of (R)-N-(2-chloro-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (0.35 g), aniline (0.117 ml), tributylamine (0.232 ml) and dichlorobis-(triphenylphosphine)palladium(II) (0.009 g) was heated at 100° C. under an atmosphere of carbon monoxide for 4 hours. Ethyl acetate (10 ml) was added and the mixture was washed with water and brine then was dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 5-50% ethyl acetate/hexane followed by passing through a Varian Isolute SCX column to give the title compound (0.17 g) as a solid. NMR: 1.6 (s, 3H), 7.1 (t, 1H), 7.35 (t, 2H), 7.75 (d, 2H), 7.92 (s, 1H), 7.98 (dd, 1H), 8.12 (s, 1H), 8.2 (d, 1H), 9.8 (s, 1H), 10,26 (brs, 1H); MS (ESP−): 386.

EXAMPLES 333-334

By the method of Example 332 using Example 197 as the starting materials the following compounds were prepared.

Ex Compound NMR MS 333 (R)-N-[2-Chloro-4-(N-n- 0.88 (t, 3H), 1.3 (m, 2H), 1.48 (m, 365 butylcarbamoyl)phenyl]-2-hydroxy-2- 2H), 1.6 (s, 3H), 3.2 (t, 2H), 7.83 (dd, methyl-3,3,3-trifluoropropanamide 1H), 7.9 (s, 1H), 8.0 (d, 1H), 8.12 (d, 1H), 8.5 (brt, 1H), 9.8 (s, 1H) 334 (R)-N-[2-Chloro-4-(piperidin-1- (DMSO-δ₆ + AcOH-δ₄, at 373K): 1.5 377 ylcarbonyl)phenyl]-2-hydroxy-2- (m, 4H), 1.6 (m, 4H), 3.44 (m, 4H), methyl-3,3,3-trifluoropropanamide 7.35 (d, 1H), 7.46 (s, 1H), 8.15 (d, 1H)

EXAMPLE 335

3-Hydroxy-3-methyl-1-(2-fluoro-4-phenylsulphonylphenyl)but-1-yne

Bis(triphenylphosphine)palladium(II) chloride (0.034 g) was added to a solution of 2-methyl-3-butyn-2-ol (0.11 ml) and 2-fluoro-4-phenylsulphonylbromobenzene (Method 1) (0.548 g) in triethylamine (3 ml) and DMF (1 ml) and the mixture was heated at 70° C. for 18 hours. The mixture was poured into water (50 ml) and extracted with ethyl acetate (2×50 ml). The extracts were washed with brine then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 40-100% ethyl acetate/hexane then triturated with hexane to give the title compound (0.112 g) as a solid. NMR (CDCl₃): 1.6 (s, 6H), 7.5-7.7 (m, 6H), 7.9 (d, 2H); MS (EI): 318 (M⁺).

EXAMPLE 336

(R)-N-{2-Chloro-4-[2-(iso-pronylaminocarbonyl)phenylsulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

N-Methylmorpholine (1.22 ml) and o-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.092 g) were added to a solution of (R)-N-[2-chloro-4-(2-carboxyphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 125) (0.10 g) and 2-propylamine (0.024 ml) in DCM (20 ml) at 0° C. The reaction mixture was stirred at this temperature for 30 minutes then allowed to warm to room temperature. stirred for a further 3 hours then evaporated to dryness. The residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 50% ethyl acetate/hexane then triturated with ether/hexane to give the title compound (0.05 g) as a solid. NMR (CDCl₃): 1.3 (d, 6H), 1.6 (s, 3H), 4.2-4.32 (m, 1H), 5.8 (brd, 1H), 7.4 (d, 1H), 7.5-7.7 (m, 3H), 7.9 (dd, 1H), 8.05-8.13 (m, 2H), 8.6 (d, 1H), 9.3 (brs, 1H); MS (ESP⁻): 491.

EXAMPLES 337-349

The aniline starting material was acylated with an appropriate acid chloride by the procedure of Method 17 or sulphonylated with an appropriate sulphonyl chloride by the procedure of Method 26 then hydrolysed by the procedure of Example 171. There were thus obtained the following compounds.

Ex Compound NMR MS SM 337 (R)-N-[2-Chloro-4-(4-benzoyl- 1.6 (s, 3H), 7.2 (d, 1H), 7.3 493 Meth aminophenylsulphanyl)phenyl]-2- (s, 1H), 7.5 (m, 5H), 7.9 12 hydroxy-2-methyl-3,3,3- (m, 6H), 10.4 (s,1H) trifluoropropanamide 338 (R)-N-[2-Chloro-4-(4-t-butyl- 1.2 (s, 9H), 1.6 (s, 3H), 7.2 473 Meth carbonylaminophenylsulphanyl) (d, 1H), 7.3 (s, 1H), 7.4 (d, 12 phenyl]-2-hydroxy-2-methyl-3,3,3- 2H), 7.7 (d, 2H), 7.9 (d, trifluoropropanamide 1H), 9.3 (s, 1H), 9.7 (s, 1H) 339 (R)-N-{2-Chloro-4-[4-(4-chloro- 1.6 (s, 3H), 7.2 (d, 1H), 7.3 527 Meth benzoylamino)phenylsulphanyl] (s, 1H), 7.4 (d, 2H), 7.6 (d, 12 phenyl}-2-hydroxy-2-methyl-3,3,3- 2H), 7.9 (m, 6H), 9.7 (s, trifluoropropanamide 1H), 10.4 (s, 1H) 340 (R)-N-{2-Chloro-4-[4-(2-methoxy- 1.5 (s, 3H), 3.3 (s, 3H), 4.0 461 Meth acetylamino)phenylsulphanyl] (s, 2H), 7.2 (d, 1H), 7.3 (s, 12 phenyl}-2-hydroxy-2-methyl-3,3,3- 1H), 7.4 (d, 2H), 7.7 (d, trifluoropropanamide 3H), 7.9 (d, 1H), 9.6 (s, 1H), 9.9 (s, 1H) 341 (R)-N-{2-Chloro-4-[4-(pyrid-3- 1.6 (s, 3H), 7.2 (d, 1H), 7.3 494 Meth ylcarbonylamino)phenylsulphanyl] (s, 1H), 7.5 (d, 2H), 7.7 (s, 12 phenyl}-2-hydroxy-2-methyl-3,3,3- 1H), 7.8 (m, 4H), 7.9 (d, trifluoropropanamide 1H), 8.8 (d, 2H), 9.7 (s, 1H), 10.6 (s, 1H) 342 (R)-N-[2-Chloro-4-(2-mesylamino- 1.6 (s, 3H), 3.0 (s, 3H), 7.4 467 Meth phenylsulphanyl)phenyl]-2-hydroxy- (m, 7H), 7.8 (s, 1H), 8.0 36 2-methyl-3,3,3-trifluoropropanamide (d, 1H), 9.7 (s, 1H) 343 (R)-N-[2-Chloro-4-(2-acetylamino- 1.6 (s, 3H), 2.0 (s, 3H), 7.2 431 Meth phenylsulphanyl)phenyl]-2-hydroxy- (m, 2H), 7.3 (m, 3H), 7.6 36 2-methyl-3,3,3-trifluoropropanamide (d, 1H), 7.8 (s, 1H), 7.9 (d, 1H), 9.5 (s, 1H), 9.7 (s, 1H) 344 (R)-N-[2-Chloro-4-(4-mesylamino- 1.6 (s, 3H), 3.0 (s, 3H), 7.2 467 Meth phenylsulphanyl)phenyl]-2-hydroxy- (m, 3H), 7.3 (s, 1H), 7.2 12 2-methyl-3,3,3-trifluoropropanamide (d, 2H), 7.8 (s, 1H), 7.9 (d, 1H), 9.7 (s, 1H), 9.9 (s, 1H) 345 (R)-N-{2-Chloro-4-[4-(phenyl- 1.6 (s, 3H), 7.1 (t, 3H), 7.2 529 Meth sulphonylamino)phenyl- (s, 1H), 7.3 (d, 2H), 7.6 12 sulphanyl]phenyl}-2-hydroxy-2- (m, 3H), 7.8 (m, 3H), 7.9 methyl-3,3,3-trifluoropropanamide (d, 1H), 9.7 (s, 1H), 10.5 (s, 1H) 346¹ (R)-N-{2-Chloro-4-[4-(ethenyl- 1.6 (s, 3H), 6.1 (m, 2H), 479 Meth sulphonylamino)phenylsulphanyl] 7.8 (q, 1H), 7.2 (m, 3H), 12 phenyl}-2-hydroxy-2-methyl-3,3,3- 7.4 (m, 3H), 7.8 (s, 1H), trifluoropropanamide 7.9 (d, 1H), 9.7 (s, 1H), 10.25 (s, 1H) 347 (R)-N-[2-Chloro-4-(3-mesylamino- 1.6 (s, 3H), 3.0 (s, 3H), 7.0 467 Meth phenylsulphanyl)phenyl]-2-hydroxy- (d, 1H), 7.1 (d, 2H), 7.3 37 2-methyl-3,3,3-trifluoropropanamide (m, 2H), 7.5 (s, 1H), 7.8 (s, 1H), 8.0 (s, 1H), 9.7 (s, 1H), 9.8 (s, 1H). 348 (R)-N-[2-Fluoro-4-(4-mesylamino- 1.6 (s, 3H), 3.0 (s, 3H), 7.1 451 Meth phenylsulphanyl)phenyl]-2-hydroxy- (m, 2H), 7.2 (d, 2H), 7.4 38 2-methyl-3,3,3-trifluoropropanamide (d, 2H), 7.6 (m, 2H), 9.6 (s, 1H), 10.0 (s, 1H) 349 (R)-N-[2-Fluoro-4-(4-acetylamino- 1.6 (s, 3H), 2.1 (s, 3H), 7.0 415 Meth phenylsulphanyl)phenyl]-2-hydroxy- (m, 2H), 7.4 (d, 2H), 7.6 38 2-methyl-3,3,3-trifluoropropanamide (m, 4H), 10.1 (s, 1H) ¹2-Chloroethylsulphonyl chloride was used for the sulphonylation; HCl was eliminated in hydrolysis step.

EXAMPLES 350-352

Following the procedure of Method 10 and using the appropriate starting material the following compounds were prepared.

Ex Compound NMR MS SM 350 (R)-N-[2-Fluoro-4-(4-amino- 1.6 (s, 3H), 6.2 (s, 2H), 6.6 (d, 405 Meth 65 phenylsulphonyl)phenyl]-2- 2H), 7.5 (d, 2H), 7.7 (q, 3H), 7.9 hydroxy-2-methyl-3,3,3- (9t, 1H), 9.8 (s, 1H) trifluoropropanamide 351 (R)-N-[2-Chloro-4-(2- 1.6 (s, 3H), 6.2 (s, 2H), 6.6 (t, 421 Meth 67 aminophenylsulphonyl) 1H), 6.8 (d, 1H), 7.3 (t, 1H), 7.7 phenyl]-2-hydroxy-2-methyl- (d, 1H), 7.9 (m, 2H), 8.1 (s, 1H), 3,3,3-trifluoropropanamide 8.2 (d, 1H), 9.9 (s, 1H) 352 (R)-N-[2-Chloro-4-(3- 1.59 (s, 3H), 5.65 (s, 2H), 6.78 421 Meth 68 aminophenylsulphonyl) (d, 1H), 7.01 (d, 1H), 7.07 (s, phenyl]-2-hydroxy-2-methyl- 1H), 7.2 (t, 1H), 7.88 (d, 1H), 3,3,3-trifluoropropanamide 7.98 (s, 1H), 8.27 (d, 1H)

EXAMPLE 353

(R)-N-[2-Chloro-4-(4-dimethylaminoacetylaminophenylsulphanyl)phenyl]-2-hydroxy-2methyl-3,3,3-trifluoropropanamide

Dimethylamine (0.17 ml of a 40% solution in water) was added to a solution of (R)-N-{2-chloro-4-[4-(2-chloroacetylamino)phenylsulphanyl]phenyl}-2-acetoxy-2-methyl-3,3,3-trifluoropropanamide (Method 19) (0.25 g) in acetone (1.5 ml). After 24 hours volatile material was removed by evaporation and the residue was dissolved in ethyl acetate, washed with water, and the organic layer was poured onto a Varian Chem Elut column. Elution with ethyl acetate gave the title compound (0.25 g) as a foam. NMR: 1.6 (s, 3H), 3.1 (s, 2H), 3.3 (s, 6H), 7.2 (d, 1H), 7.3 (s, 1H), 7.4 (d, 2H), 7.7 (m, 3H), 7.9 (d, 1H), 9.7 (s, 1H) 9.9 (s, 1H); MS (ESP⁻): 474.

EXAMPLE 354

(R)-N-{2-Chloro-4-[4-(3-ethylureido)phenylsulphonyl[phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

(R)-2,3,4,5-H₄-3-{2-Chloro-4-[4-(3-ethylureido)phenylsulphanyl]phenyl}-2,4-dioxo-5-methyl-5-trifluoromethyloxazole (Method 42) was oxidised by the procedure of Method 63 then hydrolysed by the method of Example 171 to give the title compound. NMR: 1.0 (s, 3H), 1.6 (s, 3H), 3.1 (s, 2H), 6.2 (s, 1H), 7.6 (d, 2H), 7.9 (m, 5H), 8.2 (d, 1H), 9.0 (s, 1H), 9.8 (s, 1H); MS (ESP⁻): 492.

EXAMPLE 355

By the procedure of Example 354 using the appropriate starting materials the following compound was prepared.

Ex Compound NMR MS SM 355 (R)-N-[2-Chloro-4-(4- (CDCl₃) 1.8 (s, 3H), 3.8 (s, 1H), 421 Meth 40 aminophenylsulphonyl) 4.2 (s, 2H), 6.6 (d, 3H), 7.7 (d, phenyl]-2-hydroxy-2-methyl- 2H), 7.8 (d, 1H), 7.9 (s, 1H), 3,3,3-trifluoropropanamide 8.6 (d, 1H), 9.3 (s, 1H)

EXAMPLES 356-380

The aniline starting material was acylated with an appropriate acid chloride by the procedure of Method 17 or sulphonylated with an appropriate sulphonyl chloride by the procedure of Method 26. There were thus obtained the following compounds.

Ex Compound NMR or HPLC MS SM 356 (R)-N-[2-Chloro-4-(4-methyl- 1.55 (s, 3H), 2.33 (s, 3H), 7.08 (d, 435 Ex phenylsulphonamido)phenyl]- 1H), 7.18 (s, 1H), 7.38 (m, 2H), 208 2-hydroxy-2-methyl-3,3,3- 7.68 (m, 4H), 9.54 (s, 1H), 10.43 trifluoropropanamide (brs, 1H) 357 (R)-N-[2-Chloro-4-(phenyl- (CDCl₃) 1.72 (s, 3H), 3.55 (s, 1H), 423 Ex sulphonamido)phenyl]-2- 6.52 (s, 1H), 6.92 (d, 1H), 7.30 (s, (M + H)⁺ 208 hydroxy-2-methyl-3,3,3- 1H), 7.50 (t, 2H), 7.59 (m, 1H), trifluoropropanamide 7.78 (d, 2H), 8.24 (d, 1H), 8.80 (s, 1H) 358 (R)-N-[2-Chloro-4-(4- 1.55 (s, 3H), 3.80 (s, 3H), 7.09 451 Ex methoxyphenylsulphonamido) (m, 3H), 7.19 (s, 1H), 7.65 (s, 208 phenyl]-2-hydroxy-2-methyl- 1H), 7.73 (m, 3H), 9.56 (s, 1H) 3,3,3-trifluoropropanamide 359 (R)-N-[2-Chloro-4-(4-acetyl- 1.55 (s, 3H), 2.06 (s, 3H), 7.08 (d, 478 Ex aminophenylsulphonamido) 1H), 7.19 (s, 1H), 7.70 (m, 6H), 208 phenyl]-2-hydroxy-2-methyl- 9.53 (s, 1H), 10.27 (s, 1H), 10.36 3,3,3-trifluoropropanamide (brs, 1H) 360 (R)-N-[2-Chloro-4-(4-t-butyl- 11.46 minutes (HPLC Method b) 479 Ex phenylsulphonamido)phenyl]- (M + H)⁺ 208 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 361 (R)-N-[2-Chloro-4-(3,4-di-  8.02 minutes (HPLC Method a) 483 Ex methoxyphenylsulphonamido) (M + H)⁺ 208 phenyl]-2-hydroxy-2-methyl- 3,3,3-trifluoropropanamide 362 (R)-N-[2-Chloro-4-(4-fluoro-  8.28 minutes (HPLC Method a) 439 Ex phenylsulphonamido)phenyl]- 208 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 363 (R)-N-[2-Chloro-4-(2-chloro-  8.34 minutes (HPLC Method a) 455 Ex phenylsulphonamido)phenyl]- 208 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 364 (R)-N-[2-Chloro-4-(2-methyl-  8.35 minutes (HPLC Method a) 435 Ex phenylsulphonamido)phenyl]- 208 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 365 (R)-N-[2-Chloro-4-(4-  8.27 minutes (HPLC Method a) 415 Ex methoxybenzoylamino)phenyl]- 208 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide 366 (R)-N-[2-Chloro-4-(t-butyl-  8.3 minutes (HPLC Method a) 365 Ex carboxamido)phenyl]-2- 208 hydroxy-2-methyl-3,3,3- trifluoropropanamide 367 (R)-N-(2-Chloro-4-acetamido-  7.21 minutes (HPLC Method a) 323 Ex phenyl)-2-hydroxy-2-methyl- 208 3,3,3-trifluoropropanamide 368 (R)-N-[2-Chloro-4-(benzyl-  8.28 minutes (HPLC Method a) 399 Ex carboxamido)phenyl]-2- 208 hydroxy-2-methyl-3,3,3- trifluoropropanamide 369 (R)-N-[2-Chloro-4-(2-chloro-  7.76 minutes (HPLC Method a) 421 Ex pyrid-3-ylcarboxamido) 208 phenyl]-2-hydroxy-2-methyl- 3,3,3-trifluoropropanamide 370¹ (R)-N-[2-Chloro-4-(isoxazol-5-  9.41 minutes (HPLC Method b) 376 Ex ylcarboxamido)phenyl]-2- 208 hydroxy-2-methyl-3,3,3- trifluoropropanamide 371 (R)-N-[2-Chloro-4-(N′-(3- 1.62 (m, 1H), 1.96 (s, 3H), 2.50 587 Ex methylsulphanylpropyl)-2- (m, 2H), 3.41 (s, 3H), 3.88 (t, 2H), 390 mesylphenylsulphonamido) 7.29 (dd, 1H), 7.47 (s, 1H), 7.80- phenyl]-2-hydroxy-2-methyl- 8.03 (m, 5H), 8.27 (d, 1H), 9.73 3,3,3-trifluoropropanamide (s, 1H) 372 (R)-N-[2-Chloro-4-(N′-(3- 1.58 (m, 5H), 1.95 (s, 3H), 2.45 509 Ex methylsulphanylpropyl)phenyl- (m, 2H), 3.61 (t, 2H), 7.10 (dd, 390 sulphonamido)phenyl]-2- 1H), 7.28 (s, 1H), 7.63 (m, 4H), hydroxy-2-methyl-3,3,3- 7.75 (m, 1H), 7.90 (brs, 1H), 8.00 trifluoropropanamide (d, 1H), 9.73 (brs, 1H). 373 (R)-N-{2-Chloro-4-[N′-(3- 1.60 (m, 5H), 1.95 (s, 3H), 2.46 523 Ex methylsulphanylpropyl)-4- (m, 5H), 3.60 (t, 2H), 7.08 (dd, 390 methylphenylsulphonamido] 1H), 7.30 (s, 1H), 7.43 (q, 4H), phenyl}-2-hydroxy-2-methyl- 7.80 (brs, 1H), 7.97 (d, 1H), 9.71 3,3,3-trifluoropropanamide (brs, 1H) 374 (R)-N-[2-Methyl-4-(phenyl- (CDCl₃) 1.71 (s, 3H), 2.21 (s, 3H), 402 Ex sulphonamido)phenyl]-2- 3.62 (s, 1H), 6.41 (brs, 1H), 6.83 209 hydroxy-2-methyl-3,3,3- (dd, 1H), 6.98 (m, 1H), 7.40-7.48 trifluoropropanamide (m, 2H), 7.50-7.60 (m, 1H), 7.65- 7.70 (s, 1H), 7.71-7.7 9m, 1H), 8.00 (brs, 1H). 375 (R)-N-[2-Methyl-4-(2-phenyl- (CDCl₃) 1.6 (s, 3H), 2.22 (s, 3H), 427 Ex E-ethenylsulphonamido) 3.75 (brs, 1H), 6.48 (brs, 1H), 209 phenyl]-2-hydroxy-2-methyl- 6.75 (d, 1H), 6.99-7.06 (m, 1H), 3,3,3-tnfluoropropanamide 7.07-7.10 (m, 1H), 7.30-7.42 (m, 5H), 7.55 (d, 1H), 7.69-7.73 (m, 1H), 8.06 (brs, 1H). 376 (R)-N-[2-Methyl-4-(4-methyl- (CDCl₃) 1.66 (s, 3H), 2.17 (s, 3H), 415 Ex phenylsulphonamido)phenyl]- 2.38 (s, 3H), 3.70 (brs, 1H), 6.53 209 2-hydroxy-2-methyl-3,3,3- (brs, 1H), 6.80-6.85 (m, 1H), trifluoropropanamide 6.95-6.98 (m, 1H), 7.20-7.28 (m, 1H), 7.61-7.69 (m, 3H), 8.05 (brs, 1H). 377 (R)-N-[2-Methyl-4-(2-mesyl- (CDCl₃) 1.68 (s, 3H), 2.15 (s, 3H), 479 Ex phenylsulphonamido)phenyl]- 3.48 (s, 3H), 3.65 (s, 1H), 6.97- 209 2-hydroxy-2-methyl-3,3,3- 7.04 (m, 2H), 7.59-7.88 (m, 3H), trifluoropropanamide 7.94-8.11 (m, 2H), 8.11 (brs, 1H), 8.30-8.33 (m, 1H). 378 (R)-N-[2-Methyl-4-(2- (CDCl₃) 1.50 (s, 3H), 2.18 (s, 3H), 469 Ex trifluoromethylphenyl- 3.60 (s, 1H), 6.61 (brs, 1H), 6.87- 209 sulphonamido)phenyl]-2- 6.92 (m, 1H), 6.98-7.02 (m, 1H), hydroxy-2-methyl-3,3,3- 7.50-7.75 (m, 3H), 7.84-7.92 (m, trifluoropropanamide 1H), 7.97-8.10 (m, 2H). 379 (R)-N-(2-Methyl-4-mesyl- (CDCl₃) 1.75 (s, 3H), 2.27 (s, 3H), 339 Ex aminophenyl)-2-hydroxy-2- 3.00 (s, 3H), 3.62 (brs, 1H), 6.28 209 methyl-3,3,3- (brs, 1H), 7.08-7.14 (m, 1H), trifluoropropanamide 7.11-7.14 (m, 1H), 7.77-7.82 (m, 1H), 8.06 (brs, 1H). 380 (R)-N-[2-Methyl-4-(2-chloro- (CDCl₃) 1.72 (s, 3H), 2.22 (s, 3H), 351 Ex phenylsulphonamido)phenyl]- 3.67 (s, 1H), 5.91-5.98 (m, 1H), 209 2-hydroxy-2-methyl-3,3,3- 6.21-6.29 (m, 1H), 6.38 (brs, 1H), trifluoropropanamide 6.48-6.58 (m, 1H), 6.93-7.00 (m, 1H), 7.01-7.05 (m, 1H), 7.70-7.78 (m, 1H), 8.05 (brs, 1H). ¹The product formed as a precipitate which was collected and washed with DCM.

EXAMPLE 381

(R)-N-[2-Chloro-4-(3-phenylureido)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A mixture of (R)-N-[2-chloro-4-aminophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 208) (0.198 g) and phenyl isocyanate (0.09 ml) in diethyl ether (10 ml) was stirred for 22 hours then evaporated to dryness. The residue was partitioned between water (25 ml) and ethyl acetate (50 ml). The organic phase was washed with brine (25 ml), dried and concentrated by evaporation to give the title compound (170 mg) as a foam. NMR: 1.66 (s, 3H), 7.04 (t, 1H), 7.35 (m, 3H), 7.52 (d, 1H), 7.71 (s, 1H), 7.86 (m, 2H), 8.77 (s, 1H), 8.92 (s, 1H), 9.63 (s, 1H); MS (ESP⁻): 400.

EXAMPLE 382

(R)-N-{2-Chloro-4-[N-(4-methylphenylsulphonyl)(N-methyl)amino]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A mixture of (R)-N-[2-chloro-4-(4-methylphenylsulphonamido)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 356) (0.137 g), anhydrous potassium carbonate (0.043 g) and iodomethane (0.038 ml) in acetone (8 ml) was stirred for 64 hours. Volatile material was removed by evaporation and the residue was dissolved in ethyl acetate, washed with water and brine then dried. Volatile material was removed by evaporation and the residue was purified by elution through a Varian Isolute silica 10 g column with 30% ethyl acetate/hexane as eluent to give the title compound (0.079 g). NMR: 1.60 (s, 3H), 2.38 (s, 3H), 3.11 (s, 3H), 7.11 (d, 3H), 7.32 (s, 1H), 7.43 (m, 4H), 7.94 (d, 1H), 9.67 (brs, 1H); MS (ESP⁻): 449.

EXAMPLES 383-387

By the method of Example 382 and using the appropriate starting materials the following compounds were prepared.

Ex Compound HPLC MS SM 383 (R)-N-{2-Chloro-4-[N-(4-t-butylphenylsulphonyl) 12.36 minutes 493 Ex (N-methyl)amino]phenyl}-2-hydroxy-2-methyl- (HPLC Method (M + H)⁺ 360 3,3,3-trifluoropropanamide b) 384 (R)-N-{2-Chloro-4-[N-(3,4-dimethoxypheny l-  10.7 minutes 497 Ex sulphonyl)(N-methyl)amino]phenyl}-2-hydroxy- (HPLC Method (M + H)⁺ 361 2-methyl-3,3,3-trifluoropropanamide b) 385 (R)-N-{2-Chloro-4-[N-(4-fluorophenylsulphonyl) 11.14 minutes 455 Ex (N-methyl)amino]phenyl}-2-hydroxy-2-methyl- (HPLC Method (M + H)⁺ 362 3,3,3-trifluoropropanamide b) 386 (R)-N-{2-Chloro-4-[N-(2-chlorophenylsulphonyl) 11.24 minutes 471 Ex (N-methyl)amino]phenyl}-2-hydroxy-2-methyl- (HPLC Method (M + H)⁺ 363 3,3,3-trifluoropropanamide b) 387 (R)-N-{2-Chloro-4-[N-(2-methylphenylsulphonyl)  11.3 minutes 449 Ex (N-methyl)amino]phenyl}-2-hydroxy-2-methyl- (HPLC Method 364 3,3,3-trifluoropropanamide b)

EXAMPLES 388-389

Following the procedure of Method 30 (see below) and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 388 (R)-N-[2-Chloro-4-(2- 1.56 (s, 3H), 4.76 (s, 2H), 6.56 (t, 372 Ex 206 aminoanilino)phenyl]-2- 1H), 6.66 (m, 2H), 6.75 (d, 1H), hydroxy-2-methyl-3,3,3- 6.89 (t, 1H), 6.97 (d, 1H), 7.40 (s, trifluoropropanamide 1H), 7.52 (m, 2H), 9.39 (s, 1H) 389 (R)-N-(2-Methoxy-4-amino- (CDCl₃) 1.51 (s, 3H), 3.74 (s, 3H), 277 Meth 61 phenyl)-2-hydroxy-2- 5.00 (brs, 2H), 6.05-6.15 (m, 1H), methyl-3,3,3- 6.28-6.37 (m, 1H), 7.53 (brs, 1H), trifluoropropanamide 7.72-7.78 (m, 1H), 9.08 (brs, 1H)

EXAMPLE 390

(R)-N-[2-Chloro-4-(3-methylsulphanylpropylamino)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Sodium triacetoxyborohydride (0.297 g) was added to a solution of 3-methylsulphanylpropionaldehyde (0.1 ml) and (R)-N-(2-chloro-4-aminophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 208) (0.282 g) in 1,2-dichloroethane (6 ml). The mixture was stirred for 16 hours. Saturated aqueous sodium hydrogen carbonate (25 ml) was added and the mixture was extracted with ethyl acetate (40 ml). The extracts were washed with brine (15 ml) then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a Varian Isolute silica column eluting with 25% ethyl acetate/hexane. The resulting solid was triturated with ether to give the title compound (0.089 g) as a solid. NMR: 1.54 (s, 3H), 1.78 (m, 2H), 2.05 (s, 3H), 2.55 (q, 2H), 3.09 (q, 2H), 5.93 (t, 1H), 6.54 (dd, 1H), 6.65 (s, 1H), 7.46 (m, 2H), 9.33 (s, 1H); MS (ESP⁻): 369.

EXAMPLES 391-393

By the method of Example 390 and using the appropriate starting materials and Example 208 the following compounds were prepared.

Ex Compound NMR MS 391 (R)-N-[2-Chloro-4-(benzyl- 1.54(s, 3H), 4.26(d, 2H), 6.53(m, 2H), 371 amino)phenyl]-2-hydroxy-2- 6.65(s, 1H), 7.20(m, 1H), 7.30(m, 4H), methyl-3,3,3-trifluoropropanamide 7.40(d, 1H), 7.45(s, 1H), 9.30(s, 1H) 392 (R)-N-[2-Chloro-4-(1- 1.56(s, 3H), 3.55(s, 3H), 4.15(d, 2H), 374 methylpyrrol-2-ylmethyl 5.88(m, 1H), 5.97(m, 1H), 6.13(t, 1H), amino)phenyl]-2-hydroxy-2- 6.65(m, 2H), 6.77(s, 1H), 7.46(d, 2H), methyl-3,3,3-trifluoropropanamide 9.37(brs, 1H)  393¹ (R)-N-[2-Chloro-4-(pyridin-4- 1.54(s, 3H), 4.34(d, 2H), 6.53(dd, 1H), 372 ylmethylamino)phenyl]-2-hydroxy- 6.65(s, 1H), 6.69(t, 1H), 7.33(d, 2H), 2-methyl-3,3,3- 7.41(d, 1H), 7.53(brs, 1H), 8.48(d, trifluoropropanamide 2H), 9.37(s, 1H) ¹The first-formed product was the Schiff base which was then reduced by the procedure of Method 30 to give the indicated compound.

EXAMPLE 394

(R)-N-[2-Chloro-4-(phenylsulphonyl)phenyl]-2-aminopropanamide

TFA (0.5 ml) was added drop wise to a solution of (R)-N-[2-chloro-4-(phenylsulphonyl)phenyl]-2-(t-butoxycarbonylamino)propanamide (Method 2) (0.090 g) in dry DCM (5 ml). The resulting mixture was stirred at room temperature for 3 hours. Volatile material was removed by evaporation. The resulting residue was re-dissolved in DCM (10 ml), and volatile material was removed by evaporation. This was repeated, the resulting residue was dried for 30 minutes on a high vacuum line. The residue was then dissolved in DCM and passed through a Varian Isolute SPE column containing basic residues, with DCM as the eluent to give the title compound (0.067 g) as a gum. NMR (CDCl₃): 1.32-1.40 (d, 3H), 1.52 (brs, 2H), 3.51-3.64 (q, 1H), 7.40-7.55 (m, 3H), 7.71-7.80 (m, 1H), 7.81-7.95 (m, 3H) 8.58-8.65 (m, 1H), 10.46 (brs, 1H). MS: (ESP⁺) 339.3 (M+H)⁺.

EXAMPLES 395-396

By the method of Example 394 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM 395 (R)-N-{2-Chloro-4-[4- 1.65(s, 3H), 2.65(brs, 2H), 2.8 518 Ex 220 (piperazin-1-ylcarbonyl) (brs, 2H), 3.2(brs, 2H), 3.6(brs, phenylsulphonyl]phenyl}-2- 2H), 7.65(d, 2H), 8.0-8.15(m, 4H), hydroxy-2-methyl-3,3,3- 8.2(s, 1H), 8.4(d, 2H), 9.6(s, 1H) trifluoropropanamide 396 (R)-N-{2-Chloro-4-(3-amino- 1.56(s, 3H), 1.61-1.66(m, 2H), 387 Ex 51  propylsulphonyl)phenyl}-2- 2.62(t, 2H), 3.34-3.39(t, 2H), hydroxy-2-methyl-3,3,3- 7.78-7.82(m, 1H), 7.94(s, 1H), trifluoropropanamide 8.35(d, 1H)

EXAMPLE 397

(R)-N-[2-Chloro-4-(4-{3-hydroxypropoxy}phenylsulphinyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Sodium hydride (0.06 g of a 60% dispersion in oil) was added to a solution of (R)-N-[2-chloro-4-(4-hydroxyphenylsulphinyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 89) (0.5 g) in DMF (5 ml) at 0° C. The mixture was stirred for 15 minutes then 3-bromopropanol (0.12 ml) was added as a solution in DMF (3 ml). The mixture was stirred at ambient temperature for 16 hours. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-10% methanol/DCM to give the title compound (0.34 g) as a gum. NMR (CDCl₃): 1.25 (dd, 2H), 1.7 (s, 3H), 1.8 (s, 1H), 3.8-3.9 (m, 2H), 4.1-4.2 (m, 2H), 5.1 (s, 1H), 6.95 (d, 2H), 7.4 (d, 1H), 7.5 (d, 2H), 7.6-7.65 (m, 1H), 8.45-8.55 (m, 1H), 9.3 (s, 1H); MS (ESP⁻): 464.

EXAMPLES 398-400

By the procedure of Example 397 and using Example 89 as the starting materials the following compounds were prepared.

Ex Compound NMR MS  398¹ (R)-N-[2-Chloro-4-(4-{3-amino- 1.6(s, 3H), 1.95-2.0(m, 2H), 2.90-3.0 465 propoxy}phenylsulphinyl)phenyl]- (m, 2H), 4.0-4.1(m, 2H), 7.1(m, 2H), (M + H)⁺ 2-hydroxy-2-methyl-3,3,3- 7.6-7.7(m, 3H), 7.7-7.9(m, 4H), 8.1 trifluoropropanamide (d, 1H), 9.85(s, 1H) 399 (R)-N-[2-Chloro-4-(4-{carbamoyl- 1.6(s, 3H), 4.45(d, 2H), 6.9-7.0(m, 463 methoxy}phenylsulphinyl)phenyl]- 1H), 7.0-7.2(m, 2H), 7.3-7.5(m, 2H), 2-hydroxy-2-methyl-3,3,3- 7.5-7.6(m, 1H), 7.6-7.7(m, 2H), 7.8 trifluoropropanamide (s, 1H), 8.1(d, 1H), 9.8(s, 1H) 400 (R)-N-[2-Chloro-4-(4-{N,N- 1.6(s, 3H), 2.8(s, 3H), 3.0(s, 3H), 491 dimethylcarbamoylmethoxy}pheny 4.8-5.0(m, 2H), 6.8(d, 1H), 7.0-7.1 lsulphinyl)phenyl]-2-hydroxy-2- (m, 2H), 7.35(d, 1H), 7.5-7.6(d, 2H), methyl-3,3,3-trifluoropropanamide 7.8(d, 1H), 8.15(d, 1H), 9.8(s, 1H) ¹An extra molar equivalent of sodium hydride was used. The halide was 3-aminopropyl bromide, hydrobromide salt.

EXAMPLE 401

By the procedure of Method 26 (see below) and using Example 396 as the starting materials the following compound was prepared.

Ex Compound NMR MS 401 (R)-N-{2-Chloro-4-(3- 1.61(s, 3H), 1.67-1.77(m, 465 mesylaminopropylsulphonyl) 2H), 2.84(s, 3H), 2.96- phenyl}-2-hydroxy-2-methyl- 3.02(m, 2H), 3.36-3.42(m, 3,3,3-trifluoropropanamide 2H), 7.02(t, 1H), 7.86- 7.9(m, 1H), 8.02(s, 1H), 8.34(d, 1H), 9.92(s, 1H)

EXAMPLE 402

(R)-N-[2-Chloro-4-(N,N-dimethylcarbamoylmethylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Tetrabutylammonium fluoride (1.1 ml of a 1M solution in THF) was added to (R)-N-(2-chloro-4-(triisopropylsilylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Method 28) (0.50 g) in anhydrous THF (5 ml) at −70° C. After 15 minutes 2-chlorodimethylacetamide (0.17 ml) was added and the mixture was allowed to warm up then was stirred at ambient temperature for 45 minutes. Ethyl acetate (80 ml) was added and the mixture was washed with brine (100 ml) then dried and volatile material was removed by evaporation. The residue was purified on a silica gel Mega Bond Elut column eluting with 10-50% ethyl acetate/hexane to give the title compound (0.30 g) as a solid. NMR (CDCl₃) 1.72 (s, 3H), 2.97 (s, 3H), 3.08 (s, 3H), 3.71 (s, 2H), 4.76 (s, 1H), 7.32-7.36 (m, 1H), 7.53 (d, 1H), 8.32 (d, 1H), 9.05 (s, 1H); MS (ESP⁻): 383.

EXAMPLES 403-412

Following the procedure of Example 402 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR MS SM  403 (R)-N-[2-Chloro-4- (CDCl₃) 1.75(s, 3H), 3.55(s, 3H), 370 Meth 28 (methoxycarbonylmethyl 3.72(s, 2H), 7.33-7.37(m, 1H), sulphanyl)phenyl]-2- 7.49(s, 1H), 8.32(d, 1H), 8.85(s, hydroxy-2-methyl-3,3,3- 1H) trifluoropropanamide  404 (R)-N-[2-Chloro-4-({3- (CDCl₃) 1.76(s, 3H), 1.78-1.83 383 Meth 28 N,N-dimethylamino- (m, 2H), 2.24(s, 6H), 2.43(t, 2H), propyl}sulphanyl)phenyl]- 2.93(t, 2H), 7.24(d, 1H), 7.36(s, 2-hydroxy-2-methyl-3,3,3- 1H), 8.30(d, 1H), 9.25(s, 1H) trifluoropropanamide   405¹ (R)-N-[2-Chloro-4-(3-t- (CDCl₃): 1.44(s, 9H), 1.76(s, 3H), 455 Meth 28 butoxycarbonylamino- 1.81(t, 2H), 2.92(t, 2H), 3.20- and Meth propylsulphanyl)phenyl]- 3.26(m, 2H), 3.97(s, 1H), 4.60(s, 20 2-hydroxy-2-methyl-3,3,3- 1H), 7.23-7.28(m, 1H), 7.36(s, trifluoropropanamide 1H), 8.28(d, 1H), 8.86(s, 1H)   406¹ (R)-N-{2-Chloro-4-(3- (CDCl₃): 1.75(s, 3H), 1.83(t, 2H), 397 Meth 28 acetamidopropyl- 2.05(s, 3H), 2.91(t, 2H), 3.33-3.4 and Meth sulphanyl)phenyl}-2- (m, 2H), 5.63(brs, 1H), 7.25-7.27 21 hydroxy-2-methyl-3,3,3- (m, 1H), 7.36(s, 1H), 8.3(d, 1H), trifluoropropanamide 9.06(s, 1H)   407¹ (R)-N-{2-Chloro-4-(2- (CDCl₃) 1.76(s, 3H), 3.52-3.60 338 Meth 28 propenylsulphanyl)phenyl}- (m, 2H), 5.07-5.15(m, 2H), 5.78- and allyl 2-hydroxy-2-methyl- 6.10(m, 1H), 7.27-7.28(m, 1H), bromide 3,3,3-trifluoropropanamide 7.40(s, 1H), 8.27(d, 1H), 8.78(s, 1H)   408² (R)-N-{2-Chloro-4-(2- (CDCl₃) 0.97(t, 3H), 1.47-(CDCl₃) 370 Meth 28 hydroxybutylsulphanyl) 1.62(m, 3H), 1.74(s, 3H), 2.25(d, phenyl}-2-hydroxy-2- 1H), 2.28-2.29(m, 1H), 3.09-3.14 methyl-3,3,3- (m, 1H), 7.29-7.34(m, 1H), 7.44 trifluoropropanamide (s, 1H), 7.44(s, 1H), 8.30(d, 1H), 8.86(s, 1H)   409³ (R)-N-{2-Chloro-4-(2- (CDCl₃) 1.31(s, 6H), 1.71(s, 3H), 370 Meth 28 hydroxy-2-methylpropyl- 3.09(s, 2H), 7.32-7.36(m, 1H), sulphanyl)phenyl}-2- 7.46(s, 1H), 8.23(d, 1H), 8.81(s, hydroxy-2-methyl-3,3,3- 1H) trifluoropropanamide    410^(1,4) (R)-N-{2-Chloro-4- (CDCl₃) 1.02(t, 3H), 1.62-1.69 340 Meth 28 propylsulphanylphenyl}-2- (m, 2H), 1.75(s, 3H), 2.87(t, 2H), hydroxy-2-methyl-3,3,3- 3.66(s, 1H), 7.24-7.27(m, 1H), trifluoropropanamide 7.36(s, 1H), 8.25(d, 1H), 8.77(s, 1H)    411^(1,4) (R)-N-{2-Chloro-4-(n- (CDCl₃) 0.92(t, 3H), 1.38-1.50 354 Meth 28 butylsulphanyl)phenyl}-2- (m, 2H), 1.59-1.66(m, 2H), 1.74 hydroxy-2-methyl-3,3,3- (s, 3H), 2.89(t, 2H), 3.65(s, 1H), trifluoropropanamide 7.23-7.26(m, 1H), 7.36(s, 1H), 8.25(d, 1H), 8.76(s, 1H)   412⁵ (R)-N-[2-Ethynyl-4-(4- (CDCl₃ + 1 drop DMSO-δ₆) 1.84(s, 474 Meth 57 mesylphenylsulphonyl) 3H), 3.05(s, 3H), 3.64(s, 1H), phenyl]-2-hydroxy-2- 6.60(s, 1H), 7.92(m, 1H), 8.05(d, methyl-3,3,3- 1H), 8.09-8.13(m, 4H), 8.68(d, trifluoropropanamide 1H), 9.91(s, 1H) ¹The alkylation reaction was carried out with heating under reflux and with addition of sodium iodide. ²For alkylation: heated under reflux and 1,2-epoxybutane replaced an alkyl halide. ³For alkylation: heated under reflux and 1,2-epoxy-2-methylpropane was used. ⁴The thiol intermediate was isolated and purified; sodium methoxide was used as base for the subsequent alkylation step. ⁵Only the desilylation step was carried out.

EXAMPLE 413

N-[2-Fluoro-4-(4-methylsulphanylphenylsulphanyl)phenyl]-2-hydroxy-2-trifluoromethyl-3,3,3-trifluoropropanamide

Tetra-n-butylammonium fluoride (0.48 ml of a 1M solution in THF) was added to a stirred solution of N-[2-fluoro-4-(4-methylsulphanylphenylsulphanyl)phenyl]-2-(t-butyldimethylsilyloxy)-2-trifluoromethyl-3,3,3-trifluoropropanamide (0.278 g) (Method 55) in anhydrous THF (5 ml) at −78° C. under argon. After 30 minutes ethyl acetate (50 ml) was added and the mixture was washed with aqueous hydrochloric acid (2M, 30 ml) and brine (30 ml) then dried. Volatile material was removed by evaporation and the residue was purified on a silica gel Mega Bond Elut column eluting with 10-30% ethyl acetate/iso-hexane to give the title compound (0.199 g) as a pale yellow solid. NMR (CDCl₃): 2.50 (s, 3H), 5.12 (s, 1H), 6.98 (d, 1H), 7.05 (d, 1H), 7.23 (d, 2H), 7.35 (d, 2H), 8.05-8.08 (m, 1H); MS (ESP⁻): 458,

EXAMPLE 414

(R)-N-{2-Chloro-4-(2-propenylsulphonyl)phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A solution of Oxone (1.44 g) in water (15 ml) was added to a solution of (R)-N-{2-chloro-4-(2-propenylsulphanyl)phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 407) (0.389 g) in methanol (15 ml). The mixture was stirred for 1.5 hours. Water (50 ml) was added and the mixture extracted into ethyl acetate (100 ml) and dried. Volatile material was removed by evaporation and the residue purified on a silica gel Mega Bond Elut column eluting with 20-30% ethyl acetate/iso-hexane to give the title compound as a foam (0.180 g). NMR: 1.61 (s, 3H), 4.18 (d, 2H), 5.18-5.32 (m, 2H), 5.61-5.75 (m, 1H), 7.82-7.85 (m, 1H), 7.98 (s, 1H), 8.01 (s, 1H), 8.33 (d, 1H), 9.91 (s, 1H); MS (ESP⁻): 370.

EXAMPLE 415

(R)-N-[2-Chloro-4-(2-hydroxyethylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A solution of (R)-N-[2-chloro-4-iodophenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (0.8 g) in pyridine (1 ml) was added to a deoxygenated solution of 2-mercaptoethanol (0.18 ml), sodium methoxide (0.14 g) and copper (I) chloride (0.2 g) in quinoline (2 ml) and pyridine (2 ml). The mixture was heated to 190° C. under argon for 18 hours. The mixture was allowed to cool to room temperature then dissolved in ethyl acetate (100 ml), washed with dilute aqueous hydrochloric acid (2×50 ml) and brine (2×50 ml) then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 10-60% ethyl acetate/iso-hexane to give the title compound as a gum. NMR (CDCl₃): 1.76 (s, 3H), 3.10 (t, 2H), 3.75-80 (m, 2H), 7.31-7.34 (m, 1H), 7.47 (s, 1H), 8.31 (d, 1H), 8.86 (s, 1H); MS (ESP⁻): 342.

EXAMPLES 416-427

Following the procedure of Example 415 and using the appropriate starting materials the following compounds were prepared.

Ex Compound NMR (CDCl₃) MS 416 (R)-N-[2-Chloro-4-(cyclopropyl- 0.10-0.13(m, 1H), 0.5-0.55(m, 1H), 352 methylsulphanyl)phenyl]-2- 0.81-0.89(m, 1H), 1.76(s, 3H), 2.84 hydroxy-2-methyl-3,3,3- (d, 2H), 7.26-7.30(m, 1H), 7.42(s, trifluoropropanamide 1H), 8.26(d, 1H), 8.78,(s, 1H) 417 (R)-N-[2-Chloro-4-(cyclohexyl- 1.23-1.31(m, 6H), 1.57(s, 3H), 1.73- 380 sulphanyl)phenyl]-2-hydroxy-2- 1.76(m, 4H), 3.02-3.10(m, 1H), methyl-3,3,3-trifluoropropanamide 7.31-7.34(m, 1H), 7.44(s, 1H), 8.28 (d, 1H), 8.81(s, 1H) 418 (R)-N-[2-Chloro-4-(thien-2- 1.77(s, 3H), 3.66(s, 1H), 4.27(s, 394 ylmethylsulphanyl)phenyl]-2- 2H), 6.83-6.90(m, 2H), 7.16-7.19(d, hydroxy-2-methyl-3,3,3- 1H), 7.17(d, 1H), 7.38(s, 1H), 8.28 trifluoropropanamide (d, 1H), 8.86(brs, 1H) 419 (R)-N-[2-Chloro-4-(N,N-dimethyl- 1.73(s, 3H), 2.26(s, 6H), 2.55(t, 369 aminoethylsulphanyl)phenyl]-2- 2H), 3.02(t, 2H), 7.26-7.28(m, 1H) hydroxy-2-methyl-3,3,3- 7.40(s, 1H), 8.31(d, 1H), 8.07(s, trifluoropropanamide. 1H) 420 (R)-N-[2-Chloro-4-(N-methyl- 1.73(s, 3H), 2.84(d, 3H), 3.6(s, 2H), 369 carbamoylmethylsulphanyl)phenyl]- 6.65(brs, 1H), 7.21-7.26(m, 1H), 2-hydroxy-2-methyl-3,3,3- 7.34(s, 1H), 8.34(d, 1H), 8.92(s, trifluoropropanamide 1H) 421 (R)-N-[2-Chloro-4-(iso-propyl- 1.23-1.30(m, 6H), 1.73(s, 3H), 3.28- 340 sulphanyl)phenyl]-2-hydroxy-2- 3.36(m, 1H), 7.31-7.34(m, 1H), 7.44 methyl-3,3,3-trifluoropropanamide (s, 1H), 7.78(d, 1H), 8.84(brs, 1H) 422 (R)-N-[2-Chloro-4-(cyclopentyl- 1.52-1.63(m, 7H), 1.71-1.78(m, 4H), 366 sulphanyl)phenyl]-2-hydroxy-2- 3.52-3.57(m, 1H), 7.26-7.28(m, 1H), methyl-3,3,3-trifluoropropanamide 7.2(s, 1H), 8.26(d, 1H), 8.78(s, 1H) 423 (R)-N-[2-Chloro-4-(iso-butyl- 1.02(s, 6H), 1.73(s, 3H), 1.81-1.89 354 sulphanyl)phenyl]-2-hydroxy-2- (m, 1H), 2.8(d, 2H), 3.67(s, 1H), methyl-3,3,3-trifluoropropanamide 7.26-7.31(m, 1H), 7.36(s, 1H), 8.26 (d, 1H), 8.76(s, 1H)  424¹ (R)-N-[2-Fluoro-4-ethylsulphanyl- 1.20(t, 3H), 1.65(s, 3H), 2.81-2.89 310 phenyl]-2-hydroxy-2-methyl-3,3,3- (q, 2H), 3.60(s, 1H), 7.00-7.05(m, trifluoropropanamide 2H), 8.13(t, 1H), 8.40(brs, 1H) 425 (R)-N-[2-Chloro-4-(2,3- 1.71(s, 3H), 3.00-3.05(m, 2H), 3.52- 372 dihydroxypropyl)sulphanylphenyl]- 3.60(m, 1H), 3.68-3.78(m, 2H), 6.65 2-hydroxy-2-methyl-3,3,3- (s, 1H), 7.28-7.31(m, 1H), 7.44(s, trifluoropropanamide 1H), 8.34(d, 1H), 9.42(s, 1H) 426 (R)-N-[2-Chloro-4-(2- 1.28(d, 3H), 1.76(s, 3H), 2.81-2.92 356 hydroxypropyl)sulphanylphenyl]-2- (m, 1H), 3.02-3.1(m, 1H), 3.65(s, hydroxy-2-methyl-3,3,3- 1H), 3.81-3.89(m, 1H), 7.34(d, 1H), trifluoropropanamide 7.44(s, 1H), 8.31(d, 1H), 8.84(s, 1H) 427 (R)-N-[2-Chloro-4-t- 1.28(s, 9H), 1.76(s, 3H), 3.57(s, 354 butylsulphanylphenyl]-2-hydroxy-2- 1H), 7.44-7.47(m, 1H), 7.60(s, 1H), methyl-3,3,3-trifluoropropanamide 8.63(d, 1H), 8.92(s, 1H) ¹Sodium ethanethiolate was used in place of thiol and sodium methoxide.

EXAMPLE 428

(R)-N-(2-Chloro-4-{(4-acetamidophenyloxy)sulphonyl}phenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

A solution of (R)-N-{2-chloro-4-[4-chlorosulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Method 73) (366 mg, 1.00 mmol) in DCM (25 ml) was added to a stirred solution of 4-acetamidophenol (151 mg, 1.00 mmol), dimethylaminopyridine (10 mg, 0.08 mmol) and pyridine (0.45 ml, 2.0 mmol) in DCM (25 ml). The resultant mixture was stirred at ambient temperature overnight, evaporated to dryness and the residue treated with 1M aqueous hydrochloric acid (25 ml). The aqueous solution was extracted with ethyl acetate, the ethyl acetate extracts were washed with saturated sodium hydrogen carbonate solution, brine, dried and evaporated to give, as a foam, the title compound (450 mg, 0.94 mmol); NMR 1.6 (s, 3H), 2.0 (s, 3H), 7.00 (d, 2H), 7.55 (d, 2H), 7.8 (dd, 1H), 8.0 (d, 1H), 8.1 (s, 1H), 8.4 (d, 1H), 9.9 (s, 1H), 10.03 (s, 1H); MS: m/z 479.

Preparation of Starting Materials

The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.

Methods 1-2

Following the procedure of Method 63 (see below) and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR SM 1 2-Fluoro-4-phenylsulphonyl- (CDCl₃): 7.5-7.75(m, Meth 8 bromobenzene 6H), 7.91(d, 2H)  2¹ (R)-N-[2-Chloro-4-(phenyl- (CDCl₃): 1.32-1.41(m, Meth 48 sulphonyl)phenyl]-2-(t- 12H), 4.20-4.32(m, 1H), butoxycarbonylamino) 4.71-4.80(m, 1H), 7.40- propanamide 7.54(m, 3H), 7.70- 7.78(m, 3H), 7.82- 7.92(m, 1H), 8.94(s, br, 1H) ¹The crude compound was purified by passing through an ISOLUTE SPE column containing basic residues using DCM. Methods 3-8

Following the procedure of Example 187 and using the appropriate starting materials (SM1 and SM2) the following compounds were prepared.

Meth Compound SM 1 SM 2  3¹ 2-Chloro-4- 2-chloro-4- methyl (2-methoxycarbonyl) iodoaniline thiosalicylate phenylsulphanylaniline 4 2-Chloro-4- 2-chloro-4- methyl (2-ethoxycarbonyl) iodoaniline thiosalicylate phenylsulphanylaniline 5 2-Chloro-4- 2-chloro-4- thiophenol phenylsulphanyl- iodoaniline aniline 6 2-Fluoro-4- 2-Fluoro-4- 4-(methyl- (4-(methylsulphanyl) iodoaniline sulphanyl) phenylsulphanyl)aniline thiophenol 7 2-Fluoro-4- 2-Fluoro-4- thiophenol phenylsulphanylaniline iodoaniline  8² 2-Fluoro-4- 2-Fluoro-4- thiophenol phenylsulphanyl-1- iodobromobenzene bromobenzene ¹Methanol was used as the reaction solvent in place of ethanol. ²Double the amount of palladium catalyst was used. Product used without purification. Method 9 (R)-(+)-2-Hydroxy-2-methyl-3,3,3-trifluoropropanoic acid

The title compound was resolved according to the resolution method described in European Patent Application No. EP 524781 (described for the preparation of the (S)-(−) acid) except that (1S, 2R)-norephedrine was used in place of (1R, 2S)-norephedrine or (S)-(−)-1-phenylethylamine. NMR analysis of the acid in the presence of (R)-(+)-1-phenylethylamine gave an enantiomerical purity of >98%; NMR (CDCl₃): 1.27 (s, 3H) for the (R)-enantiomer, 1.21 (s, 3H) for the (S)-enantiomer.

Method 10

(4-Acetamidophenylsulphonyl)-2-chloroaniline

Iron powder (2.5 g) was added to a stirred mixture of 4-(4-acetamidophenyl-sulphonyl)-2-chloro-nitrobenzene (Method 13) (0.67 g), water (2 ml), concentrated hydrochloric acid (0.5 ml) and ethanol (10 ml). The mixture was heated under reflux for 1 hour then evaporated to near dryness and partitioned between ethyl acetate and water. The organic layer was separated, the aqueous layer was extracted with ethyl acetate (3×15 ml). The organic extracts were combined and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-2% methanol/DCM to give the title compound (0.18 g) as a solid. NMR: 2.05 (s, 3H), 6.4 (s, 2H), 6.8 (d, 1H), 7.5 (d, 1H), 7.6 (d, 1H), 7.8 (q, 4H), 10.3 (brs, 1H); MS (ESP⁻): 323.

Methods 11-12

Following the procedure of Method 10 and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR SM 11 2-Bromo-4-(4-methylsulphanyl- (CDCl₃) 2.44(s, 3H), Meth phenylsulphanyl)aniline 4.2(s, 2H), 6.73(d, 1H), 27 7.05-7.22(m, 5H), 7.52(d, 1H) 12 (R)-N-[2-Chloro-4-{4-amino- 1.8(s, 3H), 2.2(s, 3H), Meth phenylsulphanyl}phenyl]-2- 5.5(s, 2H), 6.6(d, 2H), 18 acetoxy-2-methyl-3,3,3- 7.0(m, 3H), 7.2(d, 2H), trifluoropropanamide 9.8(s, 1H) Method 13 4-(4-Acetamidophenylsulphonyl)-2-chloronitrobenzene

Hydrogen peroxide (0.9 ml of a 30 wt. % solution in water) was added to a solution of 4-(4-acetamidophenylsulphanyl)-2-chloronitrobenzene (Method 14) (0.78 g) in glacial acetic acid (5 ml) and the mixture was stirred and heated at 95° C. for 75 minutes then poured into water (15 ml) and extracted with ethyl acetate (3×10 ml). The organic extracts were combined, washed with brine and then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-50% ethyl acetate/hexane to give the title compound (0.68 g). NMR: 2.05 (s, 3H), 7.8 (d, 2H), 7.98 (d, 2H), 8.2-8.3 (m, 2H), 8.35-8.45 (m, 1H), 10.4 (brs, 1H); MS (ESP⁻): 353.

Method 14

4-(4-Acetamidophenylsulphanyl)-2-chloronitrobenzene

A solution of 2-amino-4-(4-acetamidophenylsulphanyl)nitrobenzene (Method 15) (2.4 g) in warm glacial acetic acid (15 ml) was poured onto ice (24 ml). Concentrated hydrochloric acid (4.5 ml) was added and the mixture was stirred and cooled to <5° C. A solution of sodium nitrite (0.601 g) in water (5 ml) was added over 7 minutes and the mixture was stirred for 2 hours at 0-5° C. Aqueous sulphamic acid solution (10% w/v) was added until a negative starch iodide test was observed. In a separate flask toluene was added to a solution of cuprous chloride (0.852 g) in water (1.2 ml) and concentrated hydrochloric acid (1.3 ml) and the mixture was cooled to <0° C. The first preparation (diazonium salt) was then added to the cold cuprous chloride mixture over 5 minutes and the resultant mixture was stirred at ambient temperature for 18 hours. The organic layer was separated and the aqueous layer was extracted with toluene (3×10 ml). The organic extracts were combined, washed with water and brine then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-15% ethyl acetate/hexane to give the title compound (0.789 g). NMR: 2.1 (s, 3H), 7.1 (dd, 1H), 7.3 (d, 1H), 7.5 (d, 2H), 7.7 (d, 2H), 7.95 (d, 1H), 10.2 (brs, 1H).

Method 15

2-Amino-4-(4-acetamidophenylsulphanyl)nitrobenzene

Sodium (0.269 g) was added to ethanol (20 ml) and the resultant solution was allowed to cool to ambient temperature and 4-acetamidothiophenol (1.94 g) was added. The mixture was stirred for 5 minutes and 5-chloro-2-nitroaniline (2 g) was added. The mixture was then heated under reflux under argon for 3 hours and allowed to cool. The resultant solid was collected by filtration, washed with ethanol then dried to give the title compound (2.46 g) as a solid. NMR: 2.05 (s, 3H), 6.3 (dd, 1H), 6.6 (s, 1H), 7.4 (brs, 2H), 7.5 (d, 2H), 7.7 (d, 2H), 7.9 (d, 1H); MS (ESP⁺): 304 (M+H)⁺.

Method 16

N-[2-Chloro-4-(4-acetamidophenylsulphonyl)phenyl]-2-acetoxy-2-methylpropanamide

m-Chloroperoxybenzoic acid (50%, 0.735 g) was added to a solution of N-[2-chloro-4-(4-acetamidophenylsulphanyl)phenyl]-2-acetoxy-2-methylpropanamide (Method 17) (0.30 g) in DCM (10 ml) and the mixture was stirred at ambient temperature for 15 hours. Ethyl acetate (20ml) was added and the solution was washed with saturated aqueous sodium carbonate solution (10 ml) and brine then dried. Volatile material was removed by evaporation and the residue was purified by flash chromatography eluting with 50-80% ethyl acetate/hexane to give the title compound (0.29 g) as a solid. NMR (CDCl₃): 1.7 (s, 6H), 2.2 (2×s, 2×H), 7.5 (s, 1H), 7.7 (d, 2H), 7.8 (m, 3H), 8.0 (m, 1H), 8.6 (m, 2H); MS (ESP⁻): 451; EA: found: C, 52.9; H, 4.4; N, 6.1%, C₂₀H₂₁ClN₂O₆S requires C, 53.0; H, 4.6; N, 6.2%.

Method 17

N-[2-Chloro-4-(4-acetamidophenylsulphanyl)phenyl]-2-acetoxy-2-methylpropanamide

N-[2-Chloro-4-(4-aminophenylsulphanyl)phenyl]-2-acetoxy-2-methylpropanamide (Method 22) (0.50 g) was dissolved in DCM (10 ml) and cooled to 0-5° C. in an ice bath. Triethylamine (0.46 ml) was added followed by dropwise addition of acetyl chloride (0.1 ml) and the mixture was allowed to warm to ambient temperature over 2 hours. Ethyl acetate (20 ml) was added and the solution was washed with water (2×10 ml) and brine then dried. Volatile material was removed by evaporation and the residue was purified by flash chromatography eluting with 40-80% ethyl acetate/hexane to give the title compound (0.470 g) as a solid. NMR (CDCl₃): 1.8 (s, 6H), 2.2 (d, 6H), 7.2-7.3 (m, 5H), 7.5 (d, 2H), 8.3 (d, 1H), 8.4 (s, 1H); MS (ESP⁻): 419; EA: found: C, 56.7; H, 5.0; N, 6.0%; C₂₀H₂₁ClN₂O₄S.0.4 EtOAc requires C, 56.9; H, 5.3; N, 6.1%.

Methods 18-21

Following the procedure of Method 17 and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR SM 18 (R)-N-[2-Chloro-4-{4- 1.8(s, 3H), 2.2(s, 3H), Ex 204 nitrophenylsulphanyl} 7.4(t, 3H), 7.6(d, 2H), phenyl]-2-acetoxy-2- 7.8(s, 1H), 8.2(d, 2H), methyl-3,3,3- 9.8(s, 1H). trifluoropropanamide 19 (R)-N-[2-Chloro-4-{4-(2- 1.8(s, 3H), 2.2(s, 3H), Meth 12 chloroacetylamino)- 4.3(s, 2H), 7.1(s, 2H), phenyl sulphanyl}- 7.2(s, 1H), 7.4(d, 2H), phenyl]-2-acetoxy-2- 7.7(d, 2H), 9.9(s, 1H), methyl-3,3,3-trifluoro- 10.45(s, 1H) propanamide   20^(1,2) 3-(t-Butoxycarbonyl- (CDCl₃): 1.44(s, 9H), 3-amino- amino)-1-bromopropane 2.00-2.09(m, 2H), propyl- 3.33-3.30(m, 2H), bromide.HBr 3.42(t, 2H)  21² 3-Acetamido-1- (CDCl₃): 1.96(s, 3H), 3-amino- bromopropane 2.01-2.1(m, 2H), propyl- 3.34-3.46(m, 4H), bromide.HBr 5.65-5.75(brs, 1H) ¹The acylating agent was di-tert-butyl dicarbonate; ²An additional equivalent of triethylamine was used. Method 22 N-[2-Chloro-4-(4-aminophenylsulphanyl)phenyl]-2-acetoxy-2-methylpropanamide

Copper (I) chloride (0.90 g) was added to a mixture of N-[2-chloro-4-iodophenyl]-2-acetoxy-3-methylpropanamide (Method 23) (8.3 g), 4-aminothiophenol (1.07 ml) and potassium carbonate (9.1 g) in DMF (100 ml). The mixture was heated at 135° C. with stirring under argon for 3 hours, cooled and then filtered through diatomaceous earth. The filter was washed with ethyl acetate (3×20 ml) and the filtrates were combined and washed with water (50 ml), brine and dried. The volatile material was removed by evaporation. The crude product was purified by flash chromatography eluting with 20-40% ethyl acetate/hexane to give the title compound (4.99 g) as a solid. Mp 130-132° C.; NMR (CDCl₃): 1.7 (s, 6H), 2.1 (s, 3H), 3.8 (s, 2H), 6.6 (d, 2H), 7.1 (m, 2H), 7.2 (m, 2H), 8.2 (d, 1H), 8.4 (s, 1H); MS (ESP⁻): 377.

Method 23

N-[2-Chloro-4-iodophenyl]-2-acetoxy-3-methylpropanamide

2-Chloro-4-iodoaniline (5 g) was dissolved in DCM (100 ml) and cooled to 0-5° C. in an ice bath. Pyridine (2.1 ml) was added followed by dropwise addition of 2-acetoxy-2-methylpropanoyl chloride (3.44 ml) and the mixture was allowed to warm to ambient temperature over 15 hours. The solvent was removed by evaporation and the residue was purified by flash chromatography eluting with 10-50% ethyl acetate/hexane to give the title compound (7.5 g) as a solid. Mp 156-158° C.; NMR (CDCl₃): 1.7 (s, 6H), 2.2 (s, 3H), 7.6 (d, 1H), 7.7 (d, 1H), 8.2 (d, 1H), 8.4 (s, 1H); MS (ESP⁻): 380.

Method 24

Following the procedure of Method 23 and using the appropriate starting material the following compound was prepared.

Meth Compound NMR SM 24 (R)-N-[2-Chloro- 1.8(s, 3H), 2.2(s, 3H), 7.58(d, 2-Chloro-4- 4-nitrophenyl]- 1H), 8.26(d, 1H), 8.41(s, 1H), nitroaniline 2-acetoxy-2-methyl- 10.23(s, 1H) and Meth 49 3,3,3-trifluoro- propanamide Method 25

Following the procedure of Methods 23, 22, 17 and 16 and using the appropriate starting material the following compound was prepared.

Meth Compound 25¹ N-[2-Chloro-4-{4-N-(2,2-dimethylpropanamido) phenylsulphonyl}phenyl]-2- acetoxy-2-methylpropanamide ¹Starting material was 2-chloro-4-iodoaniline; Method 17: 2,2-dimethylpropanoyl chloride was used in place of acetyl chloride. Method 26 N-[2-Chloro-4-{4-(N,N-dimesylamino)phenylsulphanyl}phenyl]-2-acetoxy-2-methylpropanamide

N-[2-Chloro-4-(4-aminophenylsulphanyl)phenyl]-2-acetoxy-2-methylpropanamide (Method 22) (0.50 g) was dissolved in DCM (10 m) and cooled to 0-5° C. in an ice bath. Triethylamine (0.55 ml) was added followed by dropwise addition of methylsulphonyl chloride (0.11 ml) and the mixture was allowed to warm to ambient temperature over 2 hours. The solution was concentrated then the solid was dissolved in DCM (5 ml) and water (5 ml) was added. The solution was loaded onto a Varian Chem Elut column and after 3 minutes was washed through with DCM (20 ml). The DCM layer was then concentrated and the solid washed with ether and filtered to give the title compound (0.58 g) as a solid. NMR (CDCl₃): 1.7 (s, 6H), 2.2 (s, 3H), 3.4 (s, 6H), 7.2 (s, 4H), 7.4 (d, 1H), 7.5 (d, 1H), 8.4 (d, 1H), 8.5 (d, 1H); MS (ESP⁻): 533; EA: found: C, 44.4; H, 4.5; N, 5.1%; C₂₀H₂₃ClN₂O₇S₃ requires C, 44.9; H, 4.3; N, 5.2%.

Method 27

2-Bromo-4-(4-methylsulphanylphenylsulphanyl)nitrobenzene

t-Butyl nitrite (3.1 ml) was added to a slurry of copper (II) bromide (4.4 g) in acetonitrile (85 ml) at 0° C. 2-Amino-4-(4-methylsulphanylphenylsulphanyl)nitrobenzene (5.09 g), (prepared by the method described in J. Med. Chem., 1975, 18, 1164 for the preparation of 2-nitro-5-phenylsulphanylaniline but using 4-methylsulphanylthiophenol in place of thiophenol) was added portionwise over 5 minutes and the mixture was stirred a further 2 hours at 0° C., allowed to warm to ambient temperature, and stirred a further 16 hours. Volatile material was removed by evaporation and the residue was purified by flash chromatography on silica gel eluting with 10-30% ethyl acetate/hexane to give the title compound (4.5 g) as a solid. NMR (CDCl₃) 2.52 (s, 3H), 7.03-7.08 (m, 1H), 7.3 (d, 2H), 7.36-7.38 (m, 1H), 7.44 (d, 2H), 7.77 (d, 1H).

Method 28

(R)-N-(2-Chloro-4-(triisopropylsilylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Triisopropylsilanethiol (2.8 ml) was added to a stirred suspension of sodium hydride (60% mineral oil dispersion, 0.53 g) in anhydrous THF (40 ml) cooled to 1° C. under argon. After 15 minutes at this temperature tetrakis(triphenylphosphine)palladium (0) (1.21 g) was added and this solution was added to (R)-N-(2-chloro-4-iodophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 197) (5.2 g) in anhydrous toluene (40 ml) and the mixture was heated to 85° C. for 2 hours. The mixture was allowed to cool to ambient temperature, ethyl acetate (200 ml) was added and the mixture was washed with brine (100 ml) and dried. Volatile material was removed by evaporation and the residue was purified on a silica gel flash column eluting with 1-20% ethyl acetate/hexane to give the title compound (6.51 g) as a gum. NMR (CDCl₃) 1.07-1.1 (d, 18H), 1.20-1.28 (m, 3H), 1.74 (s, 3H), 3.64 (s, 1H), 7.39-7.42 (m, 1H), 7.53 (s, 1H), 8.23 (d, 1H), 8.81 (s, 1H); MS (ESP⁻): 454.

Method 29

2-Chloro-4-benzylnitrobenzene

Sodium borohydride (1.45 g) was added to a solution of 3-chloro-4-nitrobenzophenone (2.0 g) (prepared as described by R. B. Davis and J. D. Benigni, J. Org. Chem., 1962, 27, 1605) in ethanol and the mixture was stirred for 18 hours. Volatile material was removed by evaporation and the residue was suspended in water (100 ml) and cautiously acidified with dilute aqueous hydrochloric acid (50 ml) and stirred a further 2 hours. The reaction mixture was basified with 2M aqueous sodium hydroxide solution and extracted with DCM. The extracts were combined, dried and concentrated by evaporation to give an oil. This was dissolved in TFA (12.1 ml) with cooling with an ice bath then treated dropwise with triethylsilane (5.05 ml) and stirred overnight. The reaction mixture was poured onto aqueous sodium carbonate solution and extracted with DCM. The extracts were combined, dried and evaporated to give an oil which was purified by chromatography eluting with 20-50% ethyl acetate/hexane to give the title compound (0.60 g) as an oil. NMR (CDCl₃): 4.0 (s, 3H), 7.1-7.4 (m, 8H); MS (CI): 247 (M⁺).

Method 30

2-Chloro-4-benzylaniline

A solution of 2-chloro-4-benzylnitrobenzene (Method 29) (0.60 g) in ethyl acetate was treated with 10% Pd/C (0.06 g) under argon. The mixture was then stirred under a hydrogen atmosphere for 10 hours. The mixture was filtered under argon and extracted with aqueous hydrochloric acid (50% v/v, 50 ml). The aqueous layer was separated, basified with 2M aqueous NaOH and extracted with ethyl acetate to give the title compound as an oil (0.237 g). NMR: 3.6 (s, 2H), 5.1 (brs, 2H), 6.7 (d, 1H), 6.9 (dd, 1H), 7.0 (d, 1H), 7.1-7.3 (m, 5H); MS (CI): 218 (M⁺)

Methods 31-32

Following the procedure of Method 30 and using the appropriate starting materials the following compounds were prepared.

Meth Compound NMR MS SM 31 3-chloro-4-[di- 1.33(s, 18H), 341 Meth 45 (t-butyloxy-carbonyl)- 5.42(s, 2H), 6.48(dd, amino]aniline 1H), 6.62(s, 1H), 6.89(d, 1H) 32 (R)-N-(2-Chloro- 1.78(s, 3H), 325 Meth 24 4-amino-phenyl)- 2.15(s, 3H), 5.46(brs, 2-acetoxy-2-methyl- 2H), 6.50(d, 1H), 3,3,3-trifluoro- 6.64(s, 1H), 6.80(d, propanamide 1H), 9.53(s, 1H) Method 33 N-[2-Chloro-4-phenylsulphonylphenyl]-2-acetoxy-2-methylpropanamide

2-Chloro-4-phenylsulphanylaniline (Method 5) was acylated with 2-acetoxy-2-methylpropanoyl chloride by the procedure of Method 23 then the crude product was oxidised by the procedure of Example 114 to give the title compound (in 91% yield) as a gummy solid. NMR 1.57 (s, 6H), 2.05 (s, 3H), 7.6-7.75 (m, 4H), 7.8 (d, 1H), 7.92 (dd, 1H), 8.0 (apparent d, 2H), 8.08 (d, 1H), 9.4 (s, 1H).

Method 34

(R)-N-[2-Chloro-4-{4-ureidophenylsulphanyl}phenyl]-2-acetoxy-2-methyl-3,3,3-trifluoropropanamide

Water (0.34 ml), acetic acid (0.54 ml) and sodium cyanate (0.104 g dissolved in 0.3 ml of water) were added to a solution of (R)-N-[2-chloro-4-{4-aminophenylsulphanyl}phenyl]-2-acetoxy-2-methyl-3,3,3-trifluoropropanamide (0.432 g) (Method 22) in THF (0.8 ml. The mixture was stirred for 2 hours then diluted with water (5 ml) and extracted with ethyl acetate (2×20 ml). The extracts were poured onto a Varian Chem Elut column and eluted with ethyl acetate. Volatile material was removed by evaporation and the residue was triturated with ether to give the title compound (0.31 g) as a solid. NMR: 1.8 (s, 3H), 2.2 (s, 3H), 5.9 (s, 2H), 7.1 (s, 3H), 7.4 (d, 2H), 7.5 (d, 2H). 8.8 (s, 1H), 9.9 (s, 1H); MS (ESP⁻): 474.

Method 35

Following the procedure of Method 34 and using the appropriate starting materials the following compound was prepared.

Meth Compound MS SM 35 (R)-N-[2-Chloro-4-{2- 476 Meth ureidophenylsulphanyl}phenyl]- (M + H)⁺ 36 2-acetoxy-2-methyl-3,3,3- trifluoropropanamide Methods 36-40

The indicated starting material was coupled with an appropriate thiol or halide using the method of Example 250, acylated using the procedure of Method 17 then reduced by the procedure of Method 10 to give the following compounds.

Meth Compound NMR MS SM 36 (R)-N-[2-Chloro-4-{2-amino- 431 Ex 210 phenylsulphanyl}phenyl]-2- acetoxy-2-methyl-3,3,3- trifluoropropanamide 37 (R)-N-[2-Chloro-4-{3-amino- 1.8(s, 13H), 2.2(s, 431 Ex 210 phenylsulphanyl}phenyl]-2- 3H), 5.3(s, 2H), 6.5(t, acetoxy-2-methyl-3,3,3- 2H), 6.6(s, 1H), 7.0(t, trifluoropropanamide 1H), 7.2(m, 3H), 9.9(s, 1H)  38¹ (R)-N-[2-Fluoro-4-{4-amino- 1.8(s, 3H), 2.2(s, 3H), 415 2-fluoro-4- phenylsulphanyl}phenyl]-2- 5.6(s, 2H), 6.6(d, 2H), iodoaniline acetoxy-2-methyl-3,3,3- 6.8(m, 2H), 7.1(t, 1H), trifluoropropanamide 7.2(d, 2H), 9.9(s, 1H)   39^(1,2) (R)-N-[2-Fluoro-4-{4- 1.8(s, 3H), 2.2(s, 3H), 445 2-fluoro-4- nitrophenylsulphanyl}phenyl]- 7.4(m, 4H), 7.6(d, iodoaniline 2-acetoxy-2-methyl-3,3,3- 1H), 8.2(d, 2H), 10.12 trifluoropropanamide (s, 1H)   40^(2,3) (R)-2,3,4,5-H₄-3-[2-Chloro-4- (CDCl₃) 1.9(s, 3H), 3.9 415 Ex 197 (4-aminophenylsulphanyl) (s, 2H), 6.7(d, 2H), 7.1 phenyl]-2,4-dioxo-5-methyl- (m, 3H), 7.4(d, 2H) 5-trifluoromethyloxazole ¹Acylation was by the method of Example 197 using (S)-2-acetoxy-2-methyl-3,3,3-trifluoromethylpropanoyl chloride (Method 49) ²The reduction step was omitted ³Thiol coupling was by procedure of Method 22 using 4-mercaptoaniline and acylation was with allylchloroformate Method 41 (R)-N-[2-Chloro-4-{4-(2-morpholinoacetylamino)phenysulphanyl}phenyl]-2-acetoxy-2-methyl-3,3,3-trifluoropropanamide

Following the procedure of Example 353 except that morpholine was used in place of aqueous dimethylamine, the title compound was obtained (0.25 g) as a foam. NMR: 1.8 (s, 3H), 2.2 (s, 3H), 3.1 (s, 2H), 3.3 (s, 4H), 3.6 (m, 4H), 7.1 (s, 2H), 7.2 (s, 1H), 7.4 (d, 2H), 7.7 (d, 2H), 9.9 (s, 2H); MS (ESP⁻): 558.

Method 42

(R)-2,3,4.5-H₄-3-{2-Chloro-4-[4-(3-ethylureido)phenylsulphanyl]phenyl}-2,4-dioxo-5-methyl-5-trifluoromethyloxazole

Ethyl isocyanate (0.062 ml) was added to a solution of (R)-2,3,4,5-H₄-3-[2-chloro-4-(4-aminophenylsulphanyl)phenyl]-2,4-dioxo-5-methyl-5-trifluoromethyloxazole (Method 40) (0.3 g) in anhydrous ether (0.5 ml) and THF (2 ml) and the mixture was stirred for 24 hr. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with eluting with 5-60% ethyl acetate/hexane to give the title compound (0.29 g) as a gummy solid. NMR: 1.8 (q, 2H), 2.0 (s, 3H), 3.1 (m, 3H), 6.1 (t, 1H), 7.2 (d, 2H), 7.5 (d, 2H), 7.6 (d, 2H), 7.6 (d, 1H), 8.7 (s, 1H); MS (ESP⁻): 486.

Methods 43-44

Following the procedure of Method 42 and using the appropriate starting materials the following compounds were prepared.

Meth Compound NMR MS SM 43 (R)-N-[2-Chloro- 1.3(s, 9H), 1.8(s, 3H), 530 Meth 4-{4-(3-t-butyl- 2.2(s, 3H), 6.1(s, 1H), 12 ureido)phenyl- 7.1(s, 3H), 7.4(d, 2H), sulphanyl}- 7.5(d, 2H), 8.5(s, 1H), phenyl]-2-acetoxy-2- 9.9(s, 1H) methyl-3,3,3- trifluoro- propanamide 44 (R)-N-[2-Chloro- 1.8(s, 3H), 2.2(s, 3H), 550 Meth 4-{4-(3-phenyl- 7.0(t, 1H), 7.1(d, 3H), 12 ureido)phenyl- 7.3(t, 2H), 7.4(m, 4H), sulphanyl}phenyl]- 7.6(d, 2H), 8.7(s, 1H), 2-acetoxy-2-methyl- 8.9(s, 1H), 9.9(s, 1H) 3,3,3-trifluoro- propanamide Method 45 N,N-di-(t-Butyloxycarbonyl)-2-chloro-4-nitroaniline

2-Chloro-4-nitroaniline (1.726 g) was added to an ice-cooled solution of di-t-butyl dicarbonate (2.401 g) in THF (50 ml). The mixture was allowed to warm to room temperature. 4-Dimethylaminopyridine (0.01 g) was added and the solution was stirred for a further 19 hours then heated at 60° C. for 26 hours. Volatile material was removed by evaporation and the residue was partitioned between water (100 ml) and DCM (200 ml). The organic phase was washed with brine then dried and reconcentrated. The residue was purified by chromatography on silica to give the title compound (1.261 g) as a solid. NMR: 1.35 (s, 18H), 7.78 (d, 1H), 8.22 (dd, 1H), 8.42 (s, 1H); MS: 372 (M⁺).

Method 46

3-chloro-4-[di-(t-butyloxy-carbonyl)amino]-1-(2-nitroanilino)phenyl

A mixture of 1,1′-bis(diphenylphosphino)ferrocene (0.1 g) and palladium (II) acetate (0.028 g) in toluene (4 ml) was stirred at 100° C. under Argon for one hour. This was added to a mixture of dried caesium carbonate (0.912 g), 3-chloro-4-[di-(t-butyloxy-carbonyl)amino]aniline (Method 31) (0.822 g) and 2-bromo-1-nitrobenzene (0.404 g) in toluene (7 ml). The mixture was stirred for 23 hours at 100° C. under argon then cooled, filtered and concentrated by evaporation. The residue was dissolved in ethyl acetate (75 ml), washed with 1M aqueous hydrochloric acid (2×5 ml), water (25 ml) and brine (25 ml) then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 10% ethyl acetate/hexane to give the title compound (0.889 g) as a gum. NMR: 1.40 (s, 18H), 7.00 (t, 1H), 7.27 (m, 2H). 7.36 (d, 1H), 7.45 (s, 1H), 7.58 (t, 1H), 8.10 (d, 1H), 9.28 (s, 1H); MS (ESP⁻): 462.

Method 47

2-chloro-4-(2-nitroanilino)aniline

TFA (3 ml) was added to a solution of 3-chloro-4-[di-(t-butyloxy-carbonyl)amino]-1-(2-nitroanilino)phenyl (Method 46) (0.88 g) in DCM (15 ml). After 2 hours the solution was evaporated to dryness. The residue was dissolved in ethyl acetate (100 ml), washed with 1M aqueous sodium hydroxide (50 ml), water (50 ml) and brine (50 ml) then dried and reconcentrated to give the title compound (0.45 g) as a solid; MS (ESP⁺): 264 (M+H)⁺.

Method 48

(R)-N-[2-Chloro-4-(phenylsulphanyl)phenyl]-2-(t-butoxycarbonylamino)propanamide

(Based on the procedure of Villeneuve, G. B. et al., Tetrahedron Letters (1997), 38 (37), 6489.)

Triphenylphosphine (0.0.612 g) was added to a cooled (−78° C.) solution of hexachloroacetone (0.18 ml) and N-t-butyloxycarbonyl-2-methylalanine (0.441 g) in dry DCM (15 ml) under argon. The resulting mixture was stirred at low temperature for 20 minutes. Then 2-chloro-4-(phenylsulphanyl)aniline (0.5 g) (Method 5) and dry triethylamine (0.33 ml) were added. The resulting mixture was slowly warmed to room temperature, under argon, before being stirred for 1 hour at room temperature. Saturated aqueous ammonium chloride solution (15 ml) was added and the mixture was extracted with DCM (2×50 ml). The organic extracts were combined, washed with brine and dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel column eluting with 2% ethyl acetate/DCM to give the title compound. NMR (CDCl₃): 1.40-1.45 (m, 12H), 4.29-4.40 (m, 1H), 4.86-4.95 (m, 1H), 7.20-7.40 (m, 7H), 8.30-8.38 (m, 1H), 8.64 (brs, 1H); MS (ESP⁻): 405.

Method 49

(S)-2-Acetoxy-2-methyl-3,3,3-trifluoropropanoyl chloride

Acetyl chloride (11.7 ml) was added dropwise to a stirred solution of (R)-2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid (10 g) (Method 9) in toluene (100 ml) cooled in an ice bath. The mixture was then heated to 80° C. and the suspension dissolved to give a clear solution. After 2 hours the reaction mixture was cooled and then concentrated to give an oil. This oil was then redissolved in DCM (140 ml) and DMF (4 drops) was added followed by oxalyl chloride (6 ml). The solution bubbled vigorously and the reaction mixture was left to stir for 15 hours. The resultant solution of the title compound was used directly without further purification.

Method 50

(R)-N-(2-Chloro-4-{3-t-butoxy-2-hydroxypropylamino}phenyl)-2-acetoxy-2-methyl-3,3,3-trifluoropropanamide

t-Butyl glycidyl ether (0.19 ml) and copper(II) trifluoromethanesulphonate (0.018 g) were added to a solution of (R)-N-(2-chloro-4-aminophenyl)-2-acetoxy-2-methyl-3,3,3-trifluoropropanamide (0.325 g) (Method 32) in diethyl ether (5 ml). The mixture was stirred for 40 hours then volatile material was removed by evaporation and the residue was purified by chromatography to give the title compound (0.141 g) as a foam; MS (ESP⁻): 453.

Method 51

3,4-Difluorobenzenethiol

A solution of triphenylphosphine (37.0 g) and DMF (2 ml) in DCM (100 ml) was maintained at 20° C. with an ice bath during addition of 3,4-difluorobenzenesulphonyl chloride (10 g). The mixture was stirred at room temperature for 2 hours then aqueous hydrochloric acid (50 ml of a 1M solution) was added. The mixture was stirred for a further 1 hour. The organic layer was separated, dried and the solvent removed by evaporation to give the title compound as an oil which was used without purification.

Method 52

2-(4-Triisopropylsilylsulphanylphenyl)pyrimidine

Tetrakis(triphenylphosphine)palladium(0) (0.28 g) was added to a solution of 2-(4-bromophenyl)pyrimidine (1.751 g) (prepared as described in U.S. patent application Ser. No. 96-692,869 (CA 129:136175)) in toluene (40 ml) and the mixture was heated at 80° C. under argon for one hour. Trisopropylsilanethiol (2.14 ml) was added dropwise to a stirred suspension of sodium hydride (0.4 g of a 60% dispersion in oil) in dry THF (20 ml) cooled with ice/water. The cooling bath was removed and the mixture was stirred for 10 minutes to give a clear solution. This solution was added to the reagents in toluene and the mixture was stirred under reflux for 16 hours then cooled. Water (50 ml) was added and the mixture was extracted with ethyl acetate (3×50 ml). The extracts were combined, washed with brine (100 ml) and dried. Volatile material was removed by evaporation and the residue was purified by chromatography eluting with 20% ethyl acetate/hexane to give the title compound (1.49 g) as a solid; NMR (at 343K): 0.86-1.07 (m, 21H), 7.4 (t, 1H), 7.7 (m, 2H), 8.39 (m, 2H), 8.87 (m, 2H); MS (EI): 344 (M⁺).

Method 53

6-Iodoquinazolinedione

A mixture of 2-amino-5-iodobenzoic acid (3.5 g) and urea (1.56 g) in NMP (15 ml) was heated at 160° C. for 6 hours then cooled. Water (200 ml) was added and the resultant precipitate was collected, washed with water and dried to give the title compound (3.35 g) as a solid. MS (CI⁺): 289 (M+H)⁺.

Method 54

1,3-Dimethyl-6-iodoquinazolinedione

Sodium hydride (0.24 g of a 60% dispersion in oil) was added portionwise to a stirred solution of 6-iodoquinazolinedione (0.58 g) (Method 53) and iodomethane (0.63 ml) in DMF (10 ml). The mixture was stirred for 1 hour then added cautiously to saturated aqueous ammonium chloride solution (200 ml). Extraction with ethyl acetate followed by recrystallization from ethanol plus a little chloroform gave the title compound (0.48 g) as a solid. MS (CI⁺): 317 (M+H)⁺.

Method 55

N-[2-Fluoro-4-(4-methylsulphanylphenylsulphanyl)phenyl]-2-t-butyldimethylsilyloxy-2-trifluoromethyl-3,3,3-trifluoropropanamide

To a stirred solution of 2-t-butyldimethylsilyloxy-2-trifluoromethyl-3,3,3-trifluoropropanoic acid, t-butyldimethylsilyl ester (Method 56) (1.05 g) in DCM (10 ml) was added DMF (2 drops) and oxalyl chloride (0.23 ml). The reaction mixture was stirred for 17 hours and was then added to a solution of 2-fluoro-4-(4-methylsulphanylphenylsulphanyl) aniline (Method 6) (0.63 g) in DCM (5 ml) and pyridine (0.22 ml). The reaction mixture was stirred at ambient temperature for 48 hours, evaporated under reduced pressure and the residue purified by chromatography on a silica gel Mega Bond Elut column eluting with 5-20% ethyl acetate/iso-hexane to give the title compound (0.278 g) as a yellow gum. NMR (CDCl₃): 0.29 (s, 6H), 0.98 (s, 9H), 2.48 (s, 3H), 6.96-7.0 (m, 1H), 7.06 (d, 1H), 7.2 (d, 2H), 7.31 (d, 2H), 8.23 (t, 1H), 8.62 (brs, 1H).

Method 56

2-t-Butyldimethylsilyloxy-2-trifluoromethyl-3,3,3-trifluoropropanoic acid, t-butyldimethylsilyl ester

A stirred solution of 2-hydroxy-2-trifluoromethyl-3,3,3-trifluoropropanoic acid (2.26 g) in anhydrous DMF (11 ml) under argon was treated with t-butyldimethylsilyl chloride (3.37 g) followed by imidazole (3.02 g). The reaction mixture was stirred for 17 hours then extracted with iso-hexane (3×100 ml) and the organic phase washed with aqueous sodium hydrogen carbonate (2×200 ml) and dried. Volatile material was removed by evaporation to give the title compound (3.09 g) as an oil. NMR (CDCl₃): 0.01 (s, 6H), 0.87 (s, 9H); MS (EI+) 383 (M−C₄H₉).

Method 57

(R)-N-[2-(2-Trimethylsilylethynyl)-4-(4-mesylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Bis(triphenylphosphine)palladium(II) chloride (0.01 g), triphenylphosphine (0.0038 g), trimethylsilylacetylene (0.17 ml), triethylamine (0.16 ml) and copper(I) iodide (0.0013 g) were added to a solution of (R)-N-[2-bromo-4-(4-mesylphenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 140) (0.311 g) in anhydrous THF (10 ml) under argon. The mixture was heated at 50° C. for 3 hours then more bis(triphenylphosphine) palladium(II) chloride (0.01 g) and trimethylsilylacetylene (0.17 ml) were added and heating was continued for a further 3 hours. The reaction mixture was allowed to cool, ethyl acetate (50 ml) was added and the mixture was filtered through a pad of diatomaceous earth which was washed with ethyl acetate (3×20 ml). The filtrates were combined and volatile material was removed by evaporation. The residue was purified by chromatography eluting with 10-40% ethyl acetate/iso-hexane to give the title compound (in 89% yield) as a solid. NMR (CDCl₃): 0.29 (s, 9H), 1.74 (s, 3H), 3.05 (s, 3H), 3.69 (s, 1H), 7.88-7.92 (m, 1H), 8.02 (d, 1H), 8.05-8.13 (m, 4H), 8.61 (d, 1H), 9.46 (s, 1H); MS (ESP⁻): 546.

Method 58

5-Iodo-2H-benzimidazol-2-one

A mixture of iodine monochioride and 2H-benzimidazole-2-one (0.67 g) (Method 59) in glacial acetic acid (8 ml) was heated to 80° C. for 1 hour then cooled. The mixture was partitioned between saturated aqueous sodium sulphite solution and DCM. The organic layer was evaporated to dryness then redissolved in ethyl acetate. The aqueous layer was extracted with ethyl acetate then all ethyl acetate extracts were combined and washed with saturated aqueous sodium hydrogen carbonate solution, water and brine. The organic extracts were passed through a Varian Chem Elut column and washed through with ethyl acetate. Volatile material was removed by evaporation to give the title compound (0.36 g) as a solid which was used without further purification. MS (ESP⁺): 261 (M+H)⁺.

Method 59

2H-Benzimidazol-2-one

A solution of phenylene diamine 6.48 g in dry THF (150 ml) was cooled to 5° C. A suspension of 1,1-carbonyldiimidazole (10.7 g) in THF (100 ml) was added to this solution over 15 minutes keeping the temperature below 10° C. The mixture was stirred for 16 hours and the resultant solid was collected and dried to give the title compound (4.5 g); NMR: 6.9 (s, 4H), 10.5 (s, 2H); MS (ESP⁺): 135 (M+H)⁺.

Methods 60-62

Following the procedure of Example 197 and using the appropriate starting material the following compounds were prepared.

Meth Compound INMK MS SM 60 (R)-N-(2-Chloro-4-nitrophenyl)- 1.64(s, 3H), 8.13(s, 1H), 311 2-Chloro-4- 2-hydroxy-2-methyl-3,3,3- 8.28(d, 1H), 8.39(d, 1H), nitroaniline trifluoropropanamide 8.45(s, 1H), 10.0(s, 1H) 61 (R)-N-(2-Methoxy-4- (CDCl₃) 1.75(s, 3H), 4.07 307 2-Methoxy- nitrophenyl)-2-hydroxy-2- (s, 3H), 7.72-7.75(m, 1H), 4-nitroaniline methyl-3,3,3- 7.88-7.97(m, 1H), 8.50- trifluoropropanamide 8.58(m, 1H), 9.27(brs, 1H) 62 (R)-N-(2-Methyl-4-nitrophenyl)- (CDCl₃) 1.77(s, 3H), 2.39 291 2-Methyl-4- 2-hydroxy-2-methyl-3,3,3- (s, 3H), 3.5(s, 1H), 8.09- nitroaniline trifluoropropanamide 8.15(m, 2H), 8.30-8.38(m, 1H), 8.65(brs, 1H) Method 63 (R)-N-[2-Chloro-4-(2-fluorophenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

m-Chloroperoxybenzoic acid (55%, 2.39 g) was added to a solution of (R)-N-[2-chloro-4-(2-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 187) (0.906 g) in DCM (60 ml) and the mixture was stirred at ambient temperature for 6 hours. The mixture was then washed with saturated aqueous sodium hydrogen carbonate solution (3×100 ml), water (100 ml) and brine then dried. Volatile material was removed by evaporation and the residue was triturated with hexane to give the title compound (0.808 g) as a solid. Mp 90-92° C.; NMR (CDCl₃): 1.75 (s, 3H), 3.65 (brs, 1H), 7.15 (t, 1H), 7.35 (t, 1H), 7.60 (m, 1H), 7.95 (d, 1H), 8.10 (m, 2H), 8.60 (d, 1H), 9.30 (brs, 1H); MS (ESP⁻): 424.

Methods 64-66

Following the procedure of Method 63 and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR SM 64 (R)-N-[2-Fluoro-4-{2-fluoro- 1.59(s, 3H), 7.38-7.55(m, 2H), Ex 195 phenylsulphonyl}phenyl]-2-hydroxy- 7.7-7.9(m, 4H), 8.05(q, 2H), 2-methyl-3,3,3-trifluoropropanamide 9.85(brs, 1H) 65 (R)-N-[2-Fluoro-4-(4-nitrophenyl- 1.58(s, 3H), 7.75(s, 1H), 7.87 Ex 176 sulphonyl)phenyl]-2-hydroxy-2- (dd, 1H), 8.0(dd, 1H), 8.08(d, methyl-3,3,3-trifluoropropanamide 1H), 8.25(d, 2H), 8.4(d, 2H), 9.9(brs, 1H) 66 (R)-N-[2-Chloro-4-(3,4- (CDCl₃) 1.75(s, 3H), 7.25-7.35 Ex 276 difluorophenylsulphonyl)phenyl]-2- (m, 1H), 7.4(t, 1H), 7.5-7.6(m, hydroxy-2-methyl-3,3,3- 1H), 7.65-7.9(m, 2H), 8.0(m, trifluoropropanamide 1H), 8.1(m, 1H), 8.6(d, 1H), 9.3(brs, 1H) Methods 67-68

Following the procedure of Method 16 and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR SM 67 (R)-N-[2-Chloro-4-{2-nitrophenyl- 1.6(s, 3H), 8.0(m, 5H), 8.1(s, Ex 264 sulphonyl}phenyl]-2-hydroxy-2- 1H), 8.4(m, 2H), 9.9(s, 1H) methyl-3,3,3-trifluoropropanamide 68 (R)-N-[2-Chloro-4-{3-nitrophenyl- (CDCl₃) 2.75(s, 3H), 3.55(s, 1H), Ex 331 sulphonyl}phenyl]-2-hydroxy-2- 7.75(t, 1H), 7.9(dd, 1H), 8.1(s, methyl-3,3,3-trifluoropropanamide 1H), 8.25(d, 1H), 8.45(d, 1H), 8.7 (d, 1H), 8.75(s, 1H), 9.3(brs, 1H) Method 69 (R)-N-[2-Chloro-4-(4-fluorophenylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Hydrogen peroxide (0.3 ml of a 30 wt. % solution in water) was added to a solution of (R)-N-[2-chloro-4-(4-fluorophenylsulphanyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Example 188) (0.283 g) in glacial acetic acid (1.0 ml) and the mixture was stirred and heated at 100° C. for 80 minutes then allowed to cool. Ethyl acetate (40 ml) was added and the solution was washed with water (20 ml), saturated aqueous sodium hydrogen carbonate solution (20 ml) and brine and then dried. Volatile material was removed by evaporation and the residue was purified by chromatography on a silica gel Mega Bond Elut column eluting with 0-25% ethyl acetate/hexane to give the title compound (0.261 g; 72%) as a solid Mp 131-133 ° C.; NMR: 1.6 (s, 3H), 7.46 (t, 2H), 8.0 (dd, 1H), 8.08 (m, 2H), 8.15 (d, 1H), 8.3 (d, 1H), 9.85 (brs, 1H); MS (ESP⁺): 426 (M+H)⁺.

Method 70-72

Following the procedure of Method 69 and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR SM 70 (R)-N-[2-Chloro-4-{3-fluoro- (CDCl₃) 1.75(s, 3H), 3.75(s, 1H), Ex 253 phenylsulphonyl}phenyl]-2- 7.10(dd, 1H), 7.30(dd, 1H), 7.50- hydroxy-2-methyl-3,3,3- 7.70(m, 1H), 7.90(d, 1H), 8.05-8.10 trifluoropropanamide (m, 2H), 8.65(d, 1H), 9.40(s, 1H) 71 (R)-N-[2-Fluoro-4-{4-fluoro- 1.73(s, 3H), 4.26(s, 1H), 7.18(t, Ex 193 phenylsulphonyl}phenyl]-2- 2H), 7.8(t, 2H), 7.89-7.94(m, 2H), hydroxy-2-methyl-3,3,3- 8.56(t, 2H), 9.0(s, 1H) trifluoropropanamide 72 (R)-N-[2-Chloro-4-{3-chloro- (CDCl₃) 1.75(s, 3H), 5.1(brs, 1H), Ex 275 4-fluorophenylsulphonyl} 7.2-7.3(m, 1H), 7.6-7.9(m, 2H), phenyl]-2-hydroxy-2-methyl- 7.95-8.0(m, 2H), 8.65(d, 1H), 9.5 3,3,3-trifluoropropanamide (brs, 1H) Method 73 (R)-N-(2-Chloro-4-chlorosulphonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

(R)-N-(2-Chlorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide (Method 74) (13.8 g, 52 mmol) was added in portions to a cooled (0° C.) solution of chlorosulphonic acid (25 ml) over 15 mins and then the mixture was heated to 85° C. After 4.5 h the reaction mixture was cooled in an ice bath and then poured very slowly onto a stirred ice-water mixture. After stirring for 15 mins, the mixture was extracted with ethyl acetate (2×100 ml) and the combined organic layer washed with brine, dried and concentrated to yield a brown oil. This oil was purified by flash column chromatography using 10:1, iso-hexane:ethyl acetate to yield the title compound as a pale yellow solid (11 g, 30 mmol). NMR: 1.6 (s, 3H), 7.55 (dd, 1H), 7.6 (d, 1H), 7.95 (d, 1H), 9.7 (brs, 1H); MS: 364.

Method 74

(R)-N-(2-Chlorophenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide

Acetyl chloride (11.7 ml, 164 mmol) was added dropwise to a stirred solution of the (R)-2-hydroxy-2-methyl-3,3,3-trifluoropropanoic acid (Method 9) (10 g, 63 mmol) in toluene (100 ml) cooled in an ice bath. The mixture was then heated to 80° C. and the suspension dissolved to yield a clear solution. After 2 h the reaction mixture was cooled and then concentrated to yield a slight brown oil. This oil was then redissolved in DCM (140 ml) and DMF (4 drops) was added followed by oxalyl chloride (6 ml, 69 mmol). The solution bubbled vigorously and the reaction mixture was left to stir. After 15 h, this reaction mixture was added slowly to a stirred solution of 2-chloroaniline (8.7 g, 68 mmol) and pyridine (5.5 ml, 68 mmol) in DCM (150 ml). After 15 h stirring at room temperature, the resultant mixture was concentrated and the residue dissolved in methanol (500 ml). A solution of lithium hydroxide monohydrate (7.8 g, 0.19 mol) in water (120 ml) was then added and the mixture was stirred for 4 h. The mixture was then concentrated and the residue acidified to pH 2 (by addition of concentrated hydrochloric acid). Ethyl acetate(150 ml) was added and the mixture washed with water (2×100 ml) and brine, dried and evaporated to dryness. The residue was purified by flash column chromatography using 6:1, iso-hexane:ethyl acetate to yield the title compound as a white solid (13.8 g, 52 mmol). NMR: 1.6 (s, 3H), 7.1-7.25 (m, 1H), 7.3-7.4 (m, 1H), 7.55 (dd, 1H), 7.8 (s, 1H), 8.0 (dd, 1H), 9.7 (brs, 1H); MS: 266.

Method 75

Following the procedure of Method 63 and using the appropriate starting material the following compounds were prepared.

Meth Compound NMR and MS SM 75 (R)-N-[2-Chloro-4-(4-fluoro- (CDCl₃): 1.74(s, 3H), Ex 188 phenylsulphinyl)phenyl]-2- 4.16 and 4.24 hydroxy-2-methyl-3,3,3- (2 x br s, 1H), trifluoropropanamide 7.19(t, 2H), 7.49(d, 1H), 7.63(dd, 2H), 7.7(d, 1H), 8.52(m, 1H), 9.2(br s, 1H); MS 408

EXAMPLE 429

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:

(a) Tablet I mg/tablet Compound X 100 Lactose Ph. Eur 182.75 Croscarmellose sodium 12.0 Maize starch paste 2.25 (5% w/v paste) Magnesium stearate 3.0 (b) Tablet II mg/tablet Compound X 50 Lactose Ph. Eur 223.75 Croscarmellose sodium 6.0 Maize starch 15.0 Polyvinylpyrrolidone 2.25 (5% w/v paste) Magnesium stearate 3.0 (c) Tablet III mg/tablet Compound X 1.0 Lactose Ph. Eur 93.25 Croscarmellose sodium 4.0 Maize starch paste 0.75 (5% w/v paste) Magnesium stearate 1.0 (d) Capsule mg/capsule Compound X 10 Lactose Ph. Eur 488.5 Magnesium stearate 1.5 (e) Injection I (50 mg/ml) Compound X 5.0% w/v      1 N Sodium hydroxide 15.0% v/v     solution 0.1 N Hydrochloric acid (to adjust pH to 7.6) Polyethylene glycol 400 4.5% w/v      Water for injection to 100% (f) Injection II (10 mg/ml) Compound X 1.0% w/v      Sodium phosphate BP 3.6% w/v      0.1 N Sodium hydroxide 15.0% v/v     solution Water for injection to 100% (1 mg/ml. buffered (g) Injection III to pH6) Compound X 0.1% w/v      Sodium phosphate BP  2.26% w/v     Citric acid  0.38% w/v     Polyethylene glycol 400 3.5% w/v      Water for injection to 100% Note The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. 

1. A compound of formula (I′):

wherein: n is 1 or 2; R^(a) is chloro, fluoro, bromo, nitro or methoxy; R^(b) is phenyl, wherein said phenyl is substituted by at least one group selected from ii), optionally one or more groups selected from i) and iii) and optionally further substituted with one group selected from iv): i) —X^(a)—R^(c) wherein X^(a) is —O—, —S—, —SO—, —SO₂—NR^(d)— or —CONR^(e)— (wherein R^(d) and R^(e) each independently represents hydrogen or C₁₋₄alkyl which C₁₋₄alkyl is optionally substituted with one or more groups selected from hydroxy or C₁₋₄alkoxy) and R^(c) is selected from hydrogen or C₁₋₆alkyl which C₁₋₆alkyl is optionally substituted with one or more hydroxy or C₁₋₄alkoxy, or X^(a) is a direct bond and R^(c) is C₁₋₆alkyl which C₁₋₆alkyl is optionally substituted with one or more hydroxy or C₁₋₄alkoxy, with the proviso that —X^(a)—R^(c) is not C₁₋₄alkyl or C₁₋₄alkoxy; ii) a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms selected independently from O, N and S which heterocyclic moiety may be aromatic or non-aromatic and is optionally substituted with one or more groups selected from hydroxy, halo, C₁₋₄alkoxy, C₁₋₄alkyl or cyano; iii) —X^(a)—C₁₋₆alkyl-X^(b)—R^(c) wherein X^(a) and R^(c) are as defined hereinbefore and X^(b) is —S—, —SO—or —SO₂—; iv) cyano, hydroxy, halo, C₁₋₄alkoxy, C₁₋₄alkyl; or a salt thereof; or a pharmaceutically acceptable in vivo cleavable prodrug of said compound of formula (I); or a pharmaceutically acceptable salt of said compound or said prodrug.
 2. A compound of formula (I′):

wherein: n is 1 or 2; R^(a) is chloro, fluoro, bromo, nitro or methoxy; R^(b) is a carbon-linked 6 -membered heteroaryl ring containing 1-2 nitrogen atoms or a carbon-linked 5 -membered heteroaryl ring containing 1-3 heteroatoms selected independently from O, N and S, wherein said heteroaryl ring is substituted by one or more groups selected from i)-iii) and is optionally further substituted with a group selected from iv): i) —X^(a)—R^(c) wherein X^(a) is —O—, —SO—, —SO₂—, —NR^(d)— or —CONR^(c)— (wherein R^(d) and R^(e) each independently represents hydrogen or C₁₋₄alkyl which C₁₋₄alkyl is optionally substituted with one or more groups selected from bydroxy or C₁₋₄alkoxy) and R^(c) is selected from hydrogen or C₁₋₆alkyl which C₁₋₆alkyl is optionally substituted with one or more hydroxy or C₁₋₄alkoxy, or X^(a) is a direct bond and R^(c) is C₁₋₆alkyl which C₁₋₆alkyl is optionally substituted with one or more hydroxy or C₁₋₄alkoxy, with the proviso that —X^(a)—R^(c) is not C₁₋₄alkyl or C₁₋₄alkoxy; ii) a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms selected independently from O, N and S which heterocyclic moiety may be aromatic or non-aromatic and is optionally substituted with one or more groups selected from hydroxy, halo, C₁₋₄alkoxy, C₁₋₄alkyl or cyano; iii) —X^(a)—C₁₋₆alkyl-X^(b)—R^(c) wherein X^(a) and R^(c) are as defined hereinbefore and X^(b) is —S—, —SO—or —SO₂—; iv) cyano, hydroxy, halo, C₁₋₄alkoxy, C₁₋₄alkyl; and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); or a pharmaceutically acceptable salt of said compound or said prodrug.
 3. A compound of formula (I′) as claimed in claim 1 or 2 wherein R^(a) is chloro or fluoro.
 4. A compound of formula (I′) as claimed in claim 1 wherein R^(b) is substituted by a 4-12 membered heterocyclic moiety containing 1-4 heteroatoms selected independently from O, N and S which heterocyclic moiety may be aromatic or non-aromatic.
 5. A compound of formula (I′) as claimed in claim 2 which is (R)-N-{2 -Chloro-4-[4-(2 -oxo-pyrrolidin-1-yl)phenysulphonyl]phenyl}-2-hydroxy-2-methyl-3,3,3-trifluoropropanaxnide; or a salt thereof; or a pharmaceutically acceptable in vivo cleavable prodrug of said compound of formula (I′); or a pharmaceutically acceptable salt of said compound or said prodrug.
 6. A pharmaceutical composition which comprises a compound of the formula (I′) as claimed in claim 1, 4, 5 or 2 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.
 7. A process for preparing a compound of formula (I′) as claimed in claim 1, 4, 5 or 2 or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof, which process (in which variable groups are as defined for formula (I′) unless otherwise stated) comprises of: (a) deprotecting a protected compound of formula (II′):

where Pg is an alcohol protecting group; (b) oxidising a compound of formula (VI′)

(c) coupling a compound of formula (VII′):

wherein J is NH₂, with an acid of formula (VIII′):

wherein X is OH; (d) coupling an aniline of formula (VII′) wherein J is —NH₂ with an activated acid derivative of formula (VIII′); (e) reacting a compound of formula (IX′):

 with a base to yield the dianion, followed by treatment of the dianion with oxygen in the presence of a reducing agent; or by treatment with a peroxyacid; or (f) reacting a compound of formula (XII′):

 with a compound of formula R^(y)M wherein M is an alkali metal or a Grignard compound of formula R^(y)MgBr or R^(y)MgCl wherein one of R^(x) and R^(y) is CF₃ and the other is Me; and thereafter optionally: i) converting a compound of the formula (I′) into another compound of the formula (I′); ii) removing any protecting groups; or iii) forming a pharmaceutically acceptable salt or in vivo hydrolyzable ester.
 8. A method for elevating PDH activity in a warm-blooded animal in need thereof, said method comprising administering to said animal a PDH activity-elevating amount of a compound of the formula (I′) or prodrug or salt thereof, as claimed in claim 1, 4, 5 or
 2. 9. A method of treating diabetes mellitus in a warm blooded animal in need thereof, said method comprising administering to said animal an effective amount of a compound of the formula (I′) or prodrug or salt thereof, as claimed in claim 1, 4, 5 or
 2. 10. A method of treating lactic academia in a warm blooded animal in need thereof, said method comprising administering to said animal an effective amount of a compound of the formula (I′) or prodrug or salt thereof, as claimed in claim 1, 4, 5 or
 2. 11. A method of treating obesity in a warm blooded animal in need thereof, said method comprising administering to said animal an effective amount of a compound of the formula (I′) or prodrug or salt thereof, as claimed in claim 1, 4, 5 or
 2. 